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Enhancing the understanding of the biological and functional role of specific cytokines 
in the regulation of Natural Killer (NK) cell activity is vital to cell-mediated immunity 
against infections and tumour development. Binding of cytokines with 
glycosaminoglycans (GAGs) and proteoglycans (PGs) have been known as a potential 
mechanism for regulating biological activity of many cytokines. In this thesis work, the 
binding of interleukins IL-11, IL-18 and IL-22 to heparin/HS was investigated using 
an ELISA approach, alongwith examination of primary sequences, 3-D protein 
structures and molecular docking calculations. Our results demonstrate that these 
interleukins do not bind to heparin/HS, which implies that the heparin-binding property 
should not be considered a generic characteristic for any class of cytokines. Further 
research focussed on examining the functional role of NK cell-surface PG, particularly 
dermatan sulphate (DS), in IL-12 signalled IFN-γ production using a PG synthesis 
inhibitor, p-nitrophenyl-β-xyloside. Our findings show partial inhibition of IFN-γ due 
to disrupted GAG/PG metabolism. Mechanistically, DS-PG interference was found 
independent of STAT-4 phosphorylation but suggestive of involvement essentially at 
the transcriptional or post-transcriptional level. In addition, our data implies that p-
nitrophenyl-β-xyloside exerts cellular effects attenuating NK cell response to IL-12, 
independent of GAG-PGs. Finally, an interplay of molecular mechanisms between 
immunoregulatory factors, TGF-β1 and IL-12, in suppressing IFN-γ expression in 
mNK cells is studied. A clear evidence of partial inhibition of IL-12-induced IFN-γ 
production independent of NK cell proliferation is presented that does not directly 
involve key transcription factors of IFN-γ expression, STAT-4 and T-bet. However, 
promoter and early inhibition (3-6 hrs) studies suggested a possible role of TGF-β1 in 
chromatin remodelling of Ifng locus that regulates IFN-γ expression. Overall, 
identifying IL-heparin/HS interactions within different cytokine families and dissecting 
molecular events of cytokine signalling in NK cells are therapeutically important in 
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1.1 The Immune System 
 
The immune system is a diverse array of cells and their products, which collectively 
identifies, attacks and eradicates any infective foreign particles from the host body with 
minimum immunopathology. Understanding of immune system is essential to host 
defense and prevention of diseases. Nevertheless, improper functioning of the immune 
system can lead to various pathological conditions such as, infections, inflammation 
including autoimmune diseases, allergic disorders and cancers of the immune system 
(Biron & Tarrio, 2015). An overview of the immune system is described below 
(Chaplin, 2010). The purpose of this overview is to illustrate the interaction of different 
cell types in various immune mechanisms through secreted protein mediators, called 
Cytokines (Figure 1.1). Yet, the molecular basis of cytokine actions and immune cell 
activation is rather complex and less understood.  
 
 
Figure 1.1: Overview of the Immune system: The figure outlines two arms of immune system, 
innate and adaptive immunity. In response to pathogens and their products, host body initiates innate 
immune response that subsequently activates components of adaptive immune responses. Activation 
of important cells and release of cytokines in the cascade of these immune responses are also shown. 





Immune cells are primarily produced in the bone marrow by a process called 
haemopoiesis. They circulate into bloodstream from lymphoid organs such as thymus, 
spleen, lymph nodes and various lymphoid tissues in the body. As illustrated in Figure 
1.1, there are two types of immune responses (Alberts B., Et. al. 2002; Goldsby Et. al., 
2003; Chaplin, 2010; Hoffmann & Akira, 2013) 
i) Innate immunity and  
ii) Adaptive/Acquired immunity  
 
Innate immunity is the first line of defense against infection. It is not specific for a 
particular pathogen, as it is triggered by molecular markers called pathogen-associated 
molecular patterns (PAMPs) that are conserved across a wide range of pathogens.  
These PAMPs on pathogens are detected by pattern-recognition receptors (PRRs), such 
as Toll-like receptors (TLRs), on innate immune cells. In response to an infection and 
injury, the major type of innate immune cells such as mast cells, neutrophils, basophils, 
monocytes and macrophages mediate an immunologic response called inflammation. 
A series of events takes place in this response, such as migration of innate immune cells 
to the site of pathogen entry, recognition of pathogen and activation of these cells by 
the release of cytokines, specific soluble proteins. Cytokines (detailed in Section 1.2) 
act as signalling molecules that regulate the function of immune cells and underlying 
mechanisms of defense. Moreover, cells like monocytes, macrophages, neutrophils and 
dendritic cells (DCs), so called phagocytic cells engulf and kill foreign objects such as 
bacteria by phagocytosis, an innate mechanism in the eradication of pathogens. These 
phagocytic cells present PAMPs as an immunologic entity on their surfaces called 
antigens (Ags) along with self-membrane molecules encoded by major 
histocompatibility complex (MHC) genes. Therefore, these innate cells are also called 
antigen presenting cells (APCs) and further activate adaptive immune responses.  
 
One of the important components of innate immunity are natural killer cells (NK cells). 
NK cells (as detailed in Section 1.6.1) provide a non-specific, early host response due 
to their inherent ability to lyse tumour or pathogen-infected cells without prior 
sensitization.  In addition to their potent cytolytic activity, NK cells secrete a range of 
immunoregulatory cytokines that play a significant role in eliminating pathogens. In 
particular, NK cells produced interferon-γ (IFN-γ), a key cytokine in the early control 
of invading pathogens and tumour surveillance (Ikeda Et. al., 2002; Vivier Et. al., 




control of infectious diseases by activation of innate immune cells (phagocytes, NK 
cells) via secretion of cytokines that mediates cellular communications and actions; 2) 
leading to stimulation of a specific adaptive immune response (Roitt Et. al., 1998; 
Mitrovic Et. al., 2012b). 
 
An adaptive or acquired immune response is characterised by specificity for a particular 
pathogen. Unlike innate immune cells, the adaptive response is mediated by cells called 
T and B lymphocytes that expresses pathogen-specific receptors on their cell surfaces. 
B cells recognise Ags specific to its surface immunoglobulin (Ig) receptors and present 
them along with MHC class II molecules to T cells. T cells use a distinct T cell-receptor 
(TCR) to recognize an Ag presented along with MHC I/II molecules on the surface of 
a self-cell such as phagocytic cells/APCs of the innate system or an altered self-cell, 
such as virus-infected or cancerous cell. This is how a T cell activation is different from 
B cells. Thus, recognition of self and non-self is another important attribute of adaptive 
immunity. 
 
There are functionally two subpopulations of T lymphocytes, T cytotoxic (Tc) cells and 
T helper cells (Th) as distinguished by the presence of CD8 and CD4 membrane 
glycoproteins respectively on their cell surfaces. Tc/ CD8+ T cells are activated by 
recognizing ‘target cells’, infected with a virus, or other intracellular pathogens or 
cancer cells in association with MHC class I molecules. On activation, the effector Tc 
cells called CTLs (cytotoxic T lymphocytes) exhibit cytotoxic killing of target cells. 
Whilst, Th/ CD4+T cells are activated by Ags complexed with MHC class II molecules 
presented on APCs. The effector Th cells, in turn secrete various cytokines that help in 
the activation of other cells such as phagocytes, Tc cells and antibody-producing B 
cells. Th cells do not possess cytolytic activity themselves but through secretion of 
various cytokines, they activate other cells to destroy extracellular pathogens. Thus, Th 
cells regulate both innate and adaptive immune responses. Depending on the set of 
cytokines released by these effector Th cells, two subsets of population develop, Th1 
and Th2 cells (detailed in Section 1.6.2, Figure 1.10). For example, Th1 cells are 
characterised by the synthesis and secretion of cytokines such as IFN-γ, IL-2, whereas, 
Th2 cells secrete IL-4, IL-5, IL-25, IL-13, IL-31, and IL-33 (J. Zhu & Paul, 2010). 
Collectively, acquired immunity contributed by T lymphocytes (Tc/ CD8+ T and Th/ 





Interestingly, there are T cells that secrete both Th1 and Th2 cytokines, called Th0 cells. 
Another subset of T cells, called Th3 or T regulatory cells (Tregs), are known to 
downregulate immune responses by producing immunosuppressive cytokines (Crispin 
Et. al., 2004; Wan, 2010), such as IL-10 and TGF-β that primarily antagonise 
lymphocyte responses (Maloy Et. al., 2003). Moreover, following the clearance of 
infection, host responses to inflammatory reactions are suppressed by secretion of these 
anti-inflammatory cytokines, IL-10 and TGF-β as a mechanism in maintaining immune 
homeostasis (X. Ma Et. al., 2015). Tregs and TGF-β1 elicit anti-inflammatory 
responses in control of damage caused by autoimmune diseases and regulate Th1 
responses (Belkaid, 2007; Sanjabi Et. al., 2017). 
 
The research work presented in this thesis aims to enhance the fundamental 
understanding of NK cell activity and its role in development of Th1 immune responses, 
in the context of glycobiology. For this, the first part of this thesis investigates the 
cytokine ability in interacting with complex carbohydrates of the microenvironment 
such as glycosaminoglycans (GAGs)/proteoglycans (PGs) and in particular, 
heparin/HS. This GAG-interaction is a useful concept in understanding regulation of 
cytokine functions and their therapeutic application in diseases (Kufareva Et. al., 2015). 
Of particular interest are some of the key immune cytokines, interleukin (IL)-11, IL-
18, and IL-22 that have been considered for heparin/HS-binding in the current study 
(Chapter 3). The second part of this research seeks to investigate the underlying 
mechanism regulating IL-12 induced IFN-γ production in NK cells. Modulation of this 
NK cell response by GAGs/PGs (Chapter 4) and by immunosuppressive cytokines such 
as TGF-β1 (Chapter 5) is studied. This can clearly impact strategies aimed at enhancing 
or inhibiting NK cellular activity in vivo and during adoptive cell-based therapy for the 
benefit of immunocompromised individuals such as HIV infected or cancer patients 




As mentioned earlier in the overview of immune system, the physiologic role of 
cytokines is to mediate cell-to-cell communication. Cytokines are family of secreted, 
soluble glycoproteins, and non-immunoglobulin in nature that act non-enzymatically 
in nanomolar to picomolar concentrations to regulate cell function. The term ‘cytokine’ 




by leukocytes and act on leukocytes, ii) interferons-that interfere with viral infection, 
iii) chemokines-chemoattractant cytokines, iv) colony-stimulating factors- support the 
growth of cells and v) various growth factors. They are positive or negative regulators 
of several immunological and non-immunological (developmental) processes such as 
inflammatory signalling, cell migration, differentiation, proliferation, survival and 
apoptosis (Goldsby Et. al., 2003; Dinarello, 2007a).  
 
Upon external stimuli, cytokines are rapidly synthesised and secreted by different cells. 
Unlike hormones, most cytokines are not stored in glands as preformed molecules, but 
have induced expression (Haddad, 2002). Hence, the expression of most cytokines is 
strictly regulated. Cytokine dysregulation is often manifested in many autoimmune 
diseases and allergic-inflammatory disorders. A clinical example most prevalent in this 
category is rheumatoid arthritis, an autoimmune condition which is characterised by 
local inflammation in the small joints of the hand and foot. At the site of inflammation, 
tissue damage is caused by self-reactive T cells and excessive production of pro-
inflammatory cytokines such as IFN-γ (Roitt Et. al., 1998; Goldsby Et. al., 2003). 
Cytokines modulate functional activities of cells and tissues, both under normal and 
pathologic conditions. Therefore, with the profound role of cytokines in immune 
responses, they have also been considered for therapeutic intervention as vaccine 
adjuvants in which they act as immune stimulants and enhance the effectiveness of 
adoptive immunotherapies (Salgaller & Lodge, 1998; Fewkes & Mackall, 2010).  
 
Upon secretion, cytokines bind to high-affinity receptors on target cells. They have a 
short half-life and most of them function in an autocrine (secretion and stimulation of 
the same cell) or paracrine manner (stimulation of nearby cells as target cells). 
Moreover, on secretion, some cytokines diffuse locally generating a concentration 
gradient required for their neighbouring target cells to act in a concentration-dependent 
manner. Therefore, cytokine activity is mainly localised around the source of secretion. 
Except in immune reactions against systemic infections, in which, macrophages and 
other innate immune cells in the circulation secrete large amounts of cytokines that may 
be active beyond the site of secretion called endocrine mode of action. A clinical 
scenario that parallels such a condition is called ‘septic shock syndrome’ that is 
characterised by high levels of cytokines, TNF-α, IL-12 and IFN-γ in the blood, setting 
a systemic inflammation due to the response of the immune system to infection. A 




Ledger Et. al., 2009). Consequently, in pathologic states, cytokines circulate in an 
endocrine manner, however physiologically, these soluble factors stimulate immune 
responses in a paracrine mode. Moreover, the localised delivery of cytokines in a 
therapeutic application has been reviewed as an effective alternative to the systemic 
route of administration in vaccine delivery system (Salem Et. al., 2010). Therefore, this 
raises a question as to how these soluble and diffusible cytokines are retained locally 
within the tissue sites. 
  
Studies conducted almost three decades ago, by Dexter and Spooncer, showed that 
haemopoiesis in bone marrow cells co-cultured with stromal cells could be sustained 
for several monthsin-vitro , without exogenously added cytokines. Moreover, the 
cytokines were not detected in the culture supernatant. This led them to propose that 
haemopoietic cytokines being synthesised must be retained within the stromal cell 
layer, after secretion (Dexter & Spooncer, 1987). At the time of this finding, it was 
known that marrow-derived stromal extracellular matrix (ECM) contained special 
polysaccharides called glycosaminoglycans (GAGs) (Dexter, 1987). In parallel, with 
the work presented by Dexter and Spooncer, Gordan et al provided evidence that among 
GAGs, particularly, heparan sulphate (HS) on the stromal cell surfaces were able to 
bind haemopoietic cytokines like IL-3 and GM-CSF (Gordon Et. al., 1987). Moreover, 
HS-bound cytokines were biologically active to stimulate stem-cell proliferation and 
differentiation (Gordon Et. al., 1987; Roberts Et. al., 1988). Thus, this was suggested 
as the mechanism behind the in-vitro, long-term survival and maintenance of 
haemopoiesis in bone marrow cultures. The outcome of this early work highlighted that 
cytokines bind to GAGs which are present on the cell surface or ECM. Moreover, 
cytokine binding to GAGs results in selective retention of these factors close to the site 
of their secretion and paracrine signaling. Such localization of cytokine activity also 
contributed to the formation of compartmental niches defining the marrow 
microenvironment where the binding facilitated the regulation of hematopoietic stem-
cell growth and differentiation. Thus, it was understood that the role of cytokines in 
cell-regulation and immune responses is modulated by the GAG components of the 
ECM or microenvironment. 
 
Since then, a number of key immune proteins like cytokines have been shown to bind 
to GAGs and the number is steadily increasing. Consequently, GAG-binding has 




for diffusible (cytokine) and non-diffusible (matrix) signals to localise the responses of 
cells to a cytokine that is secreted (Ruoslahti & Yamaguchi, 1991; Roy & Kornberg, 
2015). Such a mechanism has been the basis for the explanation of cytokine and 
leukocyte functions in various immune processes, like leukocyte trafficking, microbial 
adhesion and infection, regulation of inflammation at the sites of infection or antigen 
exposure (Tanaka Et. al., 1993; Taylor & Gallo, 2006), and most importantly in 
angiogenesis and tumour development (Chiodelli Et. al., 2015; Peysselon & Ricard-
Blum, 2014). Thus, the implications of cytokine-GAG interactions have been 
recognized in both innate and adaptive immunity (Davis & Parish, 2013; Coombe & 
Parish, 2015; Kang Et. al., 2018). In the recent years, understanding the interaction of 
immunologically significant cytokines with GAGs at the molecular level and the 
functional significance of such interactions is a growing field of interest. This would 
allow for therapeutic manipulation of cytokine actions in the treatment of 
immunological diseases. In the subsequent sections, GAGs/PGs are introduced with 
respect to their structure, function and biosynthesis that contribute towards binding to 
proteins, importantly, cytokines. 
 
1.3 Glycosaminoglycans (GAGs) and Proteoglycans (PGs) 
 
GAGs/PGs are one of the most diverse forms of biological macromolecules. They are 
present on the surface of almost all cell types, in the ECM and in the circulation (Iozzo 
& Schaefer, 2015). Structurally, GAGs are linear polysaccharide chains covalently 
attached to serine residues of a core protein to form complex macromolecules called 
proteoglycans (PGs) (Gallagher, 2015) (Figure 1.2). Alternatively, the protein core of 
a PG is a scaffold onto which GAG chains are attached. Moreover, PGs contain a 
relatively higher polysaccharide content, compared to protein found in glycoproteins 







































1.3.1 Structure and Functions 
 
As mentioned earlier, GAG chains are unbranched, polysaccharide chains of variable 
size and composition. They are made up of specific, repeating disaccharide units of 
sugar acids such as uronic acid, either D-glucuronic acid (GlcUA) or L-iduronic acid 
(IdoA) that alternates with a sugar amine, either N-acetyl-glucosamine (GlcNAc) or N-
acetyl galactosamine (GalNAc) (Gallagher, 2015; Xu & Esko, 2014). Moreover, one 
or both of the sugar units contain sulphate residues; therefore, GAGs are highly 
sulphated and strongly negatively-charged macromolecules (Prydz & Dalen, 2000; 
Pomin & Mulloy, 2018). 
 
Based on the particular disaccharide repeat unit, GAGs can be divided into 4 subgroups 
(Prydz & Dalen, 2000; Mulloy & Rider, 2006), as shown in Figure 1.3.    
A) Heparin (H) and Heparan Sulphate (HS),  
B) Keratan Sulphate (KS),  
C) Chondroitin Sulphates (CS; chondroitin sulphate-A [CS-A], chondroitin 
sulphate-B [CS-B] or Dermatan Sulphate (DS) and chondroitin sulphate-C [CS-
C]) 
(A) Cell-surface proteoglycans  (B) ECM proteoglycans  
protein core 
GAG chains  
Figure 1.2: Proteoglycans: Proteoglycans (PGs) consists of a protein core (brown in color) to 
which glycosaminoglycan (GAG) chains are covalently attached (red and blue color). This figure 
illustrates (A) cell-surface PGs, attached to membranes or spanning the bi-layered cell membrane 
(green) and (B) Extracellular matrix (ECM) PGs, which are usually secreted or may shed from 






D) Hyaluronic Acid (HA). HA is an exception, as it is synthesised as a free GAG 





















































Figure 1.3: Disaccharide structures and composition of different types of GAGs: GAGs 
consist of repeating disaccharide units, each unit with an uronic acid and an amino sugar, except 
keratan sulphate (sugar- highlighted in yellow). Possible sites of sulphation in the disaccharide unit 





GAGs and hence PGs have a prominent role as structural components. For example, 
PGs containing HA in ECM gives cartilage a gel-like property that resists deformation 
in joints. This hydrating property of HA has been used in making specific HA-based 
formulations in regenerative medicines (Highley Et. al., 2016). Additionally, 
PGs/GAGs exhibit a range of functions depending on their composition of sugar 
residues and/or location (Powell Et. al., 2004). A CS-PG called Versican, found in 
many ECMs are ligands to receptors, TLR2 (toll-like receptor 2) and TLR6 of innate 
immune cells (W. Wang Et. al., 2009). Moreover, GAGs/PGs associated with cell 
membranes are known to function as cell-adhesion molecules, anchoring cells to the 
ECM fibres and involved in cell signalling (A. C. Rapraeger, 2000).  This is well-
illustrated by Syndecan, a cell-surface PG containing HS/CS-GAG chains on its 
external domain binds to fibrous proteins (collagen and fibronectin) present in the 
interstitial matrix surrounding the basal lamina (Afratis Et. al., 2017). Perlecan, a cell-
surface HS-PG is known to bind and accumulate various growth factors in the ECM 
(Whiltelock Et. al., 2008). GAGs like heparin, are also found segregated into 
intracellular granules in secretory cells such as mast cells. These GAGs are released 
during cell degranulation at the sites of inflammation or tissue injury (Mulloy Et. al., 
2017). Thus, the biological function of PGs is diverse, ranging from structural and 
mechanical support in tissues to the interaction with various growth factors and 
proteins. 
 
The interaction of PGs with proteins is prominently via the GAG components which, 
in turn, results in modulation of protein function. Proteins that bind to GAGs belong to 
various classes including cell adhesion molecules, morphogenetic proteins, plasma 
proteins, enzyme-inhibitors, proteins involved in lipoprotein uptake, hormones, and 
cytokines like chemokines and interleukins (Esko & Linhardt, 2009; Ori Et. al., 2011; 
Pomin, 2015). A number of scenarios have been illustrated in Figure 1.4 that shows 
binding to GAGs is an important mechanism underlying the biological outcomes of 
many of these proteins. Classically, one of the best characterised interaction between 
GAGs and proteins is the activation of a serpin protease inhibitor, antithrombin-III (AT 
III) and heparin/HS which leads to inhibition of blood coagulation cascade (Choay Et. 
al., 1983; Petitou Et. al., 2003; Mosier Et. al., 2012). GAG-protein interactions are a 
means of localising concentrations of growth factors in the ECM or at cell surfaces at 
the sites of their production (J. T. Gallagher & Turnbull, 1992b; Johnson Et. al., 2005). 




Et. al., 1988; Lortat-Jacob & Grimaud, 1991c; Clarke Et. al., 1995). This further allows 
the bound and preserved protein to be presented to its specific cell-surface receptor 
initiating signal transduction. Such an interesting interaction has been demonstrated in 
the case of fibroblast growth factor (FGF), which binds tightly to the HS chains in the 
extracellular domains of PGs (recent reviews Gallagher, 2015; Meneghetti Et. al., 
2015). This HS-bound FGF is presented to its high affinity polypeptide receptor, FGFR 
on the cell membrane to initiate signal transduction in cell growth and proliferation 
(Yayon Et. al., 1991; Itoh Et. al., 2011). The role of heparin was proposed to induce 
dimerisation of FGF molecules thereby facilitating dimerisation of respective 
receptors, FGFRs and hence their activation (Pellegrini Et. al., 2000; Schlessinger Et. 
al., 2000; Brown Et. al., 2013). Because of this, heparin/HS were referred to as co-
receptors for FGF signalling. Such early work on GAG-bound FGFs has led to the 
hypothesis that GAG-binding prevents diffusion of growth factors and retention close 
to the site of secretion supporting paracrine or juxtacrine mode of action (J. T. 























Figure 1.4: GAG-protein interactions: The figure shows the interaction of GAG chains of PGs 
with proteins that result in sequestration of proteins close to the site of secretion, presentation of 
GAG-bound protein to cognate membrane-receptors in signal transduction, oligomerisation 
leading to concentration gradient in attracting migration of leukocytes, protection from proteases 
in ECM or circulation. Each interaction depicts a specific influence of GAGs on biological 







Evidence to localisation of activity has also been observed during inflammatory 
reactions by chemokines (Kufareva Et. al., 2015; Proudfoot Et. al., 2017). Binding of 
chemokines to heparin/HS have shown to form concentration gradients that importantly 
provides directional cues to circulating neutrophils (Johnson Et. al., 2005; Rajarathnam Et. 
al., 2018). Therefore, GAG-binding property directs to a better understanding of either 
sequestration or presentation of cytokine activity. Further, it is well-exemplified by a 
heparin-binding cytokine, IFN-γ (Lortat-Jacob & Grimaud, 1991a; Lortat-Jacob & 
Grimaud, 1991c; Saesen Et. al., 2013) that binding to GAGs confers additional stability 
to cytokines. IFN-γ is an important cytokine in early host defense and is vital to both 
innate and adaptive immune responses (Schoenborn & Wilson, 2007; Larkin Et. al., 
2013). Studies have shown that free IFN-γ in circulation is cleaved along its length at 
carboxyl-terminal rendering the cytokine inactive. Whereas heparin-bound IFN-γ has 
shown to be protected from extensive proteolytic processing by circulating proteases 
that increases the half-life of IFN-γ in the circulation from 1.1 to 99 minutes, thus 
increasing its biological efficacy (Lortat-Jacob Et. al., 1996a). Moreover, IFN-γ 
binding to heparin/HS modulates the receptor interaction and hence bioactivities of this 
key cytokine in tissues (Yard Et. al., 1998, Fernandez-Botran Et. al., 1999) 
Collectively, the role of GAGs in affecting physiological events by binding to 
cytokines is many-fold; they induce oligomerisation, regulate ligand-receptor 
interaction i.e. affect biological activity by competing with cytokine membrane-
receptors. Further, they modify carboxyl-terminal processing, thereby increasing the 
stability and bio-availability of cytokines. The nature and functional consequences of 
individual GAG-cytokine interaction are different and have distinctive outcomes. 
Since, cytokines are small proteins with a short half-life in blood, GAG-induced 
cytokine activity and stability play a significant role when a cytokine is evaluated in a 
pharmacological or clinical application (Adage Et. al., 2012; Gerlza Et. al., 2015; 
Weiss Et. al., 2017). Thus, binding of a cytokine to GAGs like heparin/HS have major 
consequences on cytokine function, and that functional influence is different among 







1.3.2 Biosynthesis of GAGs and PGs 
 
The molecular basis to the binding ability of GAGs to many different classes of proteins 
is the structural complexity and diversity which arises from their biosynthesis (Esko & 
Lindahl, 2001; Gandhi & Mancera, 2008). Therefore, it is important to understand this 
process of GAG synthesis. The overview of the process is as described below and 
depicted in Figure 1.5 (Prydz & Dalen, 2000; Esko & Selleck, 2002; Mulloy & Rider, 
2006). The biosynthetic machinery to produce GAGs and PGs is largely located in the 
Golgi apparatus (Prydz & Dalen, 2000; Esko & Lindahl, 2001). PG synthesis begins 
with the sequential addition of series of monosaccharide units onto a core protein 
structure to form a long unbranched polysaccharide chain with specific disaccharide 
repeats. The biosynthetic process is fast; complete synthesis of an entire GAG chain is 
achieved in 1-3 min (Esko, 1991). This process takes place in three stages namely chain 
initiation, chain elongation and modification. 
 
Chain initiation involves transfer of the first sugar, D-xylose (Xyl) from UDP-xylose 
to a serine or threonine residue of the protein core by the enzyme, xylosyl transferase. 
To this xylosylated protein core, two galactose (Gal) residues and a glucuronic acid 
(GlcUA) unit are then added sequentially to form the tetrasaccharide core linkage 
region (GlcUA-Gal-Gal-Xyl). This tetrasaccharide linkage region is the starting point 
for polysaccharide chain elongation. Chain elongation then starts with the addition of 
fifth sugar to a tetrasaccharide linkage region. Importantly, if the fifth sugar residue is 
N-acetylglucosamine (GlcNAc), it commits the process towards heparin/ HS chain 
synthesis, whereas, for CS and DS chains, N-acetlygalactoseamine (GalNAc) is added. 
The protein core dictates the type of GAG synthesized and attached (Gallagher, 2015). 
This is followed by alternate addition of GlcUA residue to form a disaccharide repeat. 
Thus, the elongation process results in a long, non-sulphated, unbranched 
polysaccharide chain (Esko & Selleck, 2002). 
 
Whilst the GAG chain is still undergoing polymerization, it is modified by a series of 
sequential modification reactions. These modifications add significant charge density 
and structural complexity to the polymer chain (Kjellen & Lindahl, 1991; J. T. 
Gallagher Et. al., 1992a). For Heparin/HS, which are the types of GAGs with highest 
structural diversity (Kreuger & Kjellen, 2012), the N-acetyl glucosamine (GlcNAc) in 




with sulphate groups. One of the four isoforms of enzyme N-acetylglucosamine N-
deacetylase/N-sulphotransferase (NDST) could catalyse this reaction and has been 
recognised as a single protein with dual functionality. N-deacetylation/N-sulphation are 
concomitant processes in vivo and, therefore, free amino groups on glucosamines are 
rare (Aikawa Et. al., 2001). N-sulphation is a prerequisite for all subsequent 
modifications such as O-sulphation (U. Lindahl Et. al., 1986) or C5 epimerization of 
GlcUA to IdoA. This is because N-sulphate groups are necessary for substrate 
recognition by the respective enzymes. N-sulphation is carefully regulated during 
synthesis, resulting in fine structural characteristics of heparin/HS chains that can often 






















Following the N-sulphation, the glucosamine can additionally be O-sulphated at C-6 
and occasionally at C-3 positions by O-sulphotranferase enzymes or at both C-3 and 
C-6 or no sulphates. There are 6 isoforms of 3-O-sulphotranferase (3-OST) expressed 
at different levels in different tissues to form tissue-specific saccharide sequences (J. 
Liu Et. al., 1999). Therefore, based on the sulphation patterns, glucosamine in 
Figure 1.5: Steps in the biosynthesis of GAGs: Stepwise synthesis of different types of GAGs –
heparin/HS, CS, and DS form from a common tetrasaccharide linkage region present on core protein. 
Various post-modification reactions catalysed by biosynthetic enzymes such as NDST, 2OST (2-O-
sulphotransferase), 6OST (6-O-sulphotransferase), C5 epimerase which modifies glucuronic acid 
(GlcUA) to iduronic acid (IdoA) at C-5 have also been indicated as described in the text.  Figure 




heparin/HS chain can be found in different states, such as N-acetylated/N-
sulphated/free amino with N- and 3 or 6 O-sulpho groups. Moreover, the glucuronic 
acid (GlcUA) in heparin /HS either remains without modification in some disaccharide 
units, or undergoes epimerisation at C5 to IdoA, which can further be 2-O sulphated. 
Thus, GlcUA can exist in four variable states; unmodified, epimerised, N-sulphated, 
and O-sulphated. Combining the possibilities of variable states for both N-acetyl 
glucosamine and glucuronic acid, the number of modification reactions could result in 
up to 48 combinations per disaccharide unit of heparin/HS-GAGs (Sugahara & 
Kitagawa, 2002). This indicates that the potential for variations in even short 
oligosaccharide sequences is enormous in GAGs and this variation exceeds 
extraordinarily compared to other biological macromolecules like DNA (combination 
of 4 different units) or proteins (20 different units). However, out of all theoretically 
possible disaccharides, only around half of them have actually been found in GAGs, 
possibly due to limited substrate specificity offered by the enzymes involved in GAG 
biosynthesis (reviewed in (Esko & Selleck, 2002; Mulloy & Rider, 2006).  
 
An important aspect to understand about the mechanism of GAG biosynthesis is that it 
is not template-driven, only a proportion of polysaccharide chains are modified by 
enzymes (and their tissue-specific isoforms) leaving considerable scope for sequence 
diversity (Gallagher, J.T. and Lyon, M., 1989). Moreover, the sequential modifications 
of the polysaccharide chain catalysed by multiple biosynthetic enzymes do not undergo 
completion. Therefore, GAG biosynthesis is regulated by the expression and activity 
of these enzymes that, in turn, dictates structural heterogeneity in GAG chains.  
 
In the case of HA, it is not subjected to any post-modification reactions. KS and CS, 
however, undergo less modification than heparin/HS. Indeed, the heparin/ HS class has 
greater sequence variation through modifications compared to other GAGs; hence they 
have higher anionic charge density (Kreuger & Kjellen, 2012). Therefore, most GAG-
binding proteins interact with high affinity to heparin/HS. DS is derived from CS with 
the incorporation of IdoA (Sugahara Et. al., 2003). The presence of IdoA adds to the 
conformational flexibility in the modified regions of heparin/HS and DS chains that are 
most involved in binding with proteins. For this reason, many proteins including 
cytokines, bind to heparin/HS and DS over other GAGs. Indeed, the sulphation patterns 
which results in overall charge density and variations in GAG structures at the 




physiological or pathological changes in the microenvironment (Tanaka Et. al., 1993; 
Taylor & Gallo, 2006; Lindahl & Kjellen, 2013). 
 
1.3.3 Heparin and Heparan Sulphate (HS) 
 
As understood from the above sections that among GAGs, heparin and heparin sulphate 
(HS) are highly sulphated and are of particular importance for their almost universal 
existence. Among these GAGs, heparin is a highly sulphated variant of HS that is 
exclusively found in mast cell granules and is released on degranulation, during 
inflammation. HS is, however, widely distributed and is found on the cell surface of all 
mammalian cells and in the extracellular matrix as part of PGs (Bishop Et. al., 2007). 
Both are widely used GAGs due to their anticoagulant property (Capila & Linhardt, 
2002). Heparin is easy to obtain, more homogenous, and commercially available in 
bulk quantity as an anticoagulant. Therefore, for simplicity, rather than HS, heparin is 
employed for most experimental and theoretical studies, including the research work 
presented in this thesis. 
 
 Although, heparin and HS share the same repertoire of saccharide residues – 
glucuronic acid (GlcA) 1-4 linked to N-acetyl glucosamine (GlcNAc), there is an 
important difference in the structures of heparin and HS (Gandhi & Mancera, 2008; 
Gallagher, 2015). Compared to heparin, HS polysaccharide chains are distinctly 
organised into domains as illustrated in Figure 1.6, containing different types and 
densities of modifications, including sulphation, that are spaced apart along the chain 
(J. Turnbull Et. al., 2001; Rabenstein, 2002). Short regions along the polysaccharide 
chain that are highly modified and sulphated are called NS domains and this region 
resembles heparin chains. NS domains are found separated by longer regions with 
fewer modifications and low sulphation, mainly consisting of GlcA-GlcNAc repeats 
called N-acetylated or NA domains. The NA and NS domains are separated by ‘mixed 
domains’ containing, N-acetylated and N-or O-sulphated GlcNAc as well as GlcA or 
IdoA or IdoA2S (J. T. Gallagher, 2006). The NS and mixed domains are termed 
hypervariable regions that result in different functional characteristics for HS from 
different cell types (Coombe & Kett, 2005). Consequently, HS shows overall greater 
structural variation than heparin (Bernfield Et. al., 1999). Such structural pattern arises 
because of modification reactions that occur in clusters during biosynthesis, leaving 




characteristic structure of HS also differentiates it from other GAGs, which have more 
uniform structure and sulphation throughout the polysaccharide chain (Maccarana Et. 
al., 1996). 
 
NS domains are typically of 3-8 disaccharide units in length with distinct clusters of 
sulphate groups particularly N- or 3-, or 6-O- sulphated positions in close proximity 
with or without epimerisation of glucuronic acid (GlcA) to iduronic acid (IdoA) (Lyon 
& Gallagher, 1998b) as shown in Figure 1.6. IdoA may be sulphated at 2-O-position 
adding to overall charge density to the chain (J. E. Turnbull & Gallagher, 1991). 
Introduction of IdoA residues into NS-domains is a crucial modification that provides 
flexibility to the chain due to its variable conformational states and additionally 
influences the spatial rearrangement of sulphate, carboxylate, and hydroxyl groups 
attached to it and to adjacent sugars (Raman Et. al., 2003; Raman Et. al., 2005). The 
nature and pattern of modifications varies from one source of HS to another resulting 
in different compositions of NS domains, depending on cell or tissue type (U. Lindahl 
Et. al., 1998; Shi & Zaia, 2009). Therefore, the variation in NS-domain composition 
could imply another level of regulation in binding and modulating the activity of local 
cytokines, growth factors, and various other protein ligands by GAGs. Even though 
NA-domains are not directly involved in protein interaction, they act as spacers 
between two NS-domains of protein binding sites. Spacing of the NS domain has been 
observed as an important factor in the ability of heparin/HS chains to interact with 
proteins (Mobli Et. al., 2008). For example, interaction between HS and multimeric 
platelet factor-4 (PF4) involves typical S-A-S domains, where S represents the NS 
domain and A is the NA domain. Thus, two NS regions, each as a binding site, were 
found on opposite sides of the PF4 tetramer separated by unsulphated NA region 
(Stringer & Gallagher, 1997b). 
 
Although HS features alternating NA-domains and NS-domains, the levels of 
sulphation in NS-domains match the levels seen in heparin that interact with proteins 
(U. Lindahl Et. al., 1998; Mulloy & Forster, 2000; Gallagher, 2015). In comparison to 
HS, heparin exhibits shorter stretches of NA domains and contains a high ratio of 
IdoA/GlcA and more of N-sulphated glucosamine. Thus, heparin chains are 
characterised by long stretches of tri-sulphated dissacharide units, IdoA2SGlcNSO36S 
(Yamada Et. al., 1998). Therefore, both GAGs differ in their degree of sulphation, with 




although biosynthetically related to heparin, contains only one sulphate or less per 












Additionally, the solution structure of heparin is well-defined and determined by 
Mulloy Et. al. using NMR and molecular modelling techniques (Mulloy Et. al., 1993; 
Mulloy & Forster, 2000). According to this (Figure 1.7), heparin chains exists in helical 
conformation with glucosamine (GlcN) and glucuronic acid (GlcA) moieties in fixed 
conformations as well as rigid glycosidic linkages. Whilst, the IdoA residues are 
flexible to fluctuate between two conformations, 1C4 chair and 
2S0 skew-boat. These 
two conformations of IdoA are in equilibrium in solution (Das Et. al., 2001) and they 


















Figure 1.6: Strutural Organisation in Heparin/HS: Heparin/HS are complex polysaccharide 
chain with disaccharide repeat units of glucosamine and glucoronic acid. As shown heparin/HS 
chains are organized into domains of high sulphation (NS domains) are separated by low 
sulphation regions dominated by N-acetylated glucosamines (NA regions). Structural 
heterogeneity in their chains arises from varying number and position of sulphation that results in 





positions on the helical axis. Therefore, such relatively rigid and bulky structure of 










According to the structure described for heparin (Mulloy Et. al., 1993), it is tri-
sulphated disaccharide repeat. The arrangement of sulphate groups on heparin chains 
is such that a group of three sulphate ions are clustered on one side of the chain and 
alternates with a similar cluster of the next disaccharide unit on the other side of the 
chain (Mulloy & Forster, 2000), as shown in Figure 1.7. In one of the proposed models 
of heparin-mediated FGF oligomerisation (Pellegrini Et. al., 2000), two FGF-1 
molecules were on the opposite faces of a single heparin chain implicating the 
functional importance of sulphate clusters on either side of the helical conformation 
(Mulloy Et. al., 2005). The solution structure of heparin has been deposited in the 
(a) (b) 
Sulphate groups 
Figure 1.7: Solution structure of Heparin: Solution structure of heparin determined by NMR 
(Mulloy Et. al., 1993) is represented in a space-filled style and was first presented in Mulloy & 
Forster 2000. The iduronates in these heparin hexasaccharides can be seen in (a) 1C4 chair and (b) 
2S0 skew-boat conformations. As seen, heparin adopts a helical conformation and its sulphate 
groups (sulphur atoms coloured yellow and oxygen atoms colored red) align on the opposite faces 





Protein data bank (PDB) under the code 1HPN (Mulloy Et. al., 1993) and has been 
used in the current study of molecular docking to predict the location of heparin binding 
sites in selected cytokines (Chapter 3, Section 3.2.2). On the other hand, there is very 
little information on the three-dimensional structure of HS. Apparently, the NS 
domains of HS may exist in helical conformation of heparin (Khan Et. al., 2013; 
Gallagher, 2015).  
 
1.4 Cytokine - Heparin/HS Binding 
 
As described earlier, that for many cytokines binding to heparin/HS in the ECM or on 
cell-surfaces largely influences their biological activity. This led several research 
groups including Dr. Rider’s group to determine the binding of cytokines to a range of 
acidic polysaccharides representing heparin/HS and other GAGs (Ramsden & Rider, 
1992). Subsequently, our laboratory (Dr. Rider’s group) investigated and characterised 
many immunologically and developmentally significant GAG-binding cytokines such 
as IL-1α, IL-1β (Ramsden & Rider, 1992), IL-2 (Najjam Et. al., 1997a; Najjam Et. al., 
1997b), IL-12 (Hasan Et. al., 1999), IL-6 (Mummery & Rider, 2000), GDNF (Rickard 
Et. al., 2003), Artemin, Neurturin (Alfano Et. al., 2007), β-cellulin (Mummery Et. al., 
2007) and BMP-7 (McClarence, 2011). However, what was interesting to our group 
and many other laboratories with similar studies in the field (Lortat-Jacob Et. al., 1990; 
Tanaka Et. al., 1993), was the observation that cytokines exhibited selective binding 
affinity amongst GAGs. For example, IL-2 was shown to bind heparin, highly 
sulphated HS and fucoidan, a sulphated polysaccharide from brown algae but did not 
bind to CS, DS and HS with low sulphation levels (Ramsden & Rider, 1992; Najjam 
Et. al., 1997a). Similarly, IL-7 bound to heparin/HS and fucoidan, but displayed no 
affinity for CSA, KS or HA (Clarke Et. al., 1995; Zhang Et. al., 2012). Such observed 
variations in the binding profile of each cytokine led to an understanding of the nature 
and specificity in the GAG-cytokine interactions. Apparently, there is some degree of 
structural specificity contributed by each binding partner such as saccharide sequences 
and distinct sulphate groups on GAG chains that are recognised by regions or domains 
composed of basic amino acids on the cytokine (protein) structure. Even today, there 
is a considerable amount of research understanding the nature of protein-heparin/HS 
interactions (Xu & Esko, 2014). Subsequent sections describe the basis of cytokine-




highlights the characteristics of heparin-binding sites/domains (HBS/HBD) on 
cytokines. 
 
1.4.1 Nature of Cytokine-Heparin/HS interaction  
 
As learnt from the structure of heparin/HS in the previous section (Section 1.3.3),  the 
most prominent and common feature of these polysaccharide chains is the density of 
sulphate and carboxylate groups which contributes to the overall negative charge. 
Therefore, these sugar polymers are by nature highly acidic which suggests an 
electrostatic affinity towards proteins rich in basic amino acids. The basic residues that 
mainly contribute towards heparin/HS binding are arginine and lysine (Caldwell Et. 
al., 1996; Fromm Et. al., 1997; Hileman Et. al., 1998). Arginine as a basic residue has 
shown to offer 2.5 times stronger binding compared to lysine on a basis of relative 
affinity for heparin. This is due to additional, non-ionic interactions that support 
binding affinity such as hydrogen bonds formed by the guanidinio group of Arg with 
sulphate groups on heparin/HS (Fromm Et. al., 1995). Consequently, these cytokine-
heparin/HS interactions are largely dominated by simple ionic interactions between 
negatively charged sulphate and carboxylate groups on heparin/HS and the side chains 
of positively charged basic amino acids of cytokines (Fromm Et. al., 1997; Capila & 
Linhardt, 2002). In addition to basic residues, the presence of other polar amino-acids 
with small side chains such as glycine (G), serine (S), or uncharged sidechains like 
asparagine (N) and glutamine (Q) within or around the heparin-binding domains were 
shown to stabilise and further support the interaction with heparin. This was due to the 
formation of additional non-ionic interactions such as hydrogen bonds with the anionic 
groups on heparin/HS that further contributed to the specificity and affinity of binding 
(Hileman Et. al., 1998; Gandhi & Mancera, 2008; Sarkar & Desai, 2015). 
 
Besides the ionic interactions, a significant contribution from the non-ionic bonds in 
the interaction between the proteins and heparin/HS have been noted. Indeed, a 
structural study of AT III in complex with a heparin pentasaccharide showed that ionic 
interactions formed by basic residues contributed only 40% of the binding energy. 
Whereas, the remaining 60% of the binding energy was contributed by non-ionic 
interactions, such as van der Waals forces, hydrogen bonds and hydrophobic 
interactions of basic residue side-chains with the carbohydrate backbone of the 




structures of the complex between a heparin hexasaccharide and FGF-2 have 
demonstrated a significant number of these non-ionic forces that have added to the 
existing specificity and increased the binding affinity between heparin and FGF-2 
(Faham Et. al., 1996; Adage Et. al., 2012). Therefore, even if non-ionic interactions 
play a significant part, the ionic interactions are critical in heparin binding and heparin-
induced protein activity (Hileman Et. al., 1998; Gandhi & Mancera, 2008). 
 
1.4.2 Specificity of the Interactions 
 
While it is clear that the principal interactions are between the basic residues of 
cytokines and highly sulphated acidic polysaccharides, heparin/HS are ionic 
interactions, it is not merely based on overall charge complementation. Specificity is 
predominantly within ionic interactions between particular sulphate and carboxylate 
groups along the heparin chain that imparts negative charges and the arrangement of 
specific basic residues (Lys and Arg) on protein surfaces that confer positive charges 
(Hileman Et. al., 1998, Kreuger Et. al., 2006). Moreover, non-ionic interactions  add 
to specificity and also increases affinity in interactions (Adage Et. al., 2012). Therefore, 
a fully sulphated heparin chain increases the overall anionic charge density but the 
involvement of selective sulpho-groups within an oligosaccharide sequence brings 
specificity to the heparin-cytokine binding (Kreuger Et. al., 2006; Varki Et. al., 2009; 
Kayitmazer Et. al., 2010). For example, the interaction between AT-III and heparin 
occurs with high affinity through a defined pentasaccharide sequence. The key feature 
of the pentasaccharide sequence is a rare 3-O-sulphated glucosamine (Choay Et. al., 
1983). However, the presence of an N-sulphated and 6-O-sulphated glucosamine at the 
centre of the oligosaccharide also influences the affinity (Jin Et. al., 1997; Petitou Et. 
al., 2003; Mosier Et. al., 2012). Similarly, a trisaccharide sequence (GlcNS,6S-
IdoA,2S-GlcNS,6S) containing N-sulphated and 6-O sulphated glucosamines 
intervened by 2-O-sulphated iduronic acid (Maccarana Et. al., 1993) has been 
identified in high affinity interactions of heparin with most FGFs. Within this sequence 
the presence of a 6-O sulpho group on the glucosamine residues are required for direct 
interaction with FGF-1 proteins (Kreuger Et. al., 2001) but are not involved in FGF-2 
binding with heparin (A. Walker Et. al., 1994; Rusnati Et. al., 1994). Rather, FGF-2 
binds to the same N-sulphated sequence with 2- O- sulphated IdoA as the key moiety 
in the interaction (Faham Et. al., 1996). This shows different levels of specificity within 




Raman Et. al., 2005; R. Xu Et. al., 2012). However, it is now widely accepted in the 
field that the association of distinct sulphate groups in the interaction with proteins 
offers the higher degree of specificity rather than the saccharide sequences per se, in 
protein recognition by GAGs (as reviewed in Mizumoto Et. al., 2013; Chiodelli Et. al., 
2015; Meneghetti Et. al., 2015). 
 
From a proteomic side, the specific basic residues involved in the interaction could be 
from the same part of the linear sequence of the primary structure, representing a 
consensus ‘sequence motif’ as found in number of heparin-binding proteins (Cardin & 
Weintraub, 1989). Binding of domains containing linear sequence of basic amino acids 
to heparin/HS chains has been suggested to induce local conformational changes in 
protein that may attract additional basic residues in close contact to anionic groups 
leading to higher affinity and specificity (Cardin & Weintraub, 1989; Raman Et. al., 
2005). Alternatively, a positively charged cluster may be a ‘conformational 
characteristic/site’ that is formed on higher structural folding of protein. Such a 
conformational fold brings in together the basic residues distant in sequence and lead 
to protein-specific binding (Capila & Linhardt, 2002). Thus, the heparin/HS-binding 
domain (HBD) on proteins [as detailed in next section 1.4.3] is an important site with 
a specific arrangement of basic residues that recognises and facilitates best-fit binding 
with specific anionic-groups distributed on heparin chains (Hileman Et. al., 1998; 
Raman Et. al., 2005; Kreuger Et. al., 2006; D. Xu & Esko, 2014; Meneghetti Et. al., 
2015). As seen in Figure 1.8A below, the heparin/HS binding sequence in FGF-2 is 
shown with the key basic residues highlighted. Further in Figure 1.8B are the key 
contacts in the FGF-2-heparin complex. The highlighted section in Figure 1.8B shows 
specific interactions with Lys 125 and Arg 120 as critical residues of the domain. 
Although major interactions are ionic, Asn and Gln residues offer support by forming 



































1.4.3 Identification of Heparin/HS-Binding Sites/Domains (HBSs/HBDs) on 
Cytokines 
 
Studies on various heparin/HS-protein complexes have provided useful insight into the 
features of heparin/HS-binding sites or domains in proteins as recently reviewed in 
(Billings & Pacifici, 2015; Gallagher, 2015). In general, HBSs are interactive sites on 
the surface of proteins, comprising a cluster or group of basic amino acids (mainly 
Arg/Lys)forming a positively-charged surface for binding with negatively-charged, 
sulphate and carboxylate groups of heparin/HS chains. Besides containing a high 
number of basic residues, it is the arrangement of these residues on the protein surface 
and the spacing with non-basic amino acids that constitutes a heparin-binding site or 
























(B) Key basic residues in FGF-2 in contact with heparin/HS sequence 
Figure 1.8: Molecular interaction between FGF-2 and heparin: A) Heparin-binding sequence in 
FGF-2 highlights key basic residues (blue) and polar, uncharged residues (green) involved in heparin 
interactions B) Schematic representation of molecular contacts in FGF-2-heparin complex. Lys 
(K125) and Arg (R120), key basic residues in heparin-binding domain of FGF-2 forms ionic bonds 
with specific anionic groups (carboxylate, sulphate ions) on saccharide sequence of heparin (red). 
In addition to basic residues, Asn (N27, N101), Gln (Q134) support the interaction with hydrogen 





1998; Gandhi & Mancera, 2012). A HBS is recognised as the linear array of basic 
residues in the primary sequence of proteins  called ‘sequence-motifs’. Screening of 
the primary sequence is a useful starting point to reveal basic amino acids close in 
sequence that could be possibly involved in the interaction with GAG chains.  
 
Cardin and Weintraub (Cardin & Weintraub, 1989) were the first to screen a number 
of heparin-binding proteins to identify common structural elements within HBDs. They 
identified the presence of two consensus ‘sequence-motifs’ in the primary sequence of 
more than 20 heparin-binding proteins. These were XBBXBX and XBBBXXBX, 
where B is any basic amino acid and X is any hydropathic amino acid [such as 
hydrophobic and polar-uncharged amino acids, Asn (N), Ser (S), Gly (G), Ala (A), Leu 
(L), Ile (I), Tyr (Y)] (Hileman Et. al., 1998; Gandhi & Mancera, 2008). Since then, 
these motifs in the primary sequence were commonly called Cardin and Weintraub 
motif (CW motif). According to this theory, the basic residues in the CW motif line-up 
along one side on the surface of a secondary structure fold (either a β-strand or α-helix) 
while the hydrophobic residues point towards the protein core.  Such orientation 
enables the basic residues to interact with the sulphate groups on heparin chains. The 
Cardin and Weintraub motif was used as one of the most common search parameters 
among the few other proposed motifs for the initial screening of HBSs/HBDs on 
proteins (Fromm Et. al., 1997; Hileman Et. al., 1998). This has also been useful to 
predict if a protein would possibly interact with heparin/HS.  
 
Nevertheless, the universal acceptance of the outcome from this theoretical approach 
has been challenged by the subsequent advancements in the field, such as site-directed 
mutagenesis. For example, a study on GDNF demonstrated that an N-terminal deletion 
mutant of GDNF which lacks the CW motif, BXBB, still binds to heparin (Alfano Et. 
al., 2007).  Notably, cytokines like IL-4 (Lortat-Jacob Et. al., 1997), IL-8 (Webb Et. 
al., 1993; Kuschert Et. al., 1998), and GM-CSF (Roberts Et. al., 1988) bind to heparin 
even though they lack CW motifs. Additionally, with the increasing number of heparin-
binding proteins being discovered, only a few residues from the consensus sequence-
motif were found to be involved in heparin binding. Although these findings suggest 
that the presence of a Cardin-Weintraub motif in a protein is not essential for heparin 
binding, the presence of one could support the possibility of such an interaction. 




useful in predicting and correlating these consensus motifs to heparin-binding domains 
in proteins, whose three-dimensional structure is not known. 
 
Clusters of basic residues that are easily evident from the primary sequence of protein 
are called continuous heparin-binding sites. Whereas, those clusters that are formed by 
the distant basic residues brought together in a three-dimensional protein folding 
constitute discontinuous heparin-binding sites (Mulloy & Rider, 2006), also referred as 
conformational domains/sites (Gallagher, 2015). Therefore, a HBS does not always 
comprise of basic amino acids in a linear sequence, rather basic amino acids from 
different secondary structural elements of a protein can come close together on higher 
conformational folding (R. Xu Et. al., 2012; Capila & Linhardt, 2002). For example, 
FGF-2 contains a HBS comprised of basic residues K26, N27, R81, K119, R120, T121, 
Q123, K125, K129, Q134, and K135 (Figure 1.8). These residues exhibit close spatial 
proximity but are not close in primary sequence (L. D. Thompson Et. al., 1994; R. Xu 
Et. al., 2012). Multiple studies of heparin-protein complexes using structural analytical 
techniques, such as X-ray crystallography (Mulloy and Linhardt 2001), NMR 
(Kuschert Et. al., 1998), and molecular modelling (Lortat-Jacob Et. al., 2002; Mulloy 
& Forster, 2008) also support this concept.  
 
A typical heparin-binding domain/site consists of 4-6 basic residues in a single cluster 
within the linear arrangement of amino acids, or on the surface of a higher order of a 
structurally folded protein (Hileman Et. al., 1998). Moreover, heparin being a helical 
structure with relatively rigid and bulky groups  section 1.3.3) (Mulloy Et. al., 1993), 
means heparin chains cannot access clefts and folds within protein structures. 
Consequently, the cluster of basic amino acids must be exposed prominently onto the 
protein surfaces for interaction with heparin chains. Such a cluster on proteins typically 
forms surface structures such as shallow groove or cavity with a specific arrangement 
of surface basic residues (Rullo & Nitz, 2010). Additionally, analysis of a number of 
co-crystal structures of protein-heparin complexes have shown that the basic residues 
comprising a HBD were suitably spaced and oriented to match the pattern of sulphate 
groups along the heparin/HS chain (Raman Et. al., 2005; Sasisekharan Et. al., 2006). 
Supporting this, heparin was shown to induce α-helical structures in polylysine 
peptides such that the periodicity of sulphate clusters on one side of the heparin chain 
approximately matched the periodic turns on the α-helix, allowing ionic interactions 




of basic residue clusters and their accessibility to GAG-heparin/HS chains on protein 
surfaces are important factors in determining heparin-binding ability and sites on 
proteins. 
 
Overall, with the knowledge and understanding of specific structural features on 
heparin/HS for binding to a particular cytokine, novel therapeutic agents, such as 
modified oligosaccharides or heparin mimetics as competitive inhibitors are generated 
for medical intervention in the cytokine network of inflammatory diseases (Casu Et. 
al., 2010; Mohamed & Coombe, 2017) including cancer (Peysselon & Ricard-Blum, 
2014; Chiodelli Et. al., 2015; Weiss Et. al., 2017). Synthetic GAG analogs such as 
commercially available short carbohydrate chains or molecules charged with acidic 
groups that lacked the anti-coagulant activity of heparin were shown to exhibit anti-
inflammatory effects in vitro as well as in vivo in disease-specific models of 
inflammation (Severin Et. al., 2012). Thus, various strategies exploit the potential of 
heparin/HS as anti-inflammatory agents with its reduced or eliminated anti-thrombotic 
property (Rek Et. al., 2009).  A non-sulphated K5 polysaccharide derived from E. Coli 
has shown anti-viral activity (Rusnati Et. al., 2009). Heparin/HS mimetics such as PI-
88, PG-545 to block cancer growth metastasis are currently in clinical trials (Liu Et. 
al., 2014).   
 
Identification of heparin-binding sites on cytokines can be used in synthesizing anti-
inflammatory, mutant cytokines that are devoid of any affinity for GAGs. Such 
chemokine variants of MIP-1β and RANTES have been used in in vivo studies. These 
variants failed to exhibit their biological functions of recruiting cells compared to the 
wild type (WT) counterparts (Martin Et. al., 2001), suggesting an important role of 
heparin/HS in chemokine function directing cell migration. Heparin/HS binding is 
required to maintain local concentrations of chemokines for attracting leukocytes and 
to induce oligomerisation for chemotactic activity (Proudfoot Et. al., 2003). When a 
mutant to chemokine-RANTES, 44AANA47-RANTES was injected intraperitoneally, it 
was effective in antagonising cell recruitment compared to its WT in three murine 
models of inflammation such as Experimental Allergic Encephalomyelitis (EAE) and 
liver fibrosis (Johnson Et. al., 2004). Thus, cytokine-heparin interactions provide 
insight into potential advantages in the development of novel cytokine mutants for 
therapeutic intervention. Recent focus in the field has been in engineering chemokine-




G-Protein Coupled Receptor (GPCR)-binding affinity (Adage Et. al., 2012; Gerlza Et. 
al., 2015). As a result, these variants in preclinical models were shown to displace WT 
chemokines in binding GAGs but are unable to activate leukocytes. Overall, this 
reduces cellular trafficking in an inflammatory response and hence controls 
inflammation-associated tissue damage. Currently this approach is in clinical 
development as CellJammer® technology (Adage Et. al., 2012; Adage Et. al., 2015).  
Such chemokine variants have shown potential in preventing infection like CCL-5 
based decoy proteins are engineered as potential HIV entry inhibitors (Kufareva Et. al., 
2015) and CCL-2 decoy proteins in blocking tumour metastasis (Roblek Et. al., 2016).  
 
1.5 Cytokine Candidates for Heparin/HS Binding Studies 
 
Cytokines belonging to a particular family or subfamily show remarkable structure-
function relationship (Rozwarski Et. al., 1994). Even though, members of a particular 
family show low amino acid sequence homology, they exhibit similar topology in their 
three-dimensional or tertiary structures (Bazan, 1990). As part of functional similarity, 
family members bind to homologous receptors (Bazan, 1990; Sprang & Bazan, 1993). 
It is interesting to raise a question here, whether a heparin-binding property is common 
among cytokines that share structural relationship with their family members known to 
bind heparin/HS. For example, the chemokines, a large family of chemoattractant 
cytokines, contain about 50 members within four sub-families and all act via GPCR (G-
protein-coupled transmembrane receptors) for signaling (Rossi & Zlotnik, 2000; Lortat-
Jacob Et. al., 2002; Bachelerie Et. al., 2014). These members have relatively low 
sequence similarity, but they possess similar tertiary structures with the same 
monomeric folds (Schwarz & Wells, 1999; Lortat-Jacob Et. al., 2002). Their receptor 
binding shows cross-reactivity, in that a single receptor can be recognized by many 
chemokines and vice versa (Rossi & Zlotnik, 2000; Proudfoot, 2002). Interestingly, the 
majority of chemokines bind to heparin/HS in vitro (Hoogewerf Et. al., 1997) and in 
vivo (Proudfoot Et. al., 2003) and these GAGs are required for the biological function 
of chemokines in vivo (Proudfoot, 2006; Kufareva Et. al., 2015; Proudfoot Et. al., 
2017).  
 
Similarly, a quarter of members of the TGF (Transforming Growth Factor)-β 
superfamily are known to bind heparin/HS (Mulloy & Rider, 2006). GFLs (GDNF 




belonging to the TGF-β superfamily. These cytokines exhibit a characteristic, 
conserved cysteine-knot structure that results in shared tertiary structural fold in them. 
(C. C. Rider, 2006; Rider & Mulloy, 2010). Most members of the GFL subfamily, like 
GDNF (glial-cell-line-derived neurotrophic factor), artemin and neurturin are sequence 
homologues and possess heparin-binding activity (Rickard Et. al., 2003; Alfano Et. al., 
2007). In this context, heparin/HS binding is a widespread property among BMPs 
(BMP-2, -4, -7) and their protein antagonists such as follistatin, gremlin, noggin (Rider 
& Mulloy, 2010; McClarence, 2011; Gandhi & Mancera, 2012). Therefore, one can 
observe that many, if not all, members of a cytokine family/subfamily possess heparin-
binding property.  
 
This brings us to the first goal of this thesis (chapter 3) that investigates whether the 
three selected interleukins, IL-11, IL-18 and IL-22, bind to heparin/HS. These 
interleukins are thus far to be tested for their heparin-binding property and they share 
structural relationship with the respective heparin-binding members of the IL family. 
This will also provide an important insight about the extent of heparin-binding activity 
within the IL family. As described below, each of these three interleukins are key 
candidates for study because they possess basic residue clusters or sequences which are 
characteristic of heparin-binding domains. Besides, these interleukins play a central 
role in various immune responses and have significant therapeutic potential in diseases; 
therefore, it becomes highly relevant to investigate their ability to bind heparin/HS. 
Since binding to heparin/HS modulates the biological activities of cytokines, even non-
binding characteristics would draw attention to their physiological role. Thus, this 
investigation will provide a valuable insight into cytokine-heparin/HS interactions in 
the activation and regulation of immune responses. Further, as these interleukins share 
cytokine-family relationships, findings from this study would highlight differences in 
the functional implications of heparin binding within the same cytokine family. With 
regards to therapeutic application, as most recombinant interleukins have been limited 
by toxicity associated with systemic administration, investigating heparin-binding 
properties or lack thereof, may enable to the reduction of undesirable side-effects by 
supporting a localised mode of cytokine delivery and paracrine activity. Subsequent 
subsections introduce these interleukins, IL-11, IL-18 and IL-22 in more depth with 
respect to their biological importance and structural features, as compared to their 







Interleukin-11 (IL-11) is a stromal cell-derived, haemopoietic cytokine (Paul Et. al., 
1990). It has strong lymphopoietic activity and acts alone or synergistically with other 
growth factors such as IL-3, GM-CSF to regulate multiple events in the development of 
myeloid and lymphoid cell lineages (Du & Williams, 1997). Importantly, IL-11 
stimulates platelet production and therefore, rHuIL-11 is commercially available as 
‘oprelvekin’ from Neumega ® for therapeutic use in the prevention of chemotherapy-
induced or bone marrow failure-associated thrombocytopenia (Demetri, 2000). 
Moreover, clinical studies have successfully demonstrated IL-11 as an effective agent 
for improving the recovery of platelet levels and reducing the need for platelet 
transfusion after myelo-suppressive cancer chemotherapy (Bhatia Et. al., 2007). In 
addition to the role of IL-11 in cancer care, this soluble factor has gained attention as a 
systemic biomarker for various inflammation-inducing pathological stimuli 
(Negahdaripour Et. al., 2016). Indeed, recent evidence showed elevated expression of 
IL-11 with its central role in linking chronic inflammation of gastric epithelia to 
gastrointestinal cancers in humans (Putoczki & Ernst, 2010; Putoczki Et. al., 2013). 
Further findings of the emerging role of IL-11 in breast cancer and tumour progression 
has very recently been reviewed in Johnstone Et. al., (2015). Other non-haematopoietic 
functions of IL-11 include osteopoietic activity which regulates osteoclast development 
and bone metabolism (Sims Et. al., 2005). Biologically, IL-11 downregulates IL-12 
production by macrophages (Leng & Elias, 1997), and thereby modulates NK cell and 
T cell mediated inflammatory cytokine production and Th1 immune responses, 
suggesting a possible therapeutic role in bone marrow transplantation (Hill Et. al., 1998; 
Bozza Et. al., 2001). Knowing these biological and clinical implications of IL-11 
(Negahdaripour Et. al., 2016), it is potentially an interesting candidate to assess for it’s 
heparin-binding properties. The binding of IL-11 with ECM or cell-surface HS-GAGs 
may be an underlying mechanism controlling its important bioactivities.  
 
Structurally, IL-11 is a member of a family of long-chain cytokines within a superfamily 
of four α-helical cytokines (Nichola N. A. 1994). Six cytokines including IL-11, IL-6, 
leukaemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor 
(CNTF) and cardiotropin-1 (CT-1) use a common receptor-subunit, glycoprotein (gp)-
130 for signal transduction. Therefore, this group is called the gp-130 receptor family 




cytokines share biological activities due to overlapping signal transduction pathway that 
recruit and subsequently lead to homo/heterodimerisation of gp-130 (Kishimoto Et. al., 
1994; Dahmen Et. al., 1998). Many of the biological effects described above for IL-
11overlap with those of IL-6 (Musashi Et. al., 1991; Barton Et. al., 2000; Matadeen Et. 
al., 2007; Negahdaripour Et. al., 2016), which is a known heparin-binding cytokine 
(Mummery & Rider, 2000). Moreover, a secreted human IL-11 is a 178-amino acid 
polypeptide. Notably, the primary sequence of IL-11 contains 20 basic residues 
including a cluster containing four basic residues within an eight-residue sequence. 
Indeed, the arrangement of basic residues within this sequence closely resembles a 
classic Cardin-Weintraub motif. Collectively, this shows a good probability for 
interaction of IL-11 with polyanionic heparin/HS chains. Therefore, this led us to 
hypothesise that heparin-binding may be a common property in the gp-130 receptor-
cytokine family. To test this hypothesis, IL-11 was selected as one of the candidates 
from the respective family to study possible binding to heparin. 
 
1.5.2 Interleukin-18  
 
Interleukin-18 (IL-18) is a pro-inflammatory cytokine produced by monocytes and 
macrophages against microbial infections (Gracie Et. al., 2003). IL-18 was formerly 
called IFN-γ inducing factor (IGIF) and is associated with severe inflammatory 
conditions like sepsis and autoimmune diseases [as recently reviewed in (Dinarello Et. 
al., 2013)]. Therefore, IL-18 has shown to be a valid clinical target to combat the 
pathological consequences of sepsis via IFN-γ (Dinarello & Fantuzzi, 2003; Dinarello, 
2007b). Biologically, IL-18 alone or synergistically with IL-12, functions to activate T 
and NK cells to produce IFN-γ, stimulates Fas-mediated NK cell cytotoxicity, and 
regulates the development of Th1 cells (Okamura Et. al., 1995; Dinarello, 1999). 
Administration of recombinant IL-18 has been reported to have antitumour activity in 
murine models (Micallef Et. al., 1997). IL-18 has gained recent attention as a key 
cytokine in patients with metabolic diseases like type-1 (Harms Et. al., 2015) and type-
2 diabetes mellitus (Troseid Et. al., 2010). Interestingly, high circulating levels of IL-
18 in metabolic syndrome has been suggested to be central to atherosclerotic lesions 
and other inflammatory pathogenic effects (as reviewed in Troseid Et. al., 2010). Given 
the functional importance of IL-18, determining a heparin-binding activity in IL-18 may 





Structurally, IL-18 belongs to the IL-1-like β-trefoil cytokine family based on 
similarities at several levels (Dinarello, 2002; Kato Et. al., 2003; Kato Et. al., 2014).  
With the IL-1 family member, IL-1β, a heparin-binding cytokine (Ramsden & Rider, 
1992), IL-18 shares the cleavage enzyme site for caspase-1 or IL-1β converting enzyme 
(ICE) to process proIL-18 into a mature and biologically active form (Bazan Et. al., 
1996). Receptors for IL-18 belong to the IL-1 receptor family and connect signal 
transduction pathways by recruiting a similar downstream component, NF-kB (Parnet 
Et. al., 1996). At the three-dimensional structural level, IL-18 exhibits a β-trefoil 
structural fold which comprises of twelve β-strands arranged to form three anti-parallel 
four-stranded β-sheets, set in a triangular fashion to form a pyramid–like structure (Kato 
Et. al., 2003). This β-trefoil structure is a signature feature to those of IL-1 and FGF 
family members (Murzin Et. al., 1992). It has been observed that the topological 
positions of primary receptor sites for IL-1β and FGF-2 are super-imposable (Kato Et. 
al., 2003). Hence, IL-18 also extends similarity in its three-dimensional structural 
scaffold with FGF family members. IL-18 is a protein enriched in basic amino acids 
with a cluster near the carboxyl-terminal, encompassing β strands β10-β11 and their 
connecting loop. This region, between β strands, β10-β12 near the carboxyl-terminus is 
of particular significance, as it conforms to a heparin-binding domain in FGFs (Faham 
Et. al., 1998; Ornitz & Itoh, 2001a). The FGF family presently contains 22 members 
and each member exhibits a β-trefoil structural fold (Ornitz & Itoh, 2001a; Asada Et. 
al., 2009).  Despite differences in their amino acid sequences, these FGF members 
exhibit an identifiable, although varying, degree of heparin-binding activity (Raman Et. 
al., 2003; Asada Et. al., 2009). On a structural basis, it raises the possibility that IL-18 
also shares this property with FGF proteins, a family of well-characterised heparin-
binding cytokines. In this context, GAGs like heparin/HS may restrict the diffusion of 
IL-18 when secreted, favoring a paracrine rather than endocrine effect and may further 




Interleukin-22 (IL-22) is an inflammatory cytokine secreted by IL-9 stimulated mast 
cells and activated T and NK cells (Dumoutier Et. al., 2000a; Witte Et. al., 2010). An 
interesting aspect of this cytokine is that it is secreted by immune cells, but the activity 
is mainly targeted to non-immune cells, especially hepatocytes, keratinocytes and 




phase proteins (Wolk Et. al., 2004; Wolk & Sabat, 2006a; Zenewicz & Flavell, 2011). 
Clinical studies suggest the role of IL-22 is critical in mucosal immunity of the lung 
and gut (Aujla Et. al., 2008; Zheng Et. al., 2008). Although IL-22 has important 
physiological effects in local tissue damage and repair through proliferation, survival 
and regeneration of epithelial cells (Sabat Et. al., 2014), these same effects of the 
cytokine were recently implicated in pathological inflammation such as cancer (Lim & 
Savan, 2014) and autoimmune diseases (Pan Et. al., 2013). Elevated levels of IL-22 
were detected in psoriasis, a human autoimmune disease of the skin (Lowes Et. al., 
2007; Ma Et. al., 2008). IL-22 induces hyper-proliferation and induction of 
inflammatory proteins in skin keratinocytes resulting in characteristic psoriatic lesions 
(Boniface Et. al., 2005) and recruitment of immune cells to the sites of psoriatic 
inflamed tissue (Wolk Et. al., 2006b). As heparin/HS is a key regulator of most 
biological processes including cell proliferation, inflammation (D. Xu & Esko, 2014; 
Esko Et. al., 2009), it will be interesting to know whether IL-22 binds to these 
ubiquitous GAGs and whether this association is required to exert its biological effects. 
 
Given the influence of IL-22 in host defense and disease conditions, it is an attractive 
target for clinical development (Dudakov Et. al., 2015). Moreover, continued interest 
in IL-22 has set this cytokine as a well-studied example among the members of the IL-
10 family of cytokines. Structurally, IL-22 is α-helical cytokine member of the 
interferon-like/IL-10 family, along with IFN-α, -β, -γ, IL-10 and IL-19 as other 
members (Pestka Et. al., 2004; Trivella Et. al., 2010). IL-22 shares 22% amino acid 
sequence identity, and conservation of the first three of four cysteine residues with its 
structural homolog, IL-10 (Dumoutier Et. al., 2000b). Despite low sequence homology, 
IL-22 shares a strong secondary structural homology with IL-10 that contains six α-
helices in each monomeric domain of a dimer (Nagem Et. al., 2002; T. Xu Et. al., 
2005). Moreover, most of the conserved residues between IL-22 and IL-10 are located 
in the carboxyl-terminal domain of the protein. This domain has been found to be 
critical for IL-10 activity that suggests IL-22 and IL-10 may share common or related 
biological activities (Nagem Et. al., 2002). IL-22 exhibits overlapping but distinct 
signalling pathways to IL-10 (Moore Et. al., 2001). The biological activity of IL-22 is 
initiated by binding to heterodimeric cell surface receptor subunits, IL-22R1 and IL-
10R2, a shared component of IL-10 signalling. However, IL-22R1 defines the action 
of IL-22 signal transduction in cells (Bleicher Et. al., 2008; Jones Et. al., 2008a). Both 




homology to the receptors of IFN-γ, which functions as an inflammatory cytokine 
(Langer Et. al., 2004). Interestingly, IL-22 also shares significant structural similarities 
to IFN-γ, a helical cytokine, like IL-10 (Nagem Et. al., 2002). Both IL-10 (Salek-
Ardakani Et. al., 2000; Kunze Et. al., 2014; Kunze Et. al., 2016; Gehrcke & Pisabarro, 
2015) and IFN-γ (Lortat-Jacob Et. al., 1991b; Saesen Et. al., 2013) are known heparin-
binding cytokines. Additionally, the carboxyl-terminus of human IL-22 features a 
cluster of four basic residues within eight residue sequence which resembles the 
heparin-binding, carboxyl-terminal peptide of IL-10 and IFN-γ. This increases the 
likelihood of IL-22 binding to heparin/HS. Thus, a structure-function relationship with 
these two heparin-binding cytokines makes IL-22 an appropriate candidate for the 
current study. 
 
1.6 Regulation of Interleukin (IL)-12 Induced IFN-γ production in NK 
cells 
 
As mentioned at the outset of this chapter (Section 1.1), the second aspect of this thesis 
deals with the regulation of IL-12-signalled IFN-γ production in NK cells. NK cells are 
one of the critical players of innate immunity and IL-12 plays a key role in the initial 
activation of NK cells, thereby, in the production of innate IFN-γ (Zwirner Et. al., 2010; 
Marcais Et. al., 2013). NK cell-derived IFN-γ is important in the cross-talk between 
innate and adaptive immunity (Vivier Et. al., 2008). For instance, during viral 
infections such as CMV, DCs secrete chemokines and cytokines such as IL-12, which 
in turn activates NK cells to produce IFN-γ. Chemokines secreted were shown to recruit 
peripheral NK cells to the T-cell rich zones of lymph nodes to provide an early source 
of IFN-γ, essential for priming antigen-specific, CD4+ T cells and Th1 cell-polarisation 
(Martin-Fontecha Et. al., 2004). Supporting this, more recent studies clearly highlight 
that IFN-γ production by NK cells regulates susceptibility to infections (Fodil Et. al., 
2014; Freeman & Hill, 2015) and tumour development (Morvan & Lanier, 2016). This 
thesis, therefore, addresses the IFN-γ producing pathway in NK cells in response to IL-
12 stimuli. Although such pro-inflammatory functions of IL-12 in IFN-γ production 
are well characterised and essential for innate immunity (Hamza Et. al., 2010; Vignali 
& Kuchroo, 2012), if left uncontrolled, the physiological response may lead to 
induction of autoimmunity or inflammatory shock due to overproduction of IFN-γ (S. 
K. Lee Et. al., 2012; Lees, 2015). Given the critical role of IFN-γ in mediating NK cell 




between resolution of inflammation/infections versus immunopathology. Hence, the 
current study explores the role of two factors, (i) GAGs, in particular cell surface-DS 
(Chapter 4) and (ii) the anti-inflammatory cytokine, TGF-β1 (Chapter 5) in regulating 
IL-12 stimulated IFN-γ production in NK cells. Subsequent subsections introduce NK 
cells, IL-12 signalling and IFN-γ production. 
 
1.6.1 Natural Killer (NK) Cells 
 
NK cells are effector lymphocytes of non-specific, innate immunity that kill target cells 
including tumours and pathogen-infected cells (bacteria, viruses or protozoans), 
without prior immunization or exposure to foreign antigens (Vivier Et. al., 2008; 
Morvan & Lanier Et. al., 2016). They are large, granular lymphocytes, comprising 10-
15% of peripheral blood lymphocytes and are also present in the spleen and bone 
marrow (Trinchieri, 1989). The importance of NK cells in the innate system is 
illustrated by rare human diseases in which NK cells are absent, defective or 
dysfunctional. Inspite of other active innate and adaptive immune components, NK cell 
deficiency is clinically manifested by frequent and severe infections and susceptibility 
to tumour development (Orange Et. al., 2013). NK cells are attractive clinical targets 
due to their cytolytic and cytokine-producing capability. In recent years, NK cells have 
been gaining attention for their potential in cancer immunotherapies (Morvan & Lanier, 
2016). Adoptive transfer of genetically engineered NK cells to ex vivo cultivation of 
NK cells in priming against tumour cell killing are attractive strategies in cancer 
treatment (Rezvani & Rouce, 2015; Granzin Et. al., 2017). Based on these advances, a 
greater mechanistic understanding of NK cell responses is required to devise rational 
therapeutic strategies in the fight against infections, malignant transformation and 
autoimmunity. 
 
NK cells function in innate immunity through two ways, target-cell killing and 
production of cytokines. To enable a prompt and an efficient innate response, NK cells 
express multiple activation molecules and receptors on their surface to recognise 
potential target cells (Smith Et. al., 2000). Unlike T and B cells, NK cell receptors are 
not specific surface membrane TCR or immunoglobulin receptors. Indeed, they 
recognize the presence of altered MHC class I molecules on host cells which is a 
common consequence of viral infection or tumour transformation. Such an effector 




lymphocytes, importantly, T cells (Trinchieri, 1989; Vivier Et. al., 2008). Thus, NK 
cells play a crucial role in immune surveillance and thereby innate anti-tumour immune 
responses. 
 
NK cell activity is primarily triggered by cytokines such as interleukin-2 (IL-2), 
interleukin-12 (IL-12) (Trinchieri, 1998a) and IL-18 (Lauwerys Et. al., 1999; W. 
Walker Et. al., 1999) which are secreted by phagocytes or APCs in the early phases of 
infection (Borg Et. al., 2004; Marcais Et. al., 2013). Once activated, NK cells display 
spontaneous cytotoxic activity and rapidly secrete large amounts of chemokines, 
inflammatory cytokines-the most important of which is IFN-γ (Parihar Et. al., 2002). 
This NK cell-produced IFN-γ is vital to the early control of microbial invasion before 
the involvement of T cells that are significant to adaptive cell-mediated immunity. In 
vivo studies support this, as SCID mice that lack mature T and B cells exhibit resistance 
to infections (Gazzinelli Et. al., 1993; Tripp Et. al., 1994), whereas, mice deficient in 
IFN-γ, or its receptor, showed increased susceptibility to a variety of pathogens, 
infections and tumour development (Schroder Et. al., 2004). NK cell-produced IFN-γ 
has multiple biological effects (detailed in next section 1.6.2) that further aides in 
immune surveillance. Moreover, NK cell-derived IFN-γ amplifies the innate cycle of 
NK cell activation and shapes the development of subsequent and specific adaptive 
immune responses for the long-term control of pathogens or transformed cells (Moretta 
Et. al., 2008; Cooper, Elliott Et. al., 2009). For instance, NK cell activation on 
encounter with MHC class I low tumour cells was shown to stimulate DCs to produce 
IL-12. This was shown to further augment induction of CD8+ T cell responses, however 
this T cell response was influenced by NK cell-produced IFN-γ which promoted Ag-
processing and presentation by DCs activating CD8+ T cells (Mocikat Et. al., 2003). 
Thus, manipulation of NK cell activity by using cytokines is an important strategy in 
clinical settings against adaptive immune disorders such as graft transplants, 
autoimmune diseases and AIDS (Acquired Immuno Deficiency Syndrome) (Zwirner 
Et. al., 2010, Morvan & Lanier, 2016). 
 
Research work presented here employs a murine NK cell line, KY-1 (Karlhofer Et. al., 
1995), for experimental observations. KY-1 cells are more advantageous compared to 
primary NK cultures, as they provide an unlimited source of cells for mechanistic study 
and are endowed with stable or normal expression of cytokines upon activation. Studies 




associated with studies on freshly isolated primary cultures (Karlhofer Et. al., 1995). 
All these characteristics render the KY-1 cell lines as very useful for mechanistic 
studies on cytokine signalling and regulation in NK cells (Garnier Et. al., 2003). 
 
1.6.2 IL-12 Signalled IFN-γ Production 
 
IL-12 was first referred to as a natural killer cell stimulatory factor (NKSF) due to its 
ability to induce proliferation, cytotoxicity and IFN-γ production in NK cells from a 
culture of PBMCs (peripheral blood mononuclear cells) (Kobayashi Et. al., 1989). 
Structurally, IL-12 is a heterodimer of 70kDa with subunits of 35kDa and 40kDa linked 
by two disulphide linkages (Podlaski Et. al., 1992; Yuzhalin & Kutikhin, 2012). It is 
produced as a pro-inflammatory cytokine by APCs and phagocytic cells which includes 
macrophages, DCs and B cells, within hours of host invasion by microbial pathogens, 
viral infections (Chehimi & Trinchieri, 1994). The major physiological role of IL-12 is 
activation of NK cells and T cells to produce IFN-γ which is a central mediator of most 
IL-12-induced responses, as shown in Figure 1.9 (Hamza Et. al., 2010; Vignali & 
Kuchroo, 2012). NK cells are most likely the first target cells by IL-12 to produce IFN-
γ. An interesting microscopic study has shown temporal and spatial correlation between 
IL-12 production by DCs and IFN-γ production by NK cells in response to Listeria 
monocytogenes (LM) infection (Kang Et. al., 2008) indicating IL-12 leads to crosstalk 
between DCs and NK cells stimulating innate responses. Moreover, in eliciting the 
production of IFN-γ, IL-12 is also known to synergise with a variety of cytokines like 
IL-2 (Wang Et. al., 2000), IL-15 (Ni Et. al., 2012) and IL-18 (Haeberlein Et. al., 2010). 
In turn, IFN-γ further potentiates the activity of phagocytic cells in terms of microbial 
killing and stimulates more production of IL-12. Importantly, IL-12 and IFN-γ forms a 
positive feedback loop that represents the innate response to intracellular pathogens 





































Importantly, IL-12 is a key cytokine in polarizing T cells into IFN-γ secreting, T helper 
1 (Th1) subsets (Mosmann & Coffman, 1989; J. Zhu & Paul, 2010), as illustrated in 
Figure 1.10. In contrast to NK cells, resting CD4+ T cells do not express IL-12Rs. These 
naive CD4+ T cells are activated via engagement of TCR with antigen-MHC II 
complexes presented by APC and co-stimulatory signals. Activation leads to 
production of the cytokines, IL-2 and TNF-α that initiate the expression of the IL-12R 
on CD4+ T cells. IL-12 secreted by DCs initiates differentiation of naive CD4+ T cells 
and directs them to develop into Th1 cells, which in turn, secrete IFN-γ. Together with 
IFN-γ, IL-12 further drives the balance between Th1 and Th2 cells towards the Th1 
phenotype, also called cell-mediated immunity. Moreover, IL-12 alone can directly 
prime already differentiated, Ag-specific Th1 cells, independent of a TCR mechanism. 
Figure 1.9: Biological role of IL-12 showing link between innate and adaptive immunity via 
IFN-γ: IL-12 produced by  phagocytic innate cells such as macrophages, DCs and neutrophils in 
response to pathogens (bacteria, fungi, parasites and viruses) stimulates cytotoxicity and IFN-γ 
production of NK cells. This initial source of IFN-γ, firstly serves to positively amplify IL-12 
secretion and the local inflammatory response to evade pathogens. Secondly,  IFN-γ influences 
development of Th1 adaptive immunity initiated by IL-12 and indirectly inhibits Th2 or humoral 
immunity. Via TCR, IL-12 can directly and indirectly augment antigen specific adaptive immunity 
through generation of CTLs from naive CD8+ T cells, and differentiation of naive CD4+ T cells 
into IFN-γ secreting Th1 cells, together representing cell-mediated immunity. IL-12 offers 
resistance to infection, eradication of intracellular pathogens, and anti-tumour activity using both 
innate and adaptive mechanisms. Figure modified from (Romani, 1997; Szabo Et. al., 2003; Lasek 




















IL-12 can also stimulate development of IFN-γ-producing Th1 cells from resting 
memory T cells. Hence, IL-12 plays an essential role in bridging early non-specific, 
innate immunity and subsequent Ag-specific adaptive immunity via IFN-γ secretion 























On the other hand, differentiation of naive CD4+ T cells in the presence of IL-4 results 
in Th2 effector cells which secrete a different profile of cytokines, consisting of IL-4, 
IL-5, IL-10, and IL-13 as shown in Figure 1.10. These Th2 cytokines are vital in 
allergic responses and help in the activation of B cells. This drives the immune response 
toward Th2-type immunity, also called humoral immunity (Ab-dependent immunity), 
which provides protection against extracellular pathogens, such as parasites (including 
helminths) and allergens. There is reciprocal inhibition of Th1 and Th2 pathways by 
cytokines secreted by each cell lineage. Specifically, IL-12 and IFN-γ blocks the 




























Figure 1.10: T helper cell differentiation: Cytokines are major inducers of T helper cell 
differentiation. IL-12 is an essential cytokine in the differentiation of naive CD4+ T cells into IFN-γ 
secreting Th1 cells. IL-12 plays a central role in the initiation of cell-mediated immunity (Th1 
development) involved in resistance to intracellular infections and further helps in the inhibition of 
humoral immunity (Th2 cells) against allergic reactions. TGF-β1 is an immunosuppressive cytokine 
secreted by another subset of Th cells called Tregs or Th3 cells and this regulates development of 




of IFN-γ and hence, inhibit the development of cell-mediated immune responses by 
Th1 cells. Besides IL-10 (F. Ma Et. al., 2015), TGF-β is another anti-inflammatory 
cytokine that negatively regulates IL-12 production and activity (M. O. Li Et. al., 
2006). In contrast to suppressing Th1 immunity, TGF-β promotes the development of 
regulatory T cells (Tregs), Th17 cells and other Th subsets that controls pro-
inflammatory reactions following clearance of infection, thus maintaining immune 
homeostasis and tolerance (Sanjabi Et. al., 2017).   
 
Secretion of IFN-γ is indicative of the commitment to Th1 immunity. Although T cells 
are a major source of IFN-γ during infection, they require clonal expansion, 
differentiation into effector cells and they migrate to site of infection that takes several 
days to develop. Such Ag-specific IFN-γ production occurs over the course of time as 
part of an adaptive immune response. In contrast, activated NK cells secrete IFN-γ 
within hours of infection or cytokine stimulation (Cerwenka & Lanier, 2001; Stetson 
Et. al., 2003). This innate source of IFN-γ in vivo, is a critical event during the early 
immune response whereas, IFN-γ produced from activated T cells in adaptive 
immunity is a secondary signal to boost the innate positive feedback loop of IL-12 
production through activation of macrophages (Frucht Et. al., 2001). Overall, this also 
forms the basis of the mechanism by which IL-12 acts as a potent vaccine adjuvant and 
activates several components of  innate and adaptive immunity to play a role against 
infections (Wright Et. al., 2008). Thus, the biology of IL-12 has been exploited in 
various therapeutic forms to stimulate cell-mediated immunity and a stable Th1 
response in various disease settings including cancer (Tugues Et. al., 2015) and Th2 
disorders such as allergy or asthma (O'Garra & Murphy, 1996; Peterson Et. al., 2003). 
Most IL-12-mediated anti-tumour effects have been shown to be dependent on IFN-γ 
production and its effector functions (Hess Et. al., 2003). IL-12 gene therapy in mice 
was shown to inhibit liver metastasis of colon cancer cells. Moreover, this anti-
metastatic effect of IL-12 mainly relied on NK cell activation and IFN-γ production 
(Uemura Et. al., 2010). The therapeutic potential of IL-12 has been extensively 
investigated in the field of clinical oncology and is currently a focus of interest as an 
immunotherapeutic agent (Lasek Et. al., 2014; Tugues Et. al., 2015).  
 
IFN-γ, once produced modulates immune responses. Besides supporting Th1 
differentiation, functions of IFN-γ includes activation of macrophages to secrete 




microbes. IFN-γ is also directly involved in the expression of antiviral enzymes. It also 
promotes anti-tumour responses by increasing the expression of MHC class I molecules 
that aid in tumour surveillance and control (Dalton Et. al., 1993; Agnello Et. al., 2003; 
Schoenborn & Wilson, 2007). Collectively, IFN-γ favors the development of innate 
cell-mediated immune response as well as adaptive immunity. Based on these 
pleiotrophic effects of IFN-γ on various immune cells, this cytokine has been a useful 
therapeutic agent [as reviewed in (Miller Et. al., 2009)]. 
 
Whilst the positive regulation of IL-12-induced IFN-γ production is advantageous, 
negative regulation is equally essential. In the case of overexpression of IFN-γ, 
destructive, or even lethal, inflammatory responses occur (Carson Et. al., 2000). Excess 
IFN-γ has also been implicated in chronic inflammatory conditions and autoimmune 
diseases, such as insulin-dependent diabetes, multiple sclerosis, and systemic lupus 
erythematosus (SLE) (Schroder Et. al., 2004; Lees, 2015). Also, IFN-γ increased 
lymphocyte recruitment generates secretion of more pro-inflammatory cytokines and 
such prolonged activation damages the inflammed tissues. Therefore, such a role of 
IFN-γ has been clinical target for therapeutic antibodies such as HuZaf and AMG811, 
as reviewed in (Miller Et. al., 2009). Hence, understanding the molecular mechanisms 
that control IFN-γ production is of fundamental importance. In the following 
subsection, JAK-STAT pathway in IL-12 signalled IFN-γ production is described. 
 
1.6.3 IL-12 Signalling via JAK-STAT Pathway 
 
In the process of induction of IFN-γ, IL-12 signals through binding to its specific cell-
surface receptor complex and this signal is transmitted via the intracellular signal 
transduction pathway called the JAK-STAT pathway (Janus kinase-signal transducer 
and activator of transcription) as illustrated in Figure 1.11 (W. J. Leonard & O'Shea, 
1998; Hamza Et. al., 2010).  
 
The receptor for IL-12 has 2 subunits, IL-12Rβ1 and IL-12Rβ2 (Presky Et. al., 1996). 
These receptors are pre-associated with the Janus family of protein kinases (JAKS) but 
itself do not have kinase activity.  IL-12Rβ1 is required for high-affinity binding to the 
IL-12p40, a larger subunit of IL-12 and is associated with the Janus kinase family 
member, TYK2. IL-12Rβ2 recognises either the IL-12p35, a smaller subunit of IL-12 




member, JAK2 that also mediates signal transduction. Both receptor chains are 
required to mediate maximal signalling (Sinigaglia Et. al., 1999).  
 
As seen in Figure 1.11, ligation of IL-12 receptors by IL-12 results in activation of JAK 
kinases that cross-phosphorylates the receptors at tyrosine residues of their cytoplasmic 
domain. Subsequently, the phosphorylated receptors are the recruiting sites for signal-
transducing proteins. The IL-12Rβ2 chain contains three tyrosine residues that act as a 
docking site for a specific signal transducer and activator of transcription factor, STAT-
4. The interaction occurs via the SH2 domain of STAT-4 with the IL-12Rβ2 chain 
resulting into tyrosine phosphorylation of STAT-4 at Tyr-693 by JAK2 (Yao Et. al., 
1999). This phosphorylation of STAT-4 is the key event in IL-12 signalling induced 
IFN-γ production (Thierfelder Et. al., 1996; Visconti Et. al., 2000; Wang Et. al., 2015). 
On tyrosine phosphorylation, STAT-4 proteins are enabled to homodimerise and 
translocate into nucleus where they bind to specific sequences on the promoter and 
activate transcription of IL-12 inducible genes (Lammas Et. al., 2000). Out of the 20 
genes regulated, IFN-γ gene is the first gene to be induced by IL-12 and STAT-4-
dependent signalling (Lund Et. al., 2004). IFN-γ is also one of the most characterised 
target gene of STAT-4 that plays a key role in IL-12 induced Th1 differentiation (Good 
Et. al., 2009).   
 
STAT-4 knockout mice demonstrate the importance of JAK/STAT signalling in 
mediating the functional effects of IL-12. In mice lacking STAT-4, all the major 
functional effects of IL-12 on T and NK cells are markedly inhibited, including IFN-γ 
production and NK cell cytotoxic activity (Thierfelder Et. al., 1996). Thus, activation 
of STAT-4 is an important control point in modulating IL-12 function in IFN-γ 
induction. Moreover, inappropriate activation of the JAK-STAT pathway contributes 
to oncogenesis and leukaemogenesis (Bowman Et. al., 2000; T. S. Lin Et. al., 2000); 
therefore, IL-12 activated STAT-4 is one of the attractive targets to leukaemia 
therapies. Study of agonism and antagonism of the IL-12 signalling pathway will 
provide novel strategies to enhance or weaken cell-mediated immune responses 
through effects on IFN-γ induction. Thus, it is important to study IL-12 signalling 







1.6.3.1 STAT-4  
 
As described above, STAT-4 is a critical mediator of IFN-γ production in the IL-12 
signalling pathway (Good Et. al., 2009; Wang Et. al., 2015). The importance of STAT-
4 is evident from various recent in vitro and in vivo studies that highlighted a key role 
of IL-12-signalled STAT-4 alone as well as in collaboration with other transcription 
factors in inducing IFN-γ production (Thieu Et. al., 2008; J.  Zhu Et. al., 2012; 
Kurktschiev Et. al., 2014). STAT-4 is activated by IL-12 alone or in synergy with other 
cytokines like IL-18 in the induction of IFN-γ (Lawless Et. al., 2000). STAT-4 is also 
activated by IFN-α (S. S. Cho Et. al., 1996; Athie-Morales Et. al., 2004); however, this 
activation by IFN-α is only transient, whereas STAT-4 activation by IL-12 is long-
lasting and enhances production of IFN-γ. On activation by IL-12, STAT-4 is 
phosphorylated at tyrosine 693 by JAK2 and TYK2 (Bacon Et. al., 1995; S. S. Cho Et. 
al., 1996). Indeed, mutation of Tyr 693 blocked IL-12 induced STAT-4 
phosphorylation, transcriptional activity and IFN-γ secretion (Visconti Et. al., 2000). 
Therefore, tyrosine phosphorylation is necessary for IL-12-induced STAT-4 
homodimerization and DNA binding (Becker Et. al., 1998; X. Chen Et. al., 1998; W. 
J. Leonard & O'Shea, 1998). 
 
Moreover, IL-12 also activates the p38/MKK6 pathway that leads to phosphorylation 
of STAT-4 on serine 721. Serine phosphorylation of STAT-4 is not required for its 
nuclear translocation and DNA binding activity; however, it is important to induce 
maximal transcriptional activity (Visconti Et. al., 2000). Investigation of the biological 
importance of serine phosphorylation on STAT-4, reveal that it is critical for IL-12 
induced IFN-γ production and Th1 development, but not for cell proliferation. 
Additionally, serine phosphorylation of STAT-4 was shown to be partially dependent 
on earlier tyrosine phosphorylation, whereas tyrosine phosphorylation of STAT-4 can 
occur even in the absence of serine phosphorylation (Morinobu Et. al., 2002). Indeed, 
activated STAT-4 is known to bind directly to the Ifng locus and induce epigenetic 
changes leading to IFN-γ expression (Thieu Et. al., 2008; Wei Et. al., 2010). Therefore, 
it is important to study cytokine regulators of IL-12 signalling that inhibit STAT-4 




















Figure 1.11 IL-12 signalling pathway: IL-12 activates the JAK/STAT pathway. Following binding of IL-12p40 and IL-12p35 to IL-12Rβ1and 
IL-12Rβ2, respectively, JAK2 and TYK2 are transphosphorylated. Subsequently, receptor chains are phosphorylated by activated JAKs. 
Phosphorylated IL-12Rβ2 serves as a docking site for STAT-4, which then itself is phosphorylated. STAT-4 homodimers translocate to the 





1.7 Role of Dermatan Sulphate (DS) in IL-12 Signalling Induced IFN-
γ Production  
 
As previously described (Section 1.2), within the immune system, GAGs control 
number of immune responses, mainly through activation of immune cells, cytokines 
and their activities (Davis & Parish, 2013; Coombe & Parish, 2015). However, the 
mechanisms by which GAGs affect these immune processes are less explored. There 
has been increasing recognition in the field to elucidate the molecular pathways 
regulated by GAGs. For instance, the role of decorin, a DS-PG, was shown in the 
modulation of delayed-type hypersensitivity responses, leading to reduced oedema and 
the concurrent reduction in the recruitment of CD8+ T cells to the inflamed tissue using 
decorin KO (DCN-/-) mice (Seidler Et. al., 2011).  Mechanistically, the absence of DS-
PG from decorin KO fibroblasts and lymphocytes resulted in reduced expression of 
cytokines such as IFN-γ, TNF-α, CXCL-10 and their downstream effector molecules 
(Bocian Et. al., 2013), indicating a role for DS chains in inflammatory responses. 
Studies by Dekker Et. al. also supports the importance of cell-associated DS in 
influencing IL-4 signalling in monocytes and thereby modulating expression of IL-4-
mediated events (den Dekker Et. al., 2008). Our laboratory previously observed that 
IL-12, like several other interleukins binds to heparin/HS and DS (Hasan Et. al., 1999), 
but how these sulphated GAGs modulate IL-12 function, such as activation of NK cells, 
needs to be investigated. This section of the thesis seeks to investigate the underlying 
mechanism modulating IL-12 signalled IFN-γ production by NK cell-surface GAGs, 
particularly, DS (Chapter 4).  
   
1.7.1 Dermatan Sulphate (Chondroitin Sulphate B)  
 
Structurally, dermatan sulphate (DS/CS-B) is a sulphated GAG, consisting of a 
repeated disaccharide unit of [-4) GlcUA(β1-3) GalNAc(β1-]n, where GlcUA is 
glucuronic acid and GalNAc is N-acetylgalactosamine. DS belongs to the family of 
chondroitin sulphate (CS) due to the presence of GalNAc; however, GlcUA at most 
positions, along the chain is epimerised at C5 to IdoA (iduronic acid) (Trowbridge 
2002; Sugahara Et. al., 2003; Yamada & Sugahara, 2008). The presence of IdoA 
distinguishes DS from other members of chondroitin sulphate family (CS-A and CS-
C).  Nonetheless, IdoA residue is a common structural moiety in DS and heparin/HS. 




rich in IdoA to significantly inhibit proliferation of fibroblasts, than those chains 
containing higher amounts of GlcUA (Westergren-Thorsson Et. al. 1991). Therefore, 
the presence of this additional element makes DS a more important modulator of 
biological response than other CSs (Bao Et. al. 2004; Thelin Et. al., 2013). DS-GAG 
chains linked to O-serine residues of the core protein forms DS-PGs. Role of DS either 
in the form of soluble or cell-surface PG has been appreciated in various biological 
responses such as cell growth and proliferation, coagulation, wound repair, infection, 
oncogenesis, and immune defense (as reviewed in detail by Trowbridge 2002; 
Malavaki Et. al., 2008; Gubbiotti Et. al., 2016).  
 
1.7.2 DS in IL-12 signalling  
 
Role of DS in immunoregulation has been observed through its binding affinity to 
various cytokines and growth factors (Mizumoto Et. al., 2013; Gubbiotti Et. al., 2016), 
however, there were no known reports regarding the involvement of DS in IL-12 
signalling induced IFN-γ secretion until the work published by Garnier et al from our 
laboratory (Garnier Et. al., 2003). Their work demonstrated a significant impact of DS-
PG on IL-12-stimulated IFN-γ secretion by a combination of approaches that altered 
GAG expression on NK cells (Garnier Et. al., 2003). Using range of GAGases, such as 
chondroitinase ABC, chondroitinase AC, hyaluronidase, and heparinitase I and II, they 
showed that the treatment with only chondroitinase ABC weakened the NK cell 
response to IL-12 to produce IFN-γ. This suggested a role of NK cell-surface DS-PG 
in the biological activity of IL-12. In a second approach, NK cells were cultured in the 
presence of 4-methylumbelliferyl-β-xyloside that inhibited IL-12-mediated IFN-γ 
secretion. 4-methylumbelliferyl-β-xyloside is a drug used to block GAG assembly onto 
PG chains and therefore abrogates PG synthesis (detailed in next Section 1.7.3). 
Moreover, the specificity of DS-PG involvement was confirmed when exogenously 
added, soluble DS had no effect on IL-12 activity in the presence of β-xyloside (Garnier 
Et. al., 2003). Collectively, these observations with the use of chondroitinase ABC and 
β-xyloside indicated functional involvement of cell-associated DS chains in NK cell 
acitivty through a  significant reduction in IFN- γ secretion in response to IL-12.  
 
The involvement of DS, as implied in IFN-γ production (Garnier Et. al., 2003), is 
distinct from the effects of other sulphated GAGs, including different forms of CS. 




µg/ml to β-xyloside treated NK cells had no effect in either potentiating or restoring, 
β-xyloside suppressed IFN-γ secretion (Garnier Et. al., 2003). Studies with primary 
cultures of NK cells have shown that these cells in the presence of β-xyloside, mainly 
produced CS/DS GAGs. This was ascertained by complete digestion of cell-associated 
and secreted culture material with chondroitinase ABC, suggesting NK cells do not 
synthesise heparin/HS (Christmas Et. al., 1988). Additionally, studies conducted by 
Garnier Et. al.(2003) showed a lack of effect of heparinases on NK cell response to IL-
12  which suggested either the absence of heparin/HS or that these GAGs are present 
but do not have a role in IL-12-induced IFN-γ production. Among CS, CS-A is 
specifically produced by NK cells but was observed to remain confined to secretory 
granules of the cells and only released on target cell lysis (Schmidt Et. al., 1985). This 
was shown by the treatment of whole NK cells with chondroitinase ABC and such 
enzymatic treatment was unable to release the intracellular CS-A-PGs into the medium 
(MacDermott Et. al., 1985). This eliminates the possibility of CS-A involvement in 
IFN-γ secretion. Therefore, these experimental findings along with observations from 
the Garnier Et. al. study suggested that DS is an essential requirement of IL-12 
signalling in the induction of IFN-γ in NK cells. However, the mechanism of this DS-
PG involvement in IL-12 signalling remains unelucidated. Importantly, this leads to 
the second goal of this thesis that investigates the underlying mechanism in IL-12-
signalled IFN-γ production regulated by DS-PG. 
 
In order to understand the mechanistic role of DS-PG in IL-12 signalling, various 
questions could be posed. Referring to Figure 1.11 of the IL-12 signalling pathway, the 
first question that arises is whether cell-surface DS-PG affects the initial step of IL-12-
receptor binding? This would mean that DS-PG functions as a co-receptor that binds 
and presents IL-12 to its signalling receptor.  Such an interaction has been described 
for monocyte cell-surface DS-PG which facilitates IL-4-induced signalling events via 
its receptor (den Dekker Et. al., 2008). In the case of FGF-2, HS mediates cytokine-
receptor binding and signal transduction (A. C. Rapraeger Et. al., 1991; Yayon Et. al., 
1991).  Supporting this co-receptor hypothesis is the finding that IL-12 is capable of 
binding to DS, albeit weakly, but not to CS-A or CS-C (Hasan Et. al., 1999).  
 
Further, the involvement of DS in IL-12-IL-12R interactions should reflect in  changes 
in receptor-based phosphorylation of the IL-12-activated, specific transcription factor, 




pathway in endothelial cells, where the absence of DS-PG resulted in a significant 
reduction in IFN-γ-activated STAT-1 phosphorylation level and hence decreased 
downstream chemokine expression (Bocian Et. al., 2013). On the other hand, does DS-
PG indirectly interact with the components of IL-12 signalling to inhibit the events, 
downstream to STAT-4 phosphorylation? In this context, DS has been shown to 
increase expression of ICAM-1, a surface protein and its mRNA levels, independent of 
STAT-mediated signalling pathway in endothelial cells. In fact, DS-induced ICAM 
expression was initiated through activation of another transcription factor, NF-kB and 
its signalling pathway (Penc Et. al., 1999). Therefore, in the current study, it is 
conceivable that DS might be involved in either transcriptional or translational control 
of IFN-γ expression. 
 
Since Garnier et al’s report demonstrated only partial inhibition of IFN-γ secreted from 
both β-xyloside and chondroitinase ABC treated NK cells (Garnier Et. al., 2003), an 
alternative proposition for the underlying mechanism may be that DS interferes with 
the secretory pathway of IFN-γ. This implies that the role of DS-PG might be at the 
post-translational level, in extracellular secretion of IFN-γ protein. Such dependence 
on PGs at the post-translational level was suggested in the secretion of urokinase 
plasminogen activator, a protease from β-xyloside treated macrophages (Pejler Et. al., 
2003). In this context, chondroitinase ABC susceptible PGs have been suggested to be 
important for the golgi-associated intracellular transport of proteins to secretory 
granules in leukocytes (Lemansky & Hasilik, 2001; Galvin Et. al., 1999). IFN-γ is a 
secretory protein that, once translated, follows normal ER-Golgi transport system. It 
has been shown that β-xyloside treated NK cells produce CS/DS GAGs (Christmas Et. 
al., 1988) and IFN-γ is a GAG binding protein (Lortat-Jacob & Grimaud, 1991a). 
Perhaps, this indicates that IFN-γ protein remained GAG-bound and accumulated 
intracellularly. Therefore, obstruction in the secretion of IFN-γ and the consequent 
intracellular sequestration of this protein might be the reason for the low levels of IFN-
γ protein detected from chondroitinase ABC or β-xyloside treated NK cells on IL-12 
stimulation. Thus, this raises an interesting question whether DS-PG acts as an 
accessory molecule or component in IL-12 signalling that facilitates the IFN-γ 
secretion rather than its gene expression. 
  
Broadly, to test these various hypotheses addressing the mechanism by which DS-PG 




study that either rules-in or rules-out, each of the posed hypotheses. Thus, this study 
should highlight a particular level of cellular regulation by DS-PG that would later 
enable us to focus on a specific area or level of regulation. With the substantial role of 
IL-12 in immune responses, this study which investigates the functional role of DS in 
biological activities of IL-12 would be a significant finding in immune regulation. 
Moreover, because IL-12 promotes Th1 immunity, implications may extend to the 
regulation of adaptive immunity at the Th1/Th2 cell dichotomy in context with cell 
surface and ECM proteoglycans.  
 
1.7.3 Methods to Study the Functional Role of GAGs/PGs 
 
Several methods are in use to investigate the GAG/PG dependence in cytokine 
activities, this includes removing the existing PGs from  cell-surfaces with enzymatic 
treatment or blocking PG synthesis by use of chemical inhibitors.  In the current study, 
β-xyloside (a chemical inhibitor) and chondrotinase ABC (an enzyme) are used to 
understand the involvement of DS in IL-12 signalling (Chapter 4). Subsequent 
subsections briefly describes each of the approaches used and their mode of action.  
 
1.7.3.1 Use of β-xylosides as Chemical Inhibitors  
 
β-xylosides are the most widely accepted tools used to define the physiological actions 
of PGs in the last 40 years (Okayama Et. al., 1973; Fritz Et. al., 1994b; Kuberan Et. al., 
2008; Persson Et. al., 2016). β-xylosides contain D-xylose (Xyl) in β-linkage to 
hydrophobic aglycones such as p-nitrophenol, benzyl, estradiol, p-hydroxyphenol, or 4-
methylumbelliferone as shown in Figure 1.12. The hydrophobic aglycone moiety aids 
in transport of the sugar molecule through the cell membrane and permeates to golgi 
bodies, where GAG synthesis takes place (N. B. Schwartz, 1977; Izumi Et. al., 1994). 
As described earlier in section 1.3.2, in normal PG synthesis, sugar D-xylose is added 
to a serine residue of a core protein by enzyme xylosyl transferase forming ‘xylosylated 
protein core’ (Figure 1.12). Then, the enzyme galactosyltansferase I links (β1-4) the 
first galactose residue to this xylosylated protein core, followed by addition of another 
galactose unit in β1-3 linkage by enzyme galactosyl transferase II and a glucuronic acid 
moiety by glucuronyl transferase I (Gallagher, 2015; Prydz & Dalen, 2000; Prydz, 
2015). This leads to the formation of a tetrasaccharide linkage (O-Ser-Xyl-Gal-Gal-




synthesis. However, when β-xyloside is added to the cells, they act as alternate 
substrates to endogenous xylosylated core proteins and competes with it for GAG 
assembly, resulting in disrupted PG synthesis.  Indeed, β-xylosides act as exogenous 
primers stimulating the synthesis of GAG chains without the need for endogenous 
xylosylated core proteins and results in increased synthesis of free GAG chains and 
decreased PG synthesis.(N. B. Schwartz Et. al., 1974a; Steward Et. al., 1990). 
 
 
The most commonly employed β-D-xylosides include methylumbelliferyl-β-D-
xyloside and p-nitrophenyl-β-D-xyloside. These β-xylosides cause disruption of PG 
synthesis and mostly prime synthesis of CS/DS GAG chains (N. B. Schwartz Et. al., 
1974b; Rosamond Et. al., 1987; Coster Et. al., 1991; Hahn & Birk, 1992; Fritz Et. al., 
1994b). However, the composition of GAGs produced on β-xylosides depends on the 
structure of aglycone (Lugemwa & Esko, 1991) and the concentration of β-xylosides 
used (Fritz Et. al., 1994b). In most cases, β-xylosides have shown considerable 
selectivity in blocking CS/DS-PG synthesis (Hahn & Birk, 1992), with rather weak 
inhibition of HS-PG synthesis (Lugemwa & Esko, 1991; Fritz Et. al., 1994b). This was 
seen regardless of the capacity of cells to produce these GAGs (H. C. Robinson & 
Lindahl, 1981; Sudhakaran Et. al., 1981; Stevens & Austen, 1982). HS-GAG synthesis 
was shown to be selectively primed with high concentrations of p-nitrophenyl-β-D-
Figure 1.12 Mechanism of action of β-xylosides: A) Shows normal PG synthesis via the 
tetrasaccharide linkage that initiates GAG chain synthesis onto PG core protein B) Illustrates role 
of β-xyloside as an inhibitor of PG synthesis. β-xyloside contains β-xylose sugar attached to 
aglycone structure which substitutes for endogeneous xylosylated core protein. β-xyloside acts as 
a competitive acceptor ofsugar residues in the formation of a tetrasaccharide linkage that primes 




xyloside (A. Rapraeger, 1989) or when the aglycones of β-xylosides contain aromatic, 
polycyclic structures (2-naphthol and estradiol derivatives) (Lugemwa & Esko, 1991; 
Fritz Et. al., 1994b; Belting Et. al., 2002). This was thought to be based on the 
specificity of the enzyme in recognising the ‘hydrophobic signal’ which adds the first 
GlcNAc unit in heparin/HS synthesis (Lugemwa & Esko, 1991; Fritz Et. al., 1994a; 
Fritz Et. al., 1997). Thus, methylumbelliferyl-β-D-xyloside and p-nitrophenyl-β-D-
xyloside are known primers stimulating the synthesis of CS/DS GAGs and inhibiting 
respective PG synthesis (Sobue Et. al., 1987; Lugemwa & Esko, 1991). 
 
The altered biosynthesis of GAGs/PGs using β-xylosides in several systems has 
suggested various roles of GAGs/PGs in cellular activities, metabolism, growth, 
differentiation, and development (Spooncer Et. al., 1983; H. A. Thompson & Spooner, 
1983; J. T. Gallagher & Hampson, 1984; Persson Et. al., 2016). Rosamond Et. al. 
demonstrated with T lymphocytes that p-nitrophenyl-β-D-xyloside treatment 
completely inhibited synthesis of CSPG which resulted in decreased expression and 
activity of associated MHC class II molecules in antigen processing and presentation. 
However, T lymphocyte mediated target cell killing was unaffected by the presence of 
β-xyloside (Rosamond Et. al., 1987). Similarly, T and NK cells, when cultured in the 
presence of β-xylosides exhibited 50% reduced PG production and released high 
amounts of CS-GAG chains into the medium (Christmas Et. al., 1988; Steward Et. al., 
1990). However, in untreated T cells, free GAG chains were retained inside cells and 
formed ionic complexes with basic proteins within storage granules (Steward Et. al., 
1990). This indicated the role of endogenous GAGs in binding to basic proteins, such 
as in mast cells, where they form complexes with serine proteases (L. B. Schwartz Et. 
al., 1982). Another example using β-xylosides showed that the secretion of proteinases 
like MMP-9 (matrix metalloproteinase-9) by macrophages was dependent on intact 
PGs, affecting synthesis at the post-translational level (Pejler Et. al., 2003). Thus, β-
xylosides have become common tools in the elucidation of the role of GAGs/PGs in 
the activation of cellular events.  
 
1.7.3.2  Use of GAG-selective Enzymes 
 
The enzymatic method has also been used in many studies to investigate the functional 
role of cell-membrane associated GAGs. Most commonly used GAG lyases include 




depolymerise CS and DS galactosaminoglycans (Hernaiz & Linhardt, 2001). 
Chondroitinase ABC covers broad specificity for GAG substrates, including CS-A, CS-
B, CS-C, and HA (Hamai Et. al., 1997; Prabhakar Et. al., 2005). The action of this 
enzyme results in disaccharide units and core protein. It is an exolytic enzyme that 
cleaves at the non-reducing ends of galactosaminoglycan chains (Figure 1.13). In spite 
of wide substrate specificity, chondroitinase ABC does not degrade keratan sulphate, 
heparin, and HS (Hamai Et. al., 1997). Hence, use of this enzyme is most reliable in 
the preliminary studies or as supporting evidence to the involvement of specific GAGs/ 
PGs in any biological process.  Recently, to identify the nature of GAGs chains 
synthesised in the presence of β-xyloside and their effect on breast carcinoma cells, 
various types of chondroitinases, including ABC were employed. The enzymatic 
treatment showed defined CS/DS chains exhibited cytotoxic effect on breast tumour 
cells (Persson Et. al., 2016). 
 
---GalNAc (4S and 6S) 1------- 4 (GlcUA and IdoA)  




Chondroitinases have also been employed to show the importance of CS/DS GAGs in 
CNS biology (F. Li Et. al., 2010). In vivo application of chondroitinase ABC at the site 
of CNS (Central Nervous System) injury promoted axon regeneration into damaged 
CNS tissue and reduced glial scar formation. This implied that the presence of CS/DS 
prevented reconstruction of damaged tissue by inhibiting axon transverse and neural 
outgrowth (Chau Et. al., 2004; H. P. Li Et. al., 2013). Similarly, in vitro studies have 
demonstrated various roles of CS/DS using chondroitinases. When human arterial 
smooth muscle cells were treated with chondroitinase ABC, the binding of IFN-γ to 
these cells was reduced by 50%. This significantly decreased the anti-proliferative 
effect of IFN-γ on cultured smooth muscle cells, suggesting that cell surface CS/DS-
GAGs not only increased local IFN-γ concentration, but even modulated its biological 









1.8 Role of TGF-β1 in IL-12 Signalling Induced IFN-γ Production.  
 
Understanding the regulation of IL-12 effector functions during immune responses is 
the focus of most research interests because of the important implication of this 
cytokine in shaping adaptive immunity at the dichotomy of Th1/Th2 development. The 
balance between Th1/Th2 immune branches is the deciding factor in protective 
immunity against infections, as opposed to whether the response is appropriate and 
terminates without immuno-pathologies. Besides this fundamental role of IL-12 in 
enhancing Th1 cellular immunity, this pleiotropic cytokine with anti-tumour effects 
has gained central attention in the field of immuno-oncology (Lasek Et. al., 2014; 
Tugues Et. al., 2015). Importantly, intratumoural injection of an IL-12 gene (Ad-RTS-
IL-12) is the most recent FDA approved therapy in clinical trials (2015) for the 
treatment of recurrent glioblastoma, a high-grade brain cancer (website link: 
http://ir.ziopharm.com/releasedetail.cfm?releaseid=923775). This therapeutic system 
is based on the controlled expression of IL-12 in cells by an orally taken activator ligand 
(veledimex pill). This therapy resolved the side-effects and toxicity associated with the 
systemic administration of recombinant IL-12 that for a long-time limited the 
beneficial, anti-cancer use of this cytokine.  
 
Nevertheless, wider applications of IL-12 therapy in several animal tumour models and 
various clinical trials in cancer patients has shown a major setback due to 
immunosuppressive cytokines secreted by tumours as one of the immune evading 
mechanisms (Becker Et. al., 2013).  In recent years, an increasing number of studies 
have highlighted a critical role for Transforming Growth Factor-β1 (TGF-β1), as a 
suppressive cytokine produced by tumours to escape from host immunosurveillance 
(Flavell Et. al., 2010; Tu Et. al., 2014; Sanjabi Et. al., 2017). Higher serum 
concentrations of TGF-β have been reported in cancer patients leading to immune 
dysregulation and associated with poor prognosis in several cancer types such as 
hepatocellular carcinoma, aggressive breast cancer and metastatic melanoma 
(Ikushima & Miyazono, 2010). Moreover, tumour growth was shown to be amplified 
by the co-infiltration of TGF-β1 secreting Tregs (T regulatory) cells along with 
suppressed adaptive immune cells such as CTLs and Th1 cells. The suppression of 
adaptive T cell responses was led by a downregulated innate signal from NK cell 
produced IFN-γ in the presence of TGF-β1 (Seo Et. al., 2002; Flavell Et. al., 2010). 




of pro-inflammatory cytokines like IL-12, suppressing both its production from 
myeloid cells (macrophages, DCs) and effector functions on T and NK cells (Hunter 
Et. al., 1995; Bellone Et. al., 1995; Yu Et. al., 2006; Lewis Et. al., 2015). Hence, the 
negative regulation of IL-12 activity by counter-regulatory cytokines, as TGF-β1, helps 
to maintain immune tolerance and homeostasis by keeping a balance between the 
effective protection against pathogens and inflammatory shock due to IL-12 (M. O. Li 
Et. al., 2006; Oh & Li, 2013; Sanjabi Et. al., 2017).  
 
Given the renewed interest in research for both these immunocytokines and in the 
efforts to unravel how TGF-β1 regulates IL-12 effector functions, the current study 
explores the mechanism for the inhibitory effect of TGF-β1 on IL-12-signalling 
induced IFN-γ production by NK cells (Chapter 5). Overall, this study will provide a 
better understanding of the regulation between these two key cytokines, TGF-β1 and 
IL-12, when present in an endogenous cytokine network, especially in a tumour 
microenvironment or in response to viral infections. Indeed, these cytokines are the 
therapeutic targets in regulating the efficient production of IFN-γ that is central in 
boosting anti-tumour or anti-viral immunity.  
 
1.8.1 Transforming Growth Factor-β1 (TGF-β1) 
 
TGF-β1 is a prototypical member of the TGF-β superfamily of cytokines that includes 
more than 35 related cytokines in vertebrates, such as TGF-βs, bone morphogenetic 
proteins (BMPs), Activins, Inhibins, Nodals, growth differentiation factor (GDF) and 
others that are crucial in regulating embryonic development and tissue homeostasis 
(Chen & Ten Dijke, 2016). TGF-β1 is one of the three highly conserved isoforms of 
TGF-β (TGF-β1, 2 & 3) described in mammalian cells, and they share considerable 
structural and sequence homology. These members constitute a TGF-β subfamily and 
have been recognised as powerful immunomodulatory agents exerting multiple effects 
on a wide spectrum of target cells. All three isoforms have similar properties in vitro, 
but TGF-β1 is the predominant isoform expressed in the immune system (Letterio & 
Roberts, 1998; Travis Et. al., 2014). 
 
The immunoregulatory role of TGF-β1 was first established in 1990 by the generation 
of TGF-β1 knockout mice. The phenotype of these mice revealed the suppressive 




1992; Kulkarni Et. al., 1993). Mice deficient in TGF-β1 develop a widespread 
multiorgan autoimmune inflammatory disease and die within few weeks after birth 
(Kulkarni Et. al., 1993). In 2000, development of mouse models with cell-type specific 
inactivation of TGF-β signalling revealed the regulatory network of the TGF-β pathway 
in vivo (Cazac & Roes, 2000; Gorelik & Flavell, 2000). Various transgenic mice were 
generated, whose T cells were specifically unable to respond to TGF-β1 and these 
developed either widespread autoimmunity (with somewhat slower kinetics than TGF-
β1 knockout mouse) (Gorelik & Flavell, 2000) or pulmonary T cell pathologies (Nakao 
Et. al., 2000), showing the importance of TGF-β1 in regulating immune tolerance. 
These observations demonstrated that TGF-β1 has a critical immunoregulatory and 
non-redundant function as an antagonist of Th1 development in vivo. The clinical 
relevance of this role of TGF-β1 was observed on the systemic administration of TGF-
β1 that was effective in preventing Th1 cell-mediated autoimmune diseases of 
Experimental Allergic Encephalomyelitis (EAE) and Collagen-induced Arthritis (CIA) 
(Johns Et. al., 1991; Kuruvilla Et. al., 1991). To date, it has been almost 30 years of 
intensive research elucidating the immuno-regulatory and immuno-suppressive role of 
TGF-β1 in various pathophysiological conditions such as autoimmune diseases, 
inflammatory pathogenesis and infections (Gorelik and Flavell 2002b; M. O. Li Et. al., 
2006; Sanjabi Et. al., 2017). However, the precise cellular and molecular mechanisms 
regulated by TGF-β1 in immune cell functions still remains less explored.  
 
Innate immune cells such as NK cells are critical in viral infections and tumourigenesis. 
NK cells respond to various pro-inflammatory cytokines as IL-2, IL-12, or IL-18 alone, 
or in combination, to produce IFN-γ (Marcais Et. al., 2013; Zwirner & Ziblat, 2017). 
Studies, specifically in NK cells demonstrated that TGF-β1 inhibited cell proliferation, 
cytokine production as well as cytolytic activity and hence suppression of all aspects 
of NK cell biology (Bellone Et. al., 1995, Laouar Et. al., 2005; Wilson Et. al., 2011; 
Lewis Et. al., 2015; Viel Et. al., 2016). Studies also showed that TGF-β1 produced 
during viral infections limited NK cell functions, increasing susceptibility to virus 
persistence (Tinoco Et. al., 2009). A well-designed study by Laouar Et. al. (2005) 
demonstrated an in vivo significance of TGF-β1 using a transgenic mouse model in NK 
cells. They specifically expressed the dominant-negative (dn) form of the TGF-β 
receptor II which resulted in blocking TGF-β1 signalling in NK cells. Consequently, 
increased amounts of IFN-γ production from NK cells was observed, leading to a Th1 




transgenic mouse model, more recent studies showed that a disrupted TGF-β1 response 
resulted in the generation of increased numbers of NK cells in these mice (CD11c-
dnTGF-βRII), rather than DC-mediated functions. This indicated an essential role of 
TGF-β1 in the regulation of NK cell homeostasis and IFN-γ production in the early 
control of MCMV infections (Lewis Et. al., 2015) and in Th1 cell development (Laouar 
Et. al., 2005). Similar findings were reinstated in neonates showing CD11c-dnTGF-
βRII infant mice were resistant to MCMV infections due to increased NK cell numbers 
and maturation (Marcoe Et. al., 2012). Moreover, evidence from other studies support 
the role of tumour-derived TGF-β in weakening NK cell activity associated with IFN-
γ release and cytotoxicity (Wilson Et. al., 2011, Lindgren Et. al., 2011). Nevertheless, 
an important question that still remains unaddressed from these studies is how the 
inhibitory effects of TGF-β1 are mediated on NK cell-produced IFN-γ. In view of the 
critical role of IL-12-induced NK cell IFN-γ in generating cellular immune responses 
against viral infections, intracellular pathogens and tumour development, 
understanding the cellular and molecular mechanism by which TGF-β1 regulates IL-
12-mediated responses is important (M. O. Li Et. al., 2006; Marcais Et. al., 2013; Lasek 
Et. al., 2014). Collectively, this prompted interest to investigate the underlying 
mechanism of signalling cross-talk between TGF-β1 and IL-12 in the molecular 
regulation of IFN-γ expression in NK cells which is the third and final goal of this 
thesis.  
 
1.8.2 Crosstalk between TGF-β1 and IL-12 Signalling 
 
Molecular understanding in the crosstalk between TGF-β1 and IL-12 signalling is less 
understood. Conceivably, one mechanism by which TGF-β1 interferes with the 
receptor-proximal signalling events induced by IL-12 in IFN-γ production could be via 
inhibition of the JAK-STAT pathway (Figure 1.14). Supporting this, Bright & Sriram 
(1998) have reported that TGF-β1 rapidly inhibited IL-12-induced phosphorylation of 
JAK2 and TYK2 by an unknown process in mouse T cells resulting in reduced STAT-
4 phosphorylation. STAT-4 are cytoplasmic proteins which, on IL-12 stimulation, 
phosphorylate, homodimerise and translocate to the nucleus for target gene induction. 
In line with Bright et al’s finding, Pardoux and colleagues demonstrated, using human 
T cells that downstream to STAT-4 phosphorylation, that TGF-β1 also inhibited the 
DNA-binding activity of STAT-4 (Pardoux Et. al., 1999). In contrast to these findings, 




phosphorylation of JAK2 and TYR2, nor phosphorylation of STAT-4 in activated 
human T and NK cells (Sudarshan Et. al., 1999). Additionally, this study also showed 
that TGF-β1 did not inhibit nuclear translocation or DNA-binding activity of STAT-4. 
However, they still observed reduced IFN-γ transcripts correlating to suppressed IFN-
γ production in the presence of TGF-β1. Taken together, it is evident from the above 
described studies that the effects of TGF-β1 on the IL-12-receptor based JAK-STAT 
pathway provided conflicting results. In the light of these contradictory findings, the 
role of TGF-β1 in the regulation of IL-12 signalling components in IFN-γ production 
is still not well understood. Collectively, there have been disagreements in the reports 
over the effects of TGF-β1 on receptor-proximal events of the IL-12-signalling 
pathway. Therefore, it is important to address this issue. 
 
Further, downstream to receptor-based events, studies have reported impaired IFN-γ 
production by TGF-β1 that correlated to reduced IFN-γ mRNA levels, indicating 
transcriptional inhibition (Sudarshan Et. al., 1999; Hayashi Et. al., 2003; J. T. Lin Et. 
al., 2005; Thomas & Massague, 2005). Interestingly, work led by Laouar and 
colleagues also demonstrated suppression of IL-12 or IL-12/IL-18 stimulated IFN-γ 
expression at both the mRNA and protein levels in TGF-β1 treated NK cells, whilst, 
NK cells from transgenic mice which expressed dn TGFRβ-II were resistant to such 
IFN-γ suppression. Thus, their findings suggest transcriptional regulation by TGF-β1 
(Laouar Et. al., 2005). Nevertheless, the molecular basis to this transcriptional control 
by TGF-β1 in NK cells is not well defined. Therefore, another level of crosstalk in IL-
12/STAT-4 and TGF-β1/Smads signaling could be convergence at the transcriptional 
level, as illustrated in Figure 1.14. Smads are primary signal-transduction molecules in 
TGF-β signaling. One possible mechanism in transcriptional repression might be that 
TGF-β1 directly targets expression of key transcriptional factors important in IFN-γ 
expression. Besides STAT-4, one such key transcriptional factor is T-bet, which is 
markedly up-regulated by various cytokines, especially IL-12 and IL-18 in mature NK 
cells (Szabo Et. al., 2002; Townsend Et. al., 2004; Marcoe Et. al., 2012; Leong Et. al., 
2017; Zwirner & Ziblat, 2017) and T cells (Thieu Et. al., 2008; Oestreich & Weinmann, 
2012; J. Zhu Et. al., 2012). Significantly, TGF-β1 has been shown to downregulate T-
bet expression in IL-12 stimulated CD4+T cells (Gorelik Et. al., 2002a). Moreover, 
retroviral transduction of T-bet into those activated T cells abrogated the inhibitory 
effects of TGF-β1 by inducing IFN-γ expression, as an indicator of Th1 differentiation 




lacking active TGF-β signaling did show enhanced T-bet expression compared to WT 
derived NK cells during MCMV infection (Lewis Et. al., 2015). Based on these 
observations, it is important to explore the role of T-bet in TGF-β1-regulated IFN-γ 
production by NK cells (Chapter 5). The next section, 1.8.2.1, briefly reviews what is 
currently known about T-bet expression in IFN-γ production and NK cells. 
 
TGF-β1 initiates signalling via dimerization of transmembrane type I and type II 
receptor-associated serine/threonine kinases on the cell surfaces, as shown in Figure 
1.14 (Massague, 2012). This allows Receptor II, a constitutive active kinase to 
phosphorylate Receptor I kinase domain that in turn acts as a Smad-binding site in 
phosphorylation of Receptor-specific Smads (R-Smads 2/3). Smads in TGF-β1 
signalling are cytoplasmic proteins equivalent to STAT proteins in IL-12 signalling. 
Phosphorylated R-Smads interact with Common Smads (Co-Smad 4) to form Smad-
complexes (2/3/4) which translocate to the nucleus to bind to a particular promoter 
region containing Smad-binding elements (SBEs), where they act as transcriptional 
regulators in the activation or repression of target genes. Moreover, these Smad-
complexes have weak DNA-binding ability, so they associate or recruit other 
transcription factors that facilitates their binding to SBEs (Hata & Chen, 2016; Hill, 
2016). Therefore, an alternative hypothesis in the signaling cross-talk between IL-12 
and TGF-β1 could be that the TGF-β1-induced Smad complexes targets directly the 
cis-regulatory sites/elements on the IFN-γ promoter. Such binding elements for TGF-
β1-signaled Smad-complexes (SBEs) are present on the proximal IFN-γ promoter 
region. The role of smad-complexes in transcriptional repression of cytotoxic genes 
such as Gzm B (granzyme B) has been demonstrated in CD8+ T cells (Thomas & 
Massague, 2005). However, their direct role in IFN-γ promoter activity has not yet been 
established in NK cells. To explore this possibility, the current study seeks to determine 
the activity of the IFN-γ promoter in the presence of TGF-β1 in NK cells (Chapter 5). 
Indeed, the molecular targets and the mechanism by which TGF-β1 mediates IL-12-
induced IFN-γ gene repression is not completely understood. Thus, in the current study 
IL-12 signalling pathway is dissected at various levels for investigating the interference 







As mentioned above, besides STAT-4, T-bet is another key transcription factor in the 
regulation of IFN-γ production and Th1 development (recent review Leong Et. al., 
2017). T-bet stands for T-box expressed in T cells (product of gene Tbx21) and was 
first identified by Laurie Glimcher’s laboratory in 2000, during the screening for new 
transcription factors specifically expressed in lineage-defined, Th1 cells (Szabo Et. al., 
2000). T-bet was detected as a positive regulator of IFN-γ expression not only in T cells 
but also in NKT, NK cells and B cells (Szabo Et. al., 2000; Townsend Et. al., 2004; 
Matsuda Et. al., 2007). It was demonstrated that retroviral transduction of T-bet into 
either primary CD4+ T cells, developing Th2 or effector Th2 cells, resulted in the 
induction of IFN-γ expression and simultaneous repression of Th2 cytokine expression 
(Szabo Et. al., 2000). These findings suggested T-bet as a potent trans-activator of the 
IFN-γ gene and a master regulator of Th1 cell lineage commitment. 
  
Moreover, T-bet-deficient mice exhibited a profound defect in the ability of CD4+ T 
cells to produce IFN-γ with susceptibility to L. major infection and a marked in vivo 
shift of the Th1/Th2 balance towards the Th2 pathway (Finotto Et. al., 2002; Szabo Et. 
al., 2002; J. Zhu Et. al., 2012). Although T-bet plays a significant role in CD4+T cell 
differentiation (Szabo Et. al., 2000), it is also involved in the effector functions of CD+8 
T cells against HBV and HCV infections (Sullivan Et. al., 2003; Kurktschiev Et. al., 
2014), Ig class switching in B cells, and NK cell development, homeostasis and 
migration (Townsend Et. al., 2004). Reduced numbers of NK cells in spleen, liver and 
peripheral blood were observed in T-bet-deficient mice (Townsend Et. al., 2004). 
Moreover, NK cells that developed in the absence of T-bet resulted in immature NK 
cells (Yokoyama, 2004; Gordon Et. al., 2012; Daussy Et. al., 2014) with increased 
apoptosis and hence their reduced numbers in T-bet-deficient mice (Werneck Et. al., 
2008). Therefore, besides the developmental role of T-bet in NK cells, its absence leads 
to reduced life-span of NK cells in vivo. T-bet-/- NK cells also exhibit abnormalities in 
effector functions, such as low IFN-γ production and reduced cytotoxicity on 
stimulation by cytokines especially IL-12 and IL-18 (Townsend Et. al., 2004). These 
observations suggested another role of T-bet in regulating the effector functions of NK 
cells in response to cytokines in the innate phase. Significance of this T-bet-dependent 




tumour antigens which was demonstrated by increased resistance of T-bet-/- mice from 
tumour metastasis on adoptive transfer of WT NK cells (Werneck Et. al., 2008). 
 
Signaling pathways involved in the induction of T-bet are still unclear. Studies with 
CD4+ T cells (Usui Et. al., 2006) and CD8+ T cells (Y. Yang Et. al., 2007) have shown 
that T-bet expression could be induced in a STAT-4 dependent and STAT-1 
independent mode. However, contrasting these previous studies, recent evidence has 
established that in T cells, IL-12/STAT-4 and IFN-γ/STAT-1,  signaling pathways can 
independently regulate T-bet expression (Oestreich & Weinmann, 2012; J. Zhu Et. al., 
2012). In NK cells, induction of T-bet expression was found to be independent of IFN-
γ/STAT-1 signalling (Townsend Et. al., 2004). IFN-γR deficient NK cells showed no 
impairment in T-bet expression, whereas STAT-4-/- NK cells showed a significant 
defect in T-bet induction on stimulation with IL-12 and IL-18, when compared to WT 
NK cells. These findings suggested a requirement for STAT-4 as an upstream signal 
that is important for T-bet induction in NK cells (Townsend Et. al., 2004). 
 
More importantly, T-bet has been identified as a regulatory target protein by TGF-β1 
during Th1 development (Neurath Et. al., 2002; Gorelik Et. al., 2002a). TGF-β1 has 
been shown to negatively regulate IFN-γ expression and subsequent Th1 development, 
in a large part, by suppressing T-bet expression in T cells (J. T. Lin Et. al., 2005; Park 
Et. al., 2005) and NK cells (Yu Et. al., 2006, Trotta Et. al., 2008). Consistent with this, 
TGF-β1 suppressed T-bet expression was shown to control IFN-γ production in T cell-
mediated inflammatory bowel diseases (IBDs) (Neurath Et. al., 2002). Lin et al showed 
that TGF-β1 suppressed IFN-γ expression at Th1 priming with IL-12 through inhibition 
of STAT-4 expression. While at recall stimulation of Th1 effector cells, TGF-β1 uses 
a different mechanism that inhibits T-bet expression in IFN-γ suppression (J. T. Lin Et. 
al., 2005). This suggests another mechanism under the control of TGF-β1 that is 
independent of STAT-4-regulated IFN-γ transcriptional activity and mediated by 
downregulation of T-bet. Because the expression of T-bet appears to be critical to IFN-
γ production, this current study (Chapter 5) will examine T-bet expression in NK cells. 
Therefore, the direct involvement of T-bet in IFN-γ production in the presence of IL-
12 and TGF-β1 will be explored. Although a number of different transcription factors 
have been suggested to participate in IFN-γ gene regulation (K. M. Murphy Et. al., 
2000), the current study focusses on two most important factors in IFN-γ expression, 




and resistance of these mice to autoimmune diseases further reinstates the critical 
significance of these two factors in IFN-γ production and Th1 functions (Thierfelder 
Et. al., 1996; Mullen Et. al., 2002; Szabo Et. al., 2002; Thieu Et. al., 2008; J. Zhu Et. 
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 Figure 1.14 Hypothetical representation of a crosstalk between TGF-β1 and IL-12 signalling pathways regulating IFN-γ production 
in NK cells: IL-12 positively regulates IFN-γ production via activation of STAT-4 transcription factors. In contrast, TGF-β1 treatment 
activates transcription factors SMAD 2/3/4 in negative regulation of IFN-γ. Possible interaction between the components of these two 
signalling pathways in the repression of IFN-γ gene expression has been shown. (Figure modified and developed (from Massague & Chen, 




1.9 Research Aims and Objectives 
 
In recent years, there have been significant advances in the study of cytokine-regulated 
NK cell activation. This knowledge could be used to devise rational therapeutic 
strategies in the fight against infection, malignant transformation, and autoimmunity. 
The overall aim of this thesis is to advance our understanding of the regulation of NK 
cell activities and thereby dichotomy of Th1/Th2 immune responses. As explained 
earlier (Section 1.1), in first part of the thesis, research work begins with a glycomics 
approach which integrates the role of GAGs in binding to cytokines. The second part 
of the research focuses on the modulation of a biological signalling pathway activated 
by specific cytokine, IL-12 in NK cells in the production of IFN-γ. Overall, there are 
three specific goals of the thesis. Their hypothesis and objectives are as described 
below. 
 
1. Many cytokines belonging to structurally and biologically diverse families 
possess affinity for GAGs, particularly to heparin/HS in-vitro. Such affinity has 
often proved to be an indicator of a physiological importance. Therefore, an 
increasing number of cytokines have been investigated for their GAG-binding 
property. It could be hypothesised that a heparin-binding property is common 
to certain interleukins that share structural relationship with their respective IL 
family, members of which are well-characterised for their heparin-binding 
properties. The first specific goal of the thesis (Chapter 3) examines three 
interleukins, IL-11, IL-18 and IL-22 for their heparin-binding property. These 
three interleukins are yet to be examined for their heparin/HS binding 
interactions in this field of GAG-protein interactions in matrix biology. 
Interleukins, IL-11, IL-18 and IL-22 are enriched in basic amino acids, which 
are structural components of heparin-binding sequences. They also contain 
clusters of these basic residues in their primary sequences as required in the 
formation of heparin-binding domains. Our specific objectives are to determine 
(i) whether IL-11 binds to heparin as IL-6, both of which have similar biological 
activities and belong to gp-130 receptor cytokine family; (ii) whether IL-18 
exhibits heparin-binding property like FGF family members that shares tertiary 
structural fold; and (iii) whether IL-22 is a heparin-binding cytokine as its 





2. Previous work from our laboratory determined that stripping NK cells of a 
particular GAG, DS, with the action of chondroitinase ABC or a PG inhibitor, 
β-xyloside strongly inhibited IL-12 dependent IFN-γ secretion (Garnier Et. al., 
2003). From this, it could be hypothesised that NK cell-surface DS-PG may 
regulate IL-12 induced IFN-γ secretion. The second specific goal (Chapter 4) 
in this thesis is to investigate the underlying mechanism by which DS-PG is 
involved in IFN-γ secretion. To achieve this, the specific objectives are to 
determine (i) whether cell surface DS-PG directly affects IL-12/IL-12R binding 
or receptor activity as will be indicated by changes in phosphorylated levels of 
STAT-4; (ii) if receptor activation is not blocked, whether DS-PG indirectly 
regulates IL-12 signalling by interference in the later stages of STAT-4 
phosphorylation leading up to the transcriptional, translational or post-
translational level in IFN-γ expression; (iii) to deteremine the IFN-γ protein 
levels within the cells and secreted into the culture supernatant so as to indicate 
whether IFN-γ is sequestered intracellularly on removal of DS-PG. This 
objective would enable to distinguish a translational or post-translational from 
a transcriptional regulation by DS-PG.  
 
3. Further, in the light of significance of NK cell-derived IFN-γ and IL-12 in the 
regulation of Th1 immune responses, the role of TGF-β1 was investigated. 
TGF-β1 often leads to down-regulation of cell-mediated/Th1 immunity 
(Gorelik & Flavell, 2000; J. T. Lin Et. al., 2005; Sanjabi Et. al., 2017). It 
suppresses the cytotoxic activity, cytokine production, and proliferation of NK 
cells (Bellone Et. al., 1995; Laouar Et. al., 2005; Lewis Et. al., 2015). Although 
the immunosuppressive effect of TGF-β1 is being widely studied using NK and 
T lymphocytes, the molecular basis for these events are not clear. Further, 
conflicting reports in the literature on the signalling cross-talk between the 
pathways initiated by TGF-β1 and IL-12 in the regulation of IFN-γ production 
at the post-receptor level attracts the interest to address this issue. The third 
specific goal (Chapter 5) is to characterise the downregulation of IL-12 induced 
IFN-γ expression and secretion by TGF-β1 in murine NK cells. Therefore, the 
specific objectives in this study are: (i) to determine the anti-proliferative effect 
of TGF-β1 that might lead to suppression of IFN-γ; (ii) to determine the effect 
of TGF-β1 on the key event in IL-12 signal transduction pathway i.e. 




transcription factor in IFN-γ expression, T-bet in the presence of TGF-β1 (iv) 
to demonstrate the inhibitory effect of TGF-β1 on IFN-γ promoter activity. 
Thus, we unveil interplay of regulatory mechanisms between pro-inflammatory 

























2.1 Heparin Binding ELISAs  
 
A Nunc Maxisorp 96-well plate (Life Technologies, Paisley, Scotland) was coated with 
100 µl of Tris-HCl buffer (50mM, pH 7.4) containing either 25 ng of newly synthesised 
heparin-BSA conjugate (heparin-porcine intestinal mucosa, sodium salt, grade I-A 
from Sigma-Aldrich Co., Poole, UK) or the same amount of mock-conjugated BSA 
(BSA-99% purity, Sigma-Aldrich Co., Poole, UK) (Section 2.1.1) and incubated 
overnight at 5oC. The wells were then washed three times with 400 µl phosphate 
buffered saline (PBS, pH 7.4) and blocked with 200 μl per well of Blocking buffer 
[PBS containing 1% BSA (w/v)] for 15 minutes at room temperature (R.T.) on a 
rotating platform. After washing the plate three times with PBS, 100 µl of respective 
cytokines dissolved in Tris-HCl buffer (50 mM, pH 7.4) were incubated for 2 hours. 
 
Following incubation, the plate was washed three times with PBS-T [PBS with 0.05% 
tween 20 (v/v)] and incubated with specific primary antibody diluted in blocking buffer 
(1:200), for 2 hours (see Table 2.1 for list of cytokines and specific primary antibodies 
used for heparin-binding ELISAs). Subsequently, the plate was washed three times 
with PBS-T and incubated with the secondary antibody diluted in blocking buffer 
(1:1000) [Alkaline phosphatase conjugated polyclonal Rabbit anti-Goat 
Immunoglobulins (IgG) or polyclonal Goat anti-Rabbit IgG (Sigma-Aldrich Co., 
Poole, U.K.)] for 30 minutes. The plate was washed five times with PBS-T and 100 µl 
per well of p-nitrophenol phosphate solution (para-nitrophenol phosphate FAST 
tablets, Sigma-Aldrich Co., Poole, U.K.) was added as a substrate to the enzyme 
activity. After 20 minutes of incubation at room temperature on a rotating platform for 
colour development, 50 µl of stop solution (2N H2SO4) was added. Phosphatase activity 
was detected by measuring the absorbances at 405nm on an Emax microtitre plate reader 












Table 2.1: List of cytokines and primary antibodies used for heparin binding ELISAs  
 
 
2.1.1 Synthesis of Heparin-BSA Conjugate 
 
The immobilised form of heparin to be used in the ELISA was obtained by a chemical 
coupling reaction that employed sodium cyanoborohydride in the synthesis of the 
heparin-BSA conjugate, as previously described (Najjam Et. al., 1997a). The reaction 
coupled heparin chains by their reducing ends to BSA. The reaction products, 
containing high Mr complexes were separated from uncomplexed BSA and heparin by 
gel filtration using Sepharose 4B.   
 
The fractions eluted from the Sepharose 4B column were analysed for protein-BSA 
using coomassie blue, and heparin using 1, 9-dimethylmethylene blue reagent. The 
analysis of collected fractions for protein and heparin were as indicated by absorbances 
at 525nm and 595nm respectively (Figure 2.1A). The column fractions within the inset 
(Figure 2.1A) representing the upward trend of the curve were labelled 1 to 8 and 
further analyzed by polyacrylamide gel electrophoresis against standard heparin or 
BSA.  The gel was stained for detection of heparin by Azure A staining (Figure 2.1B) 
and BSA by silver staining (Figure 2.1C).  
 


















































Both the resolving gels shown in the Figure 2.1B and 2.1C contained excluded material 
which indicated the presence of high Mr components that were unable to penetrate the 
gel.  This excluded material represented the heparin–BSA conjugate. A slow migrating 
smear of material between the excluded material and the stained band for free heparin 
or free BSA also represented heparin-BSA conjugate, but of smaller size. It penetrated 
the gel as seen in Figure 2.1B and Figure 2.1C and contained a mixed size of complexes 
of heparin chains coupled to BSA.  Fractions 2-4 containing both the forms of heparin-
BSA complex were selected and pooled together as a single heparin-BSA complex 
preparation for use in ELISA experiments. Although the pooled fraction was highly 
concentrated with heterogenous heparin-BSA conjugate, it also contained small 
amounts of uncomplexed heparin and BSA. However, later fractions, from 5 onwards 
were seen to contain some amount of this complex material in addition to appreciable 
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Figure 2.1: Synthesis of heparin-BSA conjugate: The dialysed reaction mixture was eluted 
through a 1 x 85 cm column of Sepharose 4B at a flow rate of 12 ml/hr. A) Elution profile of 
fractions collected (~ 2.5ml) and assayed for protein (▲) and heparin (■). Fractions 1-8 (inset), 
representing elution volume 50-65ml, were subjected to B) GAG electrophoresis of collected 
fractions with std as heparin (2.5µg and 5µg per well) was run on 15% polyacrylamide gels stained 
with Azure A, and C) Protein SDS-PAGE with silver staining, in order to visualise heparin and 











As a control, mock-conjugated BSA was similarly resolved by gel filtration. Fractions 
obtained were labelled 1-8, as shown in Figure 2.2 and were analysed by 
polyacrylamide gel electrophoresis. The fractions 2-4 were selected as pooled fraction 
representing mock-conjugated BSA. The protein concentration of the pooled fractions 
for heparin-BSA conjugate after lyophilisation and redissolving in buffer was 
quantified as 157 ng/μl (fractions 2-4 from Figure 2.1B and 2.1C). The concentration 
of mock-conjugated BSA was determined as 295 ng/μl (fractions 2-4 from Figure 2.2).  
 
 
2.2 KY-1 Cell Line: Culture, Maintenance and Storage 
 
KY-1 cells were NK cells obtained from p53-/- (tumour-suppressor gene) mice, which 
confer immortality to these clones as tumour cell lines. However, they require IL-2 as 
a factor for in vitro growth and proliferation as described in (Karlhofer Et. al., 1995). 
This cell line, characterised by FACS (Fluorescence-Activated Cell Sorting) for the 
expression of NK1.1 and Fc receptor was received from the laboratory of Dr. Wayne 
Yokoyama (Washington University, School of Medicine, St. Louis, MO).  Frozen vials 
of KY-1 cells were thawed at R.T for 5 minutes followed by thawing at 37 oC in water 
bath with occasional and gentle swirling. All the vial contents were transferred to 10ml 
of growth media (RPMI-1640, Sigma-Aldrich Co., Poole, U.K.) supplemented with 
10% Foetal Calf Serum (FCS) (Invitrogen Ltd, Paisley, UK), 10mM glutamine 
BSA 







Figure 2.2: SDS PAGE for mock-conjugated BSA: Gel shows various fractions 1-8 resolved on 
SDS-PAGE of BSA treated under identical conditions as conjugate and stained by coomassie blue. 




(Invitrogen Ltd, Paisley, UK), 100μg/ml penicillin/streptomycin (Invitrogen Ltd, 
Paisley, UK) and 50µM 2-mercaptoethanol (Sigma-Aldrich Co., Poole, U.K.). The 
cell-suspension was spun at 1000 rpm for 3 minutes, cells were re-suspended in fresh 
5ml growth media and cell viability was determined by Nigrosin staining method 
(Section 2.6). Cells were counted using an improved Neubauer Haemocytometer and 
plated with a density of 2 x 105 cells/ml of growth media with a total volume of 5ml in 
a 25cm2 flask (T25) with vented caps (Orange Scientific, B-1420 Braine-I’ Alleud, 
Belgium). Recombinant human IL-2 (rhIL-2) (R&D Systems, Abingdon, U.K.) at a 
concentration of 37.5 ng/ml was added to the cells and the T25 flasks were incubated 
at 37oC, 5% CO2 and 95% relative humidity for 2-3 days. The KY-1 cells are mostly 
adherent cells with few cells growing in suspension. Their growth rate seems to 
improve with slightly higher density of plating (personal communications from Dr. 
Yokoyama’s laboratory). Approximately 10% cell viability was observed with freshly 
thawed cells.   
 
For continuous maintenance of these KY-1 cells in laboratory, they were cultured as a 
monolayer in a T25 flask with growth media supplemented with rhIL-2, in a 37oC 
incubator with 5% CO2 and 95% relative humidity as mentioned above. Once the cells 
reach 70-80% confluency, which is in approximately 3-4 days, the supernatant media 
was aspirated and the monolayer was treated with cell dissociation buffer (Invitrogen 
Ltd, Paisley, UK) to detach adherent cells. Once detached, 10ml of growth media was 
added to cell suspension and the contents were transferred to a 50ml falcon tube 
containing 30ml of growth media without IL-2 and spun at 1000 rpm for 3 minutes. 
The cell pellet obtained was re-suspended in 5 ml of growth media and cells were 
counted before re-seeding, using an improved Neubauer Hemocytometer. Cell viability 
was determined by Nigrosin staining method and cells were plated with a density of 1 
x 105 cells/ml in a T25 flask containing a total volume of 4ml growth media 
supplemented with IL-2. When scaling-up was required, cells were cultured in 75cm2 
(T75) flasks and cell density was proportionately calculated. 
 
For long-term storage of KY-1 cells, a cell suspension of 1 x 107 cells/ml was prepared 
in 100% sterile FCS. To that an equal volume of 20% DMSO in FCS (v/v) was added 
drop by drop so that the final DMSO concentration becomes 10% v/v.   This cell 
suspension was mixed well and 0.5 ml dispensed into individual cryovials to be kept 




USA). Next day, the cryovials were transfered to liquid nitrogen (-196 oC) for long-
term storage. 
 
2.3 Stimulation of KY-1 Cells with IL-12 
 
For the experiments described in Section 4.2 & 5.2, KY-1 cells were used as an in vitro 
model for rmIL-12 stimulated IFN-γ production in NK cells.  KY-1 cells were 
stimulated with rmIL-12 according to the modified protocol from Garnier et al, 
(Garnier Et. al., 2003).  Confluent T25 flasks with 70-80% of adherent cells were 
detached using 2.5 ml of cell dissociation buffer and washed in 40 ml of growth media. 
The cells were resuspended in the same media to give 5 x 105 cells/ml without adding 
IL-2. 0.5 ml/well of this cell suspension was used to set up a 24-well plate. For assays 
requiring 6, 12 and 96-well plates, cell numbers and volumes added per well were 
proportionately calculated to the surface area of the well. Increasing concentrations of 
IL-12 from 0 to 250 pg/ml at the interval of 50 pg were added to the wells.  The plate 
was incubated overnight (16 hrs) at 37oC with 5% CO2.  At the end of the incubation 
period approximately 250 µl of culture supernatant was collected, spun at 1000 rpm/5 
minutes to obtain cell-free supernatant samples.  Samples were used to detect IFN-γ 
secreted by KY-1 cells by ELISA (Section 2.5).   
 
2.3.1 Addition of α/β-xylosides 
 
The effect of various xylosides such as 4-methylumbelliferyl-7-β-D-xyloside, p-
nitrophenyl-β-D-xyloside, p-nitrophenyl-α-D-xyloside and p-nitrophenyl-β-D-
galactoside (all from Sigma-Aldrich Co., Poole, U.K.) was determined on IL-12-
stimulated KY-1 cells (150 pg/ml of IL-12) (Section 4.2.6).  Due to the lipophilic nature 
of these xylosides, they were dissolved in DMSO solvent (Sigma-Aldrich Co., Poole, 
UK). As an internal control in these experiments, DMSO alone, without xyloside was 
added to the cells at the same final concentration (v/v) as DMSO with xyloside.  After 
treatment with respective xyloside and the required incubation time, cell-free culture 
supernatant was collected and assayed for secreted IFN-γ by ELISA (Section 2.5) 
 
In some experiments (Section 4.2.5), the effect of xylosides was studied on cellular 
IFN-γ, that is IFN-γ protein accumulated within the cells.  For this, the supernatant 




adherent cells were washed with 350 μl/well of ice-cold TBS buffer pH 7.4.  Cells were 
then lysed by addition of cold lysis buffer which is 1% v/v Triton X-100 in TBS buffer 
pH 7.4 containing 0.1% protease inhibitors cocktail (Sigma-Aldrich Co., Poole, U.K.). 
On addition of lysis buffer, cells were scraped, and lysate was pipetted several times to 
break up cellular clumps to release intracellular proteins (Bacon Et. al., 1995; 
Sudarshan Et. al., 1999). The contents of each well was collected in 0.5ml Eppendorf 
tubes and incubated on a roller at 4 oC for 20 minutes, followed by cold spin for 15 
minutes at a maximum speed of a table-top centrifuge. The cell lysate was collected 
and cellular IFN-γ protein was detected by ELISA (Section 2.5).  
 
2.3.2 Addition of Chondroitinase ABC 
 
Chondroitinase ABC enzyme (E.C.4.2.2.4) used was a protease free enzyme obtained 
from Proteus vulgaris (Seikagaku Corporation, Tokyo, Japan). This lyophilised 
enzyme containing 20 mM Tris buffer pH 7.2 was reconstituted in 200 µl of enzyme 
buffer (prepared by mixing 0.2% BSA with 50% v/v glycerol) to get a final 
concentration of 10 U/ml. As per the product datasheet, 1 unit (U) is defined as the 
quantity of the enzyme that catalyses the formation of 1 μmole of unsaturated 
disaccharide from chondroitin sulphate-C per min at 37oC and pH 8. 
 
To determine the effect of enzyme chondroitinase ABC on IFN-γ production (Section 
4.2.2), 0.1 U/ml of this enzyme was added with IL-12 (150 pg/ml) to KY-1 cells.  As 
an internal control, equivalent amount of enzyme buffer was added with IL-12 and the 
plate was incubated overnight at 37oC and 5% CO2. Cell-free culture supernatant was 
collected and assayed for IFN-γ by ELISA (Section 2.5).   
 
2.4 Assay for detection of Chondroitinase ABC activity 
 
A qualitative assay for the detection of enzyme chondroitinase ABC activity was 
conducted [modified and adapted from (C. Rider and Hounsell E. F. 1998)]. A set of 
three tubes were prepared, with one containing 1 ml of growth media representing the 
negative control. A second tube contained standard chondroitin sulfate B (CS-B) 
solution (2 mg/ml) (from bovine mucosa, Sigma-Aldrich Co., Poole, U.K.) and 100 μl 
of enzyme chondroitinase ABC (2 U/ml) that represented the treated control or 




enzyme buffer representing the untreated control or positive control.  CS-B solution for 
both the second and third tubes was prepared in growth media. After addition of one 
drop of toluene to each of the above tubes, they were tightly closed and incubated 
overnight at 37oC. The enzyme activity was detected by the digestion of CS-B. This 
was determined by adding 100 µl of 10% (w/v) cetylpyridium chloride solution 
(Sigma-Aldrich Co., Poole, U.K.) to all the tubes, and a white opalescent precipitate 
establishes the presence of intact GAG. Only the positive control observed the presence 
of intact CS-B-GAG chains by forming a visible flocculant precipitation. However, the 
absence of precipitation in experimental test tube indicated that the enzyme preparation 
actively degraded CS-B chains and therefore was unavailable for a precipitation 
reaction. 
 
2.5 Quantification of Secreted and Cellular IFN-γ by ELISA 
 
A sandwich ELISA (indirect method) was performed for secreted and cellular IFN-γ, 
as per the manufacture’s protocol of the OPTEIA kit (Pharmingen Inc, San Diego, CA). 
 
2.6 Cell Viability Assay 
 
50 μl of cell suspension was added to 20 μl of 0.1% Nigrosin stain solution (Sigma-
Aldrich Co., Poole, U.K.) and mixed thoroughly. 20 μl of this mixture was applied to 
an Improved Neubauer Hemocytometer slide and cells were counted for viability under 
40x magnification of light microscope.  Non-viable cells were completely stained 
purple-blue due to penetration of dye whereas the viable cells remained unstained. The 
percentage cell viability was determined by comparing the number of unstained viable 
cells to the number of stained cells. 
 
2.7 Preparation of Cell Lysates for SDS-PAGE 
 
Adherent cells in the 6-well culture plate (Orange Scientific, B-1420 Braine-I’ Alleud, 
Belgium) were treated with 500µl cell dissociation buffer. The contents of the well 
were collected in eppendorf tubes and spun at 1500 rpm for 5 minutes.  To the cell 
pellet, 100µl of hot TBS- 1% SDS buffer and 5 x Laemmli’s SDS sample buffer (4 ml 




SDS, 0.4ml 2-mercaptoethanol, 0.2 ml of 5% bromophenol blue) was added. The 
samples were boiled for 5 minutes to lyse the cells and denature the proteins, then 
briefly cooled on ice. Further, to maximise the detection and identification of 
phosphorylated STAT-4, 1mM of activated pervanadate (PV) solution, 0.1% cocktail 
of Protease inhibitors (Sigma-Aldrich Co., Poole, U.K.) and Phosphatase inhibitors 
(diluted 1:100) (Sigma-Aldrich Co., Poole, U.K.) were added to the cell lysate. These 
additions protect the integrity of phosphoproteins for detection. The PV solution was 
prepared immediately prior to use by mixing 1M H2O2 and 1M sodium vanadate 
solution (both Sigma-Aldrich Co., Poole, U.K.) in a 1:1 ratio to produce 0.5M 
pervanadate solution which at 500x dilution with cell lysate resulted in 1mM final 
concentration. The samples were then stored at -20oC. Where appropriate, the protein 
content in the cell lysate samples was determined using Pierce micro BCA protein assay 
following the manufacturer’s instructions (see Section 2.8.2). Prior to use for SDS-
PAGE (Section 2.9.1), the samples were thawed on ice, then boiled for 5 minutes, and 
centrifuged for 1 minute at maximum speed in a table-top centrifuge (1000 x g). 
Samples were run at an equal protein loading on 10% SDS-PAGE gels and analysed 
by western blotting. 
 
2.8 Protein Assays 
 
Where appropriate, the protein content in the samples was determined by either using 
a Coomassie Blue assay or a Microprotein assay. 
 
2.8.1 Coomassie Blue Assays 
 
The concentration of protein in a sample was measured in a 96 well microtitre plate 
(Dynatech Laboratories Inc.) using Coomassie Blue assay by absorbance at 595nm 
(Section 2.1.1). 20 µl of sample was mixed with 200 µl of Coomassie Blue reagent 
(Pierce Coomassie Plus Protein Assay reagent, Thermo Fisher Scientific, Rockford, 
USA). Absorbance at 595nm was measured against blank control (20 µl double 
distilled H2O and 200 µl Coomassie Blue reagent). The average of three absorbance 
readings per sample was calculated and read against a calibration curve of a known 
bovine serum albumin (BSA) with concentrations from 0-1.5 mg/ml at intervals of 0.3. 
Standard BSA (Sigma-Aldrich Co., Poole, U.K.) solution was prepared in 0.25M 





2.8.2 Microprotein Assays 
 
Protein content of samples was estimated using the Pierce micro BCA and was carried 
out according to manufacturer’s instructions (Thermo Fisher Scientific, Rockford, 
USA). This method was used for some of the samples made up in SDS sample buffer.  
 
 
2.9 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 




SDS-PAGE was carried out as previously described (Laemmli, 1970) using a Bio-Rad 
minigel apparatus. The apparatus was used to cast a 10% polyacrylamide separating 
gel by mixing 2.95 ml deionised H2O, 1.9 ml separating buffer (1.5 M Tris-HCl buffer, 
pH 8.8), 2.5 ml of 30% (w/v) acrylamide (BDH chemicals, UK), and 75 μl of 10 % 
(w/v) SDS with 75 μl of 10% ammonium persulphate (APS) and 3 µl TEMED 
[tetramethylethylenediamine] (Sigma-Aldrich Co., Poole, U.K.) to allow 
polymerisation. This was followed by addition of 4% stacking gel solution prepared by 
mixing 2.9 ml deionised H2O, 950 µl of 30% (w/v) acrylamide, 1.25 ml stacking buffer 
(0.5 M Tris-HCl buffer, pH 6.8), 31.5 µl of 10% APS and 7.5 µl TEMED.  10 μl/well 
of samples obtained from the above extraction method (Section 2.7) were loaded into 
the gel, along with 5 µl of prestained protein standard (SeeBlue Plus2 Pre-Stained 
Standard, range 4-250 kDa, Invitrogen, Paisley, UK).  The casting apparatus with gels 
was placed in an electrophoresis chamber unit (Bio-Rad Laboratories, UK), filled with 
running buffer [25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS and pH 8.3]. Gels were 
elecrophoresed at a constant voltage of 200V in running buffer until the dye-
bromophenol blue in the samples reached end of the gels. 
 
2.9.2 Coomassie Blue Staining of SDS-Polyacrylamide Gels 
 
To detect protein separation after SDS-PAGE, gels were stained with Coomassie blue 
solution [0.25% (w/v) Coomassie Brilliant blue R250 (Sigma-Aldrich Co., Poole, 




were destained with destaining solution [45% (v/v) Methanol, 5% (v/v) Acetic acid in 
deionised H2O] until the protein bands were clearly visible against the background. 
 
2.9.3 Western Blotting 
 
Proteins resolved on SDS-polyacrylamide gel were transferred onto a nitrocellulose 
membrane of 0.45µm of pore size (Schleicher & Schwell, Whatman plc, Maidstone, 
Kent, UK) with a wet blotting technique (modified from (Towbin Et. al., 1979) using 
the Bio-Rad minigel system (Bio-Rad Laboratories, UK). The gel-nitrocellulose 
membrane was assembled between two sheets of Whatman filter paper (3mm) and 
transfer pressure pads. This was then placed in a blotting tank containing chilled 
blotting buffer [25 mM Tris, 192 mM Glycine, 1% (w/v) SDS with 20% (v/v) 
Methanol]. Nitrocellulose membrane and Whatman papers were pre-soaked in blotting 
buffer for 15 minutes prior to blotting.  Protein was transferred onto membrane by 
electrophoresis at a constant voltage of 100 V for 1hour.  Following the transfer, gels 
were stained with Coomassie blue solution (Section 2.9.2). Alternatively, after transfer 
of proteins by electrophoresis, the nitrocellulose membrane was stained with Ponceau 
staining solution [0.5% (w/v) Ponceau Red (Sigma-Aldrich Co., Poole, U.K.) in 3% 
(v/v) acetic acid] to determine successful protein transfer onto the membrane and 
confirms the effectiveness of blotting procedure. Blots were washed three times in 1x 
TBS buffer (136mM NaCl, 19.8mM Tris base, diluted 1/10, pH 7.6) with 10 minutes 
per wash, dried, and preserved between Whatman papers until further used for 
immunodevelopment. 
 
2.9.4 Immunodevelopment of Western Blots 
 
Following western blotting, various cellular proteins, such as tyrosine phosphorylated 
STAT-4, serine phosphorylated STAT-4, unphosphorylated STAT-4, T-bet, and β-
actin (loading control) were detected using a specific primary antibody for each of these 
proteins. Blotted membranes were washed three times in TBS with 10 minutes per wash 
then incubated for 30 minutes in blocking solution (2% marvel, 0.1% Tween-20 in 1 x 
TBS buffer) at R.T.  Following this, the blots were incubated overnight at 4oC with 
specific primary antibody diluted in blocking solution (see Table 2.2 for details of 
primary antibodies and their dilutions used). On the following day, blots were washed 




blots were incubated in secondary antibody conjugated to horseradish peroxidase 
(HRP) enzyme [usually at a dilution of 1:1000 for polyclonal goat anti-mouse IgG 
(Dako, Denmark) and 1:5000 for polyclonal goat anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories Inc., USA)] in blocking solution for 1 hour at room 
temperature for chemiluminescent reaction. Following this, the blots were washed for 
three times with TBS buffer for 5 minutes each time. Chemiluminescent substrate 
(Pierce ECL, Thermo fisher Scientific, Rockford, USA) was applied to the blots for 5 
minutes, according to the manufacturer’s protocol. Blots were covered with cling-film 
and exposed to an appropriately sized film (Hyper-film, Amersham Biosciences Plc., 
UK) for some amount of time as required (varying from a few minutes to 1 hour), 
depending on the strength of chemiluminescence. Following this exposure, the film 
was placed in developing solution for 1-2 mins, rinsed with water and placed in fixer 
for 1-2 mins. The immunoreaction between the protein of interest and antibodies was 
visualised as bands, the intensity of which was measured using software – Image J. 
Densitometric analysis of bands on western blots was performed using blots from three 
independent experiments. However, densitometric analysis should only be viewed as 
semi-quantitative due to restrictions in sample numbers and is dependent upon the 
signal strength of chemiluminescence substrate and exposure time.  
 
Table 2.2: Details of primary antibodies used for immunodevelopment of western blots 
 
Primary Antibodies  Dilution used Company Details  






1:200 Zymed Laboratories, 
CA, USA 
Rabbit polyclonal anti-STAT-4 (C-
20)  
1:800 Santa Cruz 
Biotechnology, C.A., 
USA 
Mouse monoclonal anti-β-actin (AC-
15)  
1:1000 (Sigma-Aldrich Co., 
Poole, U.K.) 
Horseradish peroxidise conjugated 
Goat polyclonal anti-mouse IgG 
  
1:1000 Dako, Denmark  
Horseradish peroxidise conjugated 
Goat polyclonal anti-rabbit IgG  
1:5000 Jackson 
ImmunoResearch 






phosphorylated (S721)-STAT-4  




2.9.5 Stripping and Reprobing of Western Blots 
 
Where appropriate, blots were stripped and reprobed for different proteins. For this, 
membranes were washed three times for 10 minutes each in TBS buffer, followed by 
incubation in Glycine-SDS buffer (25 mM Glycine buffer, pH 2.0, 1% SDS) for 30 
minutes at room temperature on a rotating platform. The blots were washed three times 
for 10 minutes each in TBS-T buffer and incubated in a secondary antibody conjugated 
with HRP for 30 minutes at room temperature. Blots were developed on a film by 
applying chemiluminescent substrate. This step was optional as it detected the stripping 
efficiency and to check the removal of original signal. If this step was performed, the 
blot was washed three times in TBS-T for 5 minutes per wash, followed by incubation 




pFL-IFN reporter plasmid (7.6kb) used in the transfection experiments is a -777bp to 
+ 48bp murine IFN-γ promoter-driven luciferase construct, D3575 (-777), which was 
received as a kind gift from Dr. Howard Young (Laboratory of Experimental 
Immunology, NCI-Frederick, MD). Originally, this plasmid was constructed by Dr. 
Ken Murphy (Washington University, St. Louis) by cloning the IFN-γ promoter 
fragment from -777bp to + 48bp relative to the transcription start site (TSS) of the 
murine IFN-γ gene in pBS-LUC (~6.8kb), a firefly luciferase-based backbone vector 
with ampicillin resistance gene (Ampr). pBS-LUC vector plasmid was generated as a 
high-copy-number, luciferase reporter plasmid by cloning 3.8kb PstI-NdeI fragment 
from PXP-2 into SacI-KpnI sites of pBSII.SK- [2958bp, Bluescript II (SK-)] plasmids. 
pBS-LUC plasmid has also been previously used for creating variously-sized IL-2 
(IL2-LUC) and IL-4 (IL4-LUC) promoter reporter vectors for tranfection in EL-4, T 
cell lines, as described in (Szabo Et. al., 1993) suggesting that the vector could be 
successfully transfected for expression in mammalian cells. 
 
To prepare an amount of DNA sufficient for transfection experiements, pFL-IFN 




cells (Invitrogen) and a single colony of cells was selected from Luria-Bertani (LB) 
agar plate containing ampicillin. The plasmid DNA was extracted and purified by DNA 
mini-prep (QIAprep Spin Miniprep Kit, Qiagen Inc, Valencia, CA, USA), followed by 
DNA maxi-prep (EndoFree Plasmid Maxi Kit, Qiagen), according to manufacturer’s 
protocol. DNA was quantified by a SmartSpec 3000, Spectrophotometer (Bio-Rad 
laboratories, Hercules, CA, USA) and absorbance readings at 260/280nm were 
calculated as per program settings in the instruction manual. Further, the construct was 
verified by sequencing performed by The Sequencing Service (College of Life 
Sciences, University of Dundee, Scotland) using standard primers, M13 Fwd (-20) and 
M13 Rev.  
 
Since the experimental vector, pFL-IFN, was a firefly-based luciferase vector, a Renilla 
luciferase plasmid, pRL-TK (Promega, Southampton, UK), was used together to co-
transfect KY-1 cells. Co-transfections with pRL-TK vector served as an internal control 
to normalise transfection efficiencies. Internal control reporter activity reflects the 
amount of DNA transfected into cells and their capability to express proteins. 
Therefore, normalisation of experimental vector with respect to co-transfected control 
vector considers transfection variability such as cell plating and transfection efficiency 
from one experimental or sample well to other. Thus, vector normalisation is generally 
recommended in for transient transfection of cells to control data variability arising 
from difference in transfection efficiency per sample well (Schagat Et. al., 2007). pRL-
TK is a commercially available, 4kb vector with the herpes simplex virus thymidine 
kinase promoter (HSV-TK) placed upstream of renilla luciferase gene. In the co-
transfections, it is important to consider that a stronger promoter in the control vector 
could mean trans effects on experimental promoter activity. Therefore, HSV-TK, 
which is considered as a moderate promoter for the constitutive expression of renilla 
luciferase reporter gene in transfected mammalian cells was selected. Further, to ensure 
independent experimental and control reporter gene expressions, preliminary co-
transfection experiments were performed to optimise the amount of total DNA and the 
ratios of control to experimental reporter vectors used. All transfections were internally 
controlled by pRL-TK reporter vector that is expressed under moderate but constitutive 







2.11 Transient Transfections and Luciferase Analysis 
 
2.11.1 Transient Transfection of KY-1 Cells 
 
NK cells are one of the difficult cells to transfect. To our knowledge, transient 
transfection of KY-1 cells has not been previously reported. Therefore, the first attempt 
to transfect this cell line was using the Amaxa nucleofection technology TM [Lonza 
(Amaxa), Basel, Switzerland] reported to be effective for NK cells (Maasho Et. al., 
2004). This contemporary nucleofection method was found to be highly efficient 
compared to other conventional methods of gene transfections, such as GeneJuice 
transfection reagent (Novagen, Germany) and lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA), that were carried out at the same time.  
 
For transfections, KY-1 cells were grown in T75 flasks to scale-up cell numbers. Once 
the cells in the flasks reached 80-85% confluence, they were used for transfection. Cells 
in highly proliferative stage (log-phase) were used, counted and cell viability was 
determined (Section 2.6) to be >90% and therefore optimal conditions for transfections. 
Transfections were performed as per the manufacturer’s protocol for the various 
methods used. Efficiency of the method was validated by the expression of either 
pEGFP plasmid (4.7kb vector encodes enhanced green fluorescent protein, Clontech 
Labs., CA, USA) or pmaxGFP® [3486bp plasmid encodes green fluorescent protein, 
Lonza (Amaxa), Basel, Switzerland] as the marker in a single plasmid transfection as 
well as in co-transfections with the pRL-TK vector. Transfections using GeneJuice and 
Lipofectamine 2000 resulted in poor efficiency in comparison to the nucleofection 
approach. Rather, post-nucleofection yielded 15-20% transfection efficiency and 
cellular confluency of ~40-60% in wells using ‘V’ solution kit [Lonza (Amaxa), Basel, 
Switzerland]. Initial co-transfections performed using Amaxa nucleofection 
technology, included pmaxGFP®, and pRL-TK vectors in the proportion of 1 (control) 
to 5 (experimental) with the total of 10µg vector DNA added to 2.5 x 106 cells. Dupicate 
wells per condition were prepared with appropriate controls, including negative 
controls (cells nucleofected without DNA) and non-transfected (NT) wells.  
 
Further, transfection conditions were optimised for co-transfections of KY-1 cells with 
pFL-IFN (murine IFN-γ reporter construct, experimental) and pRL-TK (control) 




used. Briefly, KY-1 cells in log-phase growth were harvested and nucleofected with 
plasmids, pRL-TK (1.65µg) and pFL-IFN (8.35µg) in the proportion of 1 to 5. Each 
cuvette contained 100 µl of 4 x 106 cell suspension mixed with total 10µg plasmid 
DNA in solution ‘V’ and nucleofected using NucleofectorTM II device (Lonza (Amaxa), 
Basel, Switzerland) set for program T-020 (Manufacturer’s handbook). Nucleofected 
cells were immediately transferred into the wells of 6-well plates containing 1ml pre-
warmed growth media with IL-2 and incubated at 37oC, 5% CO2. After a rest period of 
5 hours, culture media was replaced to remove cell debris produced on nucleofection, 
with fresh growth media containing IL-2 and continued for overnight incubation. Next 
day, transfected wells with ~40-50% confluency were gently washed with fresh growth 
media without IL-2 and replaced with the same. At this time, cells were treated with 
TGF-β1 (10ng/ml) for 30 mins followed by stimulation with IL-12 (10ng/ml) alone or 
IL-12 plus IL-18 (100ng/ml) for 3 hours. Duplicate wells per cytokine treatment group 
including untreated group (no cytokines) were prepared. Appropriate controls such as 
negative controls (nucleofected cells without DNA) and non-transfected (NT) wells 
were treated with the same procedure as experimental wells. After this cytokine 
stimulation of transfected cells, supernatant culture media was collected to determine 
the endogenous IFN-γ levels by ELISA (Section 2.5). Cells were lysed and extracted 
for luciferase activity (Section 2.11.2).  
 
2.11.2 Luciferase Assays by Dual-Luciferase® Reporter Assay System 
 
The Dual-Luciferase® Reporter Assay System (DLR®) (Promega, Southampton, UK) 
was used, which allows for the detection and measurement of both firefly and Renilla 
luciferase activities from a single sample of cell lysate, as per the manufacturer’s 
protocol. Briefly, after specific cytokine stimulations, transfected KY-1 cells were 
washed twice in PBS. 250 µl of passive lysis buffer (PLB) was added and plate was 
incubated for 20 mins at R.T. on a rotating platform. To ensure complete cell lysis, the 
contents of the well were mixed by active pipetting. Two aliquots of 100µl each, per 
cell lysate sample were prepared. On addition of each 100µl of sample aliquot to 100µl 
luciferase reagent (LAR II), both firefly luciferase, followed by renilla luciferase 
activities were measured sequentially using a luminometer (Turner Biosystems 
luminometer model TD 20/20; Promega, Southampton, UK). The instrument was set 
for 2-second pre-measurement delay followed by 12-seconds measurement period, 




measured as light emission over a period of 12 seconds. The Luminometer was also 
programmed to take three readings per sample that were averaged. The background 
signal due to the instrument, sample tubes and luciferase reagents was determined by 
preparing a cell lysate from non-transfected (NT) control cells and same steps as 
samples to measure luminescence was performed. This background measurement was 
subtracted from each sample reading. Three independent transfection experiments were 
performed with each experiment containing duplicate wells per cytokine treatment 
group.  
 
Since all transfections were internally controlled by co-transfection with the pRL-TK 
vector, for each transfected well, firefly luciferase activity (experimental) followed by 
the activity of renilla luciferase (control) were determined in Relative Light Units 
(RLU) and their ratio (F/R) was obtained to normalise the sample values. After 
normalisation of values to the control (pRL-TK expression), pFL-IFN expression under 
various cytokine treatment was compared to its baseline expression in untreated (no 
cytokine) wells, for which the ratio (F/R) was taken as ‘1’. This determines the 
normalised fold change in activity per cytokine treatment and also gives the relative 
difference in activity between different treatment groups. 
 
2.12 Statistical Analysis 
 
Data were presented as mean ± standard deviation (SD), or ± standard error mean 
(SEM) as appropriate. Comparative data were analysed using unpaired Student’s t test 
and one-way ANOVA with post hoc test. As appropriate, for some of the data (Chapter 
4), statistical significance was determined by the non-parametric Mann-Whitney’s test 
and Kruskal-Wallis test for group comparison. A p value of ≤0.05 was considered as 
statistically significant. All statistical analysis was performed using SPSS (versions 


























     CHAPTER 3 
 
INVESTIGATION OF BINDING OF INTERLEUKINS 11, 







Interleukins, IL-11, IL-18 and IL-22, share close structural relationships to their known 
heparin-binding family members. Thus, it was hypothesised that heparin binding is a 
common feature among the interleukins within their respective family. The goal of this 
chapter is to investigate whether these three interleukins, IL-11, IL-18 and IL-22 from 
different cytokine families can bind to heparin. Moreover, the current investigation 
stems from the knowledge that the selected interleukins displayed potential heparin-
binding domains (HBDs) which corresponds to the cluster of basic residues in their 
primary structure. In all the experimental and theoretical studies conducted here, 
heparin has been used as a representative compound for HS. Heparin being a 
pharmaceutical product is readily available in bulk as a highly sulphated analogue of 
HS. Because of this commercial availability of heparin, it is most commonly employed 
for protein-HS interaction studies.  
 
The current investigation followed a systematic approach to ensure a comprehensive 
structural and biochemical study. For this, a combination of strategies such as 
predictive docking calculations and biochemical method like ELISA were employed to 
investigate the possible binding of IL-11, 18 and 22 to heparin. Initially, the amino acid 
sequences of the chosen set of interleukins were examined to identify the potential 
clusters of basic residues in heparin binding. Thus, the number and distribution of basic 
amino acids was determined from the primary structures of IL-11, IL-18 and IL-22. 
Subsequently, the clustering of basic amino acids that could potentially form a binding 
site for heparin chains on a three-dimensional protein structure was inspected. This was 
further developed by employing docking calculations based on the high-resolution 
structures of the interleukins with those of heparin pentamers and endecamers to predict 
the possibility of heparin binding. This predictive approach was based on minimum 
interaction energy level calculations. Finally, the experimental validation of binding of 
interleukins 11, 18 and 22 to heparin was performed using a specialised heparin-
binding ELISA technique. This technique makes use of an immobilised heparin-BSA 








3.2 Results  
3.2.1 Examination of the Amino Acid Sequences of IL-11, 18 and 22 
 
An initial step in determining that a given protein might interact with heparin/HS GAG 
is to screen its amino acid or primary sequence. Screening of primary sequences can 
reveal any clusters or groups of basic residues within a short peptide region. It has been 
well-established that the basic residues, arginine and lysine largely contribute towards 
GAG binding (Caldwell Et. al., 1996; Fromm Et. al., 1997; Hileman Et. al., 1998). 
Hence, to consider the interleukins 11, 18 and 22 as likely candidates for heparin-
binding studies, the overall number and clusters of basic residues within the protein at 
the sequence level was examined first. 
 
As seen in Figure 3.1, the primary sequences of mature proteins, IL-11, -18, and -22 
contained high number of basic residues, arginine (R) and lysine (K) (colour coded). 
IL-11 contains 20 basic residues (11.2%) out of total 178 amino acids; IL-18 has 22 
basic residues out of total 157 amino acids (14%), and lastly IL-22 has 18 basic residues 
(12.3%) out of total 146 amino acids. These numbers were comparable to other known 
heparin-binding cytokines, such as IL-6, which contained 23 basic residues (12.6%) in 
total of 182 amino acids, and GDNF with 25 basic residues (18.5%) out of total 135 
amino acids.  
 
Nevertheless, besides the high number of basic residues, arrangement of these residues 
in the primary sequence of proteins constitute sequence-motifs for heparin binding. A 
typical heparin-binding site (HBS) generally, consisted 4-6 basic residues in a single 
cluster within the linear arrangement of amino acids, or on the surface of a higher order 
of a structurally folded protein (Hileman Et. al., 1998).  As seen in Figure 3.1 (yellow 
highlight), primary structure of IL-11 highlighted the presence of a basic sequence-
motif (111RLDRLLRR118) that closely resembled Cardin-Weintraub motif. 
Additionally, though IL-18 (129KERDLFKLILKK140) and IL-22 (114KLKDTVKK121) 
also exhibited presence of a cluster with about 4-6 basic residues near their carboxyl-
terminus (highlighted in yellow), these basic clusters did not exactly match any known 
consensus sequence-motifs. However, these clusters in IL-18 and IL-22 may represent 
continuous heparin-binding sites. Particularly these carboxyl-terminal basic peptides 
are part of most HBS/HBDs of cytokines (Kuschert Et. al., 1998; Lortat-Jacob Et. al., 




particularly useful in predicting and correlating basic sequences or clusters to HBD in 
the three-dimensional structure of proteins. 
 
Besides these clustered basic residues in the linear arrangement, a good number of basic 
residues were also evenly distributed through the entire primary sequences of IL-11, 
18 and 22 proteins. This can lead to discontinuous-centres for heparin binding in which 
the single and dispersed basic amino acids not close in the linear sequences of IL-11, 
18 and 22, come together to form clusters on higher order of their structural 
arrangements. Moreover, as explained earlier in Section 1.4.3 that the interaction with 
heparin chains is also dependent on the accessibility of these basic residues and their 
side chains on the surface of a three-dimensional protein structure. Hence, this further 




1    PGPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHN    50 
51   LDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKT100 




1    YFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRTIFIIS     50 
51   MYKDSQPRGMAVTISVKCEKISTLSCENKIISFKEMNPPDNIKDTKSDII     100 





1    APISSHCRLDKSNFQQPYITNRTFMLAKEASLADNNTDVRLIGEKLFHGV   50 
51   SMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLARLSNRLSTCH 100 










Figure 3.1: Primary sequences of the ILs-11, -18, -22 showing basic amino acids in putative 
heparin/ HS binding: The amino acid sequences of mature, secreted forms of human (Swiss-Prot 
accession numbers) IL-11 (P20809), IL-18 (Q14116) and IL-22 (Q9GZX6) are shown with all amino 
acid residues represented by one letter code. The basic amino acids are shown as coloured letters, 
arginine = R and lysine = K. Primary sequences with four or more basic residues in proximity are 
highlighted in yellow. Superscript numbers refer to amino acid numbering in the secreted protein 




3.2.2 Structural Studies and Molecular Docking Calculations with IL-11, 18 and 
22 
 
This structural study involved inspection of a high-resolution, three-dimensional 
structure of a selected interleukin to gain more insight into its surface features, 
particularly positively-charged patches/clusters that can possibly interact with heparin. 
Firstly, structural studies of interleukins, IL-11, IL-18 and IL-22 enabled confirmation 
of the presence of basic clusters that appeared significant from the primary sequence 
studies (Figure 3.1), onto the surface of the three-dimensional structures of the proteins. 
Secondly, it also helped to identify possible discontinuous HBSs formed by isolated 
basic residues, distant in sequence but which form into positively-charged clusters on 
tertiary and quaternary structural folding. Finally, for the protein structures that were 
experimentally determined and available in the protein data bank (PDB), such as for 
IL-18 (1J0S) and IL-22 (1M4R), molecular docking studies were applied to predict 
possible heparin binding and to locate HBS on the surface of these interleukins. 
Molecular docking calculations were performed on our behalf by a collaborator, Dr. 
Barbara Mulloy (National Institute for Biological Standards and Control, NIBSC). 
These studies were carried out as per the method (described in Forster & Mulloy, 2006; 
Mulloy & Forster, 2008). However, for IL-11, an experimentally-resolved structure 
(4MHL) was very recently published (T. L. Putoczki Et. al., 2014), therefore the 
docking calculations were not conducted for this protein at the time of this study. 
 
Below is the brief description of the molecular docking method employed in the current 
study. Molecular docking also referred to as docking calculations, is a more systematic 
approach in identifying HBDs on a protein-surface. It also determines free binding 
energy values, called energy scores that calculate binding affinity between a ligand and 
a protein.  Several published reports have used different software options for this 
purpose (Bitomsky W., 1999); however, the research work conducted in this study was 
based on using Autodock 2.4 version of software (Oxford Molecular Inc.) (G. M. 
Morris Et. al., 1996). The docking protocol starts with screening the entire surface of a 
three-dimensional protein structure for the presence of basic clusters that may offer a 
suitable binding fit to negatively-charged groups on heparin chains. This is followed 
by docking several well-defined, semi-flexible heparin oligosaccharide ligands onto 
the protein structures. Because of the structural diversity in heparin chains, the highly 




this technique.  Hence, the docking protocol uses a generic heparin model ligand based 
on the NMR structure-1HPN.  The structural details of 1HPN has been briefly 
described earlier (Section 1.3.3). This model ligand is available in the PDB (Protein 
Data Bank) files and has been used to predict binding sites on the surfaces of many 
proteins with remarkable success (Mulloy Et. al., 1993). High-resolution structures of 
interleukins IL-18 and IL-22 used in this study were also available in the PDB and were 
determined experimentally by either crystallography or NMR. 
 
The most mutually favourable binding mode for the heparin-protein complex that 
yields the lowest inter-molecular interaction energy (kcal/mol) was determined. 
Complexes with predicted energies below -1000 kcal/mol were regarded as proteins 
having the capacity to bind heparin. In addition to predicting the location of heparin-
binding sites on the target protein, the molecular docking can also determine the key 
basic residues involved in the interaction.  However, the docking method does not 
provide details on the contribution of specific sulphate groups on the heparin ligands 
to the interaction. Moreover, this molecular docking method has also limitation in the 
case of proteins that require GAGs for oligomerisation. Therefore, it is important to 
know whether the monomer or higher oligomer of a protein is more appropriate for 
GAG binding. Since IL-22 exists in both monomeric and dimeric forms, docking 
calculations were applied to each form separately. 
 
The docking protocol used in the current study has been very well validated using 
prototypical heparin-binding proteins such as FGF-1, FGF-2, and antithrombin III. It 
has also been successfully used for predicting heparin binding to various cytokines, 
chemokines and growth factors (Mulloy & Forster, 2000; Mulloy & Linhardt, 2001). 
However, the outcome of this molecular docking calculation is only predictive. This 
simulation method has been useful to illustrate and rationalize data from biochemical 
and experimental studies. In the current study, predictions from docking calculations 
in combination with heparin-binding ELISAs were employed to determine the affinity 
between heparin and the selected interleukins. 
 
3.2.2.1 Structural Model of Human IL-11  
  
At the time of this study, an experimentally derived, high-resolution structure of IL-11 




other members of long-helical or IL-6 family of cytokines to understand structure-
function relationship. Since, a group of basic residues within a short-peptide region was 
identified from the primary sequence data of IL-11 (Figure 3.1), it was decided to 
examine the proposed structural homology model of IL-11 to potentially reveal the 
location of these basic residues and hence a putative heparin-binding domain. The 
homology model of IL-11, constructed by Czupryn Et. al., (1995a) provided structural 
details that were useful in analysing and understanding features in heparin binding. This 
proposed homology model, as shown in Figure 3.2A was constructed based on amino 
acid sequence homology and common secondary structural units (four-helix bundle 
topology), a characteristic feature within the family of long-chain, haematopoietic 






As seen in Figure 3.2, IL-11 is proposed as an α-helical protein with four helices 
labelled A-D connected by loops. In Figure 3.2B, the hydrophobic residues are seen 
Figure 3.2 Proposed structural model of IL-11: Based on the sequence similarity of IL-11 with 
the members of long chain, α-helical cytokines, secondary structural elements were proposed that 
resulted in a typical four-α-helical bundle topology, characteristic of haematopoietic cytokines (M. 
J. Czupryn Et. al., 1995a). A) Topological arrangement of four α-helices labelled A-D connected 
with two loop regions (loops AB, CD) are shown with the arrows indicating N- to C-terminal 
orientation. B) Top view of the four-α-helix bundle structure of IL-11 is shown. Hydrophobic 
residues facing the core of the protein structure are highlighted together in a crescent shape. Surface-
exposed, charged residues are highlighted in circles for all helices. A notable group of Arg [R] 
residues (at positions 111, 114,117 and 118) are seen on the exposed surface of helix C. These basic 
residues could be postulated to be important surface contacts for interaction with heparin chains. 




lying at the interface formed by α-helices. However, an interesting feature observed in 
this structural model of IL-11 was an array of charged arginine (R) residues (Arg 111, 
114, 117 and 118) that formed a part of the solvent-exposed surface of helix C. Indeed, 
these basic residues forming a cluster on helix C belonged to the basic sequence-motif 
(111RLDRLLRR118), identified in the primary sequence of IL-11 (Figure 3.1). 
Therefore, this basic peptide region identified from the primary sequence analysis was 
apparently a surface-exposed feature and could be postulated as important in the 
interaction with heparin chains. However, this observation could not be confirmed by 
the molecular docking strategy. This was because, application of docking calculations 
to the structural homology models would have introduced higher uncertainty in the 
docking protocol used and may result in an artefact (Mulloy & Forster, 2008).  
 
Additionally, this proposed structural model for IL-11 and the observation regarding 
the surface-arginine residues are in good agreement with the recently reported crystal 
structure of IL-11 (T. L. Putoczki Et. al., 2014) (Figure 3.3; PDB ID 4MHL). 
Accordingly, the crystal structure of IL-11 comprised of four core helices (Figure 3.3A, 
labelled A-D) with long loop regions between helix A-B and C-D. Moreover, structural 
analysis by Putowczki et. al. showed the presence of aforementioned basic residues 
(Arg 111, 114, 117 and 118) as a positively charged patch. This was seen, particularly 
on the surface formed by helices A and C, as revealed from the distribution of surface 
electrostatic potential in IL-11(Figure 3.3B). Interestingly, a comparative structural 
study between IL-11 and IL-6 by Putoczki et al highlighted the presence of an extended 
area of positive electrostatic potential in IL-11 as a distinguishing feature. Whilst, IL-
6, a structural and functional counterpart of IL-11 within family, exhibited more 






Since, receptor binding and heparin binding, both results from the involvement of 
surface elements, it is an important comparison in further understanding IL-11-
heparin/HS interaction and its functional implications. The chemical modifications and 
site-directed mutagenesis experiments revealed the residues important for receptor-
binding and the biological activity of IL-11(tacken 1999, (M. J. Czupryn Et. al., 1995a; 
M. Czupryn Et. al., 1995b). These residues have been grouped into three sites as shown 
in the crystal structure of IL-11 (T. L. Putoczki Et. al., 2014), Figure 3.3A. Indeed, the 
comparison of receptor-binding residues with the predicted heparin-binding residues, 
Arg 111, 114, 117, and 118, from primary sequence data (Figure 3.1), showed 
overlapping at the interaction site (Site II) in IL-11 for signalling receptor subunit, 
gp130. Additionally, three of the arginine residues from the potential heparin binding 
site were observed to be important for IL-11 activity via receptor site II for gp130 
subunit (Figure 3.3A). This observation indicated that the interaction of IL-11 with 
Figure 3.3 Crystal structure of human IL-11 (PDB Id 4MHL): (A) Schematic representation 
of the IL-11 structure as ribbons indicating four alpha helices (labelled A-D) and loop regions. 
Residue contacts in binding to IL-11Rα (Site I) and to subunits of gp130 (Site II, Site III) are shown 
in stick model. Arg residues on helix C form part of putative heparin-binding region on IL-11 as 
well as gp 130 receptor-binding site II. (B) Surface representation of the IL-11 structure. 
Negative (red) and positive electrostatic potential (blue) is shown for IL-11. The presence of Arg 
residues (132, 135 and 139) on helix C is seen forming a large area of positive potential between 
helices A and C, around Site II. The orientation of both structural representation (A) and (B) is 
same. Residue numbering is according to the full-length precursor sequence of IL-11. Figure 




heparin/HS would interfere with its binding to gp130 molecule and hence signalling. 
Therefore, based on the spatial distribution and/or orientation of basic residues on a 
three-dimensional structure of IL-11, they might be available for possible heparin 
binding. However, further biochemical study was used to determine whether IL-11 
possesses heparin-binding property or not.   
 
3.2.2.2 Examination of the Structure of Human IL-18 for Possible Heparin-binding 
Sites 
 
An experimentally determined structure of IL-18 was available. As mentioned earlier, 
IL-18 exhibits the β-trefoil structural fold, a ‘signature scaffold’ present in all members 
of the FGF family that generally results in HSGAG-binding regions (Raman Et. al., 
2003). The available three-dimensional structure of IL-18 was inspected for the 
location of possible heparin-binding sites. As seen in Figure 3.4, a high-resolution, 
three-dimensional NMR structure of IL-18 (Kato Et. al., 2003) was computed and the 
residues are shown colour-coded (red/blue) as per electrostatic potential. Accessible 
and exposed surfaces of the protein structure was inspected for the presence of basic 
clusters that can be available for interaction with heparin. As seen on the left-side of 
Figure 3.4 (yellow coloured residues), this structure possessed two-independent, 
positively-charged clusters formed by the basic residues close to the carboxyl-terminus. 
One of the clusters includes residues Lys-129 and Arg-131, while the other comprised 
of Lys139 and Lys-140 (they have been circled and coloured yellow in Figure 3.4). 
Unexpectedly, a cluster of basic residues that was identified within a short-peptide 
region from the primary sequence data of IL-18 (Figure 3.1), comprising of Lys 129, 
Arg 131, Lys 139 and Lys 140 from the β strands of β10-β11 was seen transformed 
into two distinct, putative heparin-binding sites on higher order of tertiary structural 
fold. Moreover, it should also be noted that these two basic clusters (Figure 3.4) were 
interspersed by the adjoining surface acidic residues, Glu 128, 130, 141, 143 and Asp 
132, 142 that may repel possible ionic interactions with heparin chains. 
 
Further examination of the structure of IL-18 revealed a third putative interaction site 
for heparin. This was a surface cavity formed by the loop regions of β-strands, β4-β5 
and β7-β8 and consisted of basic residues, Lys-53 and Lys-93 with their protruding 
side chains (highlighted as yellow colour on right side of Figure 3.4). Moreover, at this 




structure and not surface-exposed, possibly enabling interaction with heparin. 
However, only two basic residues may not be enough to offer a stable binding-site with 
strong electrostatic forces to attract and hold interactions with heparin chains. Further, 
molecular docking and energy calculations will be useful in determining the feasibility 
of this basic cluster in forming a heparin-binding site. Overall, based on the 
observations from the three-dimensional structural study, the possibility of heparin 
binding to IL-18 remained low.  
 
Nevertheless, it was significant to obtain more information on amino acids that formed 
a critical part of IL-18 structure. It was next sought to locate the residues involved in 
receptor binding on the surface of IL-18. This highlights whether the receptor-binding 
site spatially differs or overlaps with the above proposed heparin-binding sites in IL-
18, suggesting possible structural or steric constraints for heparin/HS interactions. Site-
directed mutagenesis, deletion, and charge reversal studies demonstrated Glu 6 and Lys 
53 (coloured green in Figure 3.5) as critical amino acids for the entire IL-18 structure-
function relationship from receptor-binding to signal transduction initiating a cellular 
response (Kim Et. al., 2002). Acidic residues Asp 17, Asp 35 or Asp 132 (coloured 
aqua green in Figure 3.6A) on the surface of IL-18 were shown to be important in 
binding to its cognate receptor, IL-18Rα (Kato Et. al., 2003). Other functionally 
important residues were Lys 79, Lys 84 or Asp 98 (coloured purple in Figure 3.6B), 
significant in binding to IL-18Rβ for ternary ligand-receptor complex formation (Kato 
Et. al., 2003). Also, recent structural and mutational studies identified an important role 
for residues His 109 and Lys 112 in IL-18 binding to its with signalling receptor 
subunit, IL-18Rβ (Kato Et. al., 2014). Further, comparing the receptor-binding residues 
(for both IL-18Rα and β) with the above proposed heparin binding residues indicated 
potential overlapping functions for a single, basic residue, Lys 53 (Figures 3.4, 3.5 and 
3.6). Therefore, physiologically, this indicates minimal structural constraints in IL-18 

















Figure 3.4: NMR structure of IL-18 (mmdbId: 25207) showing basic clusters involved in 
putative heparin-binding sites: The structure is available in PDB (1J0S). It is viewed and 
annotated using the Cn3D programme and represented in a space-filled model. The surface 
residues are colour-coded according to the electrostatic potential: basic residues are in blue, 
acidic in red. Basic amino acids predicted in heparin binding, either singly or in clusters, are 
coloured yellow, circled and labelled. The structure in this view is 180o in orientation to the 
































Figure 3.5: NMR structure of IL-18 (mmdbId: 25207) showing critical residues for the 
structure-function of IL-18: The structure is available in PDB (1J0S). It is viewed and 
annotated using the Cn3D programme and represented in a space- filled model. The surface 
residues are colour-coded according to electrostatic potential: basic residues are in blue, acidic 
in red, and residues involved in IL-18Rα binding are purple. Two critical amino acids, Lys-53 
and Glu-6 required for structural-function integrity of IL-18, are coloured green, circled, and 
labelled. The structure in this view is 90o in orientation to the left of the structure in Figure 3.4 



























Figure 3.6: NMR structure of IL-18 (mmdbId: 25207) showing key residues involved in the 
IL-18-receptor (IL-18Rα / IL-18Rβ) binding: The structure is available in PDB (1J0S). It is 
viewed and annotated using the Cn3D programme and represented in a space-filled model. The 
surface residues are colour-coded according to electrostatic potential: basic residues are in blue, 
acidic in red and basic amino acids predicted in heparin binding either singly or in clusters are 
coloured yellow. A) Three key amino acids residues involved in IL-18Rα binding are coloured aqua 
green, circled, and labelled. The structure in this view is 90o in orientation to the right of the structure 
in Figure 3.4 across the central vertical line of axis. B) Three key amino acids residues involved in 
ternary complex formation (IL-18: IL-18Rα: IL-18Rβ) are coloured purple, circled, and labelled. 





3.2.2.3 Molecular Docking of IL-18 protein with Heparin endecamer ligand 
 
To further ascertain the possible binding of heparin to IL-18, molecular docking studies 
were conducted. The NMR structure of IL-18 (mmdbId: 25207) was systematically 
docked on a heparin endecamer (mmdbId: 3448) using Autodock 2.4 to determine a 
model with the lowest interaction energy (Mulloy & Forster, 2008). Figure 3.7 shows 
the computational interaction between structural IL-18 and the heparin endecamer. 
This programme performed a complete survey of the surface of IL-18 with heparin 
chains and, hence could identify a putative heparin-binding site. Interestingly, with IL-
18, residues Lys 53 and Lys 93 (Figure 3.7) facilitated favourable ionic interaction with 
the docked heparin chains. These two basic residues were situated in the region brought 
together by the loops connecting two pairs of anti-parallel β sheets (β4-β5 and β7-β8). 
Ten repeat docking calculations were performed. This molecular docking data also 
validated the proposed heparin-binding site that was observed on inspection of the 
three-dimensional structure of IL-18, (highlighted as yellow colour on right side of 
Figure 3.4). 
 
The interaction energy of the complex was calculated as -200 kcal/mol. This value is 
much higher than -1000 kcal/mol, a threshold value. A value below this threshold is 
generally considered to indicate protein ability to bind heparin. Moreover, this energy 
value is relatively much higher when compared to the interaction energy values of -
2200 kcal/mol and -3500 kcal/mol calculated for the experimentally verified, heparin-
binding interactions of IL-12 and FGF-2 respectively with the pentameric heparin 
oligosaccharides (collaborator’s personal communication). Thus, high intermolecular 
interaction energy predicted from molecular docking simulation suggested an unstable 
binding complex. Also, with only two basic residues, Lys 53 and Lys 93 involved at 
the possible heparin-binding site, this suggested that IL-18 was unlikely to bind 
heparin. Although molecular docking simulation was used as a predictive tool, further 
experimental evidence was needed to determine whether IL-18 has a measurable 
affinity for heparin. 












3.2.2.4 Examination of Monomeric and Dimeric Structures of Human IL-22 for 
Possible Heparin-binding Sites  
 
Like IL-18, IL-22 also has an experimentally determined crystal structure (Nagem Et. 
al., 2002; T. Xu Et. al., 2005). IL-22 exists in both monomeric (Figure 3.8) and dimeric 
forms (Figure 3.12). Because of this, IL-22 may possess two independent heparin-
binding sites, one on each monomer or a single co-operative binding site on a dimer 
involving both the monomers. Hence, it was necessary to perform structural 
examination and molecular docking calculations using both the available forms of IL-
22 structures for possible heparin binding.  
 
Based on X-ray diffraction studies, IL-22 has been shown to share strong secondary 
structural homology with IL-10 and IFN-γ, both heparin-binding family members. The 
high-resolution, crystallised structure of IL-22 monomer (Figure 3.8) superimposes 
well on a single domain of IL-10 and IFN-γ dimers respectively (Nagem Et. al., 2002; 
Lysine-93 
Lysine-53 
Figure 3.7: Interaction of the human IL-18 with a heparin endecamer: The β-trefoil structure 
of IL-18 has been represented by ribbons with β sheets coloured in aqua green. The NMR structure 
of IL-18 was complexed with the heparin endecamer and ten superimposable lowest energy 
complexes are shown. The interaction energy of IL-18-heparin complex was calculated and the basic 
residues (Lysine-53 and 93) identified as possible parts of heparin binding site, shown as green stick 
form. The docked heparin chains are shown as stick models with carbon-black, oxygen-red, 
nitrogen-blue and sulphur-yellow. The docking predictions were performed with Autodock version 





T. Xu Et. al., 2005). This monomeric structure of IL-22 contains 6 helices (A-F) 
arranged in an anti-parallel conformation (Figure 3.9) to form a compact, α-helical 
bundle protein, as seen in Figure 3.10 (Nagem Et. al., 2002). This contrasts with V-
shaped structures of monomeric and dimeric forms of IL-10 and IFN-γ (Zdanov, 2010). 
Moreover, IL-10 and IFN-γ are intertwined, physiological homodimers shown to bind 
to receptors with the stoichiometry of 1:2:2 for signalling (Walter & Nagabhushan, 
1995; Logsdon Et. al., 2004; Zdanov, 2010). As against, IL-22 dimer is an interfacial 
homodimer, formed at higher concentrations and is readily dissociable. It is formed by 
electrostatic interaction of charged surface residues on monomer, IL-22A and 
monomer, IL-22B (listed in Table 3.1) which results in a compact IL-22 dimer (Figure 
3.12) as revealed by crystallographic studies (Nagem Et. al., 2002; Nagem Et. al., 
2006). Almost 30% of the total surface area of each monomer is involved in its dimer 
formation. The resultant interface area in the IL-22 dimer that remains inaccessible is 
twice as much of any other dimers, generated by the specified crystallographic method 
(Nagem Et. al., 2002). With regards to receptor binding, IL-22 shares one of the 
receptors with IL-10. Thus, it recruits one IL-22R1 and one IL-10R2 to form a 
functional IL-22-receptor complex (Logsdon Et. al., 2004; Bleicher Et. al., 2008; Jones 
Et. al., 2008a). Comparing the receptor-binding residues in IL-22 (Table 3.2) with the 
interfacial surface residues (see Table 3.1), this shows that dimerisation results in 
occlusion of receptor-binding residues. This suggested that monomers of IL-22 were 
physiologically important (Nagem Et. al., 2002). Moreover, IL-22 monomers were also 
shown as the functionally active forms using SPR and gel filtration chromatography 
methods (Logsdon Et. al., 2002). 
 
Table 3.1: Residues at the interface of the IL-22 dimer (Nagem Et. al., 2002; Nagem 
Et. al., 2006)  
Monomer A Arg 142, Phe 24, Arg 40, Lys 11, Asn 
143, 
Gln 15, Lys 28, Gln 16 
Monomer B  Glu 133, Asn 143, Val 50, Ser 31, Asp 
135,  












Residues involved Method  References 
IL-22R1 Phe 14, Gln 15, Thr 
20, Phe 24, Ser 31-





(Jones Et. al., 2008a; 





Tyr 18, Asn 21, Arg 
22 on helix A and 











(Logsdon Et. al., 
2004; Jones Et. al., 
2008a; Bleicher Et. 




Lys 28, Ala 33, Val 
50, Arg 55, Pro 80, 






(Wu Et. al., 2008) 
 
 
Given that the nature of GAG-protein interaction is prominently electrostatic and 
positively charged clusters on protein surface are known GAG-binding sites (D. Xu & 
Esko, 2014), in the current study, crystallographic structures of monomeric (Figure 3.8 
and 3.10) and dimeric forms of IL-22 (Figure 3.12B) were inspected for the surface 
basic clusters a potential HBSs. Structural inspection of both forms of IL-22 protein 
revealed the presence of comparatively frequent clusters of acidic residues around basic 
clusters of interest on the protein surface (Figure 3.8, 3.10 and 3.12B). For instance, a 
group of basic residues over a short linear sequence of amino acids 
(114KLKDTVKK121) as observed from the primary sequence of IL-22 (coloured green 
in Figure 3.1) was seen interrupted by an acidic residue, Asp 117 (coloured red in 
Figure 3.8) on a three-dimensional structural fold. Because of like-charge repulsion 
between the acidic residues on the surface of IL-22 and the sulphate groups on heparin 
chains, this may interfere or prevent the stability of interaction of IL-22 with heparin. 




clusters of basic residues that can hold stable heparin interactions and hence,  show low 














3.2.2.5 Molecular Docking of Monomeric IL-22 protein with Heparin endecamer 
ligand 
 
Further, the available crystallographic structure of the IL-22 (monomer PDB:1M4R) 







Figure 3.8: Crystal structure of the monomeric human IL-22 (mmdbId: 23387) with a basic 
cluster interspersed by acidic residues: A crystal structure of monomeric IL-22 is available in the 
PDB (1M4R). It is viewed and annotated using the Cn3D programme and represented in a space-
filled model. The surface residues are colour-coded according to the electrostatic potential: basic 
residues in blue, acidic in red. Some of the basic residues are coloured in green, circled, and labelled 
to represent putative heparin binding cluster as highlighted in Figure 3.1 in the primary sequence of 
IL-22. This cluster is interrupted by acidic residues. Putative basic residues involved in heparin 
interactions suggested by molecular modelling are coloured yellow. The orientation of this structure 





docking protocol, similar to that previously used on IL-18 was followed. Heparin 
endecasaccharides (mmdbId: 3448) were systematically docked onto a three-
dimensional structure of monomeric IL-22 (mmdbId: 23387) using Autodock 2.4. The 
favourable orientation of endecameric heparin ligands on the IL-22 structure was 
observed on the face of helix A and helix D. As shown in Figure 3.9, the key basic 
residues lie in close proximity and in association with heparin probes were identified 
as Lys 11, Arg 142, Arg 55 residues at one site and Arg 40 and Lys 45 at the other site.  
Thus, the two observed heparin binding sites on the surface of helices A/D of the 
monomeric IL-22 structure seem to act in co-operation as a single heparin-binding site 
(seen as green sticks in Figure 3.9). 
 
The docking strategy calculated the interaction energy of the best fit complex between 
the IL-22 monomer and heparin endecameric chains. The predicted intermolecular 
interaction energy calculated was -1130 kcal/mol. This interaction energy value was 
slightly lower than a threshold value of -1000 kcal/mol. A value below this threshold 
indicates an ability of a protein to bind heparin. However, the binding energy for IL-
22-heparin complex was relatively higher than the values calculated for experimentally 
verified, heparin-binding cytokines like IL-12 (-2200 kcal/mol) and IL-10 (-1442 
kcal/mol) with pentameric heparin chains (collaborator’s personal communication). 
This could possibly be due to the presence of frequent acidic residues on the surface of 
the IL-22 monomer. Figure 3.10 is a superimposable view of the Figure 3.9 in a space-
filled diagram and reveals the distribution of acidic residues (coloured red) surrounding 
the basic residues (coloured yellow) that were predicted in heparin binding. Therefore, 
presence of such acidic residues might also weaken or diffuse the electrostatic potential 
of surface basic charges resulting in reduced capability of monomeric IL-22 to form 
stable complexes with heparin. However, further experimental investigation will 








































Figure 3.9: Putative Heparin-Binding Sites in monomeric human IL-22 (mmdbId: 
23387) interacting with a heparin endecamer: A crystal structure of monomeric IL-22 has 
been represented as ribbons with helices coloured red and docked with synthetic heparin 
endecamer as probe with the ten superimposable lowest energy complexes are shown. The 
basic residues, Lys 11, Arg 142, Arg 55, Lys 45 and Arg 40 were identified as possible parts 
of the heparin binding site represented as green sticks and the docked heparin chains shown 









































Figure 3.10: Crystal structure of the monomeric human IL-22 (mmdbId: 23387) with putative 
heparin-binding sites: A crystal structure of monomeric IL-22 is available in the PDB (1M4R). It 
is viewed and annotated using the Cn3D programme and represented in a space-filled style. The 
surface residues are colour-coded according to the electrostatic potential, basic residues in blue, 
acidic in red and putative basic residues involved in heparin interaction either singly or in clusters 
are coloured yellow, circled and labelled. The orientation of this structure is similar to the upper 






3.2.2.6 Molecular Docking of Monomeric IL-22 protein with Heparin pentamer ligand 
 
Generally, a shorter heparin chain identifies a core heparin-binding site, or the minimal 
size required for heparin chains to interact with the target protein. The IL-22 monomer 
was also docked with a shorter heparin chain, a pentamer, which further increased the 
interaction energy of complex to -810 kcal/mol, compared to the interaction energy 
obtained with endecamaric ligands. This suggested a reduced ability of the IL-22 
monomer to bind to pentameric ligands (Figure 3.11). The interaction energy value 
obtained with the pentameric heparin chains also indicated that the endecameric 
heparin chains provided an extended binding-site and therefore offers a more 
favourable interaction with IL-22 compared to shorter pentameric chains. Amino acids 
contributing to the predicted interaction of IL-22 with the heparin pentamer were Lys 
11, Gln 15 on helix A and Asn 143, and Arg 142 on helix D, as shown in Figure 3.11 
(Mulloy & Forster, 2008). Whereas, the residues Lys 45 and Arg 40 were additionally 
recognised by the endecamer, but not the pentamer, as observed in Figure 3.9 and 3.11, 
respectively. Though the pentameric heparin ligands interacted across the same face of 
helices A/D as endecameric ligands, the key residues in close contact with the heparin 
chains were different. In fact, the presence of contact residues Gln and Asn, which are 
known to play a lesser role in heparin/HS binding than basic residues, Arg and Lys 
(Hileman Et. al., 1998) were identified in the pentameric interaction and that could 



























Since the monomeric form of IL-22 is biologically active, the prediction of heparin-
binding ability of the IL-22 monomer by molecular docking was important. An 
interesting question that arises from this is whether the putative heparin and the 
receptor-binding sites on IL-22 monomer coincides? This evaluates whether heparin 
could possibly interfere with IL-22 signalling and activity through receptor binding. 
Table 3.2 details the residues on the IL-22 monomer involved in binding to the 
respective heterodimeric receptor subunits (Logsdon Et. al., 2004; Jones Et. al., 2008a; 
Bleicher Et. al., 2008). Comparing these residues involved in receptor-binding (from 
Table 3.2) with those at the putative HBS (Figures 3.9 and 3.11), showed an overlap of 
few residues at the site of monomeric IL-22. This suggested that heparin might affect 
the biological activity of IL-22 by competing with its cognate receptors, IL-22R1, for 








Figure 3.11: Putative Heparin-Binding Sites in monomeric human IL-22 (mmdbId: 23387) 
interacting with a heparin pentamer: A crystal structure of monomeric IL-22 has been represented 
as ribbons with helices coloured red and docked with a synthetic heparin pentasaccharide as a probe 
with the ten super-imposable lowest energy complexes shown. The basic residues Asn 143, Arg 142, 
Lys 11 and Gln 15 are represented as green sticks and were identified as possible units of interaction 
with the docked heparin chains shown as stick models with carbon-black, oxygen-red, nitrogen- 







Additionally, the basic residues predicted in heparin-binding on the IL-22 monomer 
(Figures 3.9 and 3.11) were compared with the key residues involved in IL-22 dimer 
formation (see Table 3.1; Nagem Et. al., 2002). Comparison shows that most of the 
putative heparin-binding residues on the IL-22 monomer were significant components 
in IL-22 dimerisation. These common residues included Lys 11, Arg 40, Arg 142 and 
Asn 143, which appears to be concealed at the interface, on dimer formation. Overall, 
if IL-22-heparin binding is to occur then heparin not only impedes dimerisation, but 
also competes with IL-22-specific membrane receptors. Such competition for receptor-
binding has also been demonstrated for IL-10 (Salek-Ardakani Et. al., 2000; Kunze Et. 
al., 2016) and IFN-γ (Fernandez-Botran Et. al., 1999; Saesen Et. al., 2013), the heparin-
binding members within IL-22 family. 
 
3.2.2.7 Molecular Docking of Dimeric IL-22 protein with Heparin endecamer ligand 
 
Further molecular docking between the dimeric crystal structure of IL-22 and the 
heparin endecamer using Autodock 2.4 was performed, as shown in Figure 3.12A. 
Interestingly, molecular docking calculations identified a different binding mode and 
site on the IL-22 dimer than that observed with the monomer alone. Heparin ligands 
were found positioned on the IL-22 dimer connecting both the monomeric units and 
occuping a binding site that spanned across both the units. As seen in Figure 3.12A, 
specifically lysine residues, Lys-91 and 95 of monomer A and Lys-28 of monomer B 
were found involved in the heparin-binding interface made by docking. Comparison of 
the two molecular models, one in which heparin was docked onto the IL-22 monomer 
(Figure 3.9) and the other onto the IL-22 dimer (Figure 3.12A) revealed that the basic 
residues predicted for heparin binding were different in both the forms of IL-22. 
 
Docking studies calculated the energy values of interaction between dimeric IL-22 and 
endecameric heparin ligand, as -1042 kcal/mol. With pentameric ligands, it was 
calculated as -650 kcal/mol. Overall, the interaction energies for both the forms of IL-
22 (monomer and dimer) with heparin endecamers were slightly lower than -1000 
kcal/mol. A value below this threshold indicates heparin/HS binding (Mulloy & 
Forster, 2008). However, the energetics of IL-22-heparin complex were much higher 
than the known values of experimentally detected, heparin-binding proteins, IL-10 (-




interaction for both the forms of IL-22 with heparin and hence less likelihood of 
binding to heparin. Experimental investigation would be required to further confirm 
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Figure 3.12: Putative Heparin Binding Sites in dimeric human IL-22 interacting with a heparin 
endecamer: A) A crystal structure of dimeric IL-22 has been represented as ribbons with helices 
coloured red and docked with a synthetic heparin endecamer as a probe with the ten superimposable 
lowest energy complexes shown. The lysine residues, Lys 91 and 95 of monomer A with Lys 28 of 
monomer B were identified as possible parts of the heparin binding site represented as green sticks 
and the docked heparin chains shown as stick models with carbon-black, oxygen-red, nitrogen-blue, 
sulphur-yellow. B) A crystal structure of dimeric human IL-22 (mmdb Id 23387) is available in the 
PDB (Id 1M4R). It is viewed and annotated in the Cn3D programme and represented in a space-
filled style. The surface residues are colour coded according to the electrostatic potential, basic 
residues in blue, acidic in red, and putative basic residues involved in heparin interaction as yellow, 






3.2.3 Binding of IL-11, IL-18, and IL-22 to Immobilised Heparin-BSA conjugate: 
ELISA Approach 
 
As pointed out earlier, the molecular docking data balances well with the immobilised 
heparin-binding ELISA method which provides information on affinity and specificity 
of heparin-cytokine interactions. Therefore, having performed predictive docking 
calculations, it was next sought to experimentally examine heparin binding in these 
proteins. Below is a short summary on this approach and its advantages over other 
biochemical methods. 
 
This highly sensitive ELISA method was developed in our laboratory and was routinely 
employed to quantitatively characterise various GAG-cytokine interactions. In 
principle, this approach is a simple, heparin-capture ELISA (see Section 2.1 for 
method). Because free GAG chains adsorb poorly compared to proteins onto the plastic 
surfaces of the ELISA plate, heparin was immobilised by conjugation with BSA. An 
ELISA plate coated with this conjugate is analogous to an in vitro immobilised matrix 
of heparin that mimicks in vivo HS chains presented on proteoglycans. Cytokines that 
bind to this immobilised heparin are then detected with cytokine specific antibodies. 
To test for non-specific binding of proteins on to the plastic surfaces of ELISA plates, 
a mock-conjugated BSA as a control is employed. This is BSA treated with the 
conjugation reagents but in the absence of heparin, hence, it acts as an internal negative 
control for heparin-binding experiments (Najjam Et. al., 1997a). This method was 
validated at the time of its conception using prototypical heparin-binding proteins such 
as FGF and antithrombin (Najjam Et. al., 1997a). Further, with the success of this 
approach, additional heparin-binding cytokines, such as IL-2 (Najjam Et. al., 1997a), 
IL-6 (Mummery & Rider, 2000), IL-12 (Hasan Et. al., 1999), GDNF (Rickard Et. al., 
2003), Artemin (ART), Neurturin (NTN) (Alfano Et. al., 2007), β-cellulin (Mummery 
Et. al., 2007), and BMP-7 (McClarence, 2011) were determined.  
 
The immobilised heparin-binding ELISA was mainly used to determine binding at 
physiological pH and ionic strength. Because, under low ionic conditions, any 
positively-charged basic cluster on the surface of a protein could attract and bind to 
heparin.  Therefore, the binding that is retained even at physiological conditions is most 




equally comparable to affinity co-electrophoresis (ACE) and affinity chromatography 
(Najjam Et. al., 1997a).  More to the advantage of this method has been the use of non-
radioactive reagents that have longer shelf-life. Thus, this heparin-binding ELISA has 
wide applicability with minimum requirements in the study of heparin-cytokine 
interactions. 
 
3.2.3.1 Validation of Newly Synthesised Heparin-BSA Conjugate with Immobilised 
Heparin Conjugate using GDNF 
 
The efficacy of this newly synthesised heparin-BSA conjugate and its control mock-
conjugated-BSA in heparin-binding studies was initially tested through binding of 
GDNF. GDNF is a well-studied cytokine with a high affinity for heparin (Rickard Et. 
al., 2003). Increasing doses of GDNF (0-20ng/ml) were added to ELISA plate wells 
coated overnight with either heparin-BSA conjugate or the mock-conjugated BSA. As 
seen in Figure 3.15, GDNF binds to heparin-BSA in a dose-dependent manner and 
binding was detectable with as little as 5ng of GDNF. Even though some binding of 
GDNF was observed in the absence of heparin, in the wells coated with mock-
conjugated BSA, this background binding was considerably lower and showed low 
dose-dependency. Since these results with GDNF agreed with those obtained using a 
previous batch of heparin-BSA conjugate, the current newly synthesised batch of 




























Figure 3.13: ELISA of GDNF with immobilised heparin-BSA conjugate: Increasing 
concentrations of GDNF were incubated in wells coated with either heparin-BSA conjugate (solid 
line with ♦) or mock-conjugated BSA (dotted line with ■) and the ELISA plate was then read at 
405nm. GDNF was used as a positive control for heparin binding using newly synthesized heparin-
BSA conjugate. Results represent the mean of triplicate wells at each point, with error bars showing 





3.2.3.2 ELISA of Interleukins 11, 18 and 22 with Immobilised Heparin Conjugate 
 
Having validated the heparin-BSA conjugate through the study of GDNF, the binding 
of interleukins 11, 18 and 22 to heparin was then determined. However, prior to 
performing this experimental heparin-binding assay, a simple ELISA was performed 
for each interleukin under study to detect the activity of antibody used for the assay. 
This ELISA did not involve use of heparin-BSA or mock-BSA conjugate. The 
interleukins were bound directly to adsorbent plastic surfaces of the wells and, after 
blocking, the respective antibodies were used to detect this binding. Increasing 
concentrations of each interleukin were added to the ELISA wells followed by 
incubation with their corresponding antibodies. Colour development was observed on 
addition of substrate, with dose dependent increase in absorbance values at 405 nm, 
which is shown as a solid straight line in Figures 3.14, 3.15, 3.16 for IL-11, IL-18 and 
IL-22, respectively. This suggested that the antibodies employed were reliable for the 
detection of different concentrations of individual interleukins under the conditions of 
study.  
 
The heparin-binding ELISA technique was now used to study binding of IL-11 to 
heparin. 25ng/well concentrations of heparin-BSA and mock-BSA conjugate were 
coated onto an ELISA plate, and increasing concentrations of IL-11 (0-20ng/ml) were 
added to the respective wells. Figure 3.14 shows that, despite strong reactivity of anti-
IL-11 with IL-11, there was only a trivial difference in absorbance values between IL-
11 concentrations to heparin-BSA conjugate and to mock-BSA conjugate. This 
minimal difference between IL-11 binding to heparin-BSA conjugate and internal 

































The optimised ELISA technique for heparin-binding was also  employed for IL-18. 
Irrespective of the IL-18 concentrations (5, 10, and 20ng/ml) used to incubate with 
heparin-BSA and mock-BSA conjugate, almost super-imposable absorbance values 
were obtained (Figure 3.15). This result also concluded that IL-18 had no affinity for 
heparin. 
 
Lastly, the ELISA results with IL-22 also showed no difference in observed absorbance 
values for increasing doses of IL-22 with heparin-BSA conjugate binding and 
background binding in the absence of heparin, i.e., mock-BSA conjugate (Figure 3.16). 
This indicated that IL-22 does not bind to heparin. IL-22 has been known to dimerise 
at higher concentrations and dimers have been detected at concentrations around or > 
1 µg/ml (de Oliveira Neto Et. al., 2008). In the current experimental study, low 
concentrations of IL-22 at 50-200ng/ml and pH 7.4 were used which suggested that IL-
22 tested was predominantly in monomeric form. This biologically active monomeric 
























Figure 3.14: ELISA of IL-11 not binding with immobilised-heparin conjugate: IL-11 
absorbed directly on ELISA plate wells shows dose dependent increase in absorbance values at 
405nm indicating binding of IL-11 is readily detectable with anti-IL-11 (♦). Binding of IL-11 to 
the heparin-BSA conjugate (solid line with ●) and mock-conjugated BSA (dotted line with ▲) 
coated surfaces of ELISA wells seen as overlapped absorbance curves. Results represent the 
mean of triplicate wells at each point, with error bars showing ±SEM. One representative 





Thus, in-line with the predictive molecular docking results, the ELISA assay provided 
experimental evidence for no detectable binding of IL-11, IL-18, and IL-22 to heparin 





































































Figure 3.15: ELISA of IL-18 not binding with immobilised heparin-BSA conjugate:  
Direct binding of IL-18 with anti-IL-18 on surfaces of ELISA plate wells is shown as a dose 
dependent increase in absorbance values at 405nm representing solid line (♦). Binding of IL-18 to 
the heparin-BSA conjugate (solid line with ■) and mock -conjugated BSA (dotted line with ▲) 
coated ELISA wells seen as almost indistinguishable absorbance curves. Results represent the mean 
of triplicate wells at each point, with error bars showing ±SEM. One representative experiment of 
three independent experiments performed is shown here. 
Figure 3.16: ELISA of IL-22 not binding with immobilised heparin-BSA conjugate:  
 IL-22 absorbed directly on surfaces of ELISA plate wells was readily detected by anti-IL-22 as 
shown by a dose dependent increase in absorbance values at 405nm, solid line (♦). Binding of 
IL-22 to the heparin-BSA conjugate (solid line with ■) and mock -conjugated BSA (dotted line 
with ▲) coated overnight on ELISA wells seen as overlapped absorbance curves. Results 
represent the mean of triplicate wells at each point, with error bars showing ±SEM. One 





3.3 Discussion  
  
The aim of the current study was to determine whether the interleukins, IL-11, IL-18 
and IL-22 belonging to different classes of cytokines bind to heparin/HS. They were 
selected based on structure-function relationships with their family members that 
exhibited heparin-binding activity. A strategy of a combination of various predictive 
approaches such as analysis of primary sequences, three-dimensional structures and 
molecular docking methods were employed that predicted heparin-binding sites on the 
surface of the selected interleukins. Further and experimental assay, the heparin-
binding ELISA was successfully used to validate and support the predicted data.  Most 
surprisingly, the results from this study demonstrated that none of the three selected 
interleukins bound to heparin while their respective family members were known 
heparin-binding cytokines. 
  
IL-11 did not exhibit measurable affinity for heparin binding, despite, containing a 
basic sequence motif (111RLDRLLRR118) that closely resembled a Cardin-Wintraub 
motif (BBXB) in its primary sequence. As mentioned earlier, most consensus sequence 
motifs contain basic residues in linear arrangement with hydropathic residues (X) such 
as Asn (N), Ser (S), Gly (G), Ala (A), Leu (L), Ile (I), Tyr (Y) (Hileman Et. al., 1998; 
Gandhi & Mancera, 2008).  These polar and hydrophobic amino acids in heparin-
binding domain have been shown to stabilize the interaction by formation of additional 
non-ionic bonds. However, if acidic residues, Asp (D), Glu (E), are present instead of 
the above-mentioned hydropathic residues (X) then these interactions destabilize due 
to ionic-charge repulsion with polyanionic heparin chains (Hileman Et. al., 1998; 
Gandhi & Mancera, 2008). In case of IL-18 (129KERDLFKLILKK140) and IL-22 
(114KLKDTVKK121), although the clusters of basic residues near the carboxyl-terminus 
of their primary sequences (Figure 3.1), did not match any consensus sequence motifs, 
these basic peptide sequences contained strong acidic residues such as glutamic acid 
(E) and asparatic acid (D) as adjacent residues. When the three-dimensional structures 
of these interleukins, IL-18 and IL-22, were examined these acidic residues were found 
to be surface-exposed which could have a disturbing effect on heparin interaction. 
Thus, one of the explanations to the lack of heparin-binding ability in these interleukins 
could be the position and influence of acidic residues that reduces the likelihood of 




sequences of interleukins IL-11, IL-18 and IL-22 enriched in basic residues support the 
documented views that the heparin/HS-binding sites in proteins are not always or 
necessarily defined by a unique sequence or a structural motif (Forster & Mulloy, 2006; 
Mulloy & Rider, 2006; Mulloy & Forster, 2008; D. Xu & Esko, 2014; Gallagher, 2015). 
More recently, structural studies in a subset of Neutrophil-activating chemokines were 
shown to have unique GAG binding sites formed by conserved and chemokine-specific 
amino acids that could not be predicted from primary sequence alone. Rather a 3D 
structure determined the geometry and topology of the unique GAG-binding surface of 
each individual chemokine (Rajarathnam Et. al., 2018). 
 
Additionally, these three interleukins studied were of human origin and there is high 
amino acid sequence homology observed between the human and mouse interleukins, 
such as 88% in IL-11 (J. C. Morris Et. al., 1996), 64% in IL-18 (Ushio Et. al., 1996), 
and 80.8% in IL-22 (Wolk & Sabat, 2006a). Therefore, it can be expected that the 
absence of heparin-binding characteristic would be retained across another mammalian 
species. While, all the selected set of interleukins failed to exhibit binding with 
heparin/HS on experimental testing, it is interesting to understand the reasons 
underlying this observation by comparing the structural details of putative heparin-
binding domains in them with the characterised or well-studied HBDs of members of 
their respective family that are known to interact with heparin/HS.   
 
IL-11 along with IL-6, CNTF, LIF, OSM, CT-1 belongs to a group of structurally and 
functionally related cytokines termed as IL-6 type or gp-130 receptor cytokines 
(Kishimoto Et. al., 1994; Heinrich Et. al., 2003; Negahdaripour Et. al., 2016). All 
members of this IL-6-type family cytokines signal through activation of a common 
receptor-subunit, gp-130 (Dahmen Et. al., 1998). With regards to heparin/HS binding 
within this family, LIF has not yet been experimentally determined to bind heparin. 
However, docking calculations of LIF has shown strong predictions to be able to 
interact with heparin. The plausible heparin-binding site on LIF was shown to be 
located at the end of helix C (Arg 133, lys 137) and along the length of helix A (N 25, 
Q 26, R 28) that overlaps one of the receptors, gp-130 binding sites (Mulloy & Forster, 
2008). In contrast, another member of the gp-130 receptor family, CNTF (ciliary 
neurotrophic factor), was predicted to lack heparin-binding ability, based on docking 
calculations. Also, CNTF has not been experimentally reported to bind heparin so far 




experiments, it is concluded that IL-11 does not bind to heparin/HS. Recently, the first 
crystallographic structure of IL-11 was published (T. L. Putoczki Et. al., 2014) which 
allowed us to examine the structure and to identify surface-exposed basic residues 
(mainly Arg) in the predicted heparin-binding region in IL-11. Before the availability 
of this IL-11 structure, the homology models of IL-11 were used as a template for 
structural study (Section 3.2.2.1, Figure 3.2) (M. J. Czupryn Et. al., 1995a; Tacken Et. 
al., 1999). These structural models were proposed based on sequence alignment or 
common secondary structural features with other members of family. As expected, the 
predicted heparin-binding region derived from the homology models of IL-11 
corroborated with the experimentally determined structure of IL-11. Nevertheless, it 
still remains unanswered why IL-11 does not bind to heparin/HS, despite of this 
interleukin possessing an array of basic amino acids (mainly arginine) in primary 
sequence. This cluster of Arg residues was also observed as a surface element, on the 
three-dimensional crystal structure of IL-11 (Figure 3.2) (T. L. Putoczki Et. al., 2014). 
One limitation to this understanding is the lack of molecular modelling data which 
would have enabled to gain an insight into whether these basic residues could form a 
region of high positive charge density and energetics to be able to engage GAG chains.  
Since the structure of IL-11 is solved (T. L. Putoczki Et. al., 2014), it is useful in 
highlighting the difference in heparin-binding ability of IL-11 and its close structural 
and functional homologue, IL-6. IL-6 is a well-characterised, heparin-binding 
counterpart of IL-11 within this family. In case of IL-6, strong predictions to bind 
heparin by molecular docking calculations was confirmed by experimental studies 
(Mummery & Rider, 2000). Moreover, this predictive method located the heparin-
binding domain on IL-6, as a composite site with basic residues from both the helices 
A (K 27, R 30, K 66) and D (K 171, Q 175, R 179, R 182) forming a shallow groove 
(Mulloy & Forster, 2008). Essentially, this binding site was devoid of acidic residues 
in the neighbouring units that could generate any like-charge repulsion and/or steric 
hindrance (Mulloy & Forster, 2008). It also fulfilled the typical requirement of 4-6 
basic residues, Arg (R) or Lys (K) that formed a surface basic cluster on the three-
dimensional structure of IL-6 (Hileman Et. al., 1998). Since GAG-protein interactions 
are predominantly electrostatic in nature, it was important to understand the spatial 
distribution of charges. A recent report analysed the distribution of surface electrostatic 
potential on IL-6 (1alu.pdb) (Somers Et. al., 1997) and IL-11 (4mhl.pdb) structures (T. 




patches of positive electrostatic potential on its protein surface (T. L. Putoczki Et. al., 
2014), which indeed are in agreement with the regions of heparin binding in IL-6 
(Mummery & Rider, 2000; Mulloy & Forster, 2008). However, in comparison, IL-11 
showed larger but diffused spread of positive electrostatic potential (T. L. Putoczki Et. 
al., 2014). Apparently, it seems in IL-11 that basic residues distant in sequence do not 
come close to form densely packed clusters on higher structural folding, except on helix 
C that contained cluster of surface Arg residues representing Cardin-Weintraub motif 
(111RLDRLLRR118). Of note, it is recently shown by a study that all surface basic 
residues, do not possess equal and high electrostatic potential to be identified as GAG-
binding site in proteins whether they follow Cardin-Weintraub rule or not (Sarkar & 
Desai, 2015). Thus, compared to IL-6, IL-11 appears to exhibit a weak electrostatic 
potential near its surface of basic charges in the proposed heparin-binding region, 
possibly explaining its inability to engage heparin chains.  
   
As mentioned, besides the structural resemblance, IL-11 also shares biological 
functions with IL-6 (Negahdaripour Et. al., 2016). It closely resembles the hexameric 
signalling-complex formation in IL-6, including two cytokine specific α-chain 
receptors and two gp-130 molecules (Barton Et. al., 2000). The experimental evidence 
from soluble receptor-binding and heparin-binding studies with IL-6 suggested that the 
proposed HBS was close to but did not overlap with IL-6 receptor-binding sites, IL-
6Rα and gp-130. So, heparin interaction may sterically restrict binding of IL-6 to both 
of its receptors (Mulloy & Forster, 2008). Supporting this, heparin was shown to 
weakly inhibit IL-6-srIL-6Rα complex formation but strongly inhibited the interaction 
of this complex with soluble gp-130 receptors (Mummery & Rider, 2000). Hence, the 
heparin-binding property in IL-6 functionally impacts its signal-transduction events. 
Given that IL-11 and IL-6 share number of important biological functions along with 
dominant role of IL-11 over IL-6 in GI cancers (Putoczski Et. al., 2013), the difference 
in the heparin-binding property between these cytokines could influence their 
therapeutic role (as discussed later in Chapter 6). Collectively, it can be concluded from 
this study that heparin-binding is not a common property in the family of gp-130 
receptor cytokines. 
 
IL-18 shares the three-dimensional, β-trefoil structural fold with a known family of 
heparin-binding cytokines, the FGFs (Kato Et. al., 2003). Interestingly, 




overlapping heparin-binding regions in them (Raman Et. al., 2003; R. Xu Et. al., 2012; 
Y. Li Et. al., 2016). Within this family, FGF-2 is an extensively studied example of a 
heparin-binding protein (Ornitz & Itoh, 2001a; Ori, 2009; Platonova Et. al., 2014). 
Despite sharing similar architecture, one notable difference between the HBDs of IL-
18 and FGF-2 is the presence of group of acidic amino acids in IL-18. Unlike in FGF-
2, these acidic residues in IL-18 were found located within as well as surrounding the 
cluster of basic components of the proposed heparin-binding domain (Figure 3.17). 
Findings from the current study, further highlights the important differences in the 





























In the β-trefoil scaffold of FGF-2, the HBS is a discontinuous binding-site formed from 
the β-strands, β10, β11 and the loop region between them (β10-11 loop) (L. D. 
Thompson Et. al., 1994; Faham Et. al., 1996; Ori, 2009; R. Xu Et. al., 2012; Nunes Et. 
al., 2016). Additionally, a stretch of basic residues (β11-12 loop) near the carboxyl-
terminus is also involved in the interaction with heparin (Faham Et. al., 1996). The 
HBD on FGF-2 has been well-studied fromcrystallographic structures of FGF-2 in-
complex with heparin hexasaccharides, which identified characteristic conformational 
properties of the HBS in FGF-2 (Faham Et. al., 1996). As shown in Figure 3.18, it 
consists of a narrow groove containing a basic residue, Lys 125 at the base. This residue 
is shown to be critical in the interaction with specific N-sulphate and 2-O-sulphate 
groups within the heparin chain. Moreover, the groove is surrounded by other basic 
Figure 3.17: Surface view of the β-trefoil structured cytokines, IL-18 and FGF-2 with their heparin/HS-
binding domains: A structural overview is presented here to show a notable difference in spatial arrangement of 
basic residues within the heparin-binding domains of IL-18 and FGF-2. A concentrated cluster of basic residues 
(blue) devoid of acidic residues (red) is seen in FGF-2 along with support from glutamine-Q134 (purple) and 
asparagine-N27 (aqua green) residues from surrounding (L. D. Thompson Et. al., 1994; Faham Et. al., 1996). In 
contrast, IL-18 shows two dispersed basic clusters (HBD I and HBD II) due to interfering acidic residues as 
neighbouring units. These images in space-filled representation were generated from the PDB structures of IL-18 




residues and polar amino acids close to the carboxyl-terminal region (Figure 3.18), K 
135, Q 134, N 27, R 120, K 119 and K 129 that further favours ionic interactions and 
van der Waals contacts with sulphate and carboxylate groups of the heparin/HS chains 
(L. D. Thompson Et. al., 1994; Raman Et. al., 2003; R. Xu Et. al., 2012; Gallagher, 
2015). Overall, the topology of the HBS formed by β-strands and the spatial 
arrangement of basic residues with their side-chains within and around the site in FGF-
2 is devoid of any surface acidic residues (as seen in Figure 3.17 and 3.18). Therefore, 
such a heparin-binding domain sets to maximize surface contact and strong interaction 
of the protein with heparin chains. 
 
Like FGF-2, IL-18 maintains an overall β-trefoil structural conformation and contains 
a cluster of basic residues in its primary sequence near the carboxyl-terminus. Indeed, 
these basic residues originate from similar regions as in FGF-2, comprising of β-
strands, β10 and β11 and the connecting loops β10-11 and β11-12. However, on 
inspection of the three-dimensional structure of IL-18 (Kato Et. al., 2003), this cluster 
of linearly contiguous basic residues was seen to be disrupted into two smaller 
pockets/sites of potential heparin-binding, HBD I- K 129, R 131 and HBD  II- K139, 
K140 (Figure 3.17 and 3.18). Moreover, these two sites were interrupted and spatially 
separated by adjacent acidic residues (E 128, E130, E 141, D 142 and E 143) (as shown 
in Figure 3.18) that perhaps prevent the formation of a co-operative binding-site for 
heparin. The presence of such GAG-repelling surfaces separating clusters of basic 
residues on protein structures suggest a feature not so favourable to GAG binding. This 
observation was also validated by the molecular docking method. Indeed, 
computational docking of heparin chains onto the surface of IL-18 predicted an 
additional binding site formed by the loop regions of β strands, β4-β5 and β7-β8. 
However, this predicted HBD comprised of only two basic residues, K 53 and K 93 
(HBD III) that may not be sufficiently strong to hold a stable interaction with heparin. 
Several studies on heparin-binding proteins and peptides have indicated clusters 
comprising of four to six basic amino acids that constitute a HBD on the surface of 
proteins [as comprehensively reviewed in (Hileman Et. al., 1998)]. Consequently, an 
insufficient number of basic residues defining a HBD in IL-18 could have also resulted 
in an inability of this protein to bind to heparin chains. Hence, this explains the current 
findings from biochemical experiments, which demonstrated that IL-18 does not 





In addition to the structural basis, a quantitative basis to this remarkable difference in 
heparin-binding property between IL-18 and FGF-2 was observed by comparing their 
interaction energies computed by molecular docking. The intermolecular interaction 
energy for IL-18 (-200 kcal/mol) was over 15 times higher than FGF-2 (-3500 
kcal/mol) suggesting an unstable binding site in IL-18 for interaction with heparin. This 
clearly illustrates that, even though IL-18 belongs to the same structural family as FGF-
2, it does not share the heparin-binding characteristic based on the difference in stability 
of HBD. Indeed, IL-18 lacks proper clustering of basic residues to form a coherent and 
accessible heparin-binding domain (as seen in Figure 3.17 and 3.18), which is the key 





 Figure 3.18: Comparative view of the molecular surface of a heparin-binding domain 





In contrast to the current findings on IL-18, Reeves at al have shown that IL-18 binds 
to a mixture of GAGs at high concentrations (HS, CS and HA) and at a pH lower than 
physiological levels (Reeves Et. al., 2010). Since GAG-protein interactions are 
predominantly electrostatic, low pH conditions can have profound effect on the GAG 
binding capacity of proteins (Gandhi & Mancera, 2008), as has been seen in case of 
GM-CSF (Sebollela Et. al., 2005). GM-CSF was observed to undergo conformational 
changes at low pH compared to neutral pH, which exposes residues like histidines (His) 
to additionally support surface Lys residues allowing interaction with GAGs (Sebollela 
Et. al., 2005; Wettreich Et. al., 1999). Reeves Et. al. showed that chemical 
modifications of surface Arg and Lys residues in IL-18 resulted in a significant 
reduction in binding to GAGs mixture. However, this did not completely eliminate 
association with GAGs, suggesting a significant role of other basic residues such as His 
residue (H109) in the observed binding of IL-18 to GAGs at low pH (Reeves Et. al., 
2010). This was explained on the basis that as pH falls, His residues become protonated 
and positively charged to facilitate binding with negatively charged sulphate ions on 
GAG chains (Gandhi & Mancera, 2008; Reeves Et. al., 2010). Indeed, our findings are 
more relevant at physiological levels. Another differentiating parameter in the 
experimental conditions used by Reeves et al is mixture of GAGs. The presence of 
multiple GAGs in high concentration which mainly occurs at sites of inflammation or 
pathological conditions, increases the number of different sulphation sites and overall 
anionic charge density (Bhaskar Et. al., 1998; Solic Et. al., 2005). This in turn may 
increase the GAG-binding capability of proteins but at the same time may also decrease 
the level of specificity in GAG-protein interactions. Since heparin/HS is the most 
generic form of GAGs and represents a physiological ligand to proteins, binding 
Figure 3.18: Comparative view of the molecular surface of a heparin-binding domain (HBD) 
on structures of FGF-2 and IL-18: A close-up view of the surface cavity formed by the topological 
arrangement of β-sheets (β10-β-11) is shown for FGF-2 and IL-18. Note that, in FGF-2, key basic 
(blue) residues, polar residues, Asn/Gln (purple) are involved in formation of the HBD (L. D. 
Thompson Et. al., 1994; Faham Et. al., 1996). In contrast, the close-up view of the proposed HBD 
on IL18, formed by the similar regions as in FGF-2, shows the presence of acidic residues (red) 
around the clusters of basic residues. This difference in molecular surface of the HBDs could reflect 
in the heparin-binding ability of these proteins, FGF-2 and IL-18. Amino acids with their side-chains 
are shown in stick form. The β strands are labelled according to the conventional strand 
nomenclature for FGFs (Faham Et. al., 1998; Ornitz & Itoh, 2001b). These images with ribbon 
representation of β-sheets were generated from PDB structures of IL-18 (1J0S) and FGF-2 (1FQ9) 





observed in the presence of different GAGs in combination may be prevalent under 
certain pathological conditions but cannot be extended to physiological conditions as 
employed in the current study.  
 
Further, the current study experimentally demonstrated that IL-22 does not bind 
heparin. This finding was supported by the analysis of the three-dimensional structures 
of both the IL-22 monomer and dimer, which revealed lack of continuous basic clusters 
due to a predominance of acidic residues as the neighbouring units. Therefore, this 
indicated a low likelihood of IL-22 binding to heparin/HS. Additionally, this 
observation was closely comparable with the molecular docking prediction which 
suggested a weak interaction of IL-22 with heparin chains. Because IL-22 shares a 
structure-function relationship with two known heparin-binding cytokines, IL-10 
(Salek-Ardakani Et. al., 2000) and IFN-γ (Lortat-Jacob Et. al., 1991b), it is necessary 
to understand why and how IL-22 differs from these cytokines in the ability to bind 
heparin.  
 
Despite, similar structural architecture of IL-22 with IL-10 and IFN-γ, it can be seen 
that the IL-22 monomer (Figure 3.20) is a compact helical structure as opposed to the 
‘V’ shaped structure of monomeric IL-10 (Figure 3.19) and IFN-γ (Nagem Et. al., 
2002).  In fact, the presence of a specific second disulphide bridge in IL-22 results in 
flexibility of the loop DE that allows helices E and F to fold back in the groove formed 
by helices A and D of the same polypeptide chains, resulting in a bundled protein 
(Figure 3.20) (Nagem Et. al., 2006). Whereas, in IL-10 (Walter & Nagabhushan, 1995; 
Zdanov Et. al., 1995; Zdanov Et. al., 1996; Zdanov, 2010) (Figure 3.19A) and IFN-γ 
(Ealick Et. al., 1991), lack of this disulphide bond makes the loop DE more rigid and 
helices E and F folds as a separate domain resulting in open ‘V’ shaped monomers 







Figure 3.19: Ribbon representation of monomeric IL-10 structure to illustrate the 















Figure 3.19: Ribbon representation of the monomeric IL-10 structure to illustrate the location 
of the heparin-binding domain with molecular details (A) Detailed view of the molecular 
surface of predicted heparin-binding domain on IL-10 monomer (Mulloy & Forster, 2008; Kunze 
Et. al., 2014; Kunze Et. al., 2016). IL-10 monomer is comprised of six helices A-F. The basic 
(blue), acidic (yellow) and polar uncharged (aqua green) residues within and around the proposed 
region of HBD is highlighted. As seen, the basic residues concentrated in the suggested heparin/HS 
binding region are Arg-102, -104, -106, -107, -110, Lys-117, -119 along with Asn-116 from the C-
terminal region of helix D and E on IL-10 monomer. These residues apparently form a surface 
cluster, encompassing the helices D, E and loop DE. Amino acid sequence of this region near C-
terminus is shown below (B) and contains a linear array of basic residues (Arg, R and Lys, K). This 
sequence is taken from (Salek-Ardakani Et. al., 2000). Amino acids with their side-chains are 
shown in stick form. These images with ribbon representation of α-helices were generated from 
PDB structure of IL-10 (2ILK). IL-10 monomer was edited and annotated from its dimer structure 









With regards to heparin binding, IL-10 was experimentally demonstrated using surface 
plasmon resonance (SPR) to bind heparin/HS (Salek-Ardakani Et. al., 2000). 
Moreover, the physiological significance of this IL-10-heparin binding was shown 
using IL-10-induced expression of CD-16 and CD-64 molecules on the 
monocyte/macrophage population within PBMCs in the presence and absence of 
heparin (Salek-Ardakani Et. al., 2000). A closer look at the structure of the IL-10 
monomer (Figure 3.19A) shows a cluster of basic residues on the carboxyl-terminal 
Figure 3.20: Ribbon representation of the monomeric IL-22 structure to illustrate the location 
of the HBD with molecular details. A detailed view of the predicted HBD on the face of helix A 
and D of IL-22 monomeric structure by the molecular docking is shown. The basic (blue) residues 
contributing to the proposed HBD and acidic (yellow) residues within and around this region is 
shown in comparison to the HBD of its structural homologue, a IL-10 monomer (Figure 3.20). 
Amino acids with their side-chains are shown in stick form. These images with ribbon 
representation of α-helices were generated from the PDB structure of IL-22 (1M4R). IL-22 
monomer was edited and annotated from its dimer structure (1M4R) (Nagem Et. al., 2002) using 






basic peptide region (residues 99-110) which occupies the centre of the ‘V’-shaped 
crevice. This region enriched in basic residues was very early on described as a special 
surface-feature on a three-dimensional structure of IL-10 (PDB ID: 1ILK) (Zdanov Et. 
al., 1995). This sequence of basic peptide, as shown in Figure 3.19B, was proposed to 
promote the interaction with heparin (Salek-Ardakani Et. al., 2000). Interestingly, this 
region has been identified as unique to IL-10 as it is conserved across different species 
and not shared among other members of family (Zdanov, 2010; Sabat, 2010). Very 
recently, the heparin-binding property of IL-10 has been further explored by predictive 
computational simulation methods to locate the heparin-binding site and the key 
residues involved in the interaction (Gehrcke & Pisabarro, 2015). Molecular docking 
studies predicted strong interaction of heparin chains with IL-10 via helices D (R 102, 
R 106, R 107) and E (N 116, K 117, K 119, K 125) (Mulloy & Forster, 2008; Gehrcke 
& Pisabarro, 2015). Accordingly, as seen in Figure 3.19A, the basic amino acids at the 
end of helix D and adjacent loop DE in IL-10 offers a concentrated surface of charged 
residues that is away from the core α-helical bundle (Kunze Et. al., 2014). Such a 
charged surface seems to sterically and energetically favour the interaction with 
heparin chains (Samsonov Et. al., 2014). These predictive results also corroborate with 
very recent experimental evidence by NMR citing the same GAG-binding site on IL-
10 (Kunze Et. al., 2016).  
 
In case of IFN-γ, the heparin-binding property has been detected and confirmed via 
carboxyl-terminal basic residues (Lortat-Jacob & Grimaud, 1991a). This part of IFN-γ 
(which is also a regulatory peptide for its biological activity) contains a conserved 
stretch of basic amino acids from 128-131 residues (referred to as D1 domain: KRKR) 
and 137-140 residues (D2 domain: RGRR) that shows affinity for sulphate domains on 
heparin chains (Lortat-Jacob & Grimaud, 1991a; Vanhaverbeke Et. al., 2004; Saesen 
Et. al., 2013). However, in the available crystal structure of IFN-γ (1HIG.pdb), this 
carboxyl-terminal peptide (residues 124-143) is an unfolded sequence that extends 
away from the main structural fold and is believed to be a disordered domain, therefore 
highly flexible to adapt multiple conformations (Ealick Et. al., 1991). The application 
of molecular simulation methods to proteins with such unstructured carboxyl-terminal 
regions enriched in basic residues may lead to artefactual results as discussed by 
Mulloy & Forster (2008). Therefore, to date, the predictive docking calculations have 
not been applied to the available IFN-γ structure. Nevertheless, the mechanism of IFN-




methods such as SPR, ITC (Isothermal Titration Calorimetry), NMR and electrostatic 
potential calculations. The mechanism of IFN-γ binding to heparin was identified as a 
two-step process with D1 domain basic residues offering strong electrostatic 
interactions with heparin. Whereas D2 cluster residues further stabilized and controlled 
the kinetics of interaction. This study thus highlighted that the two basic domains in 
IFN-γ contributed differently but co-operatively to induce an extended surface of 
positive electrostatic potential at the carboxyl-terminal domain of IFN-γ for heparin 
binding (Saesen Et. al., 2013). Such information with molecular details for the 
interaction of heparin/HS with IL-10 and IFN-γ provided insights into structural 
features of heparin-binding domains to compare with IL-22. 
 
Unlike in IL-10 and IFN-γ, the putative heparin-binding domain in IL-22 which is also 
in the carboxyl-terminal basic cluster is disrupted into smaller clusters by the acidic 
residues located within and those surrounding the cluster, as seen in Figure 3.20. These 
acidic amino acids by charge repulsion can restrict the interaction of any two, closely-
spaced basic patches on the protein surface to act in concert with heparin chains. Thus, 
the presence of acidic residues on the surface of an IL-22 protein possibly results in an 
ill-defined and diffused charge distribution with weak positive electrostatic potential 
within the predicted HBD (Figure 3.20). This in turn may be unable to hold a strong 
interaction with heparin. This is also reflected in the intermolecular interaction energies 
obtained here by molecular docking calculations for the best-fit complex of IL-22 
monomer (-809 kcal/mol) and dimer (-650 kcal/mol) with pentameric heparin chains 
that further supports the conclusion. The energy values for IL-22 were found to be 
almost twice the binding energy obtained when compared to the IL-10 dimer (-1442 
kcal/mol). Therefore, the differences in energetics of binding also suggests differences 
in the heparin-binding capacity of IL-22 compared to other heparin-binding cytokines, 
IL-10 and IFN-γ, within the same family. Thus, predictive results from the docking 
calculations agree with experimental data presented here for IL-22. 
 
Even though IL-10, IFN-γ and IL-22 shared secondary structural elements (Nagem Et. 
al., 2002), one notable structural difference between them is that IL-10/IFN-γ are 
intercalated, physiological homodimers (Logsdon Et. al., 2004; Zdanov, 2004; Nagem 
Et. al., 2006). IL-10 and IFN-γ monomers are stabilised by formation of intertwining, 
‘V’ shaped homodimers such that each domain of a ‘V’-shaped homodimer contained 




resulting in twofold symmetry in dimers (Walter & Nagabhushan, 1995; Logsdon Et. 
al., 2004; Zdanov, 2004). On the other hand, as described earlier (Section 3.2.2.4) the 
IL-22 monomer is a biologically active form and the dimer is an interfacial homodimer 
with a compact structure and the buried interface area being twice as much of IL-10 or 
IFN-γ (Nagem Et. al., 2002; Zdanov, 2010). Consequently, the surface basic residues 
on the IL-22 monomer remains partially buried in the dimer interface region. On the 
contrary, the surface basic clusters, particularly the heparin-binding regions on IL-10 
and IFN-γ monomers are available twice, when they are in the dimer forms (Saesen Et. 
al., 2013; Kunze Et. al., 2014; Gehrcke & Pisabarro, 2015). This explains, to some 
extent, why in the case of the IL-22 dimer the surface basic residues are less likely to 
be accessible for binding to heparin. Moreover, this may also be one of the reasons for 
the relatively reduced affinity of the IL-22 dimer than the monomer for polyanionic 
chains like heparin.  
 
Due to the above-mentioned spatial symmetry in IL-10 (Zdanov, 2004; Zdanov, 2010) 
and IFN-γ homodimers (Ealick Et. al., 1991), this constitutes to two heparin-binding 
sites in these cytokine dimers. Hence, this results in strong and detectable affinity for 
heparin/HS chains. For instance, in the IL-10 dimer, two heparin-binding regions 
occur, one on either side of the central ‘V’-shaped crevice at a distance of ~30-40oA 
(Kunze Et. al., 2014; Gehrcke & Pisabarro, 2015). Moreover, GAG chains of eight 
sugar residues or more were shown by NMR to change the IL-10-GAG binding 
stoichiometry suggesting that a single long GAG chain can engage both binding sites 
connecting the two IL-10 monomers in a IL-10 dimer (Kunze Et. al., 2014; Gehrcke & 
Pisabarro, 2015; Kunze Et. al., 2016). Whilst for HS/IFN-γ interaction, one HS 
molecule was proposed to bind an IFN-γ dimer such that two sulphated domains (NS), 
separated by an N-acetyl rich domain (NA) can bind directly to two IFN-γ C-termini 
(Lortat-Jacob Et. al., 1995). Consistently, recent studies have shown that the IFN-γ 
dimer with the HS-binding surface shows preference to intra-HS bonds over inter-HS 
chain bonds (Migliorini Et. al., 2015), thus supporting the previously proposed model 
that a single HS chain via an NA domain engages two C-termini basic clusters one on 
each IFN-γ monomers (Lortat-Jacob Et. al., 1995; Fernandez-Botran Et. al., 1999; 
Lortat-Jacob, 2006). Taken together, even though the structural elements (α-helices) in 
IL-22, IL-10, and IFN-γ are similar, the spatial distribution of basic residues along with 
the presence of frequent acidic residues do not seem to favour the formation of a 




clustering of basic residues in absence of acidic residues is important to provide optimal 
charge and surface complementarity for heparin/HS binding, as also recently 
demonstrated by Samsonov Et. al. (Samsonov Et. al., 2014; Samsonov & Pisabarro, 
2016). Hence, IL-22 lacks heparin-binding property within interferons/IL-10 family. 
 
In summary, the current study was intended to determine whether heparin-binding is a 
common property among the interleukins, IL-11, IL-18 and IL-22 that share structure-
function relationships with known heparin-binding family members. Combinations of 
various predictive and experimental approaches employed were consistent in their 
outcomes that this chosen group of interleukins do not bind to heparin. Thus, current 
findings negate the above stated hypothesis and this study further attempts to highlight 
the structural differences in the development of heparin-binding domains in some 
members and not in others of the same cytokine family. Indeed, the current findings 
with experimental evidence corroborates with another study published after our 
experimental work was completed, which used only predictive computational docking 
method to identify whether cytokines members of four α-helical family bind to heparin 
(Mulloy & Forster, 2008). More recently, NMR structural studies of a subset of 
Neutrophil-activating chemokines that bind to heparin/HS had a distinct GAG-binding 
site that were unique to each chemokine and its function, even though these chemokines 
shared similar structures and activate a common receptor on neutrophils (Rajarathnam 
Et. al., 2018).  Accordingly, the current finding underlines that neither heparin/HS-
binding property nor the binding site is conserved among all members of cytokine 
family. Thus, it can be concluded from the current study that heparin binding is a 
characteristic of an individual interleukin and not a property that is shared by all 
members of a given cytokine family. However, the functional implications of this non-
heparin binding property of interleukins, IL-11, IL-18 and IL-22 are discussed in 





















IMMUNOREGULATORY ROLE OF DERMATAN 
SULPHATE IN IL-12 INDUCED IFN-γ SECRETION IN 







While the previous chapter studied the role of GAGs in binding to interleukins, this 
chapter looks into the functional role of GAGs, specifically DS. IL-12-induced IFN-γ 
production in NK cells is a key event in establishing Th1 type, cell-mediated immune 
responses. The earlier work published by Garneir Et. al. from our laboratory showed 
that among different GAG lyases used, only chondroitinase ABC inhibited IL-12-
induced IFN-γ secretion indicating a role for DS in the activity of IL-12 (Garnier Et. 
al., 2003). This chapter attempts to follow-up on these previous observations. In 
particular, this work has sought to elucidate the underlying mechanism by which DS 
affects the IL-12 signalling pathway in NK cells. To affirm this functional influence of 
DS, chondroitinase ABC treatment of NK cells was employed. Subsequently, 
methyumbelliferyl-β-D-xyloside, an inhibitor of PG biosynthesis was used to 
investigate the role of NK cell-surface PGs in response to IL-12.  
 
As described earlier (Section 1.7.2, Figure 1.11) that to delineate the underlying 
mechanism, the proposed sites of DS-PG involvement in the IL-12 signalling pathway 
were tested. Firstly, to determine whether DS-PG directly affects ligand-receptor (IL-
12-IL12R) binding or receptor-based activity, the phosphorylation of the IL12-specific 
transcription factor, STAT-4 was examined on addition of IL-12 to β-xyloside treated 
NK cells. Subsequently, whether DS-PG interferes with the secretion pathway of the 
IFN-γ protein was tested. For this, β-xyloside treated NK cells were stimulated with 
IL-12 and the amount of IFN-γ protein secreted into the culture supernatant was 
measured. Then cells were lysed to quantify IFN-γ protein levels within the cells using 
ELISA. Addressing these objectives has enabled us to identify whether DS-PG 
regulates the transcriptional, translational, or post-translational events in IL-12-induced 




4.2.1 Optimisation of an In vitro Cellular Model for IFN-γ Secretion  
 
The in vitro cellular model of NK cell activity was measured in terms of IFN-γ secreted 
in response to IL-12. In order to conduct this study, a dose-response curve to IL-12 in 




tissue culture wells and stimulated overnight with increasing concentrations of IL-12. 
The Culture supernatant was then tested for secreted IFN-γ by ELISA. As seen in the 
Figure 4.1, there is a dose-dependent increased secretion of IFN-γ by the IL-12 
stimulated cells.  This secretion measured against the standard curve of the IFN-γ 


















IL-12 is known to induce NK cells and T cells to secrete high amounts of IFN-γ (Gately 
Et. al., 1998). These results demonstrate the same with the KY-1 cell line. Since 200 
pg/ml of IL-12 was found to be optimum concentration for IFN-γ secretion, the 
suboptimal concentration 150 pg/ml was selected for all our future experiments. This 
would allow us to detect either an increase or decrease in rate of IFN-γ secretion in the 
presence of β-xylosides or chondroitinase ABC. 
 
4.2.2 Effect of Chondroitinase ABC on IL-12 Induced NK Cell IFN-γ Secretion  
 
Having established that the KY-1 cells responded to exogenous IL-12 by IFN-γ 
secretion, the involvement of DS in NK cell produced IFN-γ was then examined using 
enzyme chondroitinase ABC, which strips cell-surface CS/DS. Previous work from our 















Figure 4.1: IFN-γ induction in response to increasing concentrations of IL-12: KY-1 cells (2.5 
x 10 5 cells/1.7cm diameter well) primed with hIL-2 were stimulated overnight with increasing doses 
of IL-12, 0-250 pg/ml. Conditioned supernatants were assayed for mIFN-γ by ELISA.  Results 
represent the mean of triplicate cultures at each point, with error bars showing ±SEM (standard error 
mean), not shown where smaller then symbol size. One representative experiment of three 




chondroitinase ABC (0.3 IU/ml) showed significant inhibition (30%) of IL-12 
stimulated IFN-γ secretion.  This effect was found to be specific to chondroitinase ABC 
activity, as use of other GAG lyases like heparinase I, heparinase II, hyaluronidase, and 
chondroitinases AC I and II did not affect IFN-γ secretion (Garnier Et. al., 2003).  
These previous observations suggested that the DS chains are involved in the process. 
In the current study, initially this enzymatic approach was adopted to establish the 
effect of the removal of cell-surface DS on the cellular response towards IL-12. The 
effect of chondroitinase ABC on IL-12 bioactivity in NK cells was sought. 
 
Prior to the addition of the enzyme, chondroitinase ABC-protease free, its activity was 
tested by cetylpyridinium chloride precipitation assay as described in Section 2.4.2 
(data not shown). This assay detects degradation of GAG chains by the enzyme, 
confirming that the enzyme preparation retained its activity when diluted with the cell 
culture medium. Once enzyme activity under the culture conditions was confirmed, 
KY-1 cells stimulated with IL-12 were cultured overnight in the presence and absence 
of 0.1 U/ml of chondroitinase ABC. Unstimulated cells receiving no treatment served 
as negative controls. Secreted IFN-γ in the culture supernatant was assayed by ELISA. 
As seen in Figure 4.2, cells treated with the enzyme chondroitinase ABC in the 
presence of IL-12 showed 36% IFN-γ inhibition (bar-3), which was found to be 
statistically significant (p=0.003) against IL-12 alone stimulation (bar-2). As such, IL-
12 alone treatment was taken as 100% IFN-γ secretion (bar-2) compared to negative 
control (bar-1). Thus, the data shown in the Figure 4.2 was comparable with the 
previously reported results (Garnier Et. al., 2003).  Indeed, this result suggests that 
digestion of cell surface CS/DS-GAGs of NK cells by protease-free enzyme, 
























4.2.3 Effect of β-Xylosides on IL-12 Stimulated NK Cell IFN-γ Secretion 
 
The previously assessed role of NK cell-surface DS in IL-12 stimulated IFN-γ 
production was further confirmed and continued using β-xylosides. As detailed earlier 
in Section 1.7.3.1, β-xylosides are well-established inhibitors of intact PG synthesis 
where they act as alternative acceptors for the enzyme galactosyltransferase in the 
initiation of GAG chain synthesis. Therefore, the treatment with β-xylosides results in 
increased synthesis and secretion of free GAG chains and decreased PG synthesis 
(Okayama Et. al., 1973; Christmas Et. al., 1988; Fritz Et. al., 1994b; Kuberan Et. al., 
2008). Our laboratory recently implicated DS-PGs in the biological activity of IL-12 at 
the cellular level, in part, by finding that in the presence of 75 µM methyumbelliferyl-
β-D-xyloside, IL-12 stimulated NK cells showed a reduction (by 70%) in the secretion 
of IFN-γ. Furthermore, the exogenous addition of soluble CS/DS or heparin as GAGs, 
Figure 4.2: Effect of recombinant Chondroitinase ABC on IL-12 induced IFN-γ secretion: KY-
1 cells (2.5 x 10 5 cells/1.7cm diameter well) were incubated overnight in the presence or absence 
of 150pg/ml of IL-12 and 0.1 U/ml of chondroitinase ABC. ELISA assayed the secreted mIFN-γ 
from the supernatant.  Results are the mean of triplicate wells with error bars showing ±SEM. 
Asterisk denote p<0.05 for enzyme chondroitinase ABC effect in comparision to IL-12 alone 
stimulation for IFN-γ secretion. One representative experiment of the two independent experiments 




along with β-xyloside, could not alter this inhibitory effect on IFN-γ secretion (Garnier 
Et. al., 2003).  
 
The current study aimed to extend this work using methyumbelliferyl-β-D-xyloside. 
To reproduce the previously reported experimental results (Garnier Et. al., 2003), KY-
1 cells stimulated with IL-12, were cultured in the presence and absence of 75 μM 
methylumbelliferyl-β-D-xyloside dissolved in DMSO. Since the inhibitor-β-xyloside 
is hydrophobic, DMSO is the most commonly used solvent for it. Therefore, it was 
necessary to include a solvent control-DMSO alone in the experiment. For this, IL-12 
stimulated cells were treated with the same concentration (v/v) of DMSO but without 
methylumbelliferyl-β-D-xyloside. This would consider the effect of DMSO itself on 












Figure 4.3: Effect of methylumbelliferyl-β-D-xyloside (mu-β-xyloside) and DMSO on IL-12 
induced IFN-γ secretion: KY-1 cells (2.5 x 10 5 cells/1.7cm diameter well) were stimulated with 
IL-12 (150pg/ml) and cultured overnight (16 hours) in the presence and the absence of 
methylumbelliferyl-β-D-xyloside (75uM) in DMSO (final concentration 0.2% v/v per well). IFN-
γ secreted into the supernatant medium was assayed by ELISA. Results are the mean of triplicate 
wells with error bars showing ±SEM. Asterisks denote p<0.05 (for both methylumbelliferyl-β-D-
xyloside and DMSO alone treatments compared to IL-12 only treatment). One representative 










As shown in Figure 4.3, unstimulated cells without treatment served as internal control 
(bar-1). IL-12 alone treatment (bar-2) resulted in significant IFN-γ production 
compared to internal control (bar-1). As such, IL-12 alone treatment was considered as 
100% IFN-γ secretion. The treatment of IL-12 stimulated cells with 
methylumbelliferyl-β-D-xyloside (75 μM) in DMSO (bar-4) shows a significant 
reduction in the secretion of IFN-γ by 56% compared to IL-12 alone treatment (bar-2). 
This was a statistically significant reduction (p=0.044) as calculated by the non-
parametric Mann-Whitney’s statistical test. Further, it was found that DMSO alone 
(0.2% v/v) in the presence of IL-12 (bar-3) was significant in curtailing IFN-γ secretion 
by 44.5% (p=0.05) against IL-12 alone treatment (bar-2). This shows that the 0.2% 
DMSO concentration was sufficient to significantly inhibit IFN-γ induction in response 
to IL-12.  
 
The effect of 75 μM methylumbelliferyl-β-D-xyloside on IFN-γ secretion (bar-4) was 
significant (56%, p=0.044) compared to IL-12 alone treatment (bar-2) but when 
compared to DMSO (0.2%) alone treatment (bar-3), the effect was not statistically 
significant (11%, p=0.306). This was determined by Kruskal-Wallis tests for group 
comparison of current experimental data (Figure 4.3). Thus, the results indicate that the 
inhibitory effect observed by methylumbelliferyl-β-D-xyloside in DMSO was 
apparently more pronounced due to effects of DMSO solvent itself. Similar effects of 
DMSO have been reported in other studies carried out with β-xylosides dissolved in 
DMSO on smooth muscle cell lines and keratinocytes (Potter-Perigo Et. al., 1992). 
DMSO in high concentrations is toxic to the growth of cells. p-nitrophenyl-β-xyloside, 
when added at 5mM final concentration in DMSO was reported to lyse the cells, 
whereas the same dose of p-nitrophenyl-β-xyloside in PBS (phosphate buffered saline) 
showed no signs of cytotoxicity (Potter-Perigo Et. al., 1992).  Therefore, it was seen 
that DMSO solvent potentiated the inhibitory effect of β-xyloside on growth and cell 
proliferation. Hence, the use of DMSO was carefully considered in our course of 
experiments and their interpretations. 
 
Nonetheless, these results (Figure 4.3) were found to differ from those previously 
reported (Garnier Et. al., 2003), who observed 70% IFN-γ inhibition with 
methylumbelliferyl-β-D-xyloside (75μM) and 20% inhibition with DMSO (0.2%) 
solvent alone, on similar molar basis and experimental conditions. Therefore, it was 




methylumbelliferyl-β-D-xyloside to achieve minimal interference from DMSO 
solvent. Moreover, as part of preliminary experiments, it was determined in the current 
study that methylumbelliferyl-β-D-xyloside was insoluble in ethanol and PBS. So, a 
stock solution of methylumbelliferyl-β-D-xyloside (1M) was prepared in DMSO. 
Further, experiments were conducted to determine the concentration of 
methylumbelliferyl-β-D-xyloside that can be added to a minimum amount of DMSO 
so as to get the least interference from DMSO itself. It was found that 
methylumbelliferyl-β-D-xyloside could be added at 60 µM and 120 µM with 
corresponding DMSO concentrations as 0.04% and 0.08 % v/v to the culture medium 
without precipitation of the inhibitor due to its lipophilic nature. Subsequently, the 
effect of 60 µM and 120 µM methylumbelliferyl-β-D-xyloside in DMSO on IL-12 
stimulated NK cell IFN-γ secretion was tested (data not shown). The difference in the 
inhibitory effect exhibited by both these methylumbelliferyl-β-D-xyloside 
concentrations compared to their respective DMSO alone effect was to a similar extent 
of about 10-15%. This was a significant effect (p= 0.05) as per non-parametric Mann-
Whitney’s statistical test. However, this observed effect of methylumbelliferyl-β-D-
xyloside was much lower compared to the reported effect by Garnier et al (Garnier Et. 
al., 2003).  
 
Additionally, use of another β-xyloside was thus contemplated in the current study. An 
analog of methylumbelliferyl-β-D-xyloside namely, p-nitrophenyl-β-D-xyloside, 
extensively known for its use as PG inhibitor in various cell culture studies was 
employed (Galligani Et. al., 1975; Schor & Schor, 1988; Manzi Et. al., 1995; Salimath 
Et. al., 1995). Prior to the use of p-nitrophenyl-β-D-xyloside, its solubility in DMSO 
and other solvents was examined in order to achieve the required drug concentration 
with the minimum of added solvent. As with methylumbelliferyl-β-D-xyloside, DMSO 
was again the most effective solvent for p-nitrophenyl-β-D-xyloside. 
 
4.2.3.1 Comparative Effects of methylumbelliferyl and p-nitrophenyl-β-D-xyloside on 
IL-12 Induced IFN-γ Secretion 
 
The inhibitory effect of methylumbelliferyl-β-D-xyloside in comparison with p-
nitrophenyl-β-D-xyloside on IL-12 stimulated IFN-γ secretion was assessed. KY-1 
cells were stimulated with IL-12 either in the presence of 60 μM methylumbelliferyl-




As a solvent control in the experiment, the corresponding concentration of solvent 
DMSO alone (0.04% v/v) was added to the IL-12 stimulated cells. As seen in Figure 
4.4, unstimulated cells without any treatment served as the internal control in the 
experiment (bar-1). As expected, IL-12 alone treatment (bar-2) resulted in significant 
IFN-γ secretion when compared to internal control (bar-1). DMSO alone treatment 
(bar-3) exhibited significant inhibition (by 17%, p=0.05), when compared to IL-12 
alone treatment (bar-2).  In addition, both 60 μM methylumbelliferyl-β-D-xyloside in 
DMSO (bar-4) and 200 μM of p-nitrophenyl-β-D-xyloside in DMSO (bar-5) were 
effective in reducing IFN-γ secretion by 15% and 25% respectively when compared to 
DMSO alone treatment (bar-3). This net inhibitory effect by methylumbelliferyl-β-D-
xyloside (bar-4) and p-nitrophenyl-β-D-xyloside (bar-5) on IFN-γ secretion were 
statiscally significant (p=0.05) against DMSO alone effect (bar-3). This was analysed 
using non-parametric Mann-Whitney’s test followed by Kruskal-Wallis test for group 
comparison.  Thus, p-nitrophenyl-β-D-xyloside was observed as a more potent 
inhibitor of IFN-γ secretion compared to methylumbelliferyl-β-D-xyloside and 





















4.2.3.2 Effect of Increasing Concentrations of p-nitrophenyl-β-D-xyloside on Inhibition 
of IL-12 Induced IFN-γ Secretion 
 
Next, to determine a dose dependent effect of p-nitrophenyl-β-D-xyloside on IFN-γ 
secretion, IL-12 stimulated KY-1 cells were treated with increasing concentrations of 
p-nitrophenyl-β-D-xyloside. Concentrations from 250 μM to 1500 μM of p-
nitrophenyl-β-D-xyloside in DMSO were added.  As a solvent control in the 
experiment, relative concentrations of DMSO alone, ranging from 0.025% to 0.15% 
v/v were added to IL-12 stimulated cells. After the treatment and incubation period, the 
culture supernatant was assayed and quantified for the levels of secreted IFN-γ protein 
by ELISA.  
 
 
Figure 4.4: Comparative effect of methylumbelliferyl and p-nitrophenyl-β-D-xyloside on 
IL-12 induced IFN-γ secretion: KY-1 cells (2.5 x 10 5 cells/1.7cm diameter well) were 
stimulated with IL-12 (150pg/ml) and cultured overnight in the presence of methylumbelliferyl-
β-D-xyloside (60μM) and p-nitrophenyl β-D-xyloside (200μM) with a relative DMSO 
concentration of 0.04% v/v. IFN-γ secreted in the supernatant medium was assayed by ELISA. 
Results are the mean of triplicate wells with error bars showing ±SEM. Asterisks denote p<0.05 
for both Methylumbelliferyl-β- and p-nitrophenyl-β-xyloside in comparison DMSO alone 




















As seen in the Figure 4.5, increasing concentrations of p-nitrophenyl-β-D-xyloside in 
the presence of IL-12 led to increased inhibition of IFN-γ secretion. Maximum 
inhibition of about 67% was observed for 1500 µM concentration of p-nitrophenyl-β-
D-xyloside (green bar-6), whereas the corresponding inhibition by DMSO (0.15%) 
alone was reduced by 21% (blue bar-6) against IL-12 alone stimulation (blue bar-2). 
Concentrations above 1000 µM of p-nitrophenyl-β-D-xyloside or methyl-umbelliferyl 





















DMSO alone (concentration in % + IL-12)
pnp-β-xyloside (µM) in DMSO (%) + IL-12
Conditions 
1 2 3 4 5 6 
IL-12 (150 pg/ml) - + + + + + 
DMSO (%)  0 0 0.025 0.06 0.1 0.15 
pnp-β-xyloside (µM) in DMSO (%)  0 0 250 600 1000 1500 
Figure 4.5: Effect of increasing concentrations of p-nitrophenyl-β-xyloside on inhibition of 
IL-12 induced IFN-γ secretion:  KY-1 cells (2.5 x 10 5 cells/1.7cm diameter well) were 
stimulated with IL-12 (150pg/ml) for 18 hours with increasing concentrations of the p-
nitrophenyl-β-xyloside from 250-1500μM (■) and to the relative DMSO concentration from 
0.025% to 0.15% v/v (■). The secreted IFN-γ in the supernatant was assayed using ELISA.  
Results represent the mean of triplicate wells at each point, with error bars showing ±SEM. One 





decreased proliferative activity or both (Sobue Et. al., 1987). However, in the current 
study, KY-1 cells exposed to concentrations higher than 600 μM of p-nitrophenyl-β-
D-xyloside showed detachment from well surface. The detached cells were assessed 
for viability using nigrosin stain as described in Section 2.6. As a result, more than 50% 
of the detached cells were found viable under various conditions used. Nonetheless, 
these cells could have lost the ability to be stimulated by IL-12 and may not secrete 
IFN-γ. Therefore, 600 μM concentration of p-nitrophenyl-β-D-xyloside was 
considered, wherein cellular detachment was not observed but decrease in IFN-γ 
secretion by 50% was observed (green bar-4). Additionally, the corresponding 
concentration of DMSO (0.06%), in the absence of p-nitrophenyl-β-D-xyloside (blue 
bar-4), had no significant effect on IFN-γ inhibition as well as on cell detachment.  
Therefore, 600 μM concentration of p-nitrophenyl-β-D-xyloside in DMSO (0.06 %) 
was selected for further experimental studies to reveal the mechanism of the DS-PG 
effect.  
 
4.2.4  Effect of p-nitrophenyl-β-D-xyloside on IL-12 Induced Tyrosine 
Phosphorylation of STAT-4 
 
Tyrosine phosphorylation of STAT-4 is a critical event associated with IL-12 receptor 
(IL-12R) activity and is upstream to IFN-γ expression in NK cells (Thierfelder Et. al., 
1996). Therefore, this event is an important control point in studying IL-12 signalling 
that could help determine whether DS-PG directly regulates IFN-γ expression via IL-
12R activity. Having established the effect of p-nitrophenyl-β-D-xyloside at 600μM in 
0.06% DMSO as an inhibitor of IL-12 stimulated IFN-γ secretion, the effect of this 
treatment on tyrosine phosphorylation of STAT-4 was examined. 
 
KY-1 cells treated with or without p-nitrophenyl-β-D-xyloside were stimulated with 
IL-12 (150 pg/ml). Unstimulated cells receiving no treatment were used as internal 
control. After incubation time, cells were lysed as described in Section 2.7. As seen in 
Figure 4.6A, tyrosine phosphorylated STAT-4 protein was detected by western blotting 
using specific anti-pSTAT-4 Ab (tyr-693) at 89kDa (Figure 4.6A, Lanes 2, 3 and 4). 
Interestingly, unstimulated cells (Figure 4.6A, Lane 1) showed no basal levels of 
tyrosine phosphorylated STAT-4 and stimulation with IL-12 resulted in high levels of 
STAT-4 phosphorylation (Figure 4.6A, Lane 2) which was unaffected by the presence 
of p-nitrophenyl-β-D-xyloside (Figure 4.6A, Lane 4) or DMSO alone (Figure 4.6A, 




STAT-4 Ab to detect the presence of total STAT-4 levels in the samples (Figure 4.6B). 
The intensity of bands in each lane for respective proteins was measured 
densitometrically using software image J, as shown in Table 4.2. Ratio of pSTAT-4 to 
total STAT-4 was calculated.  Importantly, the results in Table 4.2 demonstrated that 
there was no effect of p-nitrophenyl-β-D-xyloside on IL-12 stimulated tyrosine 



















































Lanes       1 
(control) 
  2   3   4 
IL-12 (150pg/ml)  -     +   +   + 
IL-12 + DMSO (0.06%)  -    -   +   + 
IL-12 +  p-nitrophenyl-β-D-xyloside (600μM) in  
DMSO (0.06%) 
 -    -   -   + 
                        1                            2                          3                          4 
                      1                              2                            3                            4 
89kDa 
89kDa 
(B) WB: anti-STAT-4 
(A) WB: anti-pSTAT-4 
(B)  
Figure 4.6:  Effect of p-nitrophenyl-β-xyloside on IL-12 induced tyrosine phosphorylation 
of STAT-4: KY-1 cells (2.5x 10 5 cells/ 3.4cm diameter well) cultured in the presence and 
absence of p-nitrophenyl β-D-xyloside (600μM) with relative DMSO concentration of 0.06% 
v/v for 18 hours followed by stimulation with IL-12 (150pg/ml) for 2 hours and control as 
unstimulated cells.  Western blots were immunodeveloped with anti-pSTAT-4 (A) followed by 
stripping and reprobing the blot with anti-STAT-4 (B) and corresponding bands were seen. The 
numbers below each blot indicates cellular treatment for each lane. Densitometric analysis was 
performed of the blots using Image J and the ratio of pSTAT-4 / STAT-4 of the representative 
blot is as shown in Table 4.2. Above blot is representative of duplicate wells in an experiment. 








Based on this observation on STAT-4 phosphorylation, the result implied that p-
nitrophenyl-β-D-xyloside did not block IL-12 binding to its membrane specific 
receptor, or the activation of the IL-12R. Thus, this data established that the effect of 
DS-PG in regulation of IL-12-induced IFN-γ secretion was independent of STAT-4 
tyrosine phosphorylation. In conclusion, the involvement of DS-PG appeared to be 
downstream of STAT-4 phosphorylation.   
 
4.2.5 Effect p-nitrophenyl-β-xyloside on IL-12 Induced Secreted and Cellular 
IFN-γ 
 
Downstream to STAT-4 activation, DS-PG could regulate at the transcriptional or 
translational level of IFN-γ expression. In agreement with Garnier et al’s results, the 
current study observed partial secretion of IFN-γ in the presence of p-nitrophenyl-β-D-
xyloside which indicated either reduced synthesis or secretion. Therefore, referring to 
IL-12 signalling (Figure 1.11), a possibility in this cellular investigation was to 
determine whether DS-PG mediates regulation through a role in the secretion of IFN-
γ. For this, on stimulation with IL-12 in the presence and absence of p-nitrophenyl-β-
D-xyloside, the levels of IFN-γ protein both within the cells and that secreted into 
media were quantified.  
 
Previous reports have shown in renal visceral epithelial cells that β-xyloside caused 
accumulation of GAGs in the Golgi vesicles (Kanwar Et. al., 1984). Moreover, IFN-γ 
is an inducible, secretory, glycosylated protein that follows classical ER-to-Golgi 
pathway of secretion. Therefore, it is plausible that IFN-γ, as a GAG-binding protein, 
could accumulate intracellularly, may be GAG- bound. Another report demonstrated 
the effect of β-xylosides on the expression of CS-PG-associated MHC class II 
Lanes Ratio of pSTAT-4 / STAT-4 
 
1    No IL-12 0.0 
2    IL-12 (150 pg/ml) 0.83 
3    IL-12 + DMSO (0.06%) 0.85 
4 IL-12 + p-nitrophenyl-β-D-xyloside (600μM) in 
DMSO (0.06%) 
0.82 





molecules. This study proposed a malfunctioning of Golgi apparatus that arose from 
the accumulation of CS within p-nitrophenyl-β-D-xyloside treated T cells. This 
resulted in altered biosynthesis and cell surface expression of MHC class II molecules 
and thereby disruption in antigen processing and presentation by those T cells 
(Rosamond Et. al., 1987). Thus, it is possible that the treatment of NK cells with p-
nitrophenyl-β-D-xyloside could result in the vesicular accumulation of IFN-γ, thereby 
inhibiting its secretion. Hence, it was necessary to examine the effect of p-nitrophenyl-
β-D-xyloside on the levels of secreted and cellular IFN-γ, induced by IL-12. 
 
KY-1 cells were stimulated with IL-12 in the presence and absence of p-nitrophenyl-
β-D-xyloside in DMSO. Unstimulated cells without any treatment served as the internal 
control in the experiment.  After the stimulation and incubation time, supernatants of 
the treated cells were removed and used to quantify secreted IFN-γ protein levels. The 
cells were then lysed by treatment with lysis buffer, containing 1% Triton X-100 and a 
cocktail of protease inhibitors. The cell lysate was used to determine cellular IFN-γ 
protein. So, from the same experiment, both secreted and cellular IFN-γ protein levels 
were quantified by ELISA. The data obtained from this experiment are shown in Figure 
4.7. It is worth noting that the amount of secreted IFN-γ is expressed in ng/ml (Figure 
4.7A), whereas the amount of cellular IFN-γ is in pg/ml (Figure 4.7B). As seen in the 
Figure 4.7A, the inhibitory effect of p-nitrophenyl-β-D-xyloside at 600 μM (bar-4) 
against effect of IL-12 alone (bar-2) or DMSO alone (0.06%) on IFN-γ sercretion (bar-
3) is about 45%. Further, Figure 4.7B that shows cellular IFN-γ reveals a similar pattern 
and level of inhibition (45%) when compared to secreted IFN-γ in the presence of p-
nitrophenyl-β-D-xyloside. This effect was notably a statistically significant (p=0.05) 
when compared with the effect of DMSO alone at a final concentration of 0.06% v/v. 
This was tested by a non-parametric Mann-Whitney’s test and Kruskal-Wallis test for 
group comparision. Thus, the results indicate no build-up of IFN-γ on induction with 
IL-12 within the cell either in the presence or absence of β-xyloside. This further 
eliminates the possible involvement of DS-PG in debilitating secretion of IFN-γ 
protein. Rather, this lack of sequestration of IFN-γ within the cells implies reduced 
synthesis of this protein by NK cells in the presence of p-nitrophenyl-β-D-xyloside and 























Figure 4.7:  Effects of p-nitrophenyl-β-D-xylosides on IL-12 induced secreted and cellular 
IFN-γ:  
KY-1 cells (2.5 x 10 5 cells/1.7cm diameter well) were cultured for 18 hours with 600μM of p-
nitrophenyl-β-xyloside, a proteoglycan inhibitor and a relative DMSO concentration as 0.06% v/v 
in the presence of IL-12 (150 pg/ml).  The secreted IFN-γ (■) (A) in the medium and cellular IFN-
γ (■) (B) under different conditions were assayed using ELISA.  Results are the mean of triplicate 
wells with error bars showing ±SEM. Asterisks denote p<0.05 for p-nitrophenyl-β-xyloside in 
DMSO in comparison DMSO alone treatment at both secreted and cellular level of IFN-γ induction 







4.2.6  Evaluation of Effect of p-nitrophenyl-β-xyloside as a PG-inhibitor in 
Comparison to p-nitrophenyl-α-xyloside and p-nitrophenyl-β-galactoside on IL-
12 Induced IFN-γ Secretion 
 
Thus far, β-xylosides were used in the current set of experiments, as a tool to perturb 
PG synthesis in NK cells to determine the direct influence of GAGs and, by extension, 
PGs on IL-12 induced IFN-γ secretion. In the past, a number of studies specifically 
defined the role of p-nitrophenyl-β-D-xyloside that correlated a biological effect to PGs 
by using negative controls that were unable to inhibit PG synthesis (Galligani Et. al., 
1975; H. C. Robinson & Lindahl, 1981; Schor & Schor, 1988; Potter-Perigo Et. al., 
1992; Clark Et. al., 2004). Therefore, it becomes important to ascertain that the 
observed β-xyloside inhibition of IFN-γ was due to perturbed GAG/PG synthesis, and 
not from other cellular or metabolic effects of β-xylosides on NK cells (Freeze Et. al., 
1993; Izumi Et. al., 1994). To test this in the current cellular model, the effect of p-
nitrophenyl- β-D-xyloside was evaluated by direct comparison with the effect of p-
nitrophenyl-α-D-xyloside and p-nitrophenyl-β-D-galactoside on IFN-γ secretion, 
which served as negative controls.  
 
p-nitrophenyl-α-D-xyloside and other β-linked sugar derivatives such as p-nitrophenyl-
β-D-galactoside are structural analogs of p-nitrophenyl-β-D-xyloside (Galligani Et. al., 
1975; Robinson Et. al., 1975). Because GAG synthesising enzymes exhibit specificity 
for the anomeric linkage and for the glycone structure, these exogenously added α-
xylosides and β-galactosides respectively, are unable to initiate GAG synthesis and 
alter PG metabolism (N. B. Schwartz Et. al., 1974a). Freeze Et. al. (1993) reported that 
the enzyme galactosyl transferase I (from the GAG synthetic pathway) catalyses the 
addition of the first Gal unit to both p-nitrophenyl-α-D-xyloside and p-nitrophenyl-β-
D-xyloside in CHO (Chinese Hamster Ovarian) cells. However, the subsequent 
enzyme, galactosyl transferase II distinguishes between the α and β configuration of 
the terminal xylose, where addition of second Gal residue does not occur in the α-linked 
xyloside. On the other hand, p-nitrophenyl-β-D-galactosides are ineffective in the 
synthesis of free GAG chains because of specificity in substrate recognition shown by 
enzyme galactosyl transferase I that uses only an acceptor that has a terminal D-xylose 
(N. B. Schwartz Et. al., 1974a; Robinson Et. al., 1975). Thus, the ineffectiveness of 




and in concurrent stimulation of free GAG chains makes them ideal candidates as 
negative controls.  
 
Further, KY-1 cells were stimulated with IL-12 in the presence and absence of the same 
concentration of different glycosides, namely; p-nitrophenyl-β-D-xyloside, p-
nitrophenyl-α-xyloside, and p-nitrophenyl-β-galactoside. The solvent used for these 
glycosides was DMSO, added at the final concentration of 0.06% v/v. As seen in Figure 
4.8, DMSO alone treatment (bar-3) was ineffective in suppressing IL-12-induced IFN-
γ secretion. As expected, p-nitrophenyl-β-D-xyloside showed significant inhibition by 
36% (p = 0.05) of IFN-γ secretion (bar-4), however p-nitrophenyl-α-xyloside (bar-5) 
and p-nitrophenyl-β-galactoside (bar-6) also exhibited IFN-γ inhibition by 21.4% and 
14% respectively in comparison to DMSO alone effect (bar-3). Thus, as observed, IFN-
γ inhibition by all three glycosides employed (bars 4-6) was statistically significant 
(p=0.05) against IL-12 alone stimulation (bar-2) as well as DMSO alone (bar-3) 
treatment.  Therefore, even though p-nitrophenyl-β-xyloside inhibited 36% of IL-12-
stimulated IFN-γ secretion but when compared to negative controls like α-xyloside 
(bar-5) and β-galactoside (bar-6), its net effect on IFN-γ inhibition (bar-4) was 
evaluated to be about 15-20%. Moreover, this difference in the effect between p-
nitrophenyl-β-xyloside (bar-4) and the negative controls (bars-5, 6) was found 
statistically significant (p=0.05), using Kruskal-Wallis test for group comparision. 
Hence, the results indicate that 15-20% of the overall 36% IFN-γ inhibition by p-



























 1   2   3   4   5   6 
IL-12 (150pg/ml)  -     +   +   +   +   + 
 
DMSO (0.06%)  -    -   +   +   +   + 
 
p-nitrophenyl-β-D-xyloside (600μM) in 
DMSO 
 
 -    -   -   +   -   - 
p-nitrophenyl-α-D-xyloside (600μM) in 
DMSO 
 
 -    -   -   -   +   - 
p-nitrophenyl-β-D-galactoside (600μM) in 
DMSO 
 
 -    -   -   -   -   + 
Figure 4.8:  Effects of α and β xylosides on secreted IFN-γ:  
KY-1 cells (2.5 x 10 5 cells/1.7cm diameter well) were cultured for 18 hours each with 600 μM 
equivalent of 0.06% v/v DMSO with p-nitrophenyl-β-xyloside, a proteoglycan inhibitor and p-
nitrophenyl-α- xyloside and p-nitrophenyl-β- galactoside as negative controls respectively in the 
presence of IL-12 (150 pg/ml). The secreted IFN-γ (■) in the medium under different conditions 
was assayed using ELISA.  Results are the mean of triplicate wells with error bars showing ±SEM.  
* denotes p<0.05 for all three glycosides in comparision to DMSO alone treatment.  
# denotes p<0.05 for p-nitrophenyl-β-xyloside in comparision to p-nitrophenyl-α-xyloside and p-
nitrophenyl-β-galactoside effect respectively on IFN-γ secretion. One representative experiment 





4.3  Discussion 
 
The production of IFN-γ from NK cells is an in vitro model representing initiation of 
Th1 responses. The current study showed that NK cell-surface DS-PGs were involved 
in IL-12-induced IFN-γ production. Thus, the current findings support the concept that 
GAGs can modulate immune responses. Concurrent with previous observations by 
Garnier Et. al. (2003), the current study removed cell surface CS/DS-PGs from NK 
cells using the enzyme chondroitinase ABC. This reduced the cellular response to IL-
12 stimulation and resulted in decreased IFN-γ secretion by ~36%. These results 
confirm the  previous finding from Garnier Et. al., however its  not known as to how 
the NK cell-surface DS-PG might affect the bioactivity of IL-12 to produce IFN-γ. The 
goal of the current study was therefore to elucidate the mechanism of DS-PG 
involvement in IL-12 signalling-dependent IFN-γ secretion, using a PG inhibitor, β-
xyloside. 
 
The current study has established the functional dependence of IL-12 on DS-PG in the 
production of IFN-γ using p-nitrophenyl-β-xyloside. Importantly, the current study 
attempts to highlight the level of cellular regulation at which IFN-γ expression is 
dependent on DS-PG. However, in understanding this regulatory mechanism, various 
sites in the IL-12-activated signalling pathway in IFN-γ production were proposed as 
points of possible DS-PG involvement (Section 1.7.2, Figure 1.11). Each proposed site 
was tested systematically for its validation in the current study. The first potential site 
hypothesised for DS-PG involvement was in cross-bridging the ligand-receptor (IL-12-
IL-12R) interaction, similar to the role of heparin in initiating FGF-FGFR interaction 
and signalling (Yayon Et. al., 1991). This was probed by tyrosine phosphorylation of 
STAT-4, which is a key event in IL-12 signalling and brought about by activated IL-
12 receptor-associated, JAK2 and TYK2 kinases. In this context, the current finding 
demonstrated that treatment of NK cells with p-nitrophenyl-β-xyloside did not alter IL-
12 stimulated tyrosine phosphorylation of STAT-4 (Figure 4.6). This indicated that the 
role of DS-PG in IL-12 signalling is not mediated through the transcription factor, 
STAT-4. Hence, this eliminated the first possibility of DS-PG involvement in IL-12-
IL-12R interactions and therefore, in receptor-associated JAK activity. Moreover, 
tyrosine phosphorylation of STAT-4 was shown to control its DNA-binding activity 




STAT-4 phosphorylation, STAT-4-DNA binding activity was unlikely to be regulated 
by DS-PG.  
 
Further, the results demonstrated significantly lowered amounts of IFN-γ protein in the 
culture supernatants as well as in the cell lysates on addition of IL-12 to p-nitrophenyl-
β-D-xyloside treated NK cells (Figure 4.7). Interestingly, the level of inhibition on the 
intracellular and extracellular concentrations of IFN-γ protein was same. This data 
clearly showed that the IFN-γ protein was not being sequestered intracellularly but was 
rather synthesised in reduced amounts in cells to have been secreted in lower quantities, 
extracellularly. Importantly, this data suggested that the mechanism regulating IFN-γ 
expression by DS-PG is not mediated through interference with the IFN-γ secretory 
pathway. In addition, this experimental step which determined IFN-γ protein release, 
rules-in the second possibility of transcriptional regulation and rules-out the third 
possibility of translational or post-translational blockage by DS-PG. Thus, the current 
findings validated the second potential site that was downstream of STAT-4 
phosphorylation at the transcriptional level in IL-12 signalling. However, to ascertain 
this finding, inhibitors of protein-synthesis at the translational level such as 
cycloheximide or puromycin, in the presence and absence of p-nitrophenyl-β-D-
xyloside can be used in future experiments. Further, to evaluate the role of DS-PG in 
the transcriptional regulation of IFN-γ expression, it would provide important 
experimental data to determine and quantify IL-12-induced IFN-γ mRNA levels in p-
nitrophenyl-β-D-xyloside or chondroitinase ABC treated NK cells by a ribonuclease 
protection assay or RT-PCR in future studies. Consequently, the current findings 
conclude that NK cell-surface DS-PG modulates the transcriptional process of IL-12-
induced IFN-γ synthesis. This conclusion is in concurrence with the recent findings 
from a study which demonstrated that decorin, a DS-PG affects IFN-γ expression at 
transcriptional level. This was confirmed using decorin KO mouse which showed 
significantly reduced IFN-γ mRNA expression and protein levels in response to an 
allergy-induced inflammation (Bocian Et. al., 2013).  
 
Based on the results obtained in the current study, these imply that the transcriptional 
suppression of IFN-γ production by DS-PG is independent of the IL-12-activated JAK-
STAT-pathway. Consistent with this finding, DS was shown to have no effect on 
STAT-signalling induced ICAM-1 expression. However, DS through an unknown 




transcription and expression of ICAM-1 in endothelial cells (Penc Et. al., 1999). 
Besides the well-studied JAK-STAT pathway, IL-12 is also known to activate the p38 
MAPK pathway in the transcriptional regulation of IFN-γ production and hence Th1 
differentiation (Zhang & Kaplan, 2000; Watford Et. al., 2004). This suggests the 
existence of an alternative mechanism in IFN-γ regulation and DS-PG might regulate 
through this mechanism. p38 MAPK signalling phosphorylates IL-12-activated STAT-
4 on specific serine residues. In addition to tyrosine phosphorylation, serine 
phosphorylation of STAT-4 is essential to IFN-γ production and is required for 
maximal transcriptional activity of STAT-4 (Morinobu Et. al., 2002). Thus, alteration 
in serine phosphorylation of STAT-4 could be one potential mode of transcriptional 
regulation by DS-PG via the p38 MAPK pathway.  
 
Additionally, independent of STAT-4, the direct implications of IL-12-activated p38 
MAPK pathway on IFN-γ production has been documented in NK and T cells. This 
was evident from reduced IFN-γ secretion by STAT-4-deficient Th1 cells in the 
presence of the p38 MAPK inhibitor-SB203580 (Zhang & Kaplan, 2000). In the 
absence of STAT-4, p38 MAPK is proposed to act via ATF-2 (Activating Transcription 
Factor 2), a member of AP-1 family of transcriptional activators (Zhang & Kaplan, 
2000). In this context, Rajgopal Et. al. (2006) reported that the mechanism by which 
heparin enhances IL-11-induced STAT-3 activation was independent of serine 
phosphorylation of STAT-3. However, the mechanism involved was direct up-
regulation of MAPK pathway. This was shown in osteoclast formation of murine 
calvaria cells. This study also showed that heparin augmented IL-11-induced gene 
expression of RANKL (Receptor Activator of NF-κB Ligand), an essential element in 
in vitro osteoclast formation. Further, the expression of RANKL was suggested via 
activation of the MAPK/ERK pathway (Rajgopal Et. al., 2006). Similarly, another 
study demonstrated the role of DS via p38 MAPK signalling pathway in the regulation 
of osteoclast formation and bone metabolism. The presence of DS with RANKL was 
shown to strongly reduce phosphorylation of p38 MAPK and ERK (Extracellular 
signal-Regulated Kinase) in murine monocytic cells than in cells stimulated with 
RANKL alone (Shinmyouzu Et. al., 2007). Collectively, these findings suggest that DS 
chains may regulate the p38 MAPK pathway, a plausible mechanism through which 
DS-PG can regulate IL-12-stimulated IFN-γ expression. However, this hypothesis 





During the current investigation, the specificity of β-xyloside in the inhibition of IFN-
γ production as a result of disrupted PG synthesis was also determined. However, it is 
important to note that this aspect of study was not examined in the previous work by 
Garnier Et. al. (2003). In the current study, this was demonstrated by comparing the 
effect of p-nitrophenyl-β-xyloside with the effects of p-nitrophenyl-α-xyloside and p-
nitrophenyl-β-galactoside respectively, on IFN-γ production. As explained earlier in 
Section 4.2.6, p-nitrophenyl-α-xyloside cannot initiate GAG chain synthesis (Canfield 
Et. al., 1994) due to structural anomerism whilst p-nitrophenyl-β-galactoside is 
ineffective in initiation of GAG synthesis (Bradbeer Et. al., 1990) due to glycone 
substrate specificity by enzymes in PG synthesis. Therefore, both these glycosides are 
ineffective in disrupting PG synthesis. Unexpectedly, it was observed that p-
nitrophenyl-α-xyloside and p-nitrophenyl-β-galactoside also inhibited IFN-γ secretion 
in NK cells, albeit to a lesser extent, when compared to p-nitrophenyl-β-xyloside. Thus, 
it was concluded that IFN-γ inhibition (35-45%) observed in p-nitrophenyl-β-xyloside 
treated NK cells was only partially mediated (15-20%) by disruption in PG synthesis. 
Further, the data suggests that, to varying extents, addition of any xyloside, whether α- 
or β-, weakens NK cell responses to IL-12 in terms of IFN-γ secretion. Hence, it implies 
that p-nitrophenyl-β-xyloside perhaps exerted other cellular effects, besides altering 
PG synthesis, which are shared with p-nitrophenyl-α-xyloside, as previously reported 
in number of other studies (Potter-Perigo Et. al., 1992; Freeze Et. al., 1993; Canfield 
Et. al., 1994). 
 
Even though, the mechanism(s) by which p-nitrophenyl-α-xyloside and p-nitrophenyl-
β-xyloside could have exerted cellular and physiological effects in NK cells are not 
known, few possibilities could be proposed based on their effects on other cell types 
and their metabolism. For example, both p-nitrophenyl-α-xyloside and p-nitrophenyl-
β-xyloside inhibit proliferation of several types of cells, independent of their effects on 
GAG/PG synthesis (Potter-Perigo Et. al., 1992). Similarly, p-nitrophenyl-α-xyloside is 
a comparable inhibitor of glycolipid synthesis to p-nitrophenyl-β-xyloside in variety of 
cells, such as macrophage-like cells, CHO (Chinese Hamster Ovarian) cells, and 
melanoma cells (Freeze Et. al., 1993).  Both α- and β-xylosides are also known to 
inhibit protein synthesis however, this effect was proposed to be secondary to 
glycolipid synthesis (Canfield Et. al., 1994). Thus, it has been well established that β-
xyloside has other metabolic effects besides altering PG synthesis, which apparently 




resulting from β-xyloside treatment was most likely, partially due to some of these 
other cellular effects. Indeed, this brought a limitation to the current mechanistic study. 
Unfortunately, due to comparable generalised effects of p-nitrophenyl-β-xyloside 
relative to the contribution of GAGs/PGs as revealed in current investigation, it was 
not possible to continue this study on the functional role of DS-PG in IFN-γ expression 






































































IMMUNOREGULATORY ROLE OF TGF-β1 IN IL-12 







From the previous chapter, it was seen that KY-1 cells were demonstrated to be a 
reliable in vitro model for the study of IL-12-induced IFN-γ production and regulation. 
Given the critical role of IL-12 and its effector cytokine, IFN-γ, in determining the 
nature and outcome of immune responses, particularly during infectious diseases and 
tumour development, understanding the regulation of IL-12 signalling in IFN-γ 
production is of major interest. As described earlier, in Section 1.8.1, TGF-β1 is an 
anti-inflammatory and immunosuppressive cytokine candidate and has been well 
reported to inhibit IL-12 induced NK and T cell proliferation, IFN-γ production, 
cytotoxic activity, and Th1 differentiation (Bellone Et. al., 1995; Laouar Et. al., 2005; 
J. T. Lin Et. al., 2005; Lewis Et. al., 2015). Therefore, the role of TGF-β1 was central 
to number of studies investigating the crosstalk with IL-12 signalling and IFN-γ 
production (Bright & Sriram, 1998; Pardoux Et. al., 1999; Sudarshan Et. al., 1999; Yu 
Et. al., 2006), however the mechanistic understanding of IFN-γ suppression by TGF-
β1 in NK cells is not well understood at the molecular level.  
 
The aim of this chapter is to systematically study the molecular events underlying the 
suppressive effects of TGF-β1 on IL-12-mediated IFN-γ production using KY-1 cells. 
Firstly, the anti-proliferative activity of TGF-β1 was investigated as a possible 
mechanism in the inhibition of IFN-γ production. This was followed by examining the 
effects of TGF-β1 on the components of IL-12 signalling such as tyrosine and serine 
phosphorylation of STAT-4. In addition to STAT-4, T-bet is another significant 
transcription factor in mediating IFN-γ gene expression (Szabo Et. al., 2000; J. Y. Cho 
Et. al., 2003).  Therefore, it was important to determine whether T-bet is a critical 
mediator of TGF-β1 suppressed IFN-γ production. Further investigation was made 
using reporter gene assays in the convergence of IL-12 and TGF-β1 signalling 
pathways that regulated IFN-γ gene expression. The effect of TGF-β1 on IFN-γ 
promoter activity was determined using transiently transfected KY-1 cells with an IFN-









5.2  Results 
 
5.2.1 Effect of TGF-β1 Induced Suppression of IFN-γ Secretion in IL-12 
Stimulated murine NK cells 
 
To assess the effect of TGF-β1 induced IFN-γ suppression, KY-1 cells were pre-treated 
with increasing concentrations of TGF-β1 (5, 10 and 15ng/ml) for 30 mins. This was 
followed by stimulation with 10ng/ml of IL-12 for 24 hrs. The cell free supernatant 




















As seen in Figure 5.1, in the presence of TGF-β1 (irrespective of its concentration used 
5, 10 or 15 ng/ml), IL-12-stimulated IFN-γ production was suppressed by about 50%. 
This suppressive effect of TGF-β1 was found to be statistically significant as indicated 
by p<0.05 (ANOVA). However, the presence of TGF-β1 alone had no effect on IFN-γ 
production.  Based on these observations, a concentration of 10 ng/ml of TGF-β1 was 
selected for further experimental work, which was also in accordance with the literature 
Figure 5.1: Effect of TGF-β1 on IL-12 induced IFN-γ secretion: KY-1 cells (2.5 x 105 cells/1.7 
cm diameter well) were pre-incubated for 30 mins with increasing concentrations of TGF-β1 (5, 10 
or 15 ng/ml) followed by addition of IL-12 (10 ng/ml) and cultured for 24 hrs. The secreted IFN-γ 
in the supernatant was assayed using ELISA. Results represent the mean of duplicate wells at each 
point with error bars showing ± SD, not seen where smaller than symbol size. One representative 
























(Sudarshan Et. al., 1999).  Thus, this data demonstrates partial suppression of IL-12-
stimulated IFN-γ production by TGF-β1.  
 
5.2.2  Effect of TGF-β1 on IL-12 Stimulated NK Cell Proliferation and IFN-γ 
Secretion 
 
TGF-β1 has been reported in T cells to inhibit IL-12-stimulated cell proliferation, 
survival and IFN-γ production (Bright & Sriram, 1998).  Similarly, studies have 
demonstrated that TGF-β1 suppressed NK cell proliferation, cell cycle progression and 
concurrently impaired production of cytokines, including IFN-γ in response to IL-
12/IL-15 cytokine stimulations (Bellone Et. al., 1995; Wilson Et. al., 2011) and during 
viral infections (Su Et. al., 1991). These studies suggested that the anti-proliferative 
effect of TGF-β1, partly, formed the basis for decreased IFN-γ production from these 
cells. Therefore, this raised a question whether the observed reduction in IFN-γ 
production (Figure 5.1) in the current study was a secondary effect to inhibition of cell 
proliferation by TGF-β1. To elucidate this possibility, the total cell numbers were 
counted in the presence and absence of TGF-β1 along with the measurement of secreted 
IFN-γ in the culture supernatant by ELISA, at various time points. 
 
KY-1 cells (3 x 104 cells/well) treated with and without TGF-β1 (10 ng/ml) for 30 mins 
were plated for 6 hours, 16 hours, and 24 hours with IL-12 stimulation (10 ng/ml).  
After the defined period of incubation with IL-12, secreted IFN-γ in the supernatant 
media was detected by ELISA and the cells were counted for viability using nigrosin 
stain (as described in section 2.6). Figure 5.2 shows the time course of IFN-γ secretion 
in the presence of TGF-β1, which by 6 hours was reduced by approximately 50% 
(p<0.001). Similarly, a significant level of inhibition was observed at 16 hours (by 
41.91%, p<0.001) and 24 hours (by 61.23%, p<0.001), which confirmed the 
















Using the same culture, the effect of TGF-β1 on cell proliferation in the presence of 
IL-12 was analysed by cell counting and cell viability of attached and detached cells at 
multiple time points of 6, 16 and 24 hours. As seen in Table 5.1, at 6 hours of 
stimulation with IL-12, in the absence and presence of TGF-β1 (rows 2 vs 4), there was 
no significant difference in the total cell numbers (column-Ta+d) and % cell viability 
(column-% Va+d). Yet, IL-12 stimulated IFN-γ production was reduced by 50% in the 
presence of TGF-β1 at 6 hours (column-IFN-γ, rows-2 vs 4). This indicated that TGF-
β1 rapidly inhibited IFN-γ production without affecting cell numbers and viability.  
 
Similar inference can be drawn from the data at 16 and 24 hours that the presence of 
TGF-β1 did not affect cell proliferation (column- Ta+d, rows 6 vs 8, rows 10 vs 12) 
and more importantly, the cell viability (column- %Va+d, rows 6 vs 8, rows 10 vs 12). 
Nevertheless, as time progressed to 16 hours, there was significant increase in the total 
number of cells (column-Ta+d, rows-5 to 8) indicating cell proliferation. This 
Figure 5.2:  Time course of IFN-γ secretion in the presence of TGF-β1: KY-1 cells (3 x 104 
cells / 0.8cm diameter well) were pre-incubated for 30 mins. with or without TGF-β1 (10 ng/ml) 
followed by addition of IL-12 (10 ng/ml) and cultured for 6 hrs, 16 hrs and 24 hrs, after which they 
were counted for viability using Nigrosin stain as shown in the result Table 5.1. The secreted IFN-
γ was assayed using ELISA. The left-hand panel shows IFN-γ secreted at 6 hrs on expanded axis. 
Results represent the mean of triplicate wells at each point with error bars showing ± SEM, not 
seen where smaller than symbol size. One representative experiment of three independent 






proliferative growth was seen under all conditions and was not selective to IL-12 
stimulation. After 24 hours, there was a minimal or no increase in total cell numbers 
(column-Ta+d, rows-9 to 12) to that observed at 16 hours under all cytokine treatments. 
Rather, cell viability decreased significantly over the time until 24 hours (column- V 
a+d). One possible reason could be that at both 16 and 24 hours, significant number of 
cells were found detached irrespective of any cytokine treatment as compared to 6 
hours. This was a concern as KY-1 cells are mostly adherent cells and significant cell 
detachment may indicate cell death. Therefore, the detached cells from 16- and 24-hour 
plate were assayed for cell viability (column- %Vd, rows 5 to 12), and only 25-40% of 
cells were found viable. This demonstrated that most detached cells were dead; while 
others that remained viable, might arguably have reduced protein synthesis or 
secretion. Thus, cell detachment and death observed was higher after 24 hours than at 
16 hours. Although, cell density per well was proportionately considered to the surface 
area of the well for this assay, the reason for cell detachment on longer hours of 
incubation was not clearly understood.. Importantly, the results from the time points of 
16 hours and 24 hours indicated that IL-12 did not induce cell proliferation, as seen in 
Table 5.1 (column Ta+d, rows 5 vs 6 and rows 9 vs 10). Additionally, TGF-β1 
treatment alone or in the presence of IL-12 did not result in decreased cell numbers 
(column Ta+d, rows 6 vs 8, rows 10 vs 12), despite a reduction in IFN-γ production on 
IL-12 stimulation (column- IFN-γ, rows 6 vs 8, rows 10 vs 12). Hence, the data suggests 
that the IFN-γ inhibition by TGF-β1 was independent of its effect on cell cycle 







Attached Cells x 104 per well ± SEM Detached Cells x 104 per well ± SEM Total Cells x 104 per well ± SEM  
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85 0.415 4.05± 
0.18 
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23 0.142 5.83± 
0.09 
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29 0.968 5.53± 
0.44 


















37 0.193 5.47± 
0.13 
40 0.865 16.79± 
0.57 
0.0001 
Table 5.1: Cell count, cell viability and IFN- γ secretion in the presence and absence of TGF-β1 by IL-12 stimulated NK cells at 6, 16 and 24 hrs. 







5.2.3  Early Kinetics of TGF-β1 Induced IFN-γ Suppression 
 
Studies by Thomas and Massague using CD8+ T cells showed that TGF-β1 profoundly 
inhibited expression of cytotoxic proteins, such as Perforin and Granzyme B (GzmB), 
at 24 hours which partially correlated to inhibition of cell proliferation. However, they 
also demonstrated that the expressions of these proteins were directly and rapidly 
inhibited within 4 hours by TGF-β1. This indicated that early repression of these 
proteins was independent and a separate event from TGF-β1 suppressed CD8+ T cell 
proliferation and growth arrest which occurred at later time points, around 20-24 hours 
(Thomas & Massague, 2005). Since current data at 6 hours (Figure 5.2, Table 5.1) 
demonstrated that early IFN-γ production induced by IL-12 was significantly inhibited 
by TGF-β1 independent of cell proliferation and survival, it was thought to explore 
further the early kinetics of IFN-γ production. Thus, using early kinetics data in the 
current study, an attempt was made to minimize the possibility of studying the 
overlapping inhibitory effects of TGF-β1 on KY-1 cells along with IFN-γ inhibition. 
For this, KY-1 cells were pre-treated with and without TGF-β1, followed by IL-12 
stimulation at multiple time points over 6 hours and the secreted IFN-γ by the cells was 
assayed by ELISA (Figure 5.3).  As seen in this Figure 5.3, the production of IFN-γ 
was inhibited by about 50% as early as 3 hours. This is an important data, as rapid 
production of IFN-γ plays a significant role in increasing host resistance to early hours 
of infections such as Listeria monocytogenes (Way & Wilson, 2004; Kang Et. al., 
2008), MCMV (Fodil Et. al., 2014). Moreover, significance of such a temporal aspect 
of cytokine secretion, particularly IFN-γ by NK cells was recently demonstrated in 
Table 5.1: Cell count, cell viability and IFN- γ secretion in the presence and absence of TGF-
β1 by IL-12 stimulated NK cells at 6, 16 and 24 hrs: KY-1 cells (3 x 104 cells / 0.8cm diameter 
well) were pre-incubated for 30 mins. with or without TGF-β1 (10 ng/ml) followed by addition of 
IL-12 (10 ng/ml) and cultured for 6 hrs, 16 hrs and 24 hrs. The secreted IFN-γ was assayed using 
ELISA. Both attached and detached cells were counted for cell viability as shown above in 
columns, Va= attached viable cells, NVa= attached non-viable cells, Ta =Va + NVa (Total 
attached cells), %Va = % viability of attached cells, Vd= detached viable cells, NVd= detached 
non-viable cells, Td= Vd+NVd (Total detached cells), %Vd = % viability of detached cells Ta+d 
= Total attached and detached cells, %Va+d = % viability of attached and detached cells. Rows = 
each row represents particular experimental condition. Results are mean of triplicate wells per 
condition ± SEM. p values were obtained by data analysis using ANOVA and post hoc analysis 
to determine significance within groups by Scheffe and Tukey’s tests for cells with different 
cytokine treatments. For statistical analysis on % cell viability and secreted IFN-γ, the values 
obtained from IL-12 stimulated NK cells were used as baseline for comparison with other cytokine 
treatments in the presence and absence of TGF-β1. Data from one representative experiment of 




tumour target cell recognition, consistent with their contribution in 
immunosurveillence (Fauriat Et. al., 2010). Justifiably, the subsequent mechanistic 




A) Over 24 hours   
 
 








Figure 5.3: Effects of TGF-β1 on IL-12 induced IFN-γ secretion over 24 hours: KY-1 
cells (2.5 x 105 cells /1.7cm diameter well) were pre-incubated for 30 mins. with or without 
TGF-β1 (10 ng/ml) followed by addition of IL-12 (10 ng/ml) and cultured for: A) over 24 
hours with the secreted IFN-γ (ng/ml) assayed at various time points of 0 hour, 3 hours, 6 
hours, 16 hours and 24 hours using ELISA. B) Detailed graph of inset in (A) over the first 6 
hours. Results represent the mean of triplicate wells at each point with error bars showing ± 
SEM, not seen where smaller than symbol size. One representative experiment of three 





5.2.4 Effect of TGF-β1 on IL-12 Activated STAT-4 Signalling Pathway in murine 
NK cells 
 
To understand the molecular basis of TGF-β1-induced suppression of early IFN-γ 
expression, it was next necessary to investigate the interference of the IL-12 signalling 
pathway by TGF-β1. Following IL-12 ligation, its receptor associated Janus family 
kinases (JAK2 and TYK2 kinases) phosphorylates STAT-4 at Tyr-693 (Bacon Et. al., 
1995; S. S. Cho Et. al., 1996). However, STAT-4 also requires serine phosphorylation 
at Ser-721 for complete transcriptional activity and optimal IFN-γ production induced 
by IL-12 (Morinobu Et. al., 2002). So, the effect of TGF-β1 on IL-12 induced STAT-
4 tyrosine and serine phosphorylation was determined. 
 
5.2.4.1 Effect of TGF-β1 on IL-12 Induced Tyrosine Phosphorylation of STAT-4 
 
KY-1 cells were pre-treated with TGF-β1 (10 ng/ml) for 30 mins, followed by IL-12 
(10 ng/ml) stimulation for 1 hour, 2 hours, and 3 hours. The culture supernatant was 
used to measure the secreted IFN-γ using ELISA. From the same culture, cell-lysates 
were prepared as described in Section 2.7.1. To maximise the detection and 
identification of phosphorylated STAT-4, cell lysates were treated with pervanadate, 
protease and phosphatase inhibitors. As seen in Figure 5.4A, tyrosine phosphorylated 
STAT-4 protein was detected using specific anti-pSTAT-4 Ab (Tyr-693) at 89kDa on 
a western blot. This blot was then stripped and reprobed with anti-STAT-4 Ab to detect 
the presence of total STAT-4 protein in the samples (Figure 5.4B). The intensity of 
these bands (Figure 5.4A and Figure 5.4B) were measured by using software Image J. 
The results of densitometric analysis are presented in the Table 5.2, as ratios of pSTAT-
4/total-STAT-4.  
 
As seen in Figure 5.4A, IL-12 stimulation rapidly induced tyrosine phosphorylation of 
STAT-4 (Figure 5.4A, lane 2), compared to unstimulated cells (Figure 5.4A, lane 1) at 
indicated time points, until 3 hours. Further, IL-12-induced tyrosine phosphorylated 
STAT-4 levels moderately decreased over 3 hours and this decrease was also 
unaffected in the presence of TGF-β1 (Table 5.2). Importantly, TGF-β1 alone could 
neither induce any tyrosine phosphorylation of STAT-4 protein (Figure 5.4A, lane 3) 




points indicated (Table 5.2 and Figure 5.4A, lane 4). However, a parallel inhibition of 
IFN-γ at protein levels (about 50%) was observed in the presence of TGF-β1, as shown 
in Figure 5.4C. This detection of IFN-γ protein secreted served as an internal control 
in the experimental design. 






































Lanes    1 (Control)             2           3            4 
IL-12  
(10 ng/ml) 
          _             +            _            + 
TGF-β1 
(10ng/ml) 
          _             _            +            + 
A)  Blot: anti-pSTAT-4 (tyrosine)  
                              1 hr                                               2 hr                                     3 hrs 
            ___________________           _____________________     ____________________ 
             1         2         3        4                  1        2          3        4          1         2         3        4                        
89kDa 
89kDa 
B)  Reprobe: anti-STAT-4  
                     1 hr                                                2 hr                                 3 hrs 
     ____________________             ____________________    ___________________ 
         1        2         3        4                    1        2        3        4          1         2        3        4                        




























Additionally, the effect of TGF-β1 at earlier time points of 15 mins and 30 mins on 
tyrosine phosphorylation of STAT-4 was determined using a similar experimental set-
up. The results are shown in Figure 5.5A for pSTAT-4. This blot was stripped and 
reprobed by anti-STAT-4 Ab for total STAT-4 protein (Figure 5.5B). The 
densitometric analysis, as shown in Table 5.3, indicated rapid tyrosine phosphorylation 
of STAT-4 by IL-12 (Figure 5.5A, lane 2) that was not inhibited by TGF-β1 (Figure 
5.5A, lane 4) at 15 mins to 2 hours. This result confirms that TGF-β1 does not inhibit 
IL-12 induced tyrosine phosphorylation of STAT-4, a critical event  mediated by 
activated JAK2 and TYK2 kinases in IL-12 signalling and hence IFN-γ production. 
                Lanes    1 hr   2hrs.   3 hrs. 
 
1    No IL-12 + No TGF-β1             
    0.08 
 
  0.10 
 
  0.08 
2    IL-12 (10 ng/ml)             
   0.43 
 
  0.38 
 
  0.29 
3    TGF-β1 (10ng/ml)             
   0.12 
 
  0.10 
 
  0.07 
4    IL-12 + TGF-β1(10ng/ml)           
   0.46      
 
  0.34 
 
  0.30 
Figure 5.4: Effect of TGF-β1 on IL-12 induced tyrosine phosphorylation of STAT-4: KY-1 
cells (5 x 105 cells/3.4cm diameter well) were pre-treated for 30 mins with or without TGF-β1 
(10ng/ml) followed by addition of IL-12 (10 ng/ml) and cultured for 1 h, 2 hours and 3 hours as 
indicated below each blot. (A) Western blots were immunodeveloped with anti-pSTAT-4 
followed by stripping and reprobing the blot with (B) anti-STAT-4. Numbers below each lane in 
the blot represent cytokine treatment and Table 5.2 summarizes the densitometric values of 
pSTAT-4 (tyrosine) /STAT-4 ratio. (C) The supernatant was assayed for secreted IFN-γ using 























Lanes   1 (Control)             2            3            4 
IL-12  
(10 ng/ml) 
          _             +            _            + 
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0.54 0.53 0.54 0.50 
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A)  Blot: anti-pSTAT-4 (tyrosine)  
89kDa 
89kDa 
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B)  Reprobe: anti-STAT-4  
        15mins                                  30 mins                 1 hr                     2 hr                
  ___________________________     ___________      ___________     _____________ 












5.2.4.2 Effect of TGF-β1 on IL-12 Induced Serine Phosphorylation of STAT-4 
 
In addition to Tyr693 phosphorylation on IL-12 stimulation, STAT-4 also undergoes 
phosphorylation at Ser721 (S. S. Cho Et. al., 1996; Visconti Et. al., 2000).  Since the 
results from previous experiment showed that TGF-β1 did not inhibit tyrosine 
phosphorylation of STAT-4 (Figure 5.4 and Figure 5.5), it might possibly inhibit IL-
12-induced serine phosphorylation of STAT-4.  Therefore, the blot used for detection 
of tyrosine STAT-4, as shown in the previous experiment (Figure 5.4A) was stripped 
and then reprobed using specific anti-pSTAT-4 Ab that detected phosphorylated 
STAT-4 at serine 721 (as seen in Figure 5.6). This immunoblot (Figure 5.6) was then 
further stripped and reprobed to detect the levels of total STAT-4 protein in the samples 
(Figure 5.4B). It is also important to note that each step of stripping was carefully 
performed to minimise loss of protein from the blot. Prior to reprobing, the efficiency 
of stripping method was checked to ensure removal of primary Ab as described in 
Section 2.9.5. The blots were analysed using Image J and the results of this 
densitometric analysis are shown in Table 5.4. The level of phosphorylation was 
determined by the ratio of p-STAT-4 (serine) to total STAT-4 protein.  
 
As seen in the Figure 5.6, serine phosphorylated STAT-4 was detected in unstimulated 
cells indicating base-line expression levels (Figure 5.6, lane 1), that was not 
significantly induced on IL-12 stimulation (Figure 5.6, lane 2). Further, TGF-β1 
treatment alone (Figure 5.6, lane 3) and in the presence of IL-12 (Figure 5.6, lane 4) 
was unable to affect the serine phosphorylated STAT-4 levels at any of the time points 
indicated. Thus, the results showed that even though TGF-β1 inhibited IFN-γ secretion 
(Figure 5.4C), it neither inhibited tyrosine phosphorylation nor altered the constitutive 
levels of serine phosphorylated STAT-4 in murine NK cells. Hence, the data suggested 
that the underlying mechanism in the suppression of IL-12-stimulated IFN-γ secretion 
Figure 5.5: Effect of TGF-β1 on IL-12 induced tyrosine phosphorylation of STAT-4 at 15 
mins until 2 hrs: KY-1 cells (5 x 105 cells/3.4cm diameter well) were pre-treated for 30 mins. 
with or without TGF-β1 (10ng/ml) followed by addition of IL-12 (10 ng/ml) for 15 mins, 30 
mins, 1 h and 2 hours as indicated below each blot. (A) Western blots were immunodeveloped 
with anti-pSTAT-4 followed by stripping and reprobing the blot with (B) anti-STAT-4. 
Numbers below each lane in the blot represents cytokine treatment and Table 5.3 shown 
summarises the densitometric values of pSTAT-4/STAT-4 ratio (tyrosine). Above blots are 







by TGF-β1 was independent of interference with activation of key component of IL-































          _             +            _            + 
TGF-β1 
(10ng/ml) 
          _             _            +            + 
Lanes 
 
1 hr 2hrs. 3 hrs. 
1         No IL-12 + No TGF-β1             
    0.48 
 
  0.48 
 
  0.42 
2         IL-12 (10 ng/ml)             
   0.55 
 
  0.49 
 
  0.48 
3        TGF-β1 (10 ng/ml)             
   0.52 
 
  0.45 
 
  0.49 
4        IL-12 + TGF-β1(10 ng/ml)           
   0.55     
 
  0.46 
 
  0.51 
 
89kDa 
 Reprobe: anti-p-STAT-4 (serine) 
                       1 hr                                              2 hr                                   3 hrs 
        ___________________             __________________       __________________ 
          1        2        3         4                    1         2       3        4         1        2        3        4                         
Figure 5.6: Effect of TGF-β1 on IL-12 induced serine phosphorylation of STAT-4: 
Tyrosine phosphorylated STAT-4 blot (Fig 5.4A) was stripped and reprobed with anti-
pSTAT-4 (serine) Fig 5.6. This was finally stripped and reprobed with anti-STAT-4 as shown 
in (Fig.5.4B). Numbers below each lane in the blot represents cytokine treatment and Table 
5.4 shown summarises the densitometric values of pSTAT-4/STAT-4 ratio (serine). Above 








5.2.5  Effect of TGF-β1 on T-bet Expression in IL-12 Stimulated murine NK 
Cells 
 
As mentioned earlier in Section 1.8.2.1 that besides STAT-4, another factor 
upregulated by IL-12 and positively implicated in IFN-γ expression in both T and NK 
cells is T-bet (Szabo Et. al., 2000; Szabo Et. al., 2002; Sullivan Et. al., 2003). 
Moreover, TGF-β1 controlled IFN-γ expression in T-cells was shown to be mediated 
by downregulation of T-bet (Neurath Et. al., 2002; Gorelik Et. al., 2002a; J. T. Lin Et. 
al., 2005). Therefore, it was important to examine next the effect of TGF-β1 on T-bet 
expression in KY-1 cells. The cell lysate prepared and used for STAT-4 
phosphorylation studies (in earlier Section 5.2.4) was also used in this experiment for 
the detection of the T-bet protein. This was because the experimental design and 
conditions for both the studies were the same. Consistent with the previous study 
(Szabo Et. al., 2000), it was seen in Figure 5.7A that a band for T-bet was detected at 
approximately 62 kDa, using a specific monoclonal antibody, anti-T-bet, on the 
western blot. The blot was stripped and reprobed for β-actin that was used as a loading 
control (Figure 5.7B).  Blots were then analyzed using Image J.  Table 5.5 summarizes 
the densitometric analysis of T-bet detected against β-actin levels on the same blot. The 
data revealed that T-bet expression was neither induced by IL-12 (Figure 5.7A, lane 2) 
nor affected by TGF-β1 (Figure 5.7A, lane 4). 
 
T-bet expression observed in unstimulated cells was not augmented by IL-12 
stimulation (Figure 5.7A, lanes 1 & 2). This suggests a constitutive or a base-line 
expression of T-bet in murine NK cells. Similar constitutive T-bet expression was 
observed in another NK cell line, YT but was not detected in T cell lines (EL-4 or 
Jurkat) (Szabo Et. al., 2000). This suggests that such constitutive T-bet expression 
might have a cell-specific function in NK cells than in T cells. Nevertheless, the base-
line expression of T-bet was not affected by TGF-β1 treatment (Figure 5.7A, lanes 3 & 
4), even though, in parallel, inhibition of IFN-γ protein levels was detected by ELISA 
(Figure 5.4C). The results indicate that T-bet does not drive the early production of 
IFN-γ by IL-12 (3 hours). Thus, TGF-β1 induced early suppression of NK cell IFN-γ 






















Lanes 1 (Control) 2 3 4 
IL-12  
(10 ng/ml) 
          _             +            _            + 
TGF-β1 
(10ng/ml) 
          _             _            +            + 
Lanes 
 
1 hr 2hrs. 3 hrs. 
1         No IL-12 + No TGF-β1      1.04 
 
  1.14 
   
   1.11 
2         IL-12 (10ng/ml)      1.06 
    
  1.03 
   
   0.99 
 
3        TGF-β1 (10ng/ml)      1.14 
    
  1.05 
   
   0.99 
   
4        IL-12 + TGF-β1 (10ng/ml)      1.09      
    
  1.09 
   
   1.01 
   
A) Blot: anti-T-bet 
B)  Reprobe: anti-β-Actin 
48kDa 
62kDa 
                   1 hr                                              2 hr                                    3 hrs 
        __________________                __________________    ___________________ 
           1        2       3        4                    1        2         3        4        1        2         3       4                    
                         1 hr                                               2 hr                                   3 hrs 
        ___________________              ___________________    ___________________           
           1        2         3        4                   1        2         3        4         1        2        3        4                        
Figure 5.7: Effect of TGF-β1 on T-bet expression in murine NK cells: KY-1 cells (5 x 
105 cells/3.4 cm diameter well) were pre-treated for 30 mins with or without TGF-β1 (10 
ng/ml) followed by stimulation with IL-12 (10 ng/ml) for 1 h, 2 hours and 3 hours as 
indicated below each blot. (A) Western blots were immunodeveloped with anti-T-bet 
followed by stripping and reprobing the blot with (B) anti-β-actin. Numbers below each 
lane in the blot represents cytokine treatment and Table 5.5 shown summarises the 
densitometric values of T-bet/β-actin ratio. Background noise for both the blots (A) and 
(B) were not adjusted in densitometric analysis and resulted in T-bet/β-actin ratio values 
around ‘1’. The cell culture supernatant was assayed for secreted IFN-γ using ELISA 









5.2.6  Effect of TGF-β1 on IFN-γ Gene Expression 
 
The data until now has demonstrated that the signalling crosstalk between TGF-β1 and 
IL-12 is independent of direct involvement of key transcriptional factors, STAT-4 
(Figure 5.4, 5.6) and T-bet (Figure 5.7) regulating IFN-γ gene expression. However, 
the effective production of IFN-γ requires binding of various transcription factors onto 
the IFN-γ promoter and its intronic region where they act as either activators or 
repressors, controlling IFN-γ gene transcription (Penix Et. al., 1993; Sweetser Et. al., 
1998; Tato Et. al., 2004; Zhou Et. al., 2004). Several studies observed reduced IFN-γ 
protein levels in the presence of TGF-β1 and reported a parallel reduction in IFN-γ 
transcripts, which suggests the possibility of transcriptional regulation of IFN-γ gene 
by TGF-β1 (Sudarshan Et. al., 1999; Hayashi Et. al., 2003; Laouar Et. al., 2005; J. T. 
Lin Et. al., 2005; Thomas & Massague, 2005). Nonetheless, the molecular basis to this 
transcriptional regulation is still unclear.  
 
Interestingly, a study in TCR-activated primary CD8+ T cells demonstrated that TGF-
β1-induced transcription factors, CREB and ATF-1 acted as Smad-binding partners in 
the promoter repression of a cytotoxic gene, granzyme B, GzmB (Thomas & Massague, 
2005). Additionally, in the suppression of IFN-γ promoter activity, direct binding of 
ATF-1 and Smads 2/3 to the IFN-γ promoter region that spanned across -366 to -16 bp 
from the TSS (Transcription Start Site) was observed through ChIP (Chromatin 
Immunoprecipitation) analysis. Therefore, based on the presence of ATF-1 and Smad-
binding sites close to each other within the IFN-γ promoter region (-300/+4bp), they 
proposed a mechanism in IFN-γ inhibition to be similar to the repression of GzmB 
promoter activity by TGF-β1. Therefore, one possible mechanism by which TGF-β1 
inhibits might be direct interference with the transcriptional capability of the IFN-γ 
promoter. One mode of studying transcriptional repression is analysing promoter 
function using reporter gene assays. Taken together, this prompted interest to 
investigate the effect of TGF-β1 on IFN-γ promoter activity using luciferase reporter 
assays. This should enable identification of a cis-acting regulatory region/elements 
within the IFN-γ promoter that is susceptible to TGF-β1 signalling in NK cells. 
 
In order to conduct this part of the experimental study, it was important to decide on 




reporter vector for transient expression studies. Most studies used different IFN-γ 
promoter construct sizes ranging from <100bp to 3kb upstream of the TSS of the IFN-
γ gene in reporter assays. These reporter constructs were successfully expressed and 
exhibited inducible promoter activity in both T and NK cell lines (H. Zhu Et. al., 2001; 
Soutto Et. al., 2002; J. Y. Cho Et. al., 2003; Bream Et. al., 2003). Essentially, the ‘core’ 
IFN-γ promoter region was identified as -108bp length upstream of a 5’ human IFN-γ 
gene that reflected expression of the endogenous IFN-γ gene and contained proximal 
(-73 bp to -48 bp) and distal (-96 bp to -80 bp) cis-regulatory elements. These elements 
are conserved across species and required for basal promoter function (Penix Et. al., 
1993; Aune Et. al., 1997; Soutto Et. al., 2002). Further, 5’ upstream regions of the IFN-
γ gene such as -280 to -180 bp (Ye Et. al., 1994) and -445 to -415 bp (Soutto Et. al., 
2002) had been previously described to contain binding sites for various transcription 
factors including STATs, NFAT, NF-kB, AP-1, ATF-CREB, YY-1, T-box, GATA. 
These proximal promoter regions were shown to contribute to the regulation of IFN-γ 
gene transcription in response to TCR and/or cytokine stimulations (Young, 1996; Sica 
Et. al., 1997; Sweetser Et. al., 1998; K. M. Murphy Et. al., 2000; Nakahira Et. al., 
2002).  For most of these factors, the region on the IFN-γ promoter to which it binds, 
has been determined either in vitro or in vivo.  
 
Since, the current study has been focused on two important transcription factors in IFN-
γ expression, STAT-4 and T-bet, it was necessary to understand their role in trans-
activation of the IFN-γ gene. Importantly, STAT-4 has been shown to trans-activate 
IFN-γ gene by either direct binding to the STAT-binding element (-236 bp) on the IFN-
γ promoter (X. Xu Et. al., 1996) or to enhance binding of other factors like NF-kB (D. 
Robinson Et. al., 1997) or AP-1 (-190 bp) in IFN-γ gene expression (Barbulescu Et. 
al., 1998; Nakahira Et. al., 2002). This was evident from STAT-4 -/- T cells which 
produced AP-1 levels similar to wild-type but failed to exhibit AP-1 binding in the 
presence of IL-12 (Park Et. al., 2005). Similarly, functional T-bet responsive elements 
have been determined on the proximal region of the IFN-γ promoter (Soutto Et. al., 
2002; J. Y. Cho Et. al., 2003), as a mutation in this region resulted in significant loss 
of T-bet augmented IFN-γ reporter activity in T cells (J. Y. Cho Et. al., 2003; Tong Et. 
al., 2005). Since, the current results demonstrated constitutive expression of T-bet that 
is not directly involved in IFN-γ induction (Figure 5.7), this protein might be indirectly 
involved in induction of endogenous IFN-γ promoter activity. Previous studies have 




factors in IFN-γ promoter activation (Soutto Et. al., 2002). A T-bet responsive unit 
(TRU) was identified within -565 bp to -415 bp region of the IFN-γ promoter (Soutto 
Et. al., 2002). However, Cho Et. al. (2003) further demonstrated that T-bet functionally 
mediates IFN-γ promoter activity through multiple T-box ‘half-sites’, also called 
monomeric Brachyury sites located within -300bp of IFN-γ promoter. One of the most 
important of T-bet ‘half-sites’ was located between -66 bp and -57 bp region of very 
proximal IFN-γ promoter. This 9bp sequence was shown to be required, even in the 
presence of an upstream TRU element (J. Y. Cho Et. al., 2003). Interestingly, both 
these T-bet interaction sites (-565/-415 bp and -66/-57 bp) on the IFN-γ promoter have 
been located close to consensus core binding sequences for several other transcription 
factors, mentioned above (H. Zhu Et. al., 2001; Soutto Et. al., 2002; J. Y. Cho Et. al., 
2003; Tong Et. al., 2005). This suggested that co-operation from other factors might 
come into play to enhance T-bet function in IFN-γ promoter activation.  
 
Collectively, this specific information was considered in the selection of an appropriate 
size or a region of the IFN-γ promoter for the subsequent transient reporter assays. 
Therefore, a reporter vector (denoted as pFL-IFN) containing an insert of -777bp IFN-
γ promoter region upstream of a TSS of the IFN-γ gene was selected. This pFL-IFN 
vector was constructed using a firefly luciferase plasmid, pBS-Luc (as detailed in 
Section 2.10). The pFL-IFN was one of the reporter plasmids received as a kind gift 
from Dr. Howard A. Young (National Cancer Institute, National Institutes of Health, 
Frederick, MD). A previous study by Zhu Et. al. (2001) has reported the use of this 
particular plasmid along with other IFN-γ promoter constructs of varying sizes, ranging 
from -59 to -3489 bp upstream of the TSS in the transient transfection of EL-4 cells (T-
lymphoma cells). These promoter constructs exhibited inducible expression on P/I 
stimulation, with only slight differences in the levels of inducibility between them. This 
indicated that the chosen pFL-IFN reporter vector in the current study was inducible, 
when transiently expressed in a cell line, however the strength of induction may vary 
with the stimuli used. In the current study, the expression of this pFL-IFN reporter 
construct on IL-12 stimulation was examined in transiently transfected NK cells. Also, 
the effect of TGF-β1 on IL-12-induced promoter activity was determined. In case IL-
12 alone stimulation did not result in significant induction of IFN-γ reporter activity, a 
positive control was included which contained IL-12 plus IL-18 co-stimulation. IL-18 
alone is a weak inducer of IFN-γ expression, however, it is synergistic in action with 




al., 1998; J. Yang Et. al., 1999; Nakahira Et. al., 2002). Importantly, this control 
indicates that the IFN-γ promoter fragment cloned into the luciferase reporter vector 
was active to specific cytokine stimulations used.  
 
Additionally, at this point, a bioinformatic application was briefly used as a screening 
tool to further facilitate the identification of regulatory elements that might be 
significant in TGF-β1 regulated repression of IL-12-induced IFN-γ expression. The 
selected region of the IFN-γ promoter (-777bp to +48bp) that is used in the transfection 
experiments, was analysed for the potential transcription factor binding sites using the 
program, MatInspector 8.0.5. This Genomatrix software suite V2.5 based program 
identifies a series of 4bp core sequences for each possible transcription factor binding 
within the sequences of query promoter. The outcome of the search was a broader set 
of transcription factors in addition to those mentioned above with their consensus 
binding sequence-motif. Some of the important regulatory regions residing within the 
selected size of IFN-γ promoter have been highlighted in Figure 5.8.  In the event that 
TGF-β1 repressed IFN-γ promoter activity is observed, the results of this bioinformatic 
analysis will potentially be used in mapping the region/element on the promoter which 













































Moreover, prior to performing this experimental study, it was also required to 
understand the transfection efficiency of the NK cell line (KY-1) used. In general, NK 
cells are known to be the difficult cell lines to transfect, therefore, many laboratories 
focus their investigation on regulation of IFN-γ expression using T cells (Biron Et. al., 
1999; Bream Et. al., 2004). To our knowledge, this was the first study that attempted 
transient transfection of this NK cell line, KY-1, using the Amaxa nucleofection 
method (described in section 2.11.1). Accordingly, KY-1 cells were transiently co-
transfected with the murine IFN-γ reporter vector, pFL-IFN, and pRL-TK vectors. 
pRL-TK plasmid (Renilla luciferase reporter gene) is a commercial plasmid, used as 
an internal control to normalise transfection efficiency. The details of these reporter 




Figure 5.8: Schematic representation of IFN-γ promoter reporter vector and putative 
transcription factor binding sites within the -777/+48 promoter element: IFN-γ promoter 
region of -777bp to +48bp used was inserted upstream of luciferase gene into pBS-Luc vector 
to generate the pFL-IFN reporter vector. This pFL-IFN vector was transiently transfected into 
KY-1 cells as described in the Materials and Methods. Members of various regulatory 
transcription factor families known to bind within the selected IFN-γ promoter region (Penix Et. 
al., 1993; Sweetser Et. al., 1998; Tato Et. al., 2004; Zhou Et. al., 2004) and identified by the 






Transiently co-transfected cells were left unstimulated (No cytokines), treated with or 
without TGF-β1 for 30 mins. Subsequently, these cells were stimulated with either IL-
12 alone or with a combination of IL-12 plus IL-18 for 3 hours in the presence or 
absence of TGF-β1, as seen in Figure 5.9. After stimulation with cytokines, cells were 
lysed to detect the reporter activity using Dual-Luciferase® Reporter Assays, as 
described in Section 2.11.2. The transiently expressed IFN-γ reporter activity was 
measured as an increase in firefly luciferase activity (experimental) normalised to 
Renilla luciferase activity (internal control). After normalisation for transfection 
efficiency (as shown in Figure 5.9A), IL-12 stimulation resulted in ~50% increase in 
the level of IFN-γ promoter activity (bar-2) in comparison to the ‘basal’ promoter 
activity from unstimulated cells (bar-1). Importantly, this IL-12-induced reporter 
activity was unaffected by the treatment with TGF-β1 (bar-3). As expected and 
consistent with other studies (Barbulescu Et. al., 1998; Nakahira Et. al., 2002), IL-12 
plus IL-18 co-stimulation resulted in relatively, much higher expression of IFN-γ 
reporter activity (~4 fold increase) (bar-4). As expected, it served as a positive control 
in observing the activation of IFN-γ promoter fragment.  Still, TGF-β1 was unable to 
inhibit this synergistic induction of transiently expressed IFN-γ promoter construct 
(bar-5). Thus, the results clearly demonstrated that the presence of TGF-β1 failed to 
suppress the IFN-γ promoter-driven luciferase activity induced by IL-12 alone or with 
IL-12 plus IL-18.  
 
In addition to measuring the reporter activity from cells, the culture supernatant was 
used to assay for endogenous IFN-γ production using ELISA (Figure 5.9B).  This assay 
served as an internal control that reflected the intact activities of exogenously added 
cytokines for stimulation. It also acted as an internal control to the response of the 
endogenous or native IFN-γ promoter under the experimental conditions used. As seen 
in Figure 5.9B, expectedly, IL-12 stimulation resulted in IFN-γ production from 
transiently transfected KY-1 cells (bar-2) and the presence of IL-18 with IL-12 strongly 
augmented this production (bar-4). Also, TGF-β1 significantly inhibited ~50% IFN-γ 
production induced by IL-12 alone (bar-3) or with combination of IL-12 plus IL-18 
(bar-5). This inhibitory effect of TGF-β1 on transfected KY-1 cells was found 
comparable to the effect observed with non-transfected KY-1 cells in the previous 





Nonetheless, the expression level of the exogenous IFN-γ promoter construct induced 
by IL-12 alone stimulation (Figure 5.9A) was not comparable to the native IFN-γ 
promoter activity in these transient transfections (Figure 5.9B). This shows that the 
transcriptional activity of the IFN-γ promoter construct used here does not reflect the 
transcription of the native IFN-γ gene and indicates the requirement for analysing larger 
promoter constructs in future experiments. This extended region might provide 
additional binding sites or elements in the IFN-γ promoter for the transcription factors 
induced by IL-12 and hence induce stronger transcriptional activation of the promoter 
construct. Such a study might lead to a complete ‘switch-on’ of IFN-γ gene expression, 
to investigate the effect of TGF-β1. Moreover, the analysis of the proximal IFN-γ 
promoter region within -777bp to +48bp that appeared to be important for various 
transcription factors (Figure 5.8) was not responsive to the presence of TGF-β1. This 
suggests that the repression of the native IFN-γ gene by TGF-β1 may require distal 
regulatory elements at >777bp upstream of the TSS. Thus, as suggested earlier, to 
advance the experimental work, it would be interesting to increase the size of the IFN-
γ promoter inserts into the luciferase vector and investigate its inhibition by TGF-β1. 
Once a defined region of the IFN-γ promoter that is responsive to TGF-β1 is 
determined, targeted deletion or mutational analysis of functional regulatory elements 









































Figure 5.9: Effect of TGF-β1 on exogenous and endogenous IFN-γ promoter activity: 
KY-1 cells were transiently co-transfected with pFL-IFN and pRL-TK plasmids. Transfected 
cells were treated with or without TGF-β1 (10 ng/ml) for 30 mins, subsequently cells were 
stimulated by either IL-12 (10 ng/ml) alone or IL-12 plus IL-18 (100 ng/ml) for 3 hrs. (A) 
Cells were lysed to detect luciferase reporter activity. Results shown are expressed as ratio of 
relative light units (RLU) of firefly (F) to renilla (R) that are normalised to the fold change in 
activity by referring the ratio obtained in untreated (No cytokines) transfected wells as ‘1’. (B) 
The supernatant culture media from transfected cells was collected and assayed by ELISA to 
measure endogenous IFN-γ protein levels. Error bars show ± SD. The data are representative 







5.3  Discussion 
Prior to the current investigation, several published works reported inhibition of IFN-γ 
production by TGF-β1. However, the signalling crosstalk between TGF-β1 and IL-12 
in IFN-γ production was not well understood. Moreover, as described earlier in chapter 
1 (Section 1.8.2), conflicting reports over the inhibitory effects of TGF-β1 on IL-12 
receptor-proximal events highlighted the need for further investigation. This chapter, 
therefore, sought to investigate the underlying mechanism in the regulation of IL-12-
induced IFN-γ production by TGF-β1 in NK cells and hence, enhances understanding 
towards the pivotal role of NK cell-derived IFN-γ in early innate immune responses to 
tumours and opportunistic infections such as in immunocompromised individuals 
inAIDS. Thus, this study has potential implications for NK cell functions in health and 
disease. 
Particularly, an attempt has been made to decipher the interference of TGF-β1 on IL-
12 signalling elements in IFN-γ production and gene expression. Interestingly, the 
current results demonstrated that early IFN-γ production (3-6 hours) was suppressed 
by TGF-β1 (Figure 5.3), which indicated a mechanism independent of cell 
proliferation. The inhibitory effect of TGF-β1 on IFN-γ production observed in the 
current study (Figure 5.3) is in line with a number of previous studies (Bellone Et. al., 
1995; Bright & Sriram, 1998; Sudarshan Et. al., 1999; Pardoux Et. al., 1999; Thomas 
& Massague, 2005; Yu Et. al., 2006; Lindgren Et. al., 2011; Marcoe Et. al., 2012; 
Lewis Et. al., 2015). However, these previous studies demonstrated the effect over 
longer hours of treatment with TGF-β1 (overnight to 48 hours) which, in part, might 
include contributions from other suppressive actions of TGF-β1 such as anti-
proliferation (Bellone Et. al., 1995; Bright & Sriram, 1998; Wilson Et. al., 2011) or 
induction of factors in cell-cycle inhibition (Ahuja Et. al., 1993; Bellone Et. al., 1995). 
Indeed, the current results highlight the independence of two TGF-β1 regulated 
pathways, namely, cell proliferation and IFN-γ production.  The data also indicates 
(Figure 5.2 and Table 5.1) that reduced IFN-γ secretion was not due to reduction in 
numbers of NK cell population in the presence of TGF-β1. This data is critical in 
immune responses in vivo that are dependent on NK cells, and prior to activation of T 
cells. Such a scenario could arise during early hours of infections with intracellular 
bacterial or viral pathogens (French & Yokoyama, 2003). Studies with murine 




Et. al., 2008) and CMV (Cytomegalovirus) (Fodil Et. al., 2014; Lewis Et. al., 2015) 
have shown that IFN-γ production by NK cells and not by T cells is associated with 
providing resistance to infections. 
 
To investigate the potential interference of TGF-β1 in IFN-γ production, the IL-12-
activated JAK-STAT pathway in NK cells was examined. IL-12 signals through the 
IL-12R-associated Janus family kinases, JAK2 and TYK2, which in turn tyrosine 
phosphorylates and activates STAT-4 (Bacon Et. al., 1995; O'Shea, 1997). In the 
current study, IL-12 induced tyrosine phosphorylation of STAT-4 was not affected by 
TGF-β1, despite inhibition of IFN-γ secretion (Figure 5.4, 5.5). This suggested that IL-
12 receptor-proximal events such as activation of JAKs and kinase activity was normal 
in the presence of TGF-β1. These results are also in agreement with the previously 
reported findings of Sudarshan Et. al. (1999) who demonstrated using T and NK cells 
that pre-treatment with TGF-β1 did not inhibit IL-12-stimulated tyrosine-
phosphorylation of STAT-4 and its DNA binding activity. Moreover, the current study 
extends their findings by demonstrating that the inhibitory effect of TGF-β1 was also 
independent of serine phosphorylation of STAT-4. 
 
Although, tyrosine phosphorylation is the primary regulator of STAT activity, maximal 
activation of STAT requires both tyrosine and serine phosphorylation (S. S. Cho Et. 
al., 1996; Visconti Et. al., 2000). Phosphorylation of STAT-4 at Ser721 is required for 
IL-12 induced full transcriptional activity and IFN-γ production (Morinobu Et. al., 
2002). In the current study, IL-12 stimulation did not result in any increased levels of 
serine phosphorylation of STAT-4 (Figure 5.6). Rather, STAT-4 was detected to be 
constitutively serine-phosphorylated in this NK cell line, KY-1. One possible 
explanation for the constitutive levels of serine phosphorylated STAT-4 could be 
maintenance of these KY-1 cells in IL-2, which is one of the known stimulants of p38 
MAPK (Hunt Et. al., 1999). The p38 MAPK pathway mediates serine phosphorylation 
of STAT-4, with the effect that the inhibitors of p38 MAPK inhibit IFN-γ production 
(Visconti Et. al., 2000).  
 
Alternatively, the KY-1 cell line used in the current study was obtained from a p53 
knockout mouse which may contain constitutively activated p38 from MAPK family. 
This is because, deletion of p53 gene (a tumour-suppressor gene) gives these NK cells 




of serine phosphorylated STAT-4 to the constitutively activated p38 MAPK kinase in 
human T-cell leukaemia virus type I (HTLV-1) transformed T cell lines has been 
reported (Higashi Et. al., 2005). Similar to STAT-4, other STATs, like STAT-1 and 
STAT-3, were also reported to be constitutively serine phosphorylated in leukaemic T 
cells from chronic lymphocytic leukaemia patients (Frank Et. al., 1997). Thus, there 
could be a possible contribution of the p38 MAPK pathway in constitutive serine 
phosphorylation of STAT-4 in KY-1 cells. Importantly, TGF-β1 treatment did not 
result in the reduction or inhibition of this constitutive level of serine phosphorylated 
STAT-4.  This suggests that even if STAT-4 was serine phosphorylated by constitutive 
p38 MAPK activity, it is quite unlikely for TGF-β1 to have a profound effect on this 
signalling pathway to reflect in IFN-γ production. Consistent with this, Trotta Et. al. 
(2008) also showed that TGF-β1 did not inhibit early signalling intermediates such as 
p38 kinase, STAT-4/5 in IFN-γ production by NK cells via CD-16 and IL-12 activation. 
Overall, the data strongly supports a STAT-4 independent role of TGF-β1 in 
suppression of IL-12-induced IFN-γ production (Section 5.2.4). 
  
IFN-γ has been identified as one of the target genes for a T-box transcription factor, T-
bet (Szabo Et. al., 2002; Townsend Et. al., 2004). In the current study, T-bet expression 
was detected at similar levels in IL-12 stimulated and unstimulated cells in KY-1 cells. 
This means that T-bet is constitutively expressed in these NK cells and does not 
correlate to rapid IFN-γ production observed on short-term (3 hours) stimulation with 
IL-12. A similar early burst of IFN-γ release by NK cells was shown to be unaffected 
by the absence of T-bet on stimulation with IL-12/IL-18 in-vitro (Townsend Et. al., 
2004). Moreover, it has been shown that T-bet dependent IFN-γ production varies with 
the type of stimulation used. T-bet was shown to strongly increase IFN-γ production in 
T-bet expressing Th2 cells or STAT-4-/- T cells when stimulated with P/I but did not 
strongly influence IFN-γ production when stimulated with antigen/APC or IL-12 + IL-
18 (Afkarian Et. al., 2002). Further, cytokine-induced IFN-γ expression remained 
dependent on STAT-4 even in the presence of ectopically expressed T-bet in T cells 
(Afkarian Et. al., 2002). Consistent with this, the current findings also showed that in 
the presence of T-bet, STAT-4 signalling in response to IL-12 could induce IFN-γ. In 
this context, recent studies have shown that neither retroviral T-bet expression in 
STAT-4-/-T-bet-/- double deficient T cells nor IL-27 induced Tbx21 expression in 
STAT-4-deficient T cells was sufficient to increase IFN-γ production compared to WT. 




expression to WT levels (Thieu Et. al., 2008). This indicated that while STAT-4 is 
critical, T-bet without STAT-4 does not induce IFN-γ production (Thieu Et. al., 2008; 
J. Zhu Et. al., 2012). Further these studies have shown that both T-bet and STAT-4 act 
in collaboration to induce IFN-γ production (J. Zhu Et. al., 2012) by mediating distinct 
chromatin modifications such as histone acetylation at the Ifng locus (Thieu Et. al., 
2008; Balasubramani Et. al., 2010; Balasubramani Et. al., 2014). Therefore, the 
constitutively expressed T-bet might possibly enable the recruitment of activated 
STAT-4 or other factors in IL-12 stimulated IFN-γ production (Thieu Et. al., 2008; 
Kurktschiev Et. al., 2014).  
 
More importantly, the constitutive expression of T-bet observed in the current study 
was found unaltered in the presence of TGF-β1 (Figure 5.7). In line with this, another 
study has shown that T-bet expression was not affected by TGF-β-mediated IFN-γ 
suppression in NK cells from healthy individuals that was also consistent with T-bet 
expression in cancer patient-derived NK cells (Lindgren Et. al., 2011). The molecular 
mechanism by which T-bet positively regulates IFN-γ gene expression has been well 
addressed using T cells, however it remains insufficiently explored in NK cells. As a 
classic transcription factor, T-bet directly binds to the sequences on the IFN-γ promoter 
and induces transcription (Szabo Et. al., 2000). Indirectly, in collaboration with other 
transcriptional factors, T-bet has been shown in T cells to influence the induction of 
IFN-γ transcription or block the recruitment of transcriptional repressors that regulate 
IFN-γ gene expression (Soutto Et. al., 2002; J. Y. Cho Et. al., 2003; Djuretic Et. al., 
2007). Current data indicates that TGF-β1 suppressed early IFN-γ production is not 
through a mechanism that involves direct transcriptional function of T-bet. Supporting 
this finding, the activity of -777 to +48bp IFN-γ promoter construct that contained 
multiple functional sites for T-bet was investigated in the presence of TGF-β1. Results 
from the reporter assays demonstrated that induction of IFN-γ promoter activity on IL-
12 stimulation remained unresponsive to TGF-β1 (Figure 5.9a), inspite of the presence 
of T-bet responsive cis-regulatory elements within 300bp upstream of TSS of IFN-γ 
gene (J. Y. Cho Et. al., 2003). Some of these sites have been highlighted in Figure 5.10 
(Green region). Thus, it can be concluded that the potential T-bet interaction sites in 
the proximal region of IFN-γ promoter were not the target regulatory elements in TGF-
β1-induced early IFN-γ repression. However, this does not rule out the possibility that 
T-bet in co-operation with other transcription factors might function in trans-activation 





Notably, the IFN-γ promoter construct used in the reporter assays also contained the 
binding sites for various other factors important in IFN-γ expression such as AP-1, YY-
1, NF-AT, NF-kB, and STATs, in addition to T bet (Ye Et. al., 1994; K. M. Murphy 
Et. al., 2000; Soutto Et. al., 2002). Still, TGF-β1 was unable to repress IL-12-induced 
IFN-γ promoter activation (Figure 5.9a). This, to some extent, suggests that TGF-β1 
does not target the indirect role of T-bet in influencing IFN-γ promoter activity. 
However, it will be useful in future to confirm the role of this constitutively expressed 
T-bet on IFN-γ promoter activity and can be tested in vitro by EMSA or by ChIP assays. 
This will enable the functional interaction of T-bet protein with IFN-γ promoter 
construct to be determined. Indeed, the current findings clearly indicate that the effect 














While the current research was ongoing, Yu Et. al. proposed two molecular 
mechanisms for TGF-β1 induced IFN-γ suppression in human NK cells via Smad 
proteins, one of which was T-bet-dependent and other was T-bet-independent (Yu Et. 
al., 2006). From the investigations to date (recent reviews by Marcais Et. al., 2013; 
Sanjabi Et. al., 2017), this is the only study conducted that is closely-related and their 
findings remain relevant to the current study. It is thus essential to understand the key 
differences between the current study and Yu Et. al’s study. They showed that, on 24 
hours of stimulation with IL-12 plus IL-18 in the presence of TGF-β1, IFN-γ 
production was inhibited either directly via activated Smad-3 or indirectly by Smad-









Figure 5.10: Partial sequence of the mouse IFN-γ promoter is shown:  
Three characterised T-bet binding sites (TGTGAA/TGTCAC) are highlighted green (J. Y. Cho Et. 
al., 2003). Two potential SMAD binding sites (GTCT) are highlighted in yellow (Yu Et. al., 2006). 
Superscript numbers indicate the positions of nucleotides in sequence to transcription start site 





another study also demonstrated a T-bet-dependent pathway as the underlying 
mechanism in TGF-β1-mediated IFN-γ suppression (Koutoulaki Et. al., 2010). 
Koutoulaki Et. al. showed that TGF-β1 treatment of DCs stimulated with IL-18 for 24 
hours resulted in suppression of IL-18-up-regulated T-bet expression to constitutive 
levels in IFN-γ production. In the current study, neither stimulation with IL-12 resulted 
in increased T-bet expression nor was TGF-β1 able to down-regulate constitutively 
expressed T-bet levels. Thus, this rules out the proposed T-bet-dependent regulation of 
IFN-γ by TGF-β1 in KY-1 cells.  
 
An important difference between the current study and Yu Et. al’s study was the time 
of stimulation (3-6 hours vs 24 hours) with IL-12 in the presence of TGF-β1. This is 
significant with regards to the induction of T-bet. Perhaps, in the current study, a short-
term stimulation with IL-12 was adequate for rapid IFN-γ production but might not be 
sufficient to induce T-bet expression. Other studies have reported using T-bet-/- NK 
cells that early and rapid production of IFN-γ is T-bet independent (6 hours). However, 
after 24 hours of cytokine stimulation, IFN-γ production was found to be significantly 
reduced in the absence of T-bet (Szabo Et. al., 2002; Townsend Et. al., 2004). This 
suggested the importance of this factor in the later production and maintenance of IFN-
γ levels (Way & Wilson, 2004; Leong Et. al., 2017). In this context, Matsuda Et. al. 
(2007) demonstrated using an ectopically inducible form of T-bet in CD4+ T cells that 
early induction and nuclear translocation of T-bet occurred in 2 hours of stimulation by 
a synthetic drug. Yet, the T-bet-mediated effect on IFN-γ production is delayed and 
required between 12 to 24 hours. Similarly, naïve CD4+ T cells on TCR stimulation 
showed T bet expression in 1 hour but the effector cytokine production was not seen 
until 48 hours (Yu, Wu Et. al., 2014). Thus, the current findings in conjunction with 
Yu et al’s findings raises an intriguing possibility in temporal control of IFN-γ 
expression by TGF-β1 via T-bet. Because of the short-term activation time used in the 
current study, T-bet induction by IL-12 and its inhibition by TGF-β1 that could occur 
at later time points was not observed. However, to address this, studies with kinetics of 
T-bet expression on IL-12 stimulation in the presence and absence of TGF-β1 will be 
required as future work.  
 
Another mechanism proposed by Yu Et. al. was the direct regulation of IFN-γ 
expression by Smads (T-bet independent pathway). This pathway was shown to be 




spanning -204 bp from TSS of IFN-γ gene by Smad proteins (Smad 3 and 4). Further, 
by electrophoretic mobility shift assay (EMSA), they demonstrated direct binding of 
Smad-3 to distinct regions on the IFN-γ promoter (-204 to -138 bp), called Smad 
binding elements (SBE) (Yu Et. al., 2006). However, the current study demonstrated 
that TGF-β1 did not affect IL-12-induced IFN-γ promoter activity, within a -777bp to 
+48bp promoter sequence that was transiently expressed in NK cells (Figure 5.9A).  
Even though, as determined through bioinformatic analysis, this region of the promoter 
contained two SBE (GTCT), as shown in Figure 5.10 (yellow region). Thus, in contrast 
to the proposed Smad-mediated model, the current findings suggest that the molecular 
basis to early IFN-γ suppression observed was not due to direct binding of TGF-β1-
activated Smads to IFN-γ promoter. Hence, the proposed T-bet independent pathway 
by Yu et al seems unlikely as a possible mechanism in our case. One important point 
of distinction to note is the difference in species. Yu Et. al.’s study was performed using 
a human IFN-γ promoter construct with a sequence between -204 and -138bp, that 
contained three consensus Smad-binding motifs, with two sites adjacent to each other 
and a third one in close proximity. Whereas, in the current study, the murine counterpart 
contained only one motif within the specified region which may not be sufficient to 
exhibit direct Smad-mediated IFN-γ promoter repression and hence, observed lack of 
TGF-β1 effect on IFN-γ promoter activity.  
 
It is also worth noting that, in the above-mentioned Yu Et. al. study, the approach used 
to demonstrate the T-bet-dependent and independent mechanism via Smads in IFN-γ 
suppression was overexpression of specific Smads or T-bet proteins respectively, the 
effects of which warrants careful consideration. Overexpression of these proteins do 
not reflect the physiological or endogenous signalling pathway activated by specific 
stimuli. For instance, the key events in TGF-β1-mediated signalling are 
phosphorylation and association of specific Smads with each other. It was evident from 
some of the Yu Et. al’s results that modest IFN-γ inhibition with overexpressed Smad-
3 proteins was further enhanced in the presence of TGF-β1 (Yu Et. al., 2006). 
Moreover, phosphorylation of transcription factors results in their transition between 
cellular compartments during a signal transduction pathway (N. S. Chang Et. al., 2005). 
Trotta and colleagues showed using a specific inhibitor of TGF-β1 receptor kinase 
(SB431542) in NK cells that nuclear phosphorylation of Smad-3 is necessary for the 
inhibition of IFN-γ by TGF-β1. They further showed that the difference in the levels of 




absence of TGF-β1, reflected in the differential inhibition of IFN-γ production (Trotta 
Et. al., 2008). Likewise, ectopic expression of T-bet has been known to up-regulate 
endogenous T-bet levels that functions to induce histone modifications and chromatin 
remodelling events in IFN-γ expression, even in the absence of STAT-4 or IL-12 
signalling (Mullen Et. al., 2001; Shnyreva Et. al., 2004; Tong Et. al., 2005).  
 
Nevertheless, from these studies, it seems there are multiple mechanisms in TGF-β1-
mediated IFN-γ suppression as the subsequent findings from Yu Et. al’s group have 
shown that Smad-3-/- and T-bet-/- NK cells exhibited IFN-γ production that was partially 
and strongly inhibited by TGF-β1 (Trotta Et. al., 2008). Thus far, the mechanism and 
the mediators of this are still unknown. In fact, consistent with our findings, a study 
from another group of investigators demonstrated that TGF-β treatment of NK cells did 
not alter T-bet or STAT-4 mRNA expression but resulted in an increased expression of 
transcripts for a transcription factor, GATA-3 (Lindgren at al., 2011). GATA-3, a Th2 
transcription factor is known to inhibit IFN-γ production (Kaminuma Et. al., 2004). 
Lindgren et al also noted a similar trend in expression of transcripts for these 
transcription factors (T-bet, STAT-4 and GATA-3) in NK cells from cancer patients 
supporting the role of tumour-derived TGF-β in the suppression of IFN-γ. Their 
findings suggested a possible role of GATA-3 in TGF-β-mediated suppression of IFN-
γ (Lindgren at al., 2011). However due to the lack of data on whether T-bet or GATA-
3 proteins are expressed, this hypothesis requires further investigation to establish a 
definitive association between GATA-3 and TGF-β. Hence, the results from the current 
study alludes to existence of an alternative mechanism in the early and rapid 
suppression of IL-12-signaled IFN-γ by TGF-β1 within hours. 
  
It is still important to understand, by what mechanism TGF-β1 inhibits IFN-γ 
production within hours? One possible scenario could be that TGF-β1 might induce 
chromatin remodeling in transcriptional repression of the IFN-γ gene in NK cells. In 
fact, the current results that demonstrates IFN-γ production within hours of IL-12 
stimulation (as seen in Figure 5.4C), also correlates with the ‘open’ status of Ifng locus 
in NK cells (Tato Et. al., 2004). This ‘open’ status in NK cells refers to a constitutively 
modified form of chromatin at Ifng locus such as histone acetylation and demethylation 
that permits accessibility to transcriptional machinery for IFN-γ production, whereas 
this status is acquired in T cells through cell cycle progression and proliferation (Tato 




with previous reports which had demonstrated in ChIP assays using antibodies to 
acetylated H3 that Ifng locus in NK cells is highly acetylated around the IFN-γ 
promoter. Moreover, these levels of H3 acetylation (an indicator of accessible 
chromatin) in resting NK cells matched to the levels in differentiated CD4+ T cells, 
whereas naive CD4+ and CD8+ T cells expressed low levels of histone acetylation 
(Stetson Et. al., 2003; Tato Et. al., 2004). This indicated that, unlike in T cells, the 
derepressed Ifng locus in NK cells is apparently accessible to transcription factors, 
which in turn, allows immediate production of IFN-γ on cytokine stimulation. 
 
However, it is also known that besides the constitutive acetylation patterns in resting 
NK cells, these cells additionally acquire histone acetylation patterns at certain regions 
of the IFN-γ gene depending on the specific cytokine (IL-12/IL-12+IL-18) signalling 
pathway that activates IFN-γ gene transcription. For instance, stimulation of resting 
NK cells with IL-12 for 6 hours resulted in a specific increase in H4 histone acetylation 
levels at -6kb 5’ of the IFN-γ gene to a similar extent as Th1 cells but did not modify 
other acetylated or non-acetylated regions of the IFN-γ gene (S. Chang & Aune, 2005). 
IL-12-activated STAT-4 was shown to alter the chromatin microenvironment of the 
Ifng locus in Th1 cells by inducing histone hyperacetylation and recruiting chromatin 
associated enzymes (Thieu Et. al., 2008; Balasubramani Et. al., 2014). Thus, even 
though the Ifng locus in NK cells is in a permissive state for rapid transcription, it 
undergoes chromatin remodelling on stimulation with IL-2/IL-12 (Bream Et. al., 2004), 
IL-12/IL-18 (S. Chang & Aune, 2005) that induces active IFN-γ gene transcription. 
 
Consistent with this view, it is interesting to note that TGF-β-activated Smad 
complexes have shown to directly recruit chromatin-modifying proteins or Smad-
associated repressor proteins in transcriptional repression (as recently reviewed by Hata 
& Chen, 2016; Hill, 2016). For example, phosphorylated Smad-3 has been shown to 
recruit HDAC 4/5 in repression of TGF-β regulated gene expression (J. S. Kang Et. al., 
2005).  The recruitment of HDACs reverses histone modifications by removing histone 
acetylation mediated by activating factors or induces repressive histone marks that 
results in limited accessibility of the DNA template to transcription factors (Wolffe Et. 
al., 2000).  Transcriptional repression can also be achieved by Smads in association 
with co-repressor proteins such as TG3-interacting factor (TGIF). TGIF bridges Smad 
complexes (Smad-2/4) with chromatin condensing histone deacetylases (HDACs) onto 




Therefore, based on such direct interaction of TGF-β-activated Smads with chromatin-
modifying proteins or co-repressors in repression of gene transcription, one could 
further hypothesize that the potential mechanism responsible for TGF-β1-mediated 
IFN-γ inhibition might be through epigenetic regulation that is chromatin remodeling 
of the Ifng locus. 
 
Interestingly, in line with this proposition, research work in the field studying an 
integrated signal from cytokines, TGF-β1 and IL-6 has shown to converge at the 
chromatin level within 4 hours, which regulated the functional activities of FOXP3, a 
specific transcriptional repressor in Treg cells. Expression and acetylation of FOXP3 is 
associated with suppressive functions of Treg cells in autoimmunity or pro-
inflammatory conditions. TGF-β1 alone treatment resulted in increased acetylated 
levels of FOXP3 and in turn enhanced chromatin binding that lead to repression of the 
IL-2 promoter. While IL-6 signalling in the presence of TGF-β1 reduced chromatin 
binding of FOXP3, a process that was shown to be reversed by a HDAC inhibitor, 
sodium butyrate (Samanta Et. al., 2008). Thus, a cross-talk between TGF-β1 and IL-
12 signalling in IFN-γ production might be at the chromatin level. Since, the general 
view in the field suggests that histone acetylation of promoter precedes active 
transcription, changes in acetylation might reflect to alterations at transcription level 
(Narlikar Et. al., 2002; Hill, 2016). Therefore, to explore this possibility, the acetylation 
status of Ifng locus in the presence or absence of TGF-β1, using quantitative ChIP 
assays and anti-acetyl histone H3/H4 antibodies could be determined in the future 
work.  
 
Consistent with many other studies (Bellone Et. al., 1995; Bright & Sriram, 1998; 
Sudarshan Et. al., 1999; Hayashi Et. al., 2003; Yu Et. al., 2006; Trotta Et. al., 2008; 
Koutoulaki Et. al., 2010), the current study observed only a partial decrease in IFN-γ 
produced by NK cells in the presence of TGF-β1 but the in vivo consequences for NK 
cell-dependent responses may be profound. For example, TLR9-deficient mice 
exhibited only 25–30% reduction in NK cell-produced IFN-γ (Krug Et. al., 2004). 
Despite this partial reduction in IFN-γ production, the ability of TLR9-deficient mice 
to clear murine cytomegalovirus (MCMV) infection was significantly impaired in 
comparison with wild-type (WT) mice (Krug Et. al., 2004). Moreover, as implied from 
our studies and that of other investigators in the field (recent reviews by Marcais Et. 




degree of NK cell activation is determined by the balance of inhibitory (TGF-β1/ IL-
10) and stimulatory (IL-12/ IL-2/ IL-15/ IL-18) cytokines present in the 
microenvironment, significantly in a tumour microenvironment. Therefore, 
information from this study on cytokine signalling cross-talk could help design 
strategies in the management of cell-mediated immune responses in individuals, most 
importantly immunocompromised individuals, including cancer patients, against 












































The overall aim of this thesis was to enhance the mechanistic understanding of NK cell 
activity and thereby regulating the balance of Th1 /Th2 type immune responses through 
the role of cytokines and complex carbohydrates such as GAGs/PGs. This thesis sought 
to elucidate a molecular understanding of cytokine binding to heparin/HS, and 
regulation of IL-12 signalling-induced IFN-γ production in NK cells by DS-PG and 
TGF-β1.  
 
The specific goals of this research were: 
1. To examine three interleukins from different families of cytokines, for their 
heparin-binding property through identification of putative heparin binding 
domains within their primary, secondary and/or tertiary structures of IL-11, IL-
18 and IL-22 (Chapter 3). 
2. To investigate the underlying mechanism by which DS-PGs might participate 
in the induction of IFN-γ secretion (Chapter 4). 
3. To analyse molecular mechanisms underlying the inhibitory effects of TGF-β1 
on IL-12 induced IFN-γ expression and secretion (Chapter 5). 
 
The following sections summarise the key findings for each of these goals, discuss their 
implications, and the ideas for future work. 
 
6.1 Binding Studies of IL-11, IL-18 and IL-22 to Heparin/HS 
 
To the best of our knowledge, to date, the results presented in Chapter 3 are the first to 
demonstrate that interleukins 11, 18, and 22 do not bind to heparin at physiological pH 
and ionic strength. This comprehensive research work integrated structural and 
experimental approaches to screen and determine heparin-binding characteristics on 
each of three interleukins. The results confirm that these interleukins do not share the 
heparin-binding property with their respective family members, despite sharing a 
pronounced protein structural fold. On comparing each of these interleukins, IL-11, IL-
18 and IL-22 with their heparin-binding counterparts, one of the key findings is that 
the presence and position of acidic amino acids pose unique challenges in the formation 
of stable heparin-binding domain. Our results also parallel that of TGF-β3 which does 
not bind to heparin/HS, while other isoforms (TGF-β1 & TGF-β2) within the TGF-β 




our key finding that each cytokine of interest needs to be studied individually when 
seeking to determine its heparin-binding characteristics. 
 
Current findings in Chapter 3 led to a discussion in understanding the structural basis 
of non-heparin-binding characteristic of interleukins 11, 18 and 22 compared to their 
respective heparin-binding family members. As mentioned previously in Chapter 1 
(Section 1.5) that, in the event of negative findings, in which case, the selected 
interleukins do not bind to heparin/HS, this may still have significant biological 
implications as discussed here. For IL-11 and IL-22, the lack of affinity for heparin 
may be a desirable property that enables these interleukins to remain unbound and free. 
Once secreted, these interleukins may travel freely through circulation to reach their 
receptors on remote target organs. This theory could be supported knowing that IL-11 
mainly functions in the development and maturation of myeloid and lymphoid cells 
during haemopoiesis in the bone marrow but also plays a role in many other distant 
tissues such as brain, gut, testis and bone (Du & Williams, 1997; Sims Et. al., 2005). 
Interestingly, recent findings provide evidence for the role of IL-11 in breast cancer 
metastasis to distant sites, particularly to bone (Johnstone Et. al., 2015). Indeed, IL-11 
with osteotrophic properties is a key regulator in bone metabolism through 
differentiation of osteoblasts into osteoclasts by binding to their cell surface receptors 
(Sims Et. al., 2005). One mechanism suggested in this osteolytic metastasis was 
increased osteoclast activation by tumour microenvironment secreted IL-11 (Kozlow 
& Guise, 2005). In this context, ectopic expression of IL-11 in colorectal cancer cells 
was shown to result in enhanced metastasis to multiple organs compared to minimal 
metastasis observed by ectopically expressed IL-6, a heparin-binding counterpart of 
IL-11 (Calon Et. al., 2012). Given the recently known role of IL-11 in various cancer 
types (Hanavadi Et. al., 2006; Putoczki Et. al., 2013; Negahdaripour Et. al., 2016) and 
in the light of current findings, one could attribute some of the endocrine effects of IL-
11 over distant sites to its non-heparin-binding property, however this correlation 
remains to be established in future investigations. 
 
Similarly, IL-22 produced by immune cells at the site of local inflammation has actions 
on non-immune cells. This functional effect remarkably distinguishes IL-22 from other 
members of IL-10 family of cytokines (Witte Et. al., 2010; Dudakov Et. al., 2015). 
Functional IL-22 receptors are present on the epithelial cells and fibroblasts of various 




targets for this cytokine, resulting in innate, non-specific immunity in these far-off 
tissues (Wolk Et. al., 2004; Sabat Et. al., 2014). In this context, following local tissue 
inflammation, the presence of IL-22 has been detected in the circulation (Wolk Et. al., 
2006a; Wolk Et. al., 2007; Pan Et. al., 2013). For example, crohn’s disease (CD), a 
chronic inflammatory bowel disease which is characterised by infiltration of activated 
immune cells in the intestine, results in secretion of IL-22 into the circulation. This 
systemic IL-22 was shown to exhibit a protective role by inducing production of anti-
bacterial proteins by hepatocytes into the blood, thus preventing systemic inflammation 
in CD patients (Wolk Et. al., 2007). This example clearly indicates a possible endocrine 
role of IL-22. Moreover, independent expression of IL-22-specific signalling receptor, 
IL-22R1 on diverse and distant tissues further support the systemic function of IL-22 
(Sabat Et. al., 2014). Collectively, these instances suggest the effects of IL-11 or IL-22 
over longer distances through diffusion into blood circulation. Thus, selectivity of 
cytokines in not binding to heparin and its influence on a biological process can be the 
focus of future studies. 
 
IL-18 has been observed as a biomarker in patients with metabolic syndrome, in which 
many organs and tissues such as adipose, muscle tissues secrete IL-18, resulting in 
elevated levels in the circulation (Troseid Et. al., 2010). The circulating high levels of 
this cytokine was shown to play a crucial role in the development of type 2 diabetes 
mellitus and cardiovascular diseases (Hivert Et. al., 2009). It is thus, plausible to 
suggest from these observations that IL-18 can freely diffuse from the tissue 
microenvironment or matrix into blood circulation to cause these pathogenic effects in 
patients with metabolic syndrome. Very recently many cytokines and growth factors 
including some members of FGF family have been reported to exhibit non-heparin-
binding properties that allows diffusion and free flow in circulation (Itoh Et. al., 2015; 
Nunes Et. al., 2016), thus activating distant receptors in physiological events or off-
targets in pathophysiological roles. Based on the data presented here that IL-18 does 
not bind to heparin/HS, one could possibly explain the free diffusion of secreted IL-18 
and its effects through the blood circulation. However, this association remains to be 
determined for IL-18 until now, whereas it is known for other cytokines like FGFs-15, 
-19, -21, -23.  
 
Strikingly, FGFs-15, -19, -21, -23, the new members of the classical FGF family, 




FGF family members exhibited weak or no affinity for heparin (Goetz Et. al., 2007). 
This group of non-heparin binding FGFs belong to the FGF-19 sub-family and are 
referred to as endocrine FGFs based on their systemic mode of action controlling 
various metabolic processes (Itoh Et. al., 2015; Nunes Et. al., 2016). The contrast in 
the heparin-binding property between the endocrine FGFs from the rest of the paracrine 
FGF family members existed due to the unique conformation adopted by the 
regions/loops within the β-trefoil scaffold, as revealed by superimposition of their 
crystallised structures (Goetz Et. al., 2007), while the heparin-binding FGF members 
such as FGF-2 exhibited a HBS, a composite basic site contributed by the loop regions 
of β strands, β10 and 11 forming a surface groove as seen in Figure 3.18. Moreover, 
the basic residue at the base and those surrounding the groove enabled a stable and 
stronger interaction with heparin/HS (L. D. Thompson, 1994; Faham Et. al., 1996; 
Raman Et. al., 2003; R. Xu, Et. al., 2012). On the other hand, Goetz et al revealed that 
HBS in members of the FGF-19 subfamily possessed a positively-charged, surface 
crest or ridge, formed by the loop regions of β1-2 strands and components of β10 and 
12 strands. Additionally, these narrow surface structures were reported to be sterically 
weak to support HS binding (Goetz Et. al., 2007; Goetz & Mohammadi, 2013).  
 
FGF family members are considered prototypical heparin-binding proteins with an 
absolute requirement of heparin/HS for their biological function (Yayon, 1991; 
Rapraeger Et. al., 1991). Indeed, much of the thinking in the field has been stimulated 
by the FGF-heparin story. Therefore, these findings by Goetz et al in 2007 
demonstrated diversification within the FGF family with regards to heparin/HS 
interaction. This has also staged the intriguing research on non-GAG-binding cytokines 
and their biological significance at the forefront in the field of matrix biology. As 
proposed for these specific endocrine FGF proteins, the lack of affinity for heparin 
enables them to be more mobile in the extracellular and intravenous environment. 
Whilst, remaining unbound to tissue HS, these proteins are available to distant target 
organs, and therefore exhibit an endocrine mode of action. For example, FGF-19 is 
produced in the intestine but acts on liver regulating bile synthesis and cholesterol 
metabolism (Wu Et. al., 2007). Similarly, FGF-23 is produced in bone and acts on 
receptors expressed by kidney cells regulating calcium absorption and vitamin D 
synthesis (Kurosu Et. al., 2006). This is in contrast to paracrine/autocrine mode of 
activity used by the majority of heparin-binding members of FGF family to exert their 




Itoh Et. al., 2015; Nunes Et. al., 2016). Analogous to these examples of FGF-19 
subfamily members, which have a role in regulation of metabolic activities, in the case 
of IL-11, IL-18 and IL-22, the non-heparin binding property maybe of additional 
benefit to these cytokines to act in an endocrine mode to fulfil some of their biological 
functions, as described earlier. 
 
In fact, findings have confirmed that the FGF-19 subfamily members are required to 
bind to special receptors called α or β klotho proteins expressed on the target tissues to 
signal. Binding to these receptors substitute the need of binding to heparin/HS-GAGs 
for signalling. Similar to the role played by heparin/HS in FGF signalling, these klotho 
proteins act as co-receptors for endocrine FGFS, as they can bind co-operatively to 
both the ligand (FGFs) and their respective FGFRs (Beenken & Mohammadi, 2009; 
Kuro-o, 2012; Belov & Mohammadi, 2013). Structural studies are awaited, 
determining the crystal structure of ternary complexes by endocrine FGF, FGFR and 
klotho receptors (Goetz & Mohammadi, 2013). Since, these klotho co-receptors were 
found co-expressed with paracrine FGFs (Urakawa Et. al., 2006), it has now been 
established that, by binding to FGFRs, these Klotho receptors play a dual role in 
inhibiting paracrine FGF signalling and concurrently enhancing the specificity of 
FGFRs for endocrine FGF ligands (Goetz Et. al., 2012a; Goetz Et. al., 2012b). Among 
widely expressed FGFRs, tissue-specific expression of klotho proteins allows these 
endocrine FGFs to determine their target organs and hence define specificity in FGF-
FGFR interaction (Kuro-o, 2012; Itoh Et. al., 2015). The role of klotho receptors and 
endocrine FGFs is an intriguing story and is still unfolding. Based on recent reviews, 
efforts are presently being directed in understanding the molecular basis of endocrine 
FGF signalling complex formation as compared to paracrine FGF signalling (Itoh Et. 
al., 2015; Nunes Et. al., 2016; Sun Et. al., 2016). Similar information on the biological 
relevance of other non-GAG-binding cytokines is lacking. Nonetheless, non-GAG-
binding cytokines are now attracting considerable interest in this field of research.  
 
The subject of GAG-binding and bioavailability may be particularly important in the 
evaluation of cytokines for potential therapeutic use. In some circumstances, it may be 
more effective to employ a non-heparin binding than a heparin-binding cytokine. For 
example, IL-18 functionally resembles IL-12 in vitro and in-vivo (Trinchieri Et. al., 
2003). The recombinant forms of both cytokines have been exploited as vaccine 




administration of rIL-12 has been known to be associated with dose- and schedule-
dependent toxicity (Rook Et. al., 2001). Toxicity is related to the combined activity of 
both the cytokines, IL-12 and the induced IFN-γ, (J. P. Leonard Et. al., 1997; Lenzi Et. 
al., 2007). Interestingly, both these cytokines are known heparin-binding proteins 
(Lortat-Jacob Et. al., 1991b; Hasan Et. al., 1999). Indeed, heparin-bound IFN-γ has a 
markedly increased biological half-life in the circulatory system (from 1.1 to 99 mins) 
(Lortat-Jacob Et. al., 1996a). Therefore, persistently high serum IL-12 and IFN-γ 
concentrations may explain the toxicity associated with systemic administration of rIL-
12. On the other hand, IL-18 is a weaker inducer of IFN-γ than IL-12 (Yoshimoto Et. 
al., 1998). The serum IFN-γ concentration in cancer patients receiving rIL-18 was 
found to be substantially lower than that observed on rIL-12 administration (Robertson 
Et. al., 1999). Moreover, as demonstrated in the current study that IL-18 does not bind 
heparin, this protein may therefore, be retained for less time in the circulatory system. 
This in part, may explain the mild toxicity associated with IL-18 administration. This 
possibly also explains why threefold higher doses of rIL-18 could be administered than 
doses of rIL-12 (J. P. Leonard Et. al., 1997). Hence, the non-heparin-binding property 
may present an advantage in the clinical development of rIL-18 monotherapy over rIL-
12 for systemic cancers.  
 
This is also true in the case of IL-11 and IL-6 which have overlapping functional 
properties (Musashi Et. al., 1991; Negahdaripour Et. al., 2016). These cytokines have 
potential compensatory roles due to a common receptor-subunit, gp130-associated 
signalling pathway (Dahmen Et. al., 1998; Barton Et. al., 2000). However, IL-6 is a 
well-characterised, heparin-binding equivalent of IL-11 (Mummery & Rider, 2000). 
When rIL-6 was administered as therapeutic agent in the management of haematologic 
disorders, such as thrombocytopenia due to myelodysplastic syndromes (MDS), it was 
reported with only low to modest thrombopoietic activity but a significant dose-
limiting toxicity (M. S. Gordon Et. al., 1995). Whilst, when the role of IL-11 as 
thrombopoietic growth factor was investigated in a clinical setting (Goldman, 1995; M. 
S. Gordon, 1999), this cytokine was successful at low dose in patients with bone 
marrow failure (BMF)-associated thrombocytopenia due to MDS (Tsimberidou Et. al., 
2005). Further, the clinical use of IL-11 was extended as an effective treatment in 
chemotherapy-induced thrombocytopenia in malignant patients (Bhatia Et. al., 2007). 
However, the observed reduced efficacy of rIL-6 in the clinical setting could be well 




was shown to reduce the availability of this cytokine ligand to its receptor complex 
(Mummery & Rider, 2000). Supporting this, use of heparin mimetics such as suramin 
not only blocked IL-6 binding to its cell-surface receptors but also inhibited its 
biological activity (Strassmann Et. al., 1993). On the other hand, the presence of 
heparin was shown to synergistically and mechanically augment IL-11 activity (Walton 
Et. al., 2002; Rajgopal Et. al., 2006). This effect, coupled with the current results 
demonstrating that IL-11 does not bind to heparin/HS, possibly explains the potential 
use of IL-11 as a therapeutic intervention in place of IL-6. Moreover, this substitution 
in clinical application is gaining particular attention with the emerging role of IL-11 in 
GI cancers over IL-6 (Putoczki Et. al., 2013; Negahdaripour Et. al., 2016). The data 
presented here highlights an important difference affecting the functional mechanism 
of IL-11 compared to IL-6 that will be useful in improving the therapeutic efficacy of 
IL-11 and its recombinant variants. Collectively, in consideration of our results, the 
chosen group of cytokines, IL-11, IL-18 and IL-22 can be evaluated for efficacy in 
future clinical trials as single agents, or in adjuvant combinations with other cytokines 
or drugs. 
 
Whilst the current investigation was underway, there have been no additional 
publications on binding of IL-11, IL-18 and IL-22 to heparin/HS. Therefore, these 
interleukins could be added to a relatively small group of known non GAG-binding 
cytokines, such as IL-9, IL-16, and TNF-α (Rickard Et. al., 2003). GAG-protein 
interactions are a long standing research area and remarkable progress has been made 
in this field of matrix biology to identify heparin-binding proteins (HBPs) and to gain 
additional insights into such interactions. Interestingly, chemokine CXCL11 was 
demonstrated to hold two different affinity levels for heparin, suggesting ‘structural 
plasticity’ in its protein conformation that enabled such a heterogenous heparin-binding 
property (Severin Et. al., 2010). In addition to this example of CXCL11, the non-
heparin-binding members from FGF family as described above shows that the 
interactions between cytokines and GAGs are more diverse than previously 
understood. Thus, the findings from the current research described in Chapter 3, along 
with recent work in the field have contributed to the changing view that demonstrates 
the existence of diversity in cytokine-heparin/HS interactions within the same class of 
cytokines (recent reviews by Itoh Et. al., 2015; Nunes Et. al., 2016; Y. Li Et. al., 2016; 
Rajarathnam Et. al., 2018). Indeed, this is consistent with other studies that a GAG-




(Coombe, 2008; Dyer Et. al., 2016). Therefore, the current work re-emphasizes the 
importance of knowing whether GAG binding is a requisite to the function of the 
cytokine or whether GAG binding ability is only an added advantage to cytokine 
function.  
  
With regards to the future work in heparin-binding studies, IL-23 may be proposed as 
a likely candidate. IL-23 is a more recently discovered member of the IL-12 family of 
heterodimeric cytokines that also shares the heparin-binding subunit, p40 of IL-12 
(Oppmann Et. al., 2000; Vignali & Kuchroo, 2012). Like IL-12, IL-23 is primarily 
produced by antigen presenting cells, macrophages and dendritic cells.  Both IL-12 and 
IL-23 have overlapping functions of inducing lymphocyte (NK and T cells) 
proliferation and IFN-γ production, thus a role in cellular immunity and inflammation 
(Langrish Et. al., 2004; Duvallet Et. al., 2011; Teng Et. al., 2015). Moreover, IL-23 
drives development of Th17 cells that is central to the development of chronic 
autoimmune diseases (Langrish Et. al., 2005; Lubberts, 2015). Therefore, both IL-12 
and IL-23 are attractive therapeutic targets for various autoimmune diseases (as 
reviewed in Floss Et. al., 2015). Nonetheless, IL-23 has been shown to contribute 
largely to local inflammatory responses in contrast to the systemic inflammation 
induced by IL-12. This differential role of IL-12 and IL-23 was demonstrated in the 
murine model of inflammatory bowel diseases (IBDs), which indicated that IL-23 
could be a selective drug target in IBDs (Uhlig Et. al., 2006; Teng Et. al., 2015). The 
proposed goal in determining the heparin-binding ability of IL-23, or lack thereof, 
would likely be used to selectively target the cytokine and modulate its response. 
 
Structurally, IL-23 is a combination of p40 subunit of IL-12 with p19 subunit. Though 
p40 subunits, besides forming the heterodimers with p19 and p35 subunits, which are 
distantly related, they are also known to form homodimers. These p40 homodimers 
have biological activity antagonistic to IL-12 (Gillessen Et. al., 1995; Trinchieri & 
Scott, 1995a) and IL-23 (Shimozato Et. al., 2006). However, IL-12 p40 deficient mice 
showed impaired antigen-stimulated IFN-γ production and Th1 responsers (Magram 
Et. al., 1996). With this regulatory role, p40 proteins are also found secreted in excess 
over the p70 heterodimers of IL-12 in many disease states (Abdi Et. al., 2014).  IL-23 
binding via the p40 subunit to heparin/HS of the ECM is functionally significant as p40 
is a target protein in number of autoimmune and chronic inflammatory diseases (review 




antibody that blocks IL-12/IL-23 signalling (Benson Et. al., 2011) is an approved 
therapeutic treatment for psoriasis (Yielding Et. al., 2012).   
 
Interestingly, the heparin-binding property of IL-12 was shown being largely located 
in the larger subunit, p40 rather than its smaller subunit p35 that is involved in IL-12-
receptor interactions (Jayanthi Et. al., 2017; Garnier Et. al., 2018). Moreover, previous 
studies from our laboratory have shown that the p40 subunit by itself exhibited strong 
binding affinity like IL-12 to heparin /HS (Hasan Et. al., 1999). Importantly, recent 
studies have extensively characterized this interaction using chemically modified 
heparins as competitive inhibitors and theoretical docking calculations to locate basic 
charge clusters involved in heparin binding (Garnier Et. al., 2018). They have shown 
that the heparin binding site on IL-12 and a homodimer of its p40 subunit consists of a 
cluster of six basic amino acids at the tip of C’D’ loop within the D3 domain of its 
carboxy-terminus, as shown in Figure 6.1. Moreover, this cluster is analogous to the 
carboxy-terminal cluster of 4-5 basic residues as observed in IFN-γ (Lortat-Jacob & 
Grimaud, 1991a), IL-8 (Webb Et. al., 1993) and CXC chemokines (Witt & Lander, 












According to another study which conducted a comparative structural analysis of 
interfaces formed by the p40 subunit with p19 and p35 subunits respectively, revealed 
that the p40 subunit uses the same binding surface and the majority of contact residues 
are common in binding independently with p19 and p35 subunits (Lupardus & Garcia, 
2008). In fact, this same study showed that p40 conserves a structural ‘hotspot’, critical 
in the formation of heterodimeric complex in IL-12 as well as IL-23. However, when 
the p19 subunit of IL-23 engages with p40, there are substantial changes with respect 
Figure 6.1: Primary sequences of putative heparin/ HS binding binding site in human p40 
showing basic amino acids:  
The sequence of mature, secreted form of human p40 with basic amino acids shown as coloured 
letters, arginine = R and lysine = K. All amino acid residues are represented by one letter code. The 
sequence is taken from (Wolf Et. al., 1991) with superscript numbers referring to amino acid 





to the docking modes on p40, which are structurally distinct from the interaction by the 
p35 subunit of IL-12. This was revealed by superimposition of the p40 subunit from 
both complexes of respective cytokines (IL-12 and IL-23) highlighting the structural 
differences and contact residues (Lupardus & Garcia, 2008). Thus, an investigation of 
whether p40 retains the heparin-binding property while combining with p19 to form 
IL-23 is justified. Since p40 itself binds to heparin/HS and retains this property when 
in combination with p35 to form IL-12, the likelihood remains that IL-23 may also 
possess this binding property. Nevertheless, as highlighted by the current findings, 
there are various factors that influence the formation of a heparin-binding domain in 
protein based on its three-dimensional structure. Indeed, the p40 subunit contains a 
heparin-binding sequence, but the structural interaction of this subunit with another 
subunit-p19 with spatial orientation of basic residue clusters will determine whether 
IL-23 binds to heparin/HS or not. As proposed in the case of IL-12, that the heparin-
binding site was conformationally formed of basic residues from unordered and 
flexible loop regions within the D3 domain of the C-termini, any conformational 
change can affect the availability of exposed residues for interaction with heparin. The 
crystal structure of IL-23 is available in the PDB (PDB ID: 3DUH) (Lupardus & 
Garcia, 2008). Very recently, a high-resolution structure of the IL-23 in complex with 
its cognate receptor, IL-23R has been generated (Bloch Et. al., 2018). They have shown 
that the receptor chain mainly engages with the exposed end of the p19 subunit. In this 
receptor interaction there is also a minor contact with an aminoterminal domain, the 
D1-D2 region of the p40 subunit which slightly influences carboxy-terminal domain 
D3 orientation, but the surface of the p40 domain, D3 remains largely exposed. This 
suggests an increased likelihood of IL-23 to be able to bind heparin/HS via the p40 
subunit. Using a strategy of combined structural and experimental approaches as 
employed in the current study, one can investigate heparin-binding property of IL-23. 
 
6.2 Role of DS in IL-12-induced IFN-γ Secretion 
 
Chapter 4 of this thesis focused on the functional role of GAGs/PGs, particularly the 
role of DS in NK cell regulation. The current study presented data that confirmed the 
previously demonstrated role of NK cell-surface DS in the regulation of innate IFN-γ 
production in response to IL-12 using chondroitinase ABC and β-xyloside treatment 
(Garnier Et. al., 2003). In addition, the current study further extended the previous 




mechanism by which DS-PG mediates IL-12-signalled IFN-γ secretion. Firstly, the 
results indicated no significant effect of DS-PG on phosphorylation of the IL-12-
specific transcription factor, STAT-4. Secondly, the data that the IFN-γ protein was not 
sequestered intracellularly eliminated the possibility that DS-PG affects the 
translational or post-translational events in IFN-γ expression. Therefore, this study 
concludes that DS-PG potentially modulates IL-12 activity in IFN-γ expression at the 
transcriptional stage. This is well-supported by a recent finding which demonstrated 
low levels of IFN-γ in decorin, a DS-PG KO mouse, leading to a reduced allergy-
induced inflammatory response. Although the absence of DS-PG resulted in reduced 
IFN-γ mRNA levels and hence reduced protein expression in tissues of decorin KO 
mice, the mechanism of this transcriptional regulation of IFN-γ gene by DS-PG is still 
unknown (Bocian Et. al., 2013). 
 
As discussed earlier in Section 4.3, that one potential mechanism in the transcriptional 
control of IFN-γ expression by DS-PG could be p38 MAPK signalling. This signalling 
pathway has been indicated in both the direct and indirect regulation of IL-12 
dependent IFN-γ expression (Visconti Et. al., 2000; Zhang & Kaplan, 2000; Watford 
Et. al., 2004). Hence, it would be important to determine whether DS-PG affects IFN-
γ expression via p38 MAPK signalling. This can be experimentally demonstrated by 
stimulation of β-xyloside or chondroitinase ABC treated NK cells with IL-12 in the 
presence of the p38 inhibitor, SB203580. In this context, the effect of DS on p38 
MAPK signalling pathway has been reported. For example, DS was shown to regulate 
osteoclast formation, in part, by inhibiting phosphorylation of p38 MAPK and ERK in 
RANKL stimulated monocytic cells (Shinmyouzu Et. al., 2007). 
 
Also, as mentioned earlier and discussed in detail in Chapter 4 (Section 4.3), a 
limitation to the approach used in the current investigation was encountered. This was 
due to possible cellular effects in addition to altered PG synthesis on NK cells by p-
nitrophenyl-β-xyloside . Thus, it was not possible to continue and test the above 
proposed hypothesis that the functional role of DS-PG in IL-12-mediated IFN-γ 
transcription and production is mediated by p38 MAPK pathway. Since our work, in 
addressing this limitation, the recent advancements in this field of study have led to 
generation of new series of β-xylosides with a wide variety of aglycone structures and 
are known to be selective in inhibiting PG synthesis (Kuberan Et. al., 2008; Tran Et. 




glycoconjugates, like glycoproteins/glycolipids (Garud Et. al., 2008). Some of these 
new xylosides are reported to prime not only synthesis of specific GAG chains, but also 
affect the pattern or extent of sulphation on those GAG chains (Victor Et. al., 2009; 
Tran & Kuberan, 2014). Therefore, with more stability and versatility offered by these 
xylosides, they have been used in animal models, such as zebrafish, to understand the 
role of HS-PGs in developmental signalling events (Nguyen Et. al., 2009). For 
example, these types of xylosides were successfully used by injecting in zebrafish 
embryos to demonstrate the effect of specific GAGs chains and valency, in vivo. 
Multimeric HS-PG primed on these added xylosides were shown to positively 
modulate FGF-FGFR signalling which resulted in an elongated phenotype during 
embryonic development (Nguyen Et. al., 2013). Thus, one possibility to advance the 
current work would be the use of this new generation of xylosides.  
 
Additionally, the novel phage display-derived antibodies, GD3A12 and LKN1 which 
can specifically recognise DS (den Dekker Et. al., 2008; Ten Dam Et. al., 2009) are 
now available. These antibodies can determine whether the β-xyloside/chondrotinase 
ABC treatment has resulted in significant, or complete removal of cell-surface DS-
GAG chains. Moreover, these antibodies do not react with other classes of GAGs 
including CS and HS (Lensen Et. al., 2006). Therefore, after the treatment with PG 
inhibitor or enzymes, decreased binding of these antibodies to the sulphated, cell-
surface DS of NK cells could then be strongly correlated to IFN-γ production. 
 
Broadly, the current findings also open more avenues to explore in this field that would 
highlight the importance of DS-GAGs/PGs in NK cell activation and effector functions. 
For instance, it remains to be determined whether NK cell-surface DS is also involved 
in regulating IL-12 induced activities other than IFN-γ production. IL-12 activated NK 
cells also produce other cytokines, such as TNF-α and GM-CSF, which contribute to 
innate immunity (Bellone Et. al., 1995). Therefore, it would be a significant finding to 
determine whether the role of DS-PG is confined only to IFN-γ expression or could be 
extended to other NK cell-derived cytokines. In addition, DS-PG may have influence 
on other effector functions of NK cells. Regarding the tumour microenvironment, IL-
12 enhanced NK cell cytolytic activity is one of the most important function. Whilst, it 
has been known that NK cell-CSPGs are mediators of target cell-lysis (Schmidt Et. al., 
1985), work with p-nitrophenyl-β-D-xyloside treated NK cells has been reported to 




exogenously added GAGs, CS-A, CS-C and DS showed no effect on NK cell-mediated 
cytotoxic activity (Yamamoto Et. al., 1985). However, it is still not known if this 
cytolytic capacity of β-xyloside cultured NK cells remains unaffected upon IL-12 
stimulation. This could be demonstrated by cytotoxicity assays using NK cells and 
target cell lines, YAC-1 (Karlhofer Et. al., 1995) or K562 (Bellone Et. al., 1995) in the 
presence of IL-12 and β-xyloside. This would indicate whether altered GAG/PG 
expression plays a role in modulating IL-12 activity in mediating NK cell functions and 
in doing so influences development of Th1 immune responses.  
 
Since this investigation commenced, there have been no studies reporting the 
mechanistic role of NK cell-surface DS-PG in IL-12 induced IFN-γ expression that is 
important in understanding the influence of GAGs/PGs in cytokine expression and 
thereby contribution to immune responses. In this context, while DS-PG was shown as 
a key PG in the endometrial localization of CD16 (-) NK cells from the peripheral 
circulation (Kitaya & Yasuo, 2009), recent findings by Seidler et al demonstrated the 
role of decorin, a DS-PG, in the network of signalling pathways regulating cytokine 
expression, in vivo and in vitro (Bocian Et. al., 2013). Consistent with our finding, the 
absence of DS-PG resulted in transcriptionally reduced IFN-γ expression in endothelial 
cells, thereby influencing reduced recruitment of CD8+ T cells to inflamed tissue. 
Further, using DCN-/- mice, loss of decorin was shown to affect IFN-γ-induced STAT-
1 signalling in chemokine CXCL-10 expression, thus explaining molecular basis to the 
role of DS-GAG/PG in modulating DTH (delayed type hypersensitivity), an allergic 
inflammatory response (Seidler Et. al., 2011; Bocian Et. al., 2013).  
 
Moreover, unlike the current study, alternative studies conducted in this field have 
demonstrated the effect of exogenously added GAGs on cytokine expression. Some of 
these studies have also attempted to elucidate the underlying signalling mechanism. 
Yet, the study of the precise mechanisms is at an early stage and as the field develops, 
it will be interesting to learn from more examples. For instance, immuno-modulatory 
effects of soluble CS-A and CS-C were studied in LPS-stimulated TLR-4 pathway in 
chondrocytes. This was shown to be mediated by inhibition of a transcriptional 
regulator, NF-κB which consequently reduced inflammation (Campo Et. al., 2009). 
Similarly, expression of several pro-inflammatory cytokines (IL-6, TNF-α) was shown 
to be strongly inhibited by CS-C in part, through suppression of NF-κB activation in 




which CS-C inhibits NF-κB activation is still unknown. Hence, the current study and 
those described above exhibit continued efforts being directed towards understanding 
how signalling mechanisms are initiated and regulated by GAG/PGs, particularly in 
cytokine expression. This could be helpful in the design of effective 
immunomodulatory therapies for inflammation-associated diseases such as 
autoimmunity.  
 
6.3 Role of TGF-β1 in IL-12-induced IFN-γ Secretion 
 
The current study (Chapter 5) provides a molecular explanation for how TGF-β1 might 
regulate early IFN-γ production in NK cells in the presence of IL-12. On TGF-β1 
treatment, IL-12 induced IFN-γ production was significantly inhibited in NK cells. 
Although this observation is consistent with number of earlier studies (Bellone Et. al., 
1995; Bright & Sriram, 1998; Sudarshan Et. al., 1999; Laouar Et. al., 2005; Lindgren 
Et. al., 2011; Lewis Et. al., 2015),  an important aspect of the current research was to 
study this inhibitory effect of TGF-β1 independent of NK cell proliferation. This was 
supported by the early kinetics data which clearly demonstrated TGF-β1 suppressed 
IFN-γ production within 3-6 hours. This suggests that the inhibitory effect by TGF-β1 
on NK cells preceded its action on cell transit through cell cycle. Such TGF-β1 
dependent down-regulation of early IFN-γ production is likely to be significant in vivo, 
as NK cell-derived IFN-γ is an important component of tumour surveillance (Fauriat 
Et. al., 2010; Wilson Et. al., 2011) and has been implicated in Ag-independent and 
innate protection against various infections by microorganisms (Lewis Et. al., 2015).  
 
To investigate the interference of TGF-β1 in IL-12 signalled IFN-γ production, a 
systematic approach was adopted that tested the key components of the IL-12 signal 
transduction pathway in IFN-γ expression. Results on this clearly showed that IFN-γ 
inhibition by TGF-β1 was not dependent on IL-12-activated STAT-4 via the JAK-
STAT pathway. In addition, the results also showed that TGF-β1-mediated early IFN-
γ inhibition was not directly mediated by downregulation of a positive trans-activator 
of the IFN-γ gene, T-bet expression (Szabo Et. al., 2000; J. Y. Cho Et. al., 2003). Since 
transcriptional regulation is a complex process that requires several transcription 
factors in a collaborative effort controlling promoter-driven transcription, TGF-β1 
might inhibit binding of T-bet and other significant factors that may co-operatively 




al., 2003). To test this hypothesis, reporter assays were conducted using a -777bp to 
+48bp region of the proximal IFN-γ promoter that contained interaction sites for T-bet 
and notably, for various other transcription factors. These assays demonstrated that IL-
12 activation of the IFN-γ promoter construct was insensitive to TGF-β1-induced 
repression suggesting TGF-β1 neither targets the direct action of T-bet in binding to its 
functional sites, nor inhibits the indirect role of T-bet influencing other factors in IFN-
γ promoter activation. Importantly, results from reporter studies revealed that the TGF-
β1 sensitive regulatory region could be further upstream of -777bp from the TSS of the 
IFN-γ gene. However, as mentioned earlier,this work on promoter analysis is 
preliminary and should be substantiated with more promoter mapping or deletion 
studies in future. This will enable the regions of the IFN-γ promoter that may be both 
necessary and sufficient for TGF-β1-induced IFN-γ repression to be determined. In 
conclusion, this study on signaling cross-talk between TGF-β1 and IL-12 has 
demonstrated that molecular regulation of early IFN-γ expression is independent of 
conventional and direct role of two key transcriptional factors, STAT-4 or T-bet in NK 
cells. Indeed, as discussed and proposed earlier in Chapter 5 (Section 5.3), the current 
data on early and rapid inhibition of IFN-γ production by TGF-β1, rather, highlights a 
possibility to explore and evaluate that TGF-β1 mediates repression of the Ifng locus 
through chromatin remodeling events such as transcriptionally repressive histone 
modifications which silences early Ifng expression.  
 
Knowing the significance of IFN-γ in immune processes, it is not surprising that the 
regulation of this cytokine expression is complex and has been suggested to act at many 
different levels such as epigenetic, transcriptional and post-transcriptional (Schoenborn 
& Wilson, 2007; Young & Bream, 2007; Mah & Cooper, 2016; Leong Et. al., 2017). 
Besides epigenetic modifications such as chromatin remodeling of the Ifng  locus by 
TGF-β1, from the current findings, transcriptional and post-transcriptional events are 
other possible avenues to explore. This will provide a more detailed view of IFN-γ 
regulation by TGF-β1 in NK cells. As explained earlier, NK cells exhibit a 
constitutively ‘open’ status of the Ifng locus which promotes accessibility to 
transcription factors (Tato Et. al., 2004). This open configuration of the Ifng locus has 
also been shown to correlate with the presence of constitutive IFN-γ transcripts in these 
cells and their ability to rapidly produce IFN-γ protein on activation (Stetson Et. al., 
2003). Further, stimulation with cytokines IL-2/IL-12 has shown to increase the 




NK cells (Hodge Et. al., 2002). Thus, NK cells are poised with constitutive IFN-γ 
mRNA expression which are further induced on cytokine stimulation. However, very 
low levels of IFN-γ protein have been suggested in the translation of this basal gene 
transcription (Stetson Et. al., 2003; Tato Et. al., 2004). Therefore, this leads to two 
possibilities in the control of NK cell production of IFN-γ by TGF-β1. First, TGF-β1 
may directly act on IFN-γ transcription and secondly, TGF-β1 may affect a post-
transcriptional mechanism such as mRNA stability.  
 
Supporting the first hypothesis of transcriptional regulation by TGF-β1, earlier studies 
have shown that addition of TGF-β1 to NK cells suppressed IFN-γ mRNA levels 
concurrent with IFN-γ protein levels (Sudarshan Et. al., 1999; Hayashi Et. al., 2003; 
Laouar Et. al., 2005). Since the current data demonstrates TGF-β1 mediated early and 
rapid inhibition of NK cell produced IFN-γ (3-6hrs), it therefore becomes an imminent 
need to measure IFN-γ mRNA levels by RT-PCR as part of future work. This will be 
insightful to determine the transcriptional control by TGF-β1. While, in support of the 
second hypothesis, IL-18 induced IFN-γ transcriptional activity in NK cells was shown 
to be unaffected by TGF-β1. Instead, it was shown to decrease the stability of IFN-γ 
mRNA leading to degradation of transcripts and hence reduced protein levels (Hayashi 
Et. al., 2003). Hence, it will also be important to consider the latter possibility of post-
transcriptional regulation of IFN-γ to further explore the findings from the current 
study. This will enable to determine whether TGF-β affects post-transcriptional events, 
such as IFN-γ mRNA stability. Rapid decay of IFN-γ mRNA could be a potential 
molecular mechanism in ‘switching off’ the IFN-γ expression by TGF-β1. 
 
mRNA degradation is central to the post-transcriptional regulation and controlled by 
AU-rich elements (AREs), which are typically present as a pentameric sequence of 
AUUUA in the 3’ untranslated region (3’UTR) of mRNAs (C. Y. Chen & Shyu, 1995). 
IFN-γ mRNA is one such labile transcript that contains several typical AU-rich 
elements (AREs) present in the 3’ untranslated region (3’UTR) (Nagy Et. al., 1994; Ye 
Et. al., 1995). Investigations at this level of IFN-γ regulation is gaining increasing focus 
in recent years (Schwerk & Savan, 2015; Leong Et. al., 2017). The importance of this 
region was shown by targeted substitution of a conserved 162 AU-rich nucleotide 
sequence in the 3’UTR region of IFN-γ with random nucleotides in a mouse model. 
This resulted in low, chronic IFN-γ mRNA and protein expression in the circulation 




However, little is known about the trans-acting factors that are involved in or regulate 
ARE-mediated mRNA destabilization, though there are proteins known to bind ARE 
sequences  that participate in mRNA degradation. For example, earlier studies reported, 
HuR, as an ARE binding protein that regulated mRNA stability (Peng Et. al., 1998). In 
recent years, TTP (Tristetraprolin), an ARE-binding protein was shown to mediate 
degradation of IFN-γ transcripts in T lymphocytes by its direct interaction with 
AUUUA-rich motifs on IFN-γ mRNA. Moreover, TTP deficient T cells showed that 
absence of this protein resulted in an increased half-life of IFN-γ mRNA and increased 
expression on activation (Ogilvie Et. al., 2009). Since the current study demonstrated 
rapid inhibition of IFN-γ protein production by TGF-β1, it forms an attractive 
hypothesis that TGF-β1 mediates its effect on IFN-γ mRNA stability. Thus, TGF-β1 
may alter the stability of IFN-γ mRNA induced by IL-12 alone or in synergy with IL-
18 and may result in rapid decay of these transcripts. To address this mechanism, NK 
cells treated with or without TGF-β1 should be stimulated with IL-12 alone or IL-12 
plus IL-18 in the presence and absence of a transcriptional inhibitor, actinomycin D. 
Quantifying IFN-γ mRNA at different time-points over the treatment with actinomycin 
D would enable detection of IFN-γ mRNA decay. Therefore, comparing the half-life 
of IFN-γ mRNA in IL-12 stimulated NK cells in the absence and presence of TGF-β1 
would further suggest whether IFN-γ mRNA stability is affected by a TGF-β1-
dependent signal. Further investigations will be required to elucidate the role of TGF-
β1 in the induction of ARE-binding proteins and hence regulation of IFN-γ mRNA 
stability in NK cells.  
 
Additionally, another molecular mechanism that has attracted recent recognition in the 
post-transcriptional control of IFN-γ expression by TGF-β1 is the induction of 
microRNAs (miRNA) (Hata & Chen, 2016; Mah & Cooper, 2016). miRNAs are 
endogenously produced small (~22 nucleotides) noncoding RNAs that post-
transcriptionally regulate gene expression by inducing target mRNA degradation or 
inhibiting their translation (Bartel, 2009). They exert a regulatory role by binding to a 
partial complementary sequence in the 3’ UTR region of a target mRNA (Schwerk & 
Savan, 2015). These miRNAs are emerging as critical players in the negative regulation 
of TGF-β-controlled gene expression and can regulate 100’s of mRNAs simultaneously 
(Blahna & Hata, 2013; Hata & Chen, 2016). miRNAs are known to regulate IFN-γ 
production in NK and T cells (Savan, 2014; Leong Et. al., 2017). An interesting study 




Dicer-deficient CD4+ T cells which lack an important enzyme for miRNA processing, 
exhibited Th1 programming with secretion of high amounts of IFN-γ (Muljo Et. al., 
2005). Notably, miR-29, a specific miRNA expression has been shown to suppress 
IFN-γ production in NK and T cells by binding directly to the 3’UTR region of IFN-γ 
mRNA and inhibiting translation (F. Ma Et. al., 2011). In contrast, another study 
demonstrated that miR-29 regulates IFN-γ production in T cells by directly targeting 
3’UTR binding sites in degradation of T-bet and Eomes mRNAs, two key 
transcriptional regulators of IFN-γ expression (Steiner Et. al., 2011). Very recently, up-
regulated expression of miR-29 in NK cells from leukaemic patients was shown to 
correlate with reduced expression of T-bet and Eomes. This also resulted in overall 
downregulation of NK cell maturation and activity suggesting a mechanism in evasion 
of immunosurveillance (Mundy-Bosse Et. al., 2016). Additionally, miR-155 was also 
shown to positively regulate expression of IFN-γ in NK cells on co-stimulation with 
IL-12 and IL-18 (Trotta Et. al., 2012). Given the important clinical implications of 
miRNAs, especially miR-29 and miR-155 in multiple cancers and viral infections 
(Wang Et. al., 2013; Leong Et. al., 2017), further insights into the role of miRNAs in 
the regulation of IFN-γ is important. Future investigations can evaluate the expression 
of these miRNAs on TGF-β1 treatment of NK cells in the context of the post-
transcriptional regulation of IFN-γ suppression.  
 
On the whole, this part of the research in the thesis demonstrated a role for TGF-β1 in 
the suppression of innate IFN-γ synthesis by NK cells that impacts T cell activation 
towards Th1 and cell-mediated immune responses. This is relevant to various infectious 
diseases, such as leishmaniasis and L. monocytogenes, where a rapid innate response is 
vital to clearance of the infection versus persistence leading to chronic infection (recent 
review Sanjabi Et. al., 2017).  Similar pathological relevance is supported by studies 
demonstrating that viral specific proteins enhance TGF-β production and its cellular 
activity (Karimi-Googheri Et. al., 2014). Consistently, in vivo studies have shown that 
TGF-β signalling in NK cells reduced IFN-γ expression, limiting their early anti-viral 
response and increased susceptibility to infections, particularly MCMV and LCMV 
(Lewis Et. al., 2015). The clinical implications of current findings are not limited to the 
context of viral infections; they are significantly important in tumour settings as well. 
The current findings demonstrated that the suppressive effects of TGF-β1 on NK cell-
produced IFN-γ is independent of its effect on cell proliferation and survival. This is 




of NK cells but did not affect their survival as against the anti-proliferative and 
apoptotic effect of TGF-β1 on T cells suggesting that strategies blocking TGF-β 
activity has the potential to retrieve NK cell functions in tumour microenvironments 
(Sanjabi Et. al., 2009; Wilson Et. al., 2011). 
 
Besides secretion of TGF-β1, tumours escape recognition from cytotoxic T cells by 
several other mechanisms such as shedding of tumour-Ags and loss of MHC class I 
expression (Drake Et. al., 2006). In-fact, the latter mechanism is associated with the 
activation of non-specific, NK cell-directed tumour cell killing and secretion of IFN-γ 
that further aides in tumour surveillance (Waldhauer & Steinle, 2008). Notably, in 
recent years, NK cells have gained attention as an important cellular tool in various 
tumour immunotherapies (Morvan & Lanier, 2016). In addition to the suppressive 
effects of tumour-derived TGF-β on NK cells, another major source of TGF-β are the 
regulatory T cells (Tregs) that is another route to evasion of tumour immune 
surveillance (Wing Et. al., 2010; Sanjabi Et. al., 2017). Tregs have been shown to 
inhibit IFN-γ secretion of NK cells (Pedroza-Pacheco, 2013). Therefore, to date, 
challenges remain in the successful use of these NK cells in cancer therapies. 
Downregulation of effector functions of immune cells by TGF-β1 in the tumour 
microenvironment has led investigators in the field to direct their efforts in 
therapeutically targeting TGF-β1 signalling (as reviewed in Tu Et. al., 2014). NK cell-
based immunotherapies with strategies that target TGF-β1 signalling are now attracting 
interest and particular focus is on engineering patient-derived NK cells for re-infusion 
of these ex-vivo activated NK cells which are capable of boosted IFN-γ production 
(Tarek & Lee, 2014; Granzin Et. al., 2017). However, the blockade of TGF-β1 
signalling by drugs or agents has posed a challenge that requires balancing the 
immunosuppressive effects of TGF-β1 with the beneficial role of TGF-β1 in immune 
homeostasis (Flavell Et. al., 2010; Akhurst, 2017). These observations and findings 
necessitate a thorough understanding of the mechanisms by which TGF-β1 regulates 
IFN-γ production from NK cells. Studies, including ours, to some extent, contribute in 
the elucidation of this underlying mechanism that unleashes the potential of NK cells 
in generating more effective tumour immunotherapies and underscores the relevance 
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